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 1 
1 Introduction 
1.1 Technological change in the pharmaceutical industry 
In simple words the pharmaceutical industry links activities and business accomplishing 
the discovery, development, production and commercialisation of drugs (i. e. products 
with therapeutic properties). Accordingly, product innovation is based on the search 
and development of molecules that may have desirable therapeutic effects. Basically 
new drugs can be developed either with the application of organic chemical synthesis 
or from the separation of compounds produced by natural microorganisms, which as an 
application of biotechnology1. The development of these technologies (chemical 
synthesis and biotechnology) during 19th and 20th centuries has tremendously changed 
the conditions for innovation in the pharmaceutical industry. An interesting aspect of 
the pharmaceutical industry is the interaction between science and technology. 
Scientific advances have contributed to the development of the knowledge base 
underlying drug discovery and development. Indeed, the pharmaceutical industry can 
be considered an extreme case of a science-based industry (Gambardella 1995). 
Accordingly, to exploit innovative opportunities, the companies in this industry (the drug 
producers) have been forced to develop new competencies for the application of the 
novel scientific advances (Santos 2003; Galambos, Sturchio 2003). 
During the establishment of the modern pharmaceutical industry in the last decades of 
the 19th century, the scientific principles of organic chemistry guided drug discovery 
without providing understanding about the biological processes of diseases. However, 
this constraint did not prevent drug producers from developing promising drugs by 
synthesising compounds which could be tested for therapeutic properties using animal 
models. The German drug producers mastered this technology, which allowed them to 
dominate the industry until World War II.  
In contrast, after a period of successful application at the beginning of the 20th century, 
biotechnology for drug production remained more or less a niche technology in 
pharmaceuticals until the 1960s.2 Scientific advances in molecular biology and 
                                                
1  Biotechnology refers to the processing of materials with biological agents to provide goods and 
services (Bull et al. 1982). The revolutionary discoveries in the 1970s of artificially controlled 
recombinant DNA (rDNA) enabled the direct manipulation of genetic material of biological agents 
involved in the processing of goods and services. The techniques of rDNA are the basis of modern 
biotechnology, which has created enormous expectations for industrial applications. The body of 
literature on innovation studies often uses the term "biotechnology revolution" to refer to this 
technological development. However, biotechnology has a long historical record (Bud 1993). 
2 At the beginning of the 20th century microbiological applications and a large number of biotech-
nological processes had already been introduced. Waste water treatment, distillery, brewery, vinegar 
2  
biochemistry provided drug discovery with scientific knowledge on protein structure and 
on the function of proteins. To describe the contributions of biochemistry and of 
molecular biology in pharmaceuticals scholars refer to a transition from a chemical/ 
random screening to a biological drug design model (Gambardella 1995; Henderson et 
al. 1999). Moreover, after the 1970s, with the discoveries of recombinant DNA (rDNA) 
and monoclonal antibodies, biotechnology became a key tool for drug discovery and 
development and production. However, German actors in the pharmaceutical industry 
had problems in adjusting to the dynamics of the knowledge environment of the 
industry. Germany’s innovative performance in the pharmaceutical industry in the last 
half of the 20th century has been very disappointing, especially if compared with the 
strength of the industry before World War I.  
Due, on the one hand, to the revolutionary character of the rDNA discovery (which 
provided encouraging prospects of being able to develop complex protein-based drugs 
and understanding its effects) and on the other hand, to the emergence of a 
biotechnology industry in the west and east coasts of the USA (which appeared to 
facilitate the access to skills in genetic engineering to those actors not involved in aca-
demic research), the emergence of modern biotechnology in the 1970s has attracted 
increasing attention of policy-makers and social scientists for these developments.  
Contributions to innovation studies and explorations of industry dynamics and pro-
cesses of creative destruction have chosen the advent of modern biotechnology in the 
pharmaceutical to study, among other issues, the reactions of incumbents in the 
pharmaceutical industry to the shift in their knowledge environment. However, in 
general terms, the studies analysing the reactions of incumbent drug producers to the 
new technological opportunities after the 1970s do not consider explicitly the historical 
conditioning of technological change, a process where history matters. An exception is 
Henderson (1994), who traces the development of the competencies of pharmaceutical 
companies involved in drug discovery in the last quarter of the 20th century.  
This contribution aims at exploring technological change in the German pharmaceutical 
industry to unfold the mechanisms underpinning the changes in the relative importance 
of technologies, to identify the factors driving these transitions and the consequences 
for industry incumbents. The study aims at understanding the processes, develop a 
model formalising them and testing the outcomes against historical experience. 
 
                                                                                                                                            
production, wine production, creamery, tannery, fertilizers, sugar production and production of 
organic acids were some of the fields and production processes were biotechnology was first applied 
(Marschall 2000). 
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1.2 Technological change from an evolutionary perspec-
tive 
How does technological change in the pharmaceutical industry occur? Which are the 
mechanisms shaping the relative importance of technologies and their development 
paths? How do firms contribute to these processes? How do firms react when new 
technologies emerge outperforming the technologies they master?  
This study attempts to understand these processes guided by evolutionary theory. Dosi 
and Nelson (1994, p. 154) use the term “evolutionary” to define theories, models or 
arguments with the following characteristics:  
i. The analysis is explicitly dynamic. The purpose is to explain why something is 
what it is a certain moment in time in terms of how it got there. 
ii. The explanation involves random elements which generate some variation in 
the variables in question.  
iii. The models involve some processes of imperfect (mistake-ridden) learning and 
discovery and some selection processes. 
iv. The selection processes imply the identification of a unit of selection (profit, 
price, quality etc.) and certain mechanisms through which selection operates. 
Evolutionary theories, models or arguments may match these features more or less 
precisely, depending on the issues explored and on the authors analysing them. 
However, the term “evolutionary” in economic models explicitly rejects the neo-classical 
scenario of general equilibrium and its assumption of rational agents following profit 
maximising patterns.  
There are several reasons why we consider the evolutionary framework as appropriate 
to explore technological change.  
Firstly, it provides comprehensive theoretical explanations suggesting that the 
aggregate pattern of technological change at the industry level draws on mechanisms 
at lower levels of aggregation such as the level of the firm. Additionally, it provides the 
conceptual tools to explore technological change as a process relying on the 
accumulation and transmission of knowledge, skills, and behaviour among the actors 
involved. Moreover, the evolutionary approach to explore technological change admits 
its historical conditioning. Hence, from an evolutionary perspective historical recon-
struction needs to be merged with the analysis of the process of technological change. 
The acknowledgement of history dependent processes of technological change at an 
aggregate level (such as the level of the industry or the economy) does not necessarily 
imply the need of the historical characterisation of micro behaviours. History de-
4  
pendence at the system level can be the outcome of an invariant choice process 
subject to some sorts of externality, dynamic increasing returns, multiple locally stable 
equilibria etc. However, the analysis of technological change can very much profit from 
the historical-characterisation of micro behaviours. Which technologies emerge and 
how they develop and diffuse cannot generally be considered independently from the 
particular sequence of actions of their developers and adopters (Dosi et al. 1992, p. 4.) 
Finally, formal modelling plays a significant role, but it is not central. Nelson and Winter 
(1982, pp. 154-155) make the distinction between "formal" and "appreciative" 
theorising. Different from formal theory, appreciative theory is strongly influenced from 
empirical findings. Hence, appreciative theorising involves verbal explanations based 
on empirical findings. These explanations challenge formal theory and modelling, which 
are meant to act as a formalisation tool to identify gaps in the verbal stories or to test 
there logic. Additionally, formal modelling may identify new research questions 
reorienting empirical research. From this perspective, formal theory is hence supposed 
to provide guidance and a conceptual framework to empirical study (Hodgson 1993, p. 
166).  
This contribution aims at combining appreciative theorising and formal modelling by 
developing a history-friendly model of technological change and technology adoption to 
study technological change German pharmaceutical industry during the 20th century.  
The challenge of history-friendly models is to select research phenomena on firms and 
industries, generate hypothesis about the process of technological change using em-
pirical facts (qualitative and quantitative) and to set up a model specification to test the 
outcome against the historical experience in a rigorous manner. Thus, the methodo-
logical approach of evolutionary history-friendly models draws on appreciative theo-
rising and includes (i) a set of stylised facts characterising the phenomenon to be 
explored, (ii) verbal logic on how the processes occur, (ii) formal representation of the 
verbal logic in a model, and finally (iii) the implementation of a numerical computer 
simulation replicating the phenomenon explored. 
The contribution is structured as follows: 
The next chapter introduces the theoretical and methodological frameworks. Drawing 
on a literature review, the discussion starts by giving a presentation on the main 
schools of economic thought contributing to develop evolutionary thinking. Next, chap-
ter 2 specifies a conceptualisation of technology and elaborates on the main seminal 
contributions and concepts put forward by evolutionary scholars that can be useful for 
answering the research questions regarding technological change and the role of the 
firm in this process. The goal is to put together a toolbox to explore the technological 
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transitions in the German pharmaceutical industry and firms' performance. The 
chapter includes an introduction to simulation models and their value for evolutionary 
analysis of socio-economic phenomena. Chapter 2 ends with the presentation of 
history-friendly models and key methodological issues of the approach relevant for the 
purposes of this contribution. 
Chapter 3 aims at specifying the research phenomenon. In other words, it presents the 
empirical analysis of the major changes in the knowledge base underlying drug dis-
covery and development since the establishment of the modern pharmaceutical 
industry in the last quarter of the 19th century and the implications for the industry and 
for the German drug producers. The analysis considers the historical conditioning of 
technological change and takes a historical perspective. The findings are combined 
with a quantitative analysis using patent indicators. Additionally, at the organisational 
level, a case study approach is followed to analyse the ability of four German drug 
producers to exploit the technological opportunities of biotechnology after the advent of 
modern biotechnology in the 1970s. The complete material collected for the case 
studies is included in the annexes. However, all relevant results for our purposes are 
included in chapter 3.  
Chapter 3 identifies the stylised facts specifying the mechanisms underpinning 
technological change in the German pharmaceutical industry during the 20th century 
and putts forward interesting issues to be explored with a history-friendly model. 
Together with the theoretical concepts discussed in chapter 2, the findings elaborated 
in chapter 3 build the ground for the specification of the simulation model presented in 
chapter 4. 
Chapter 4 draws, to some extent, on previous models of technological change in the 
evolutionary tradition discussed in chapter 2. The goal is to build an artificial 
environment to explore the logic of the appreciative theory and the role of relevant 
processes and variables identified in the empirical analysis. The model includes the 
four characteristics outlined by Dosi and Nelson (1994, p. 154) to define evolutionary 
models given at the beginning of this section: the specification is dynamic, it includes 
random elements, discovery and selection processes and mechanisms through which 
selection operates.  
Finally chapter 5 summarises the main findings and draws the conclusions. 
 
 
 7 
2 Theoretical and methodological framework 
2.1 Introduction 
The idea of evolutionary technological change comes largely, on the one side, from 
historical and sociological research traditions and, on the other side, from evolutionary 
economics (Nelson, Nelson 2002, p. 265; McKelvey 1996, p. 36). 
From a historical perspective Vicenti (1990) for instance, explores the way technology 
evolves. Drawing on empirical evidence from the aircraft industry he analyses 
engineers’ strategies on solving technical problems and on improving technical solu-
tions. He proposes a blind trial and error process to compare the different technological 
alternatives to improve planes. This process leads to the identification of what ex-post 
can be defined as the better technology. The criteria determining the superior 
technology could emerge from an evaluation mechanism which is innate in the 
technological problem, thus the criterion is based on technical parameters such as 
speed or power. An additional evaluation mechanism he considers is the set of beliefs 
and opinions of the technological community contributing to solve the technological 
problems. Hence Vicenti's approach suggests that technology development is the 
result of a search process shaped by technological possibilities and the shared 
knowledge and practices of communities of engineers. 
On the other hand, evolutionary economists explore technological change in the 
context of economic development and market dynamics. According to Kwasnicki (1999, 
pp. 18-19) in the most general understanding the term evolutionary economics is used 
to emphasise the role of change in socio-economic processes in opposition to an 
analysis focussed on static equilibrium properties. In a narrow sense, "evolutionary" 
relates to a socio-economic analysis based on analogies and metaphors borrowed 
from theories of biological evolution.3 However, the term "evolutionary economics" 
                                                
3  The theory of biological evolution is associated with the name Charles Darwin. The 
Darwinian theory of biological evolution states that evolutionary change in a heterogeneous 
population is due to natural selection of organisms according to their suitability to the 
environment in which they interact. Organisms hold a genetic make-up (genotype) that 
results in different morphological structures and behavioural characteristics (phenotype) 
that may be suitable or not for their environment. The poor adopters perish but the best 
adopters survive passing their genetic information to their offspring. The mechanism of 
selection and information transfer can be "Lamarckian" (if novelty is intentional and 
organisms develop variations in order to adapt to environmental conditions, passing on 
such adaptations to their offspring) or "Darwinian" (if novelty is random and genetic 
variations are produced through a random process. The environment may affect organisms 
but the results of these effects can not be transmitted to the offspring). Even though there 
is no clear evidence for a Lamarckian selection mechanism in biological evolution, this type 
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applies to a confusingly wide array of approaches analysing socio-economic 
phenomena.  
The following section presents the main schools of economic thought contributing to 
the development of evolutionary economics. Next, a conceptualisation of the nature of 
technology and its implications for the analysis of technological change from an 
evolutionary perspective is presented in section 2.3. Section 2.4 covers the issues of 
technology emergence and diffusion in decentralised economies and presents relevant 
taxonomies of technological change. The role of firms in driving technological change 
from an evolutionary perspective is discussed in section 2.5. Finally, the chapter closes 
with the introduction of computer simulation as a method to explore technological 
change and technology adoption from an evolutionary perspective. 
2.2 The building blocks of evolutionary economics 
This strand of economic theory emphasises the relevance of dynamic analysis in the 
study of socio-economic phenomena and the need to build realistic assumptions about 
human agency (i. e. about how decision-making processes work). Hodgson (1999, 
pp. 127-129) and Kwasnicki (1999, pp. 18-19) identify at least three main schools of 
economic thought which can be grouped under the umbrella phrase “evolutionary 
economics”: the Austrian School, Institutional Economics and the work influenced by 
Schumpeter (or the so called neo-Schumpeterian economics).4  
Table 1: Main schools of economic thought contributing to the development of 
evolutionary economics 
Schools of  
economic thought 
Important  
exponents 
Selected general concepts 
Austrian  
School 
Friedrich  
Hayek  
• Rejection of equilibrium theorising; 
• Human action is considered purposeful; 
• Emphasis on the role of knowledge in 
economic analysis; 
• Biological idea of social evolution. 
                                                                                                                                            
of mechanism is most suitable for the exploration of socio-economic development 
(Hodgson 1988, pp. 141-144). 
4  To this selection Hodgson (1999, pp. 127-129) adds three additional approaches asso-
ciated with the word "evolutionary": (i) The economics of writers such as Adam Smith, Karl 
Marx, Alfred Marshall and others, (ii) developments in mathematical economics under the 
phrase "evolutionary game theory" inspired by related work in theoretical biology and (iii) 
work typically developed at the Santa Fe Institute (http://www.santafe.edu) in the USA 
described as "complexity theory". The approach draws on application of chaos theory and 
various types of simulation approaches such as replicator dynamics and genetic algo-
rithms. 
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Table 1 continued 
Schools of  
economic thought 
Important  
exponents 
Selected general concepts 
Institutional  
Economics 
Thorstein  
Veblen 
• Rejection of equilibrium analysis to explore 
processes of change; 
• Human action is considered purposeful, 
rationally bounded and coevolves with its 
environment; 
• Darwinian metaphor of economic evolution 
involving institutions (i. e. habits, roles and 
conventional behaviour). 
neo-Schumpeterian 
Economics 
Nelson and  
Winter 
• Rejection of equilibrium analysis to explore 
processes of change; 
• Human action is rationally bounded and 
shaped by institutions; 
• Lamarckian metaphor of economic evolution 
involving institutions (i. e. routines). 
Table 1 sketches a selection of relevant conceptual aspects. The next sections 
elaborate briefly on the main characteristics of these strands of economic theory. 
2.2.1 The Austrian School 
The fundamental premise of the Austrian School is the rejection of both equilibrium 
theorising and the existence of rigid preference functions determining agents' decision-
making processes. Its members explicitly recognise that human action is purposeful.5 
Therefore, an agent's choice is not determined by the environment in the sense that his 
or her goals are not predetermined. Additionally, the work of the Austrian School puts 
great emphasis on problems of information and the role of knowledge in the economic 
process. 
The contributions of Hayek in the 20th century represent one of the most developed and 
important applications of the evolutionary analogy (Hodgson 1993, p.153). Hayek's 
work is grounded, on the one side, on the purposeful behaviour of agents (already 
stressed in his early writings). However, according to Hodgson (1989, p. 258), Hayek 
recognised that individuals' goals and tastes were not predetermined, he considered 
that the formation and moulding of individual tastes and preferences were beyond the 
scope of economic analysis. Moreover, Hayek develops in his later writings a modern 
biological idea of social evolution.  
                                                
5  "Purposeful behaviour" assumes that agents have the capacity to change both behaviour 
and goals without external stimulus. In contrast, orthodox economic theory assumes "goal-
directed behaviour" in which agents' goals and preferences are exogenously given and 
agents do not have a will (Hodgson 1988, p. 11). 
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2.2.2 Institutional Economics: the legacy of Thorstein Veblen 
and the developments of new Institutional Economics 
This school draws on the intellectual heritage created and developed by early twen-
tieth-century economists such as Thorstein Veblen.6 His work aimed at developing an 
alternative to the orthodox theoretical framework. Veblen's critique of the orthodox 
approach focused on its inadequacy for the theoretical purpose of analysing the 
process of change and transformation in the economy. Under Veblen's point of view, 
the relevant research question lies on why innovations take place (and not on the 
conditions for equilibrium after new technological possibilities have been established).  
Nelson and Nelson (2002, p. 266) suggest that in Veblen's work institutional analysis 
(in the sense of the exploration of the set of factors moulding and defining human 
interaction) and evolutionary analysis of socio-economic development were intertwined. 
Regarding the institutional aspects of his work on the exploration of agents' behaviour, 
Veblen stresses that human nature or preference functions are not given for granted. 
Both, circumstances and character of an individual are involved in the cumulative pro-
cess of change. Hence, both the agent and the environment are the outcome of a 
cumulative process. To elaborate this idea he introduces the role of institutions in the 
analysis of human behaviour. Economic institutions are seen as complexes of habits, 
roles and conventional behaviour. In contrast with the Austrian idea that all action is 
purposeful, and with the neoclassical idea that all action is determined by preference 
functions, in the sense of Veblen habits are essentially non-deliberative and even 
unconscious. Moreover, breaking with the orthodox picture of the agent's maximising 
behaviour (and in reminiscence of the idea of Simon (1957) of bounded rationality or 
limited computational capacity) he recognises the agent's problems of global 
calculation of maximisation opportunities.  
With regard to Veblen's elaboration of evolutionary concepts, his work presents an  
attempt to develop a theory of socio-economic evolution using the Darwinian evolu-
tionary metaphor (where institutions and habits of thought act as genes in the biological 
sense). In this sense, Veblen suggests a mechanism specifying the sustenance and 
procreation of action and institutions as units of selection.7  
                                                
6  This school uses very often the terms "evolutionary" and "institutional" as synonyms. For 
instance, in the USA the school is represented by the Association for Evolutionary 
Economics (AFEE) and in Europe by the European Association for Evolutionary Political 
Economy (EAEPE). 
7  See footnote 3 for a short elaboration of the concept of Darwinian evolutionary processes. 
Veblen described himself as Darwinian because he puts greater emphasis on the selection 
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The contributions of the Institutionalist school of Veblen and his colleagues built up a 
prominent paradigm among American economists in the 1920s and 1930s which 
emerged largely out of their critique of orthodox assumptions regarding the behaviour 
of agents embedded in a socio-economic system. However, the fundamentals of their 
work defining human agency and their methodological approach (largely based on 
empirical work on the nature and function of institutions) were not able to compete with 
the formalistic and mathematical developments pushing the neo-classical approach 
after World War II (Hodgson 1989).  
In the 1970s, institutions were placed again in the centre of economic analysis by the 
strand called new Institutional Economics. Its best known exponents are Williamson 
(1985, 1993) (developing organisational theory) and North (1990) (who takes a 
historical perspective). Even though they try to break with neoclassical theory, their 
work embraces much of the core neoclassical fundamentals (Hodgson 1989). For 
instance, even though new Institutional Economics admit the bounded rationality of 
agents, they include optimising exercises (by minimising transaction costs) in agents' 
decision-making processes. Edquist and Johnson (1997, pp. 44-45) point out that 
Williamson's contribution largely draws on the transaction cost theory put forward by 
Cose (1937). The central aim of Williamson's transaction costs economics is to explain 
the nature and existence of economic institutions such as markets and firms using 
concepts of opportunism and transaction costs involved in trading. The organisation of 
firms and markets can be explained in terms of existing transaction costs and the 
search for organisational structures minimising them. North develops a theory of the 
development of institutions involving the concept of transaction costs and a theory of 
property rights. 
2.2.3 Neo-Schumpeterian Economics: the work influenced by 
Schumpeter 
A continually growing body of literature under the umbrella phrase neo-Schumpeterian 
economics has been modelling economic processes inspired by Schumpeter's work in 
the last 30 years. 
Saviotti and Metcalfe (1991) summarise the fundamentals of Schumpeters' work as 
follows. Schumpeter's main research interest was to explain the phenomena of "eco-
nomic evolution". In his view, "economic evolution" corresponds to economic change 
                                                                                                                                            
process through which some institutions prosper and others decline. Whether Veblen's 
theory was really Darwinian (in the sense that he excluded purposeful behaviour and the 
possible transmission of adaptations to the environment) is unclear. His work leaves room 
for different interpretations (Hodgson 1993, pp. 134-135). 
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driven by innovation and all its effects (including the responses from the economic 
system).8 Additionally, he stresses the non-equilibrium aspects of economic 
development in capitalist economies. For Schumpeter "evolution" means the denial that 
equilibrium can be attained as a permanent state of rest, and the assertion of constant 
novelty and change. In his view, evolution is hence a disturbance of existing structures 
and more likely a series of explosions than a moderate transformation.9 Finally, 
regarding the entrepreneurial act, Schumpeter suggests a conception of behaviour as 
fundamentally rule-governed, rejecting rationality (Langlois 2002, p. 14).  
Schumpeter's early writings focus on the role of the entrepreneur as main responsible 
for technological change by seizing upon exogenously given inventions and 
transforming them into economic innovations without explicit planning of innovative 
activities. Innovations disequilibrate and alter hence the given market structure. 
However, the emergence of inventions was not explored in his early work. Basic 
inventions are treated more or less as exogenous to the economic system. On the 
other hand, his later work, Capitalism, Socialism and Democracy, was mainly 
concerned with the role of large corporations, their rational calculation when planning 
research and development, and the effects of monopolistic practices on innovation and 
economic development. In these writings invention becomes a purposeful and, to some 
extent, planned activity carried out by large firms. Due to the different pictures of 
technological change presented in Schumpeter's writings, his work has been often 
classified as Schumpeter I (referring to its early writings, or the 1934 English translation 
                                                
8  Schumpeter's concept of innovation goes far beyond technological change in a narrow 
sense. The concept includes the introduction of a new good, a new method of production, 
the opening of a new market, the involvement of new sources of raw material, and the 
enforcement of a new industrial organisation such as the taking up of a monopoly position 
(Schwitalla 1993). 
9  However, the evolutionary character of Schumpeter's work is not explicit. Hodgson (1993) 
points out that Schumpeter's own notion of "economic evolution" is explicitly distanced from 
evolution of in a biological sense and excludes any suggestion of a Darwinian or a 
Lamarckian process of selection and information transfer. For Schumpeter, "economic 
evolution" meant change in general. His idea clearly accepts structural, qualitative and 
cultural change. However, according to Hodgson, his notion is too broad for an implicit 
evolutionary analogy in the biological ubnderstanding, which should include elements of 
selection. Challenging Hodgson's view, Andersen (1995) supports the evolutionary 
character of Schumpeter's work and appeals to consider Schumpeter's own distinction 
between the analytic tools available to him and his evolutionary vision. According to 
Andersen, "Schumpeter formulated his evolutionary theory in connection to a (pseudo)-
Walrasian framework (…) Schumpeter's sole reliance on innovation rather than selection 
should instead be seen as reflecting the inadequate tools available to him" (Andersen 
1995, pp.6-7). 
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of his Theory of Economic Development) and Schumpeter II (referring to his work 
Capitalism, Socialism and Democracy) (Schwitalla 1993; Freeman 1982).10 
Schumpeterian analysis experienced a renaissance in the 1980s with the work of 
Nelson and Winter (1982), which at the same time opened up the development of 
formal evolutionary modelling. Inspired by Schumpeter, Nelson and Winter (1982) 
stress the role of technological change as the motor of economic growth and 
emphasise the role of firms in this process. In addition, they explicitly adopt a biological 
metaphor considering industries as populations of profit-seeking firms. The market 
represents the selection environment and determines the definition of firm’s success. 
Firms try to adapt to market conditions in order to fulfil this definition. As in biological 
selection, firms that best adapt to the conditions of competition are able to survive. In 
the spirit of Veblen, Nelson and Winter introduce institutionalist concepts in their 
analysis of technological change and industry evolution with the notion of routines, 
which store essential information for the organisation such as how to accomplish 
certain processes or how to interpret market signals. In their biological metaphor to 
illustrate industry evolution organisational routines act as "genes". However, for Nelson 
and Winter industry evolution allows for the inheritance of acquired characteristics 
through a "Lamarckian" process of information transfer (Nelson, Winter 1982, pp. 134-
136).11 Finally, using formal methods and computer simulations, the evolutionary 
model of economic growth elaborated in chapter 9 of their 1982 contribution generates 
standard macroeconomic series describing growth were all three elements (labour 
productivity, real wages and capital intensity) increase. As Hodgson (1993, p. 166) puts 
forward, in the early 1990s their work was still "the most extensive and rigorous 
application of the application of the evolutionary metaphor from biology in economics". 
                                                
10  The literature of technological change offers a conventional interpretation of the differences 
between Schumpeter I and II according to which Schumpeter changed his fundamental 
position on the nature of innovation because of trends he saw developing in 20th century 
US-American capitalism. Langlois (2002) emphasises that the interpretation of different 
fundamental positions in Schumpeter's work is wrong. According to him, Schumpeter's 
ideas are consistent with different stages of capitalist economies where the access of 
agents to knowledge changes. The early Schumpeter writings are based on an economic 
framework in which the access of agents to knowledge is limited, rationality is bounded and 
hence innovation can not be planed. In this context, progress depends on entre-
preneurship, i. e. on taking risks and transforming resources in unconventional directions. 
His later writings, on the other hand, draw on an economic framework in which the bounds 
of rationality are broken, limits to knowledge are disappearing and a planned economic 
activity (far away from conditions of perfect competition) can lead to innovation and growth. 
11  See footnote 3 for a description of "Lamarckian" evolutionary mechanisms of selection and 
information transfer.  
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The neo-Schumpeterian literature developing Nelson and Winter's approach considers 
economic phenomena as dynamic, historical processes in which macroeconomic 
characteristics are the result of economic agents' activity at the micro-level. Hetero-
geneity of agents is a fundamental feature of economic evolutionary processes where 
selection and search for innovation are the two basic mechanisms of development 
(Kwasnicki 1999).  
A key difference between neo-Schumpeterian economics and the Institutionalist and 
Austrian Schools introduced above is their methodological approach. According to 
Kwasnicki (1999, p. 22), neo-Schumpeterian economics are characterised by the wide 
application of formal modelling and simulation tools for economic analysis, while the 
Institutionalist and Austrian Schools make use of verbal and graphical representations 
to describe and analyse economic phenomena. 
However, Nelson and Nelson (2002, pp. 266-267) suggest that the Institutionalist and 
neo-Schumpeterian schools share important theoretical premises regarding human 
action in the sense of Veblen (i. e. the consider human action as the result of shared 
habits of action and thought). Additionally, both approaches try to understand the 
determinants of economic performance and why performance differs across countries. 
Most importantly, recent developments have seen the strands of Institutional and neo-
Schumpeterian economics converge. For instance, some of the scholars contributing to 
the development and establishment of neo-Schumpeterian economics and its 
formalisation have also elaborated heuristic frameworks to integrate institutions as the 
main factors moulding technologies used by societies. The results are empirical studies 
of technology and industry evolution as well as approaches like National Innovation 
Systems, Sectoral Innovation Systems and Technological Systems.12  While these 
heuristic approaches have been able to account for institutions in their analysis of 
technological change, the pure formal neo-Schumpeterian approaches are still de-
veloping conceptual and methodological tools to integrate institutional aspects in their 
analysis (Nelson, Nelson 2002).13 
                                                
12  This section skips a review of the extensive literature on the Systems of Innovation 
approach and its main exponents. Freeman (1988) and Nelson (1988) introduced the 
concept of National Systems of Innovation which was further developed by Lundvall 
(1992), Nelson (1993) and Edquist (1997). Carlsson and Stankiewicz (1991) propose the 
concept of Technological Systems and Breschi and Malerba (1997) use the concept of 
Sectoral Systems of Innovation.  
13  Schwitalla (1993, pp. 40-41) already pointed out these different developments in the neo-
Schumpeterian strand of evolutionary economics. Grupp (1998) introduces this aspect in 
his overview of theoretical approaches exploring the innovation process as well. He speaks 
of Institutional neo-Schumpeterian innovation theories to refer to neo-Schumpeterian 
economists explicitly embracing and developing the institutional approach in concepts such 
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Even though technological change is considered to be the main driver of economic 
development, the focus of neo-Schumpeterian economics remains mostly on eco-
nomics-related questions such as economic growth, industrial dynamics and firms' 
strategies. McKelvey (1996), who has analysed the relevance of evolutionary patterns 
of technological change for evolutionary economic theories stresses that “economists 
often assume that technical change is evolutionary without exploring the issue” 
(McKelvey 1996, p.36). 
The next sections discuss more deeply the issue of evolutionary technological change 
from a neo-Schumpeterian perspective. The aim is to set the theoretical and me-
thodological framework to explore technological change and technology adoption in the 
German pharmaceutical industry. This theoretical framework combines institutional and 
evolutionary elements in their narrower meaning. Accordingly, the presentation aims (i) 
at conceptualising the nature of technology and its implications for the analysis of 
technological change, (ii) at including search and selection mechanisms in the 
processes of technological change, (iii) at emphasising the role of institutions in firms' 
decision-making14, and finally (iv) at identifying the processes underpinning the 
acquisition and transmission of knowledge at the level of the firm. 
2.3 A conceptualisation of the nature of technology  
A key step towards the characterisation of technology is the recognition of its imposed 
function, which determines how technology should behave or the task it should  
accomplish. For instance, if I had an air-conditioning system in my office I would expect 
it to control the room temperature and cool it if it gets too hot; hence this is the imposed 
function of the air-conditioning technology. Therefore, technology involves a trans-
formation of the world in order to reach a predefined behaviour (Nightingale 1998, 
2004).  
Metcalfe puts forward a dualistic approach to technology according to which 
technologies have two dimensions: the artefact dimension and the knowledge 
dimension (Metcalfe, Boden 1992).  
                                                                                                                                            
as innovation systems. While the neo-Schumpeterian approaches developing formal 
models and stressing fundamentals of behavioural theories at the micro level to explore 
macroeconomic processes are referred to in Grupp’s work as Evolutionary neo-Schum-
peterian innovation theories. Grupp applies the adjectives Institutional and Evolutionary in 
their narrow sense (Grupp 1998, pp. 68-76).  
14  "Institution" here refers to the "the sets of common habits, routines, established practices, 
rules, or laws that regulate the relations and interactions between individuals and groups" 
(Edquist, Johnson 1997, p. 46). 
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The artefact dimension refers to the physical devices articulating the transformation 
process of inputs into outputs. Moreover, it embodies the physical achievements in the 
development of a technology which can be captured in terms of performance of outputs 
(for instance functional or qualitative performance) or of production processes applied 
(in terms of necessary equipment and its costs or environmental criteria, for example).  
On the other side, technology as knowledge refers to the concepts, theories and 
practices underlying the transformation process and the actions that enable its 
operation. Technology involves different types of knowledge such as tacit knowledge 
(which can not be easily articulated and communicated) and codified knowledge (which 
can be expressed in symbolic form and easily articulated).15 Nelson and Winter (1982)  
suggest that real life knowledge can often be placed on a continuum between perfectly 
codified and tacit knowledge. Moreover, the nature of knowledge in terms of degree of 
"codifiability" may change overtime (Saviotti, Metcalfe 1991).  
An important issue in innovation studies and in science and technology policy is the 
interaction between technology and science. To explore this interaction it is necessary 
to understand the differences between science and technology.16   
In simple words, science provides understanding about the world. Accordingly, 
scientific activities involve experimental practices in order to match scientists' ideas 
about the world with the facts they observe under specific conditions. Science provides 
understanding of how phenomena occur. In contrast to technology, science is not  
supposed to work correctly (since it does not involve an imposed function). Science is 
supposed to deliver statements that match the evidence (Nightingale 1998, 2004). 
Metcalfe and Boden have stressed the differences between science and technology by 
focussing on their problem-solving nature. A technological problem is solved with the 
development of an artefact that works, or when the performance standards of an 
artefact are improved (Metcalfe, Boden 1992, p.60). Therefore, technological problem-
                                                
15  Polanyi (1962) analysed the role of tacit knowledge. This type of knowledge that can't be 
easily articulated is embodied in skills and is accumulated through experience. 
16  For a literature review on the body of research developing theory on the distinctiveness 
and complementarities of science and technology see Metcalfe (1998, pp. 108-111). He 
starts by discussing the traditional linear model of innovation, which considers technology 
as merely applied science and science as the driver of technological change. This 
perspective served as rationale for public science investments for at least three decades 
after the publication of the Vannevar Bush Report “Science – The endless Frontier” in 
1945. In the 1980s a new body of research established an alternative approach to the 
interactions of science and technology recognising their different and independent nature. 
According to this perspective, both science and technology contribute to economic growth 
and the role of science and technology policy is to support their interaction. 
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solving is subject to a test which is shaped in an economic or social context. On the 
other side, scientific explanations are judged by the truthfulness of the knowledge in 
explaining observed phenomena under specified conditions.  
For these reasons technology is not applied science (Pavitt 1987). Technologies can 
exist without science (because we may be able to make a fire without understanding 
the fundamentals of combustion processes). Therefore, technology and science are 
independent bodies of knowledge. In some cases science contributes to technology 
development by guiding technological problem solving (Nelson 1982), even though 
scientific results can't be applied by users at no cost. For instance, companies willing to 
apply scientific results need, at least, to cover the costs of employees with the capa-
bilities of understanding those results and adapting them to the specific processes and 
products of the firm (Pavitt 1987; Nightingale 1998, 2004). Moreover, there is strong 
empirical evidence sustaining that interaction between science and technology varies 
across industries (Grupp, Schmoch 1992; Meyer-Krahmer, Schmoch 1998). Finally, 
technology may also complement science (even stimulate it) by providing it with new 
phenomena to be explained or with new engineering solutions unveiling new questions 
for scientific research (Nelson, Rosenberg 1993, p. 9; Rosenberg 1990). 
2.3.1 General principles to characterise technology  
The issues discussed above raise the challenge of drawing general principles that 
characterise technology and of deriving implications for the analysis of technological 
change. Since the 1980s, the evolutionary perspective of technological change has 
produced valuable contributions to the understanding and conceptualisation of tech-
nology. From this perspective and in general terms, technology is specific, complex 
(which makes it unpredictable), cumulative in its development and frequently tacit.17 
Technology is specific 
Most technological activity is carried out in firms where intentional research and de-
velopment tries to improve products and processes. Consequently, firms aim at 
accumulating codified knowledge and skills and articulate them in new product or 
process artefacts (or in improvements of artefacts that already exist). There is strong 
empirical evidence for the similarities of the knowledge base of firms within the same 
industry (Pavitt 1998). However, the articulation of firms' knowledge bases into useful 
technological solutions leads to artefacts with different characteristics across firms. In 
                                                
17  See for example Pavitt (1987) or Metcalfe (1998). This section is largely inspired by these 
contributions. 
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other words, each firm has a more or less unique way of transforming inputs into 
outputs. At the level of the industry the specific nature of technology is not so obvious, 
however, the closer we get to the firm and to the product, the more specific technology 
is. 
Technology is complex 
To reproduce its imposed function technology draws on the combination of different 
bodies of knowledge from different sources. There interaction "makes things work". A 
strong implication of complexity is ex-ante uncertainty in the application of technology 
(Dosi 1982), which makes an early assessment of either the performance or utility of an 
innovation impossible. To capture this characteristic of technology, Nightingale (2004) 
refers to the unpredictability of technology. 
Efforts to advance technology are to a large extent "blind" because, even though 
research and experimental activities devoted to improve technological solutions have 
an intention and draw on a large body of different types of knowledge; whether the 
efforts to articulate the interaction of knowledge will be successful from a technological 
and/or economic point of view remains uncertain. Success is determined through ex-
post competition, after technology is confronted with alternatives. 
Technology is cumulative in its development 
As already mentioned, most technological activity is carried out by profit-seeking firms. 
They carry out technological activity by building up incrementally from what they 
already know. Their technological experimental activity is therefore constrained by what 
they have learned in the past. In many cases this constraint can be loosened with the 
contribution of firm's extramural knowledge base (which involves knowledge and 
experiences of firms they purchase or they collaborate with and knowledge available 
from university research and public research institutions). Even though technological 
activity may not necessarily result in a better solution, experimental processes 
enhances firm's existing knowledge base.18 In the words of Nelson and Winter, "the 
result of today's searches is a natural starting point for the searches of tomorrow" 
(Nelson, Winter 1982, p. 257).  
                                                
18  Accordingly, even though innovative effort may have diminishing returns in the short run 
(as performance improves it takes progressively more effort to achieve further 
improvements), the additional knowledge created through the experimental processes 
becomes part of the knowledge available for the next periods and, in the long run, the 
process of technical advance becomes less demanding in terms of effort (Metcalfe, 
Georghiou 1998, p. 116). In other words, the long run can be characterised by increasing 
returns to expenditures in research and development. 
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Partial tacitness of technology 
Technology can not be completely codified. While many elements of design and 
problem-solving activity may be easily articulated and even public (such as scientific 
inputs), the specific transformation of these elements into useful technological solutions 
(product or process artefacts) is largely tacit and hard to imitate. Technologies can be 
hence characterised in terms of their degree of "tacitness" versus "publicness". 
Technological accumulation therefore involves learning through experience, example 
and training, especially if the degree of tacitness is large. As technology becomes 
easier to articulate (i. e. less tacit), the extent to which it can be transferred and 
reproduced increases. 
Once the cumulative, firm-specific, complex and tacit nature of technology are 
recognised, technology can't be considered as generally applicable, easy to reproduce 
and reuse. Technology development, whether in terms of knowledge or in terms of 
artefacts, is costly. Users and adopters may have to undertake technological 
modifications or obtain additional knowledge in order to use or integrate a technology in 
their production processes. Even borrowers of technology need to develop their own 
skills and make their own expenditures on research, development and production 
engineering to be able to reproduce technology's imposed function properly. Inventing 
around other people's patents can not be done at no cost. Innovation and imitation are 
often indistinguishable, both in their inputs and in their outputs (Nelson, Winter 1982). 
Consequently, technological change can't be conceptualised as a process in which 
firms help themselves from a stock of technological knowledge freely available to find 
technological solutions. Neither can technological change be considered a random 
process. Observed patterns of technological change account for a certain ordered 
nature and, moreover, search and discovery activities around a technological problem 
are relatively limited to a small subset in the space of technological solutions that a 
technician can think of (Dosi 1988a).  
Given these considerations, and taking into account that technological change is the 
result of interactions among individuals, populations and environments over time, the 
following section discusses the process of technological change from an evolutionary 
perspective. 
2.4 Technological change from an evolutionary perspec-
tive 
In non-planed economies most technological activity is carried out in incentive driven 
organisations which conduct trial and error experiments (sometimes guided by 
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scientific knowledge) in order to solve technological problems or to improve existing 
technological solutions. Technological activity may provide organisations with high 
rewards as long as they are able to develop successful innovations. Consequently, 
competition in technological activities is to a large extent innovation driven. 
Traditionally the so called "technology push" and "demand pull" theories have  
attempted to explain the drivers and patterns of technological change by focussing 
either on the supply factors shaping new technological opportunities to be exploited 
(such as scientific development) or, alternatively, on the needs of users and bene-
ficiaries of technology as main drivers of technological activities.  
Dosi (1982) points out that both approaches have different understandings of the role 
of market signals in the process of technology development and, moreover, they fail to 
provide a theoretical framework for technological change.  
On the one hand, the demand-pull approach implies a-priory recognition of the needs 
of technology users (Mowery, Rosenberg 1979). This assumption contradicts the 
uncertain nature of technology discussed above. Even if technology developers were 
able to identify a priori the needs of technology users, the range of products or 
processes satisficing their needs may be unknown. Even in the best case - that is, if 
these artefacts were known - the scientific and socio-economic environment might set 
strong constraints to develop them. Technological solutions are not readily available 
(Rosenberg 1976, p. 63). In other words, market signals alone are not able to drive 
technology development. 
On the other hand, the technology-push approach is not reconcilable with the obvious 
fact that socio-economic factors (and not technological and scientific conditions 
exclusively) are important in shaping the direction of the innovation process. Users of 
technology, for instance, have a strong influence on the path of technological change. 
To conciliate the independence of technology development from socio-economic 
mechanisms (suggested by the technology push approach) and their relevance 
shaping technological change (suggested by the demand-pull approach), evolutionary 
economists point out that technological change does not happen at once, it is rather a 
gradual process. Tentative models aiming at explaining this process should consider 
that technological change involves firstly the emergence of possible technological 
solutions (in other words, the generation of variety or the establishment of a set of 
alternative technological solutions to solve a problem). This process is followed by 
further selection procedures in a socio-economic context that limit the set of alternative 
solutions, determine their relative importance over time and the direction of 
technological development. 
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From an evolutionary perspective in capitalist economies technological change is a 
complex dynamic process of search for possible technological solutions and selection 
among them. In the generation of variety (i. e. the search of possible technological 
solutions) profit-seeking actors operate in a wider institutional matrix. This matrix 
involves institutions and mechanisms shaping the variety creation process by 
determining the set of technological solutions or opportunities available. Accordingly, 
elements such as beliefs of technicians, experience, skills, scientific explanations, 
theories, etc. shape the search process of technicians when the technological solutions 
are emerging. This is the phase of technology emergence or variety creation. After the 
set of technological solutions has been created, socio-economic forces shape what we 
could call the ex-post selection process (since the technological options are jet known) 
by stimulating specific solutions, rewarding their developers and, in consequence 
hindering the development of alternative technological solutions. Moreover, the process 
of variety creation and technological selection ex-post influence each other in complex 
feed back mechanisms.19 McKelvey (1996) stresses that for technology developers the 
selection process is not deterministic. Since selection processes are fundamentally 
processes of social interaction between market forces, government decisions, public 
debate, and the state of relevant scientific knowledge, technology developers can not 
accurately predict what users want or what competitors will do. 
2.4.1 The emergence of technologies (or the search for alter-
native technological solutions and the creation of variety) 
In this framework, technological change involves first the exploration of alternative 
directions in which to search for novel technological solutions or technological 
improvements. However, this choice is not random. Technicians in their problem-
solving activities develop beliefs about what is worth attempting, or to which extent 
certain improvements may be feasible or not. This range of possible directions of 
development based on technicians' assessments has been called by Nelson and 
Winter a technological regime (Nelson, Winter 1977). Most importantly, technicians 
have their own specific understandings regarding the potentials (the boundaries) of 
these regimes.  
Within a technological regime some directions of technology development may appear 
more obvious than others. Nelson and Winter (1977, p. 57) called these sometimes 
almost "inevitable" development paths in the eyes of technicians natural trajectories. 
Nelson and Winter specified the following characteristics of natural trajectories:  
                                                
19  See for example Dosi (1982), Dosi (1988) or De Liso and Metcalfe (1996). 
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• Natural trajectories can be complementary;  
• While natural trajectories have special elements associated with a particular 
technology, certain natural trajectories can be common to a wide range of 
technologies (such as the progressive exploitation of economies of scale and the 
increasing mechanisation of hand operations); 
• Underlying the movement along natural trajectories is a body of knowledge. In some 
cases this knowledge is well articulated knowledge;  
• The extent to which scientific understanding can contribute to technology 
development along natural trajectories differs across industries. 
The contribution of Nelson and Winter is very broad and relies largely on technicians’ 
assessment to develop both the concept of technological regime (as scheme setting up 
the possible development paths of technology) and the natural trajectories technologies 
may follow on the ground of a regime.  
Building on the theoretical conceptualisation put forward by Nelson and Winter, and by 
drawing on an empirical analysis of the semiconductor industry, Dosi tries to be more 
specific in the identification of the factors shaping technician’s beliefs, their criteria to 
select among different technological solutions and the role of social, institutional and 
economic factors in guiding technological change. His starting point is an analogy with 
the notion of the scientific paradigm of Kuhn (1962). Dosi introduces the concept of 
technological paradigm.20 In simple words, Dosi's technological paradigms shape 
technological activity (which he presents as a problem-solving activity) by specifying 
the following elements: 
• The problem to be solved or the generic task to be accomplished; 
• The technologies involved; 
• The technological or economic dimensions experimentation should focus on. 
Most importantly, such paradigms embody guidance on the direction technological 
change should follow and on which technological options should be neglected. 
Accordingly, a paradigm is a focusing device; a set of heuristics embodying pre-
scriptions. These direct the search towards certain technological solutions and cause a 
degree of blindness with respect to potential alternatives. Examples of technological 
paradigms are the combustion engine, oil-based synthetic chemistry or semicon-
ductors. Dosi defines a technological paradigm "as a 'model' and a 'pattern' of solution 
                                                
20  Despite the broad analogy between science and technology Dosi explicitly states that the 
analogy should not be taken as an entity (Dosi 1982, p. 152).  
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of selected technological problems, based on selected principles derived from natural 
sciences and on selected material technologies" (Dosi 1982, p. 152).  
Given this set of rules defining problems and suggesting workable solutions, problem 
solving is supposed to follow a pattern which Dosi (1982, pp. 154-155) defines as 
technological trajectory. Technological trajectories present the following characteristics: 
• Trajectories might be more general or more specific as well as more or less powerful 
(in terms of the number of trajectories they exclude);  
• Trajectories can complement each other to the extent that developments in one 
technology may foster developments in other technologies;  
• It is possible to determine a technological frontier which corresponds to the highest 
level of the most relevant technological or economic dimension reached by a 
technological solution;  
• Technical progress retains some cumulative features in the sense that future 
advances may depend on the technological level reached vis-à-vis the existing 
technological frontier; 
• If the technological paradigm guiding problem-solving changes, the problem-solving 
activity has to be restarted almost from the beginning. For this reason it might be 
difficult to change from one trajectory to an alternative one;  
• Due to the uncertain nature of research and experimentation activities, the objective 
comparison of alternative technological paths can only be carried out ex-post (even 
if objective criteria or indicators are available). 
Dosi's work systematically develops the concept of technological regime proposed by 
Nelson and Winter by specifying the factors and mechanisms shaping technicians' 
assessment on the technological options that might be worth developing and the 
conditions determining the set of possible technological solutions. The concepts 
presented (technological regimes and paradigms) aim at identifying the elements 
guiding creative activities in the process of searching for technological solutions. Both 
approaches agree on the existence of focusing devices which shape the set of 
technological solutions firms are most likely to consider. In addition, it is suggested that 
firms' problem solving does not occur in isolation. In the process of searching and 
identifying potential technological solutions firms are embedded in a set of institutions. 
Firms draw on a set of knowledge, experiences, specific and uncodified capabilities 
and apply search modes. These elements guiding technological activity are shared and 
supported to a large extent by a body of actors.  
Furthermore, both approaches (the Nelson and Winter approach and Dosi’s approach) 
point out the complementary nature of technologies and their different degrees of 
specificity in the sense that some technologies can be apply to solve a large range of 
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different problems while others are specific to the problem under consideration. 
However, while Nelson and Winter remark the knowledge dimension of technology and 
the role of scientific knowledge in technology development, Dosi brings up the 
implications of the cumulative nature of technology development and the implications 
for experimentation in alternative directions. This cumulative aspect is directly related 
to the difficulty of adopting new technologies for problem solving instead of the ones 
already adopted in the past, even though the conditions for problem solving might have 
changed. 
2.4.2 Technology diffusion (or the ex-post selection mechanisms 
in the process of technological change) 
At a certain point, when the set of alternative technological solutions is better known by 
the institutions involved, the solutions undergo a monitoring process that determines 
their relative importance and the pattern of technological changed observed. Thus 
selection environments frame the processes of competition and technological accu-
mulation, determining the technological improvements that become innovations and 
their relative importance over time.  
They do this by monitoring technological solutions and rewarding technology 
developers that are better able to fulfil the criteria of the monitoring mechanism. The 
extent to which technology developers are capable to fulfil the selection criteria will lead 
to changes over time in the relative importance of the technological solutions. The 
process of technological experimentation and competition may persist until a dominant 
design emerges (Utterback, Abernathy 1975). A selection environment draws hence on 
the definition of "worth" or "merit" of a technological solution, the criteria according to 
which technological developers are rewarded or penalised. The users/beneficiaries of 
the technological solutions can play a key role in the selection environment since these 
may impose some restrictions to the technology and influence these criteria.  
Selection environments differ greatly in the structure of the demanders and monitors 
and in the manner and strength in which these mould and constrain the behaviour of 
firms (Nelson, Winter 1977). But most importantly, selection environments involve 
factors shaping investment decisions of firms (such as incentive structures) and 
conditions for knowledge sharing among firms (which may facilitate or hamper imitation 
and knowledge diffusion and influence the possibility of firms to appropriate the 
economic returns of their research and development efforts). An important phe-
nomenon influencing how selection environments shape technological change are 
externalities arising in the process of technology selection and development. These 
are, for instance, information flows, interdependencies among sectors, technologies 
 25 
and firms that result in inducements or constraints for the selection of technologies or 
for technology development in certain directions. Dosi (1988a) notes that "technological 
progress along any trajectory is linked with (a) the development of specific 
infrastructures; (b) system scale economies; (c) complementary technologies; and (d) 
particular technical standards that positively feed upon specific patterns of innovation" 
(Dosi 1988a, p. 1146). Dosi emphasises the influence of network externalities and 
increasing returns to scale on the direction of technology development. These ideas 
belong to the path-dependence perspective of technological change put forward by 
Paul David (1985) and Brian Arthur (1988).  
According to the path dependence perspective, once a technology is some what ahead 
of the others in the selection environment, a variety of factors will reinforce the de-
velopment of this technology. Moreover, this relative importance of a technology over 
the alternatives can become stable since these factors can influence the choice for one 
technology in future periods. If this occurs, the process is said to be path dependent. 
Arthur (1988) identifies the following sources of path dependence: (a) learning by 
using; (b) network externalities; (c) scale economies in production; (d) informational 
increasing returns; and (e) technological interrelatedness. 
To sum up, after the set of possible technological solutions is known it undergoes a 
monitoring process based on the definition of worth or merit determined by the 
selection environment where firms compete to seize innovation opportunities. The 
monitoring process selects which technological solution develops further and diffuses. 
However, this endogenous competition of technologies and problem-solving methods 
in the selection environment is influenced by network externalities and forms of 
dynamic increasing returns. For instance, the development of particular technologies 
and the development of specific problem solving-methods increase the capabilities of 
firms in these specific directions, increasing the incentives to do so in the future. 
Experience and incentives of firms in the selection environment are hence important 
factors determining technological change. The same holds for the existence of 
complementary technologies or standards. These elements may prevent firms to 
deviate from established technological solutions and from experimenting along 
alternative technological trajectories. 
2.4.3 Taxonomies of technological change 
The exploration of the impact of technological change on organisational, institutional 
and socio-economic environments has motivated empirical and theoretical studies to 
suggest more or less established taxonomies or different types of technological change 
according to the nature and degree of its impact. This section summarises the main 
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theoretical conceptualisations which provide qualitative criteria to explore the nature of 
technological change.21 These approaches can be classified in three blocks:  
(i) approaches focusing on the direction of technological change and on the changes in 
its paradigmatic basis, (ii) approaches exploring the impact of technological change on 
the environment for innovation and the consequences for the profit-seeking 
organisations carrying out technological activities and (iii) approaches exploring the 
impact of technological change on the whole economy. 
2.4.3.1 Taxonomies focusing on the direction of technological change 
and on its paradigmatic basis  
Dosi, for instance, refers to two main types of technological change: technological 
change along the same technological trajectory guided by the set of rules of a 
technological paradigm and extraordinary technological attempts related to the search 
for new technological directions and the establishment of new technological paradigms. 
The first ones can be motivated by technology-push and demand-pull factors in 
interaction or in isolation. The latter emerge either in relation to new opportunities 
opened up by scientific developments or to the increasing difficulty in going forward on 
a given technological direction (for technological, economic reasons or both). Changes 
in the socio-economic environment (demand-pull mechanisms) usually are not able to 
establish new technological paradigms (Dosi 1982, p. 157). De Liso and Metcalfe 
(1996, pp. 79-80) note that in many cases a new paradigm does not replace or 
overcome the previous ones: old and new technological paradigms can coexist. It is 
only their relative degree of economic and social application that determines the extent 
to which a technological revolution occurs. Moreover, due to the artefact and 
knowledge dimension of technologies, it is difficult to distinguish between incremental 
and revolutionary forms of technological change. A radical change in the knowledge 
dimension of technology may be articulated in incremental changes in the artefact 
dimension (since the articulation of the new forms of knowledge into artefacts may 
need a time lag or require new communities of practitioners to articulate the new 
paradigm). 
2.4.3.2 Taxonomies focusing on the impact of technological change on 
organisational capabilities 
Focusing on the artefact dimension of technology and using empirical material from the 
minicomputer, cement and airline industries, Tushman and Anderson (1986) explore 
                                                
21  Empirical contributions have also developed quantitative methodological approaches to 
capture the nature of technological change and innovation. For a detailed see Grupp 
(1998, chapter 3). 
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the impact of technological change (new or improved product and process artefacts) on 
the environment for innovation.22 They put forward the differentiation between 
incremental technological changes versus technological discontinuities.  
Incremental technological changes are continuous improvements of established pro-
duct or process artefacts. In this sense, they reinforce the established technical order. 
They occur through the interaction of many organisations, in most cases driven by the 
prospect of economic returns. On the other hand, technological discontinuities are far 
reaching advances, dramatic technological shifts that incorporate a major competitive 
progress compared with alternative technologies. Technological discontinuities can be 
competence enhancing (in the sense that build on existing know-how and result in 
over-magnitude improvements and increases of efficiency in the established core 
technology) and competence destroying (in the sense that the emerging technological 
advances are so fundamentally different from previous dominant technologies that the 
skills and knowledge base required to operate the core technology shift). Tushman and 
Anderson (1986) attempt to demonstrate that technology evolves through periods of 
incremental change punctuated by technological breakthroughs that either enhance or 
destroy the competence of firms in an industry. Competence-enhancing technological 
breakthroughs are initiated by existing firms and are associated with decreased 
environmental turbulence, while competence-destroying technological breakthroughs 
are initiated by new firms and associated with increased environmental turbulence. 
Henderson and Clark (1990) explore different types of technological change in terms of 
their impact on the capabilities of the firm. Their unit of analysis is a manufactured 
product. By choosing a systems perspective they distinguish between the product as a 
whole (the system) and the product in its parts (the components).23 Accordingly, 
successful product development requires two types of knowledge, component 
knowledge on the particular components and architectural knowledge on the ways the 
components are linked together. In this framework the traditional categorisation of 
technological change as either incremental or radical is incomplete. Henderson and 
Clark (1990) propose 4 types of technological change:  
(i) Radical innovation: it establishes a new dominant design, a set of new 
components linked together in a new architecture; 
                                                
22  They focus on three aspects of the environment for innovation: the degree of uncertainty, 
the opportunities for economic growth and the entry and exit rate of firms in an industry. 
23  Component is defined in the sense of Clark (1985) as “a physically distinct proportion of the 
product that embodies a core design concept and performs a well-defined function” 
(Henderson, Clark 1990). 
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(ii) Incremental innovation: it improves or extends an existing design. Individual 
components might be refined but the underlying core design concepts and the 
links between them remain the same; 
(iii) Modular innovation: it changes the core design concepts of a technology (such 
as replacement of analogue with digital telephones) without changing the 
product architecture; 
(iv) Architectural innovation: it reconfigures an established system to link 
components in a new way. 
In line with Tushman and Anderson (1986), Henderson and Clark (1990) suggest that 
radical innovations destroy the usefulness of the existing capabilities of established 
firms while incremental innovations tend to reinforce their positions. Architectural 
innovations present a challenge for established firms since the firm’s component 
knowledge may be very valuable but the architectural knowledge available in the 
organisation may handicap the firm. Due to the fact that architectural innovations are 
not as explicit as radical innovations, organisations may have difficulties in capturing 
the true dimension of the innovation and acquiring the new architectural knowledge that 
it needs. 
Finally, Abernathy and Clark (1985) have drawn a distinction between innovation that 
challenges the technical capabilities of an organisation and innovation that challenges 
the organisation’s knowledge of the market and of customers needs. 
2.4.3.3 The impact of technological change on the whole economy 
From a broader perspective than the approaches presented above, and attempting to 
explore the impacts of technological change on the economy as a whole, Freeman and 
Perez (1988) introduce a taxonomy of innovations based on empirical work carried out 
at the Science Policy Research Unit (SPRU) in the United Kingdom. According to them, 
innovations (technological improvements that are rewarded in a selection environment) 
can be incremental, radical, they may involve changes of the technology system or, 
with their stronger impact, involve changes in what Freeman and Perez call the 
"techno-economic paradigm". 
In the framework of Freeman and Perez "incremental innovations" occur more or less 
continuously. They are not the result of deliberate research activities but improvements 
suggested by those involved in production or by users. These innovations contribute to 
productivity growth but can't have dramatic effects. "Radical innovations" on the other 
hand are usually the result of a deliberate research activity. They often combine pro-
duct, process and organisational innovation, bringing about productivity improvements 
together with structural change (in the sense that they usually largely stimulate 
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industrial activity and large flows of investments such as the development of nylon or 
oral contraceptives). However, unless they occur together with other radical 
innovations, they have no impact on the aggregate economy as a whole as in the 
development of the semiconductor or synthetic materials industry. These so called 
"changes of the technology system" are further reaching changes that affect several 
branches of the economy and give rise to entirely new sectors. Some of the changes in 
the technology systems are so far reaching that they influence drastically the behaviour 
of the entire economy. Changes in the so called "techno-economic paradigm", as 
Perez (1983) suggests, are very broad, reaching beyond technological trajectories or 
new directions of research (as captured in Dosi´s concept of new technological 
paradigm). Thus, a new "techno-economic paradigm" affects the input cost structure, 
conditions for production and distribution and modes of growth throughout the system, 
influencing the technological capability and limitations of the economic system, 
organisation forms of firms and forms of cooperation and competition (Freeman, Perez 
1988, pp. 45-57). 
2.5 The firm in the process of technological change 
The body of neo-Schumpeterian research exploring technological change in the last 
30 years has provided comprehensive theoretical explanations suggesting that the  
aggregate pattern of technological change that has been discussed in the previous 
sections draws on mechanisms at lower levels of aggregation such as the level of the 
organisation. From this perspective firms are the carriers of technologies and the 
driving force behind innovation. 
The seminal work of Nelson and Winter introduced in section 2.1 was a tentative of 
explaining how the strategies of heterogeneous firms in the pursuit of competitive 
advantage are significant factors determining the rate and direction of technological 
change (Nelson, Winter 1982). 
2.5.1 Theory of the firm in the Nelson and Winter approach 
Drawing on organisational and behavioural concepts (such as bounded rationality and 
satisficing behaviour) developed by March and Simon (1958) and Cyert and March 
(1992), the main assumptions of Nelson and Winter regarding the behaviour of the firm 
deal with the question of why firms do what they do, or in other words, which are the 
factors shaping firms’ decision-making.  
In the Nelson and Winter framework, firms are heterogeneous profit-seeking actors 
aiming at improving their position vis-à-vis their competitors. In this context, the 
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possible behaviour of a firm is determined by its so called "routines". Routines may be 
considered as collective rules or procedures that programme the behaviour of firms 
over which the selection environment will operate. Rather than the result of opti-
misation problems, strategies are hence shaped by these behavioural and cognitive 
regularities.24 Agency can influence the evolution and implementation of routines. 
However, rather than a "maximising" behaviour (as proposed by orthodox economic 
approaches) agents, in their decision-making process, display what Nelson and Winter 
called "satisficing" behaviour (Nelson, Winter 1982, p. 211). Even though firms aim at 
enlarging their profits, their decisions are not the result of a profit-maximisation 
analysis, since firms do not have enough information to optimise solutions (incomplete 
information on their environment) and are not able to compute alternatives (due to 
uncertainty and complexity inherent to the process of technological change). Under 
these conditions firms try to develop more effective means of production, or solutions to 
technological problems, relative to their current practice and relative to the practice of 
the industry. Moreover, firms have an incentive of applying modes of problem solving 
that have been successful in the past (in the sense of "good enough" rather than 
optimal). 
Routines store hence essential information of the organisation which are remembered 
(or transferred between individuals). Due to the context-dependence of the problem-
solving activity and the influence of firm's collective experience, routines have a path-
dependent character. Accordingly, they provide some stability of behaviour, making it 
to some extent predictable. However, routines only depict potential patterns of firm 
behaviour over time. The complex and unpredictable environment where firms are 
embedded determines (ex-post) the firms' behavioural patterns we observe. The 
current characteristics of firms and their strategies to articulate knowledge into useful 
artefacts are hence the expression of firm’s routines in their competitive environment 
(Nelson, Winter 1982, pp. 134-136).25 In an evolutionary framework, those firms whose 
behaviour is best suited to prosper in the environment become dominant, and with 
them, their problem-solving schemes. 
                                                
24  As pointed ou by Becker (2004) the concept of "routine" as Nelson and Winter proposed it 
is not associated with the every-day meaning of the term in many languages. Variation and 
change are phenomena that are not in opposition to the concept of routines.  
25  Despite the enormous impact of the notion of firm's routines in various disciplines, the 
concept of routine remains unclear. For a discussion on this issue see for example 
Cohendet and Llerena (2003). Becker (2004) presents a review of the literature that has 
contributed to develop the notion of routines, what they are and the effect they have on 
organisations. 
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A large number of contributions have further developed the theory of the firm 
suggested by Nelson and Winter. These theoretical and empirical frameworks have 
brought about a large body of literature and the proliferation of terms and concepts that 
can be clustered under the so-called organisational capabilities approach or 
knowledge-based theory of the firm.26  
2.5.2 The knowledge-based view to the theory of the firm 
This section discusses the role of firms in shaping technological change at the 
aggregate level from the perspective of the knowledge-based view of the firm. Under 
this framework the firm can be defined through its knowledge base and is considered 
an organisation aiming at generating and applying knowledge (Grant 1996). 
2.5.2.1 The building blocks of a firm's knowledge base 
The body of literature drawing on Nelson's and Winter's concept of routines has 
introduced further terms conceptualising the knowledge base of the firm. These are 
mainly "organisational capabilities", "core competencies" and "skills".  
According to Dosi et al. (2000), capabilities are know-how (embodied knowledge) that 
enables organisations to perform activities such as designing a new product, offering 
services or organising a marketing campaign. In a pharmaceutical company, capa-
bilities are the forms of embodied organisational knowledge that account for the 
organisation’s ability to identify and develop new pharmaceuticals. With regard to the 
differences with routines, capabilities are usually larger units of analysis in the sense 
that routines are the building blocks of capabilities. Moreover, routines do not usually 
have an explicit purpose, while a main feature of a capability is the output that it is 
supposed to enable. In this sense, a capability is shaped by a conscious decision in its 
development and deployment and involves organised activity. A routine does not.  
Prahalad and Hamel (1990) speak of core competencies instead of capabilities. 
According to Dosi et al. (2000), the concept of core competence is narrower than the 
concept of capability since it covers only the areas of “hard technology". The know-how 
required for accomplishing activities such as logistics, marketing or distribution are not 
included in the concept of competencies.  
                                                
26  According to Foss (2003) the organisational capabilities approach comprises capability, 
dynamic capability, and competence approaches as well as the evolutionary theory of the 
firm. In a recent contribution, Foss and Klein (2005) refer to this body of literature as the 
knowledge-based approach of the firm. 
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Finally, individual skills are knowledge at the level of the individual. The skills of the 
organisation are the collectivity of skills possessed by individuals in the organisation 
and represent the building blocks of the organisational routines.  
2.5.2.2 Accumulation of knowledge for technological change: Organisa-
tional learning 
In creating, acquiring and adapting knowledge over time, organisations are performing 
something that in the management literature is referred to as organisational learning. 
Inspired by a group of contributions that stressed the role of knowledge in the 
absorption and generation of new technologies by firms, Malerba (1992, pp. 847-848) 
advances a conceptualisation of learning by firms with the following propositions: 
(i) Learning is a costly and targeted process that takes place within the firm;  
(ii) Learning is linked to different sources of knowledge that might be either internal 
or external to the firm. The different sources of knowledge can be accessed with 
different types of learning processes; 
(iii) Learning is a cumulative process increasing the firm's stock of knowledge. The 
type of learning process determines the types of knowledge that can be 
accumulated through time;  
(iv) The firm's specific stock of knowledge generates mostly local and incremental 
innovations. 27 
From the second proposition Malerba derives a taxonomy of learning processes which 
can be grouped in two main categories: learning internal to the firm and learning 
external to the firm. The taxonomy is presented in Table 2. 
Table 2:  Taxonomy of firm's learning processes 
Learning internal to the firm Learning external to the firm 
• Learning by doing • Learning from advances in science 
and technology 
• Learning by using • Learning from inter-industry spill-overs 
• Learning by searching • Learning by interacting 
Source: Malerba (1992) 
                                                
27  Malerba (1992) draws on contributions to the knolwedge-based approach such as Cohen 
and Levinthal (1989), Teece (1986) and Winter (1987) among others. 
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Learning internal to the firm is related to activities taking place within the firm and 
related to production (learning by doing), to the use of products, machinery and inputs 
(learning by using) or mainly related to formalised activities aiming at generating 
knowledge such as research and development. On the other hand, learning external to 
the firm is related to the absorption of new developments in science and technology, to 
what other actors in the industry are doing or to the interaction with suppliers, users or 
other firms in the industry. The knowledge-based approach of the theory of the firm 
views interaction as a channel to exploit complementary assets and to create new 
capabilities.28 
The distinction between tacit and codified knowledge introduced in section 2.3 is  
essential in the context of organisational learning. The ability of firms to integrate 
knowledge outside their boundaries decreases the higher the degree of tacitness of 
knowledge.  
2.5.2.3 Firm's performance in dynamic environments  
In the knowledge-based approach, firms are different because they have different 
knowledge bases and different strategies to articulate their knowledge into innovations. 
An important consequence of the difference in knowledge bases across firms is that 
(even though firms may interact in the same industry and face the same signals) firms 
can interpret the signals differently and develop different patterns of actions (Cohendet 
et al. 2001). A relevant issue for firm strategy is the extent to which firms are able to 
interpret the signals and react adequately. 
To stress the cognitive differences between firms in the way they perceive signals from 
their environment (or from their current technological regime in the sense of Nelson 
and Winter or technological paradigm in the sense of Dosi), interpret them and react to 
reach their business objectives (given the companies' technological capabilities), 
Metcalfe and Boden (1992) put forward the concept of "strategy paradigm", which 
                                                
28  In the last two decades at least 3 theoretical approaches have focussed on the role of 
cooperations in the innovation process. Transaction cost economics (Williamson 1985), the 
knowledge-based approach of the dynamic capabilities of the firms (Teece, Pisano 1994) 
and network theories (Håkansson 1989; Powell et al. 1996) agree that cooperation plays a 
central role in the innovative process. However, these theoretical frameworks present 
different rationales for collaboration. Both transaction cost economics and the dynamic 
capabilities perspective present collaboration as an alternative to internalising activities 
within the firm. The first focuses on cost reduction and opportunism arguments whereas 
the latter on the exploitation of complementary assets. On the other side, network theories 
present collaboration as an asset and not as a substitute for in-house activities. They argue 
that the knowledge gained within the innovation network can hardly be generated with 
existing firm capabilities, especially in fast evolving sectors. 
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relates to the competitive process at the level of the organisation. Firms competing in 
the same technological regime articulate their knowledge in different ways, take 
different bets. The crucial role of the strategy paradigm of a business unit is hence the 
generation of hypotheses at the interface of a selection environment and the 
technological capabilities of the firm (Metcalfe, Boden 1992, p. 65). In contrast to the 
notion of technological paradigm introduced in section 2.4.1, the strategy paradigm is 
firm specific and is embodied in the decision-making process of the firm by establishing 
the technological alternatives that can be considered, the technological options and the 
implementation model to develop them. The behaviour of firms in a dynamic 
environment is hence very much determined by their strategy paradigm.29 
For Teece et al. (1997) a firm's success in competitive environments depends on the 
bodies of knowledge within the firm that differentiate it from its competitors strategically 
and are difficult to imitate. Therefore, the innovative opportunities of a firm are rather 
constrained by the set of firm-specific assets. As we have seen, according to Tushman 
and Anderson (1986) in a dynamic environment technological change can enhance or 
destroy firms' competencies. In some cases firm-specific assets can boost up 
development and incremental innovation as long as (after the shift) the industry 
remains in the same technological regime; or in other words, as long as the 
technological advance reinforces the established technological order. However, if these 
are technological discontinuities, firm-specific assets can foster incumbent inertia not 
only because these are difficult to change (since the adjustment may require a strong 
mobilisation of resources), but because firm-specific assets reflect accumulated 
behaviours and beliefs based on early corporate success that shape organisational 
culture and norms (Leonard-Barton 1992). 
Theoretical contributions suggest that, under such circumstances, the innovative 
strength of the corporations in dynamic environments draws on their ”combinative 
capabilities”, i. e. the ability to acquire and synthesise knowledge resources and build 
new applications from those resources (Kogut, Zander 1992). Similarly, the "dynamic 
capabilities" approach, emphasises the ability to integrate, build and reconfigure 
internal and external competencies as the key to address rapidly changing 
environments (Teece et al. 1997).  
If we consider the work of Cohen and Levinthal (1990), the strength of the combinative 
or dynamic capabilities of a firm draws probably on how firms equilibrate and 
complement external and internal learning processes. With the concept of "absorptive 
                                                
29  Also Witt (1999) stresses that firms can shape the cognitive structures of their employess 
by imposing them business conceptions that guide their problem solving strategies.  
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capacity" Cohen and Levinthal put forward the interrelation of these types of learning 
and their relevance for firms competing in rapidly changing knowledge environments. 
Absorptive capacity refers to the firm’s ability to recognise the new technological 
opportunities and assimilate them. The important aspect of this concept is that 
absorptive capacity is a function of the knowledge of the firm. In other words, the extent 
to which firms are able to articulate knowledge from internal and external sources into 
useful innovations depends on firms’ knowledge bases. Moreover, considering that 
firm’s ability to acquire new knowledge and develop new capabilities is not independent 
from the history of the firm, absorptive capacity is hence path-dependent (Dosi et al. 
1992). We can conclude that firms which have been able to perceive and integrate 
changes in their knowledge environment in the past are more likely to be able to do so 
in the future. 
These contributions focusing on the role of firms shaping technological change are only 
a short review of the extensive literature in this subject from the knowledge-based view 
of the firm. However, due to the diversity of concepts and authors shortly discussed, 
the presentation demands a brief paragraph stressing the main ideas: 
(i) From an evolutionary perspective firms are the carriers of technology. Firms 
display the novelty that is monitored in the selection environment introduced in 
section 2.4.2. In this process, due to the uncertainty and complexity inherent to 
the innovation process, the way firms do things is not part of a maximising 
exercise. 
(ii) An important aspect of the knowledge-based view of the firm is heterogeneity. 
Firms are different because they embody different knowledge bases and have 
different strategies to articulate their knowledge into specific artefacts.  
(iii) In their problem solving activities firms draw on internal and external sources of 
knowledge. Accordingly, the process of knowledge accumulation (organi-
sational learning) can be external and internal to the firm.  
(iv) Firms compete in dynamic environments and perceive signals from their 
environment in different manners and react as well differently. Their knowledge 
bases and their abilities to perceive and react to their environment build on 
experience.  
(v) Experience and knowledge accumulation allows firms to develop capabilities, 
competencies and skills that distinguish them from their competitors. However, 
in dynamic environments these firm-specific assets may need to be recon-
figured to adapt to the new conditions. In this case, the ability to recognise new 
knowledge sources and integrate them is essential for firm's competitive 
strength. This ability is not independent from the history of the firm. 
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2.6 Simulation models to explore technological change 
2.6.1 Simulation models in socio-economic research30 
In simple words, computer implemented simulation models are artificial environments 
defining entities and relations between them which aim at representing real dynamic 
phenomena. However, a model of a real phenomenon remains a simplified, idealised 
and approximate representation of the phenomenon under consideration. The con-
struction and analysis of simulation models can be applied (i) to understand and 
explain (ii) to forecast and (iii) to support decision-making. However, in socio-economic 
research the goal is understanding qualitative developments and pattern formation 
rather than developing accurate models from a quantitative perspective. In general 
terms, the use of simulation models allows researchers in socio-economic fields to 
explore dynamic phenomena including stochastic processes. Moreover, research may 
require the exploration of non-linear systems that can not be solved through analytic 
reasoning. In this case numerical approaches are effective tools for experimentation in 
socio-economic research.  
Figure 1:  Logic of simulation  
 
Source: Drawn from Gilbert and Troitzsch (1999, p. 16) 
Figure 1 sketches the logic of simulation. The implementation of a model and the 
simulation require the definition of a target, in other words, the specification of a 
phenomenon to be represented and explored by the model. In socio-economic re-
search the target is dynamic. Usually the definition of a target entails hence the 
development of a theory of how the process works. Given the target, the model is the 
                                                
30  This section is largely based on Gilbert and Troitzsch (1999, Chapter 2) 
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result of an abstraction and formalisation process that specifies (i) the relevant entities 
of the phenomenon, (i) their relationships (which may include random elements) and 
(iii) their change over time. The process of formalisation involves being precise in the 
definition of the entities and their relationships. However, complex models may require 
the development of assumptions regarding the way specific processes involved 
occurred or in terms of the parameters (input values). Input values may need to be 
assumed, not measured. Nonetheless, the logic of how the phenomenon occurs needs 
to be complete and coherent. Next, through real data gathering, empirical observations 
need to be collected that describe the output of the processes of interest or behaviour 
to be explored.  
Through simulation the model should hence be able to reproduce the collected real 
data. If not, the model needs to be improved by better specifying and formalising the 
entities involved and their relationships. In some cases the improved specification of 
the model may require further empirical research and analysis of the real phenomenon. 
Accordingly, the process of model building, before the simulation experiments are  
carried out, entails already a process of improving researcher's understanding of how 
real phenomena work. This process does not end until the model can be relied on to 
reflect the behaviour of the target. Therefore, the data collected from the target (the 
real data) are the reference to validate the model. If the model includes random 
elements it is necessary to keep in mind that computers work with pseudo-random 
numbers and the result of just one simulation run is not reliable. Therefore it is 
necessary to test whether the results are robust with respect to different random 
values. Once the model is validated, a sensitivity analysis is carried out by varying 
selected parameters of the model and observing the differences in the outcomes. The 
aim is to find out whether the behaviour of the simulation model is sensitive to the 
assumptions that have been made. 
2.6.2 Value of simulation for the evolutionary approach to 
technological change 
The potential of simulation models to explore economic growth and technical change 
has been emphasised by evolutionary scholars. The development of computer-
implemented simulation models has been indeed an important factor fostering the 
wave of neo-Schumpeterian evolutionary modelling (Kwasnicki 1999, pp. 20-21; Dosi, 
Nelson 1994, p. 154). The usefulness of simulation models builds mainly on their ability 
to deal with the complexity of the evolutionary process of technological change, its 
fundamental uncertainty and the requirement to consider heterogeneity between firms. 
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To illustrate how complexity influences the analysis of evolutionary processes we draw 
on social theoretical investigations. Gilbert (1998) points out how, even if the behaviour 
of individuals may follow very simple rules, their interactions can create systems of 
great complexity (Gilbert 1998, p. 11). Complexity can be linked to the existence of 
emergent properties in economic and innovation processes.31 In capitalistic econo-
mies, industries, for instance, have emergent properties because, even though their 
existence draws on the interaction of firms, the interesting properties and patterns of 
development (such as size distribution of firms or the relative importance of 
technologies) can't be described from the perspective of the individual agents 
interacting in them. The properties of the industry are the output of decentralised 
behaviour of individual firms. They flow from the mechanisms at the micro level, which 
might involve stochastic processes. However, the subject of analysis is not the 
individual firm but rather the industry.  
Pyka and Faggiolo (2005) translate this concept to neo-Schumpeterian economics by 
describing socio-economic systems as systems with micro-macro relationships. 
Figure 2 sketches such a system that could be used to analyse a process of 
technological change (i. e. the changes in the relative importance of technologies over 
time). 
Figure 2: System with micro-macro relationships  
Macro level
Micro level
Legend
Technological
Capabilities  Firms Collaboration  
                                                
31  “Emergence occurs when interactions among objects at one level give rise to different 
types of objects at another level. More precisely, a phenomenon is emergent if it requires 
new categories to describe it which are not required to describe the behaviour of the 
underlying components” (Gilbert 1998, p. 12). 
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The micro-level contains heterogeneous entities (firms for instance) with different 
characteristics (such as the stock of capabilities in two different technologies 
represented in the figure with dark and light squares). Repeated interactions among 
these firms and their performance in a selection environment change the micro-
economic patterns (their stock of capabilities in each technology). The aggregation of 
these micro patterns generates macro dynamics for the aggregate variable of interest 
(capabilities of the industry in each technology represented in the figure with a dark and 
light square in the macro level). The behaviour at the macro level is generated from the 
behaviour of entities at the micro level. The behaviour at the macro level is hence an 
emergent property.  
The problem of processes presenting emergent properties is their exploration. 
Computer-implemented simulation models can be given the necessary structure to link 
the interaction of heterogeneous agents to the development of variables at a higher 
level of aggregation (such as the industry or the economy) (Lane 1993a; Lane 1993b). 
Given that from an evolutionary perspective, in decentralised economies firms are the 
carriers of technology, the exploration of technological change at the industry level 
involves the exploration of a system with micro-macro relationships. 
If we consider the nature of technology we must also outline the fundamental element 
of uncertainty in the process of technological change. As pointed out in section 2.3, an 
implication of the complexity of technology is the ex-ante uncertainty in its application. 
However, as Dawid (2004, p. 5) points out, uncertainty not only flows from the 
unpredictability in the articulation of different bodies of knowledge into useful artefacts, 
but also from the reaction of competitors to the new artefacts. Also Dosi (1988b) puts 
forward that innovation involves “the search for new products, new production 
processes and new organisational set-ups”. By definition the outcome of the search 
activity can not be predicted before the exploration has started. This fundamental 
uncertainty does not come from lack of information but mainly because the impossibility 
of “precisely tracing consequences to actions” (Dosi 1988b, p. 222). As discussed in 
section 2.5, to make constraints on computability explicit and to restrict the information 
of the agents to what is available evolutionary modelling takes a behavioural view with 
rule-based decision-making processes. Simulation models can be design to 
incorporate sets of rules to determine investment or technology adoption decisions 
(Dawid 2004, pp. 5-6). 
As discussed in section 2.5, technological change (with regard to the relative 
importance of technologies in industries or economies) is an aggregate behaviour 
drawing on the heterogeneity of knowledge and capabilities held by different firms in an 
industry. Firms drive innovation to distinguish themselves from their competitors or to 
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imitate them hoping to improve their position in the selection environment vis-à-vis their 
competitors. Consideration of heterogeneity of firms seems essential to understand the 
processes governing technological change. Simulation models can be designed to 
include heterogeneous agents with different strategies (in which heterogeneity is not 
only induced by differences in the endowments of firms but also by differences in 
behaviour) without having to reduce the analysis to a representative agent (Dawid 
2004, p. 6). 
2.6.3 The Nelson and Winter simulation models 
As already pointed out in section 2.1, the strand of new evolutionary economics has 
increasingly relied on computer simulation models to explore economic processes. The 
work of Nelson and Winter (1982) was a strong impulse in this direction. This seminal 
work included the joint efforts of the authors to explore macroeconomic patterns 
breaking with heterodox assumptions on firm behaviour such as rationality, perfect 
information and optimising behaviour. Their assumption of macroeconomic properties 
flowing from microeconomic behaviour of agents was the basic reason for the 
necessity of using computer simulation models (Nelson, Winter 1982, pp. 207-208).  
In their seminal contribution Nelson and Winter (1982) present an evolutionary model 
of economic growth (chapter 9) and a model to explore the interactions among market 
structure, R&D spending, technical change and certain firm's behavioural rules relevant 
for the process of improving production techniques (chapter 12) in an industry 
producing an homogenous good. The latter has been called a model of "Schum-
peterian competition".  
The firm is the key unit in the specification of their models. However, the interesting 
processes to be explored occur at the level of the population (the industry). The 
condition of the industry at any moment t is described by the capital stock and the 
behavioural rules of each firm (which involve the productivity of capital). Through 
search and selection processes the firms evolve over time, changing the productivity of 
capital. However, search and selection are stochastic processes. The firm's investment 
rate determines the stochastic realisation of a change in productivity of capital. In other 
words, investment rates in period t determine the probability distribution for innovation 
and hence the productivity of capital in period t+1. Moreover, it is assumed that the 
state of the economy prior to period t does not influence the transition probability 
between t and t+1 (Nelson, Winter 1982, p. 19). 
Successful innovations increase productivity and tend to enhance the profitability of a 
firm. Accordingly, firms compete to develop the best technology. The market introduces 
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selection forces which apply to those firms who are less profitable, or, in other words, 
to those firms who are not able to keep up with the pace of technological progress of 
their competitors. Firm's profitability determines whether firms expand or contract.  
The key idea behind the transition mechanism from one state of the industry to the next 
one in the Nelson and Winter models is that the state of the economy in any period 
determines the probability distribution of the state of the economy in the next period. 
The models contain hence a complete specification of the transition from the state at t 
to the state at t+1 which has the character of a stochastic Markov process. 
The consideration of different scenarios characterised by different scenarios of 
conditions for innovation (such as different degrees of difficulty of imitation, speed in 
the growth of knowledge or degree of variety of innovations) or firm's strategies (in 
terms of investment rules of firms) allows evaluating the extent to which technological 
change and industry concentration are sensitive to the scenario considered. 
Nevertheless, certain aspects are highly simplified. For instance, firms never adapt 
their decision rules. This aspect was improved by Winter (1984) who extends the 
Nelson and Winter approach by specifying adaptive innovation strategies (in terms of 
spending in innovative and imitative research and development) and firm entry. 
Moreover, innovation probabilities in the Markov process only depend on current 
investments. There is neither accumulation of research investment nor explicit role for 
knowledge accumulation at the firm. Llerena and Oltra (2002) develop the Nelson and 
Winter approach to include this aspect. Firm's innovation probabilities depend on the 
stock of accumulated knowledge rather than on current investment. Also Pyka (Pyka 
1999) develops an approach specifying spill-overs and the role of firm's absorptive 
capacity to integrate them in the innovation process. 
Finally, the representation of technological change is very rudimentary. The Nelson and 
Winter models do not specify how research and development funds result in pro-
ductivity increases. 
2.6.4 Evolutionary history-friendly modelling 
The Nelson and Winter models have had great influence on evolutionary modelling. 
Following the theoretical and methodological approach of Nelson and Winter, and in 
some cases extending it in different directions, the field of new evolutionary economics 
has advanced since the 1980s in the development of general theory of economic 
growth and industrial dynamics. Important followers of Nelson and Winter are among 
others Winter (1984), Silverberg et al.(1988) and Silverberg and Verspagen (1994).  
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Evolutionary simulation models have been able to generate plausible patterns of 
economic growth or changes in the concentration of industries. However, there has 
been little effort to use simulation models to generate hypothesis about technology 
development and to test outcomes against historical experience in a rigorous manner 
(Ruttan 2001, p. 107). On the other side, the neo-Schumpeterian strand embracing 
Institutional Economics and recognising the range of institutions involved in 
technological change has elaborated a large body of empirical and historical case 
studies (Nelson 1995). As already discussed in section 2.2, even though this strand of 
neo-Schumpeterian contributions lacks mathematical abstraction, it explicitly explores 
the role of institutions in shaping technological change, economic growth and 
differences between regions, countries and industries. 
Attempting to fill up the gap between formal modelling to build general theories and 
empirical analysis of specific cases, Malerba et al. (1999) put forward the history-
friendly model approach. In this framework simulation models aim at reproducing 
observed patterns of socio-economic change. Most importantly, the theory under-
pinning the models draws on empirical regularities (i. e. stylised facts) and verbal 
causal relationships (i. e. appreciative theory) explicitly considering the role of insti-
tutions in shaping the phenomena under exploration. 
In their approach Malerba et al. (1999) develop appreciative theorising as suggested by 
Nelson and Winter (1982, p. 46). The appreciative theory of a phenomenon is the 
verbal logic explaining it with causal arguments and descriptive explanations. History 
friendly models draw hence on appreciative theorising and include (i) a set of stylised 
facts characterising the phenomenon to be explored, (ii) verbal logic on how the 
processes occur, (ii) formal representation of the verbal logic in a model and (iii) the 
implementation of a numerical computer simulation replicating the phenomenon 
explored.  
In the history-friendly framework, formal modelling should be considered firstly as an 
attempt to asses the consistency of the verbal arguments that constitute the 
appreciative theory. This assessment involves, on the one side, verifying that the 
model can generate the historical patterns observed. On the other side, assessing the 
consistency of the appreciative theory involves testing whether parameter settings 
contradicting the accepted stylised facts yield to "history divergent" results (Malerba et 
al. 1999, pp. 4-5). Given the consistency of the appreciative theory, the models can be 
validated and used as experimental environments to explore the same phenomenon 
under different conditions (Orsenigo 2003). 
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To sum up, history-friendly model building attempts to reconcile formal and appre-
ciative theorising of economic evolution. It requires firstly the identification of stylised 
facts describing a phenomenon of interest and the understanding of the factors and 
mechanisms shaping the processes observed. How these factors and mechanisms 
shape the process observed needs to be articulated with verbal arguments. Secondly, 
the verbal arguments are formalised in a model and implemented in a computer 
simulation in order to replicate the patterns observed. Even though the specification 
and parameterisation of history-friendly models is largely based on empirical findings 
(i. e. stylised facts of highly qualitative nature), the architecture of the models is similar 
to the Nelson and Winter type of models. The firms, their behavioural rules and the 
transition dynamics defining the evolution from state t to state t+1 (including selection 
mechanisms and stochastic processes) constitute the fundamental structure of the 
models. 
2.6.5 Examples of evolutionary history-friendly models 
Evolutionary history-friendly models developed so far focus on issues of industrial 
dynamics. The phenomena considered refer to changes in terms of concentration, 
firm's entry and exit and the formation of hybrid forms of industry structures such as 
networks. In their first attempt Malerba et al. (1999) centre their approach in the 
computer industry and the changes in its structure since the 1950s. Using the same 
methodological framework, Malerba and Orsenigo (2002) explore the factors and dy-
namic processes accounting for the evolution of the pharmaceutical industry and 
biotechnology. Pyka and Saviotti (2005) develop a history-friendly model representing 
the emergence of a new industrial organisation in the so called biotechnology-based 
sectors (pharmaceuticals, agriculture, food, environment etc.).  
Before elaborating the issues concerning a history-friendly model of technology 
adoption and technological change in the pharmaceutical industry, the next paragraphs 
describe briefly the main aspects and results of the modelling efforts that have already 
applied the history-friendly approach. 
With regard to the history-friendly model exploring the computer industry, Malerba et al. 
(1999) start by elaborating an appreciative theory of how the industry has evolved, in 
particular the transitions of the industry in terms survival of incumbent firms and 
success of new entrants as new technologies emerged in the industry (from transistor 
to microprocessor technology) and new markets emerged (from mainframe computers, 
minicomputers through personal computers). The new technologies had a competence 
destroying effect in the market segments where a few dominant firms held the stronger 
market shares. New firms enter the industry carrying the new technologies and opening 
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up new market segments. The "old" established leaders will manage to enter the new 
markets segments but will not be able to sweep away the newcomers nor to reach the 
strong positions they held in their original market. 
After elaboration of the verbal logic involving factors and mechanisms shaping this 
process, the next step is the development of the simulation model and its imple-
mentation. The authors formalise the following aspects nested in the competitive 
dynamics of industries: 
• Interacting heterogeneous firms, their investment and price decisions and the 
evolution of their technological capabilities. The representation of firm behaviour is 
very simple, relying on fix percentage investment rules. Firms' strategies are 
assumed to be fixed; 
• Adoption of new technologies by incumbent firms and their diversification into new 
markets. These actions follow simple probabilistic rules; 
• Different user types of computers shaping different market segments. 
Finally, by considering empirical observations from the computer industry in a highly 
qualitative way (i. e. stylised facts, the authors choose a set of parameter values 
(difficulty of market entry, technology adoption and diversification costs, customer 
sensibility to quality etc.) to run the model and try to “replicate” the historical patterns 
observed in terms of industry structure and firm entry during the transition from one 
technology to another (from transistor to microprocessor technology). In order to test 
the logic of the appreciative theory the model is based on, the authors specify a set of 
parameters that produce ‘history-divergent’ results. This exercise brings insights to the 
mechanisms shaping the evolution of the computer industry, especially the role of 
demand, and the conditions for technology adoption, market diversification and firm 
entry in the structure of the computer industry. In a latter contribution Malerba et al. 
(2001) extend their descriptive analysis to explore the effect on the market structure of 
antitrust measures in the computer industry and of several measures to support firm 
diversification and firm entry as new markets emerge. 
In their exploration of the pharmaceutical and biotechnology industries Malerba and 
Orsenigo (2002) identify stylised facts largely based on the experience of American 
pharmaceutical companies. Drawing mainly on the American experience, their 
appreciative theory (or verbal account of the changes in the industry) establishes 
3 major epochs: the period between 1850 and 1945 (in which little new drug de-
velopment occurred and minimal research was conducted with primitive methods)32, 
                                                
32  In Europe, especially in Germany, the industrialisation of research and development in the 
pharmaceutical industry occurred already in the first quarter of the 20th century. German 
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the period between 1945 and 1970 (characterised by the institution of industrial R&D 
laboratories and faster rates of new drug introduction based on random screening 
procedures) and the period after the 1970s (which was characterised by the influence 
of molecular biology in research and the transition from a different search regime in 
drug discovery: drug discovery by design). The key aspects defining the specification of 
their model are: 
• The absence of economies of scale and scope in pharmaceutical innovation. 
• The exogenous "advent of science" which enlarges the opportunities for innovation 
and introduces a technological discontinuity. The technological discontinuity is 
specified exogenously through the variation of the possible behaviour of incumbent 
pharmaceutical firms in their innovation activities and allowing for the entry of 
companies with the ability to exploit the new opportunities for innovation.  
• Biotechnology firms challenge the industrial position of large pharmaceutical com-
panies. The incumbent pharmaceutical companies do not react immediately to the 
discontinuity; they learn gradually and seize collaborative arrangements with the 
new entrants. 
Their analysis concentrates on the role of market fragmentation and the level of 
opportunities for innovation (before and after the technological discontinuity) to explain 
the observed patterns of industry evolution (in terms of industry concentration). Even 
though the model introduces some aspects of a science-based industry, the relation-
ships between science and innovation, the role of scientific knowledge and the process 
of knowledge accumulation within the firm to develop capabilities for innovation are not 
included in the model specification. Using highly qualitative data to set the parameters 
and define the probabilistic distributions the history-friendly model replicates key 
historical features of the industry structure and dynamics such as low degree of 
industry concentration and weak impact of the emergence of the biotechnology industry 
in the concentration of the pharmaceutical industry. This is mainly due to the inability of 
biotechnology companies to replace incumbent pharmaceutical firms and the 
development of collaborative arrangements between large pharmaceutical firms and 
biotechnology companies. 
The contribution of Pyka and Saviotti (2005) develops a history-friendly model 
replicating the emergence of networks in the so called biotechnology-based sectors 
(pharmaceuticals, agriculture, food, environment etc.). Their analysis focuses on the 
importance of knowledge generation and accumulation featuring the biotechnology 
field. Based on the empirical findings and on the existing case studies on the 
                                                                                                                                            
dyestuff companies developing drugs followed science-based strategies in their drug 
discovery processes (see section 3.4.2). 
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biotechnology-based sectors, the authors develop a formal representation of the 
development of the industry structure. The authors admit that the analysis leaves open 
the issue of the asymmetries among countries and the different roles Dedicated 
Biotechnology Firms (DBFs) may play in each region. The results give insight to: 
• The two roles of the DBFs as translators (to cover the competence-gap of the 
established companies at early stages) and explorers (to investigate the scientific 
fields that established companies are not willing to enter in an irreversible way); 
• The existence of innovation networks in the biotechnology-based sectors as stable 
phenomena and efficient forms of industrial organisation against the traditional 
dichotomy between the market and hierarchical organisations. 
2.7 Towards a history-friendly model of technological 
change and technology adoption in the German 
pharmaceutical industry 
The evolutionary history-friendly models introduced in the previous section are bottom-
up approaches exploring industrial dynamics. In other words, by specifying the 
behaviour of heterogeneous firms at the micro level and the competitive environment 
where they interact, the models explore the structure of the industry over time in terms 
of degree of concentration and network formation. Malerba et al. (1999) and Malerba 
and Orsenigo (2002) introduce technological change in the history-friendly models by 
allowing for entry of firms in the industry mastering a new technology and changing the 
conditions for innovation. Incumbent firms can adopt the new technology or not. 
Apart from important assumptions at the organisational level (such as rejection of 
maximising behaviour and the implicit specification of routines), the evolutionary aspect 
of history-friendly models of industrial dynamics lies on the exploration of industry 
evolution with specification of search and selection mechanisms involving random 
processes. Moreover, the transition dynamics from the stage of the industry at time t to 
the stage at time t+1 are specified (implicitly) through Markov processes.  
The analogy between these models of industrial dynamics and biological evolution is 
sketched in Table 3. While history-friendly models of industry evolution choose the 
population of firms as unit of evolution, this contribution proposes a history-friendly 
model of technological change. Accordingly, as sketched Table 3, the unit of evolution 
is the body of technological capabilities constituting the pharmaceutical industry. The 
unit of selection is the firm (as carrier of technological capabilities). Firms will hence 
face a selection environment where they are rewarded (or not) according to their 
adaptability to the environment. Inspired by the theory of the firm suggested by Nelson 
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and Winter (see section 2.5), firms' adaptability will be determined by the expression of 
their routines in the selection environment. 
Table 3: Levels of aggregation in evolution  
Level of  
aggregation 
Biology Industrial 
Dynamics 
Technological Change 
Unit of  
variation 
Genotype 
(units accumulating 
and transferring 
information) 
Routines 
(behavioural and 
cognitive regularities 
storing and transferring 
information) 
Routines 
(behavioural and cognitive 
regularities storing and 
transferring information and 
building up the technological 
capabilities of the firms) 
Unit of  
selection 
Phenotype  
(organisms) 
Firms Firms  
(as carriers of technological 
capabilities) 
Unit of  
evolution  
Pool of genes Population of firms 
constituting industries or 
national economies 
Cumulative body of  
technological capabilities 
constituting industries or national 
economies 
Source: Adapted from McKelvey (1996) 
The evolutionary analogy can be represented by a system with micro-macro 
relationships as the one give in Figure 3.33 
Figure 3: Micro-macro relationships in a model of technological change 
Unit of evolution
Cumulative body of technological
capabilities in the industry
Unit of selection
Firms (as carriers of
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In the history-friendly model of technological change proposed in this contribution, the 
phenomenon to explore is the relative importance of capabilities in two technologies 
                                                
33  See section 2.6.2 for a short elaboration on systems with micro-macro relationships. 
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(synthetic organic chemistry and biotechnology) in the aggregate level of capabilities of 
the German pharmaceutical industry over time. This phenomenon is the unit of 
evolution in Figure 3, where the capabilities of the industry in each technology are 
represented with a dark and a light square. Taking the neo-Schumpeterian perspective 
that the aggregate pattern of technological change draws on mechanisms at lower 
levels of aggregation such as the level of the organisation, the exploration of 
technological change demands hence the consideration of heterogeneous firms as 
carriers of technologies. German drug producers are considered the heterogeneous 
agents carrying technologies, interacting and facing a selection environment (i. e. unit 
of selection in Figure 3). Firms are heterogeneous because they have different 
"routines" (behavioural and cognitive regularities, in simple words modes of carrying 
out their business and of managing their research and development activities). As a 
model of technological change, the focus lies on the technological capabilities firms 
apply to adapt to their environment and on the processes underpinning the 
accumulation of these capabilities. Capabilities are represented in Figure 3 with a dark 
and a light square in each firm and determine, to a large extent, adaptability to the 
competitive environment34. Due to the science-based character of the pharmaceutical 
industry, the development of technological capabilities to discover and develop 
medicines draws on the understanding and application of scientific results. Therefore, 
the knowledge environment of the firms (i. e. firms extramural knowledge base) and its 
dynamics plays an important role in the process of technological change we are 
exploring. 
Taking this basic structure as staring point to define the phenomenon to explore, the 
next step is the specification of how the knowledge environment changes and how 
firms interact to acquire knowledge and develop capabilities. History friendly models 
specified these elements on the ground of appreciative theorising. Accordingly, an 
empirical analysis identifies stylised facts of the industry and describes the observed 
pattern of technological change.  
In this contribution the empirical analysis to develop an appreciative theory will 
concentrate firstly on the study of the environment where firms interact and 
subsequently on firms' strategies for acquiring and developing technological capa-
bilities to adapt to the requirements imposed by the selection environment. The 
analysis will focus on the following aspects of the German pharmaceutical industry: 
(i) The knowledge environment shaping technology development; 
                                                
34 The nature capabilities is discussed in section 2.5.2.1. 
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(ii) The implications of changes in the knowledge environment for the conditions for 
innovation in the pharmaceutical industry;  
(iii) Firms' strategies to integrate knowledge and develop technological capabilities. 
With regard to the first aspects concerning the knowledge environment of firms, the 
concepts of technological regimes and technological trajectories put forward by Nelson 
and Winter (1977) and Dosi (1988b) introduced in section 2.4.1 provide a theoretical 
basis to explore the knowledge environment shaping technology development and the 
implications for the conditions for innovation in the pharmaceutical industry. Malerba 
and Orsenigo (1993, pp. 47-49) make these concepts operational for empirical analysis 
and define technological regimes according to the following dimensions:35 
(i) Innovation opportunity conditions: These refer to the effort needed to develop 
new successful solutions to a technological problem.  
(ii) Characteristics of the knowledge base underpinning technological change: The 
knowledge base of a technological regime can be largely tacit and firm specific, 
or rather codified and universal. Moreover, it can present different degrees of 
complexity in respect to the disciplines contributing to its development or in 
respect to the number of competences needed to develop technological 
solutions.  
(iii) Appropriability conditions: These reflect the extent to which firms are able to 
protect their innovations and appropriate the innovation rents (in other words 
the ease of imitation or the existence of knowledge spill-overs). 
(iv) Degree of cumulativeness of technological knowledge: Extent to which 
technology improvements within a technological regime demand experience 
and accumulation of knowledge.  
The empirical analysis focusing on biotechnology and organic chemical synthesis and 
on the extent to which they have shaped drug discovery and development should be 
able to identify these dimensions and their changes over time. Due to the difficulties in 
measuring these dimensions however, the analysis will be highly qualitative and asses 
the dimensions as been "high" or "low" in different periods of evolution of the 
pharmaceutical industry. Moreover, the empirical results should specify whether the 
dimensions differ across the trajectories under consideration: biotechnology and the 
organic chemical synthesis.  
                                                
35  Malerba and Orsenigo (1993) use the concept of technological regime to explore the 
adequacy of firm's strategies to the environments they operate in.  
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With regard to firms' strategies to integrate knowledge and develop technological 
capabilities to adapt to dynamic environments, the empirical analysis will take an 
organisational perspective. At this point the empirical exploration will draw on the 
theoretical concepts put forward in the presentation of the knowledge-based theory of 
the firm sketched in section 2.5.2. Accordingly, considering that firms are different with 
regard to their knowledge bases and their interpretation of the environment, the 
empirical effort will try first to gain insights on the knowledge bases of the German drug 
producers in terms of routines and capabilities and their changes over time. Next, 
drawing on the categorisation of firm's learning processes presented in Table 2 in 
section 2.5.2.2, the stylised facts should be able to characterise firms' patterns of 
internal and external learning in the processes of accumulating technological 
capabilities. Finally, the appreciative theory will explore the ability of industry 
incumbents in recognising changes in their dynamic knowledge environment. Given 
that the phenomenon to explore deals with technological change in a science-based 
industry with strong discontinuities in its scientific knowledge base, the stylised facts at 
the organisational level should give insight to the processes shaping technology 
adoption by German drug producers after the advent of modern biotechnology in the 
1970s.  
After the empirical effort is accomplished and stylised facts are identified, the 
appreciative theory of technological change and technology adoption in the German 
pharmaceutical industry will be formalised in a model and implemented in a numerical 
computer simulation following the steps sketched in section 2.6.1. 
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3 An appreciative theory of technological change and 
technology adoption in the German pharmaceutical 
industry during the 20th century 
3.1 Introduction 
The aim of this chapter is to identify the main variables and causal relationships 
shaping technological change and technology adoption in the German pharmaceutical 
industry during the 20th century. In other words, the goal is to develop a verbal 
explanation of how the interesting processes have occurred. For this purpose the 
exploration draws on a literature review in the fields of history of technology and 
empirical industrial dynamics and innovation research. Moreover, the analysis uses 
quantitative and qualitative indicators to study selected issues. 
As discussed in chapter 2, from an evolutionary perspective the aggregate pattern of 
technological change that can be observed at level of the economy or at the level of the 
industry draws on mechanisms at a lower level of aggregation (such as the level of the 
firm) and on the features of the knowledge environment where firms conduct their 
profit-driven activities. Accordingly, the attempt of developing an appreciative theory to 
explain verbally the process of technological change in the German pharmaceutical 
industry during the 20th century demands the consideration of the complex interaction 
between (i) the knowledge environment shaping technology development, (ii) the 
industry (as selection environment) and the implications of changes in the knowledge 
environment for the conditions for innovation and finally (iii) the strategies of the firms 
to develop capabilities to accomplish their risk-taking and profit-driven activities in a 
dynamic knowledge environment. 
Therefore, to develop an appreciative theory of technological change, this 
chapter explores the German pharmaceutical industry in the 20th century from three 
perspectives: (i) the knowledge environment perspective, (ii) the industrial perspective 
and (iii) the organisational (or the firm) perspective.  
From the perspective of knowledge environment section 3.2 focuses on the 
development of two technologies (organic chemical synthesis and biotechnology) and 
their scientific knowledge bases. This short excursion in the history of these 
technologies does not intend to provide new insights on their emergence and 
development. The presentation draws on contributions to the history of technology and 
presents the main facts relevant for understanding the changes in the bodies of 
knowledge shaping their development and their influence in the German pharma-
ceutical industry. 
52  
Section 3.3 presents the evolution of the pharmaceutical industry in Germany with 
special attention to the changes in the knowledge base for drug discovery and 
development induced by the possibilities to apply synthetic organic chemistry and 
biotechnology. The exploration points out the successful innovative performance of 
German drug producers during the first half of the 20th century applying the principles 
of organic chemistry and the problems of the industry in adapting to the paradigmatic 
change towards the application of biotechnology in drug discovery and development 
after World War II. 
Finally, from the organisational perspective, section 3.4 explores the strategies for 
adjustment of the German drug producers to the changes in the knowledge base after 
the revolutionary discoveries in molecular biology in the 1970s. The analysis presented 
considers the historical conditioning of the adjustment of firms to this technological 
discontinuity taking into account that the German corporations active in drug discovery 
and production come traditionally from two different sectors: the traditional pharmacy 
and the coal-tar dyestuff industry. Until the 1950’s both sub-sectors of the 
pharmaceutical industry were different in their organisational capabilities, their product 
lines and most importantly their attitudes towards the application of biotechnology. 
Section 3.4 follows a case study approach combining qualitative and quantitative 
tools.36 
Section 3.5 closes the chapter with a short discussion of the main findings (in relation 
to the theoretical concepts introduced in chapter 2 and a presentation of the main 
issues to be explored in the history-friendly model to be developed in chapter 4.  
3.2 Tracing the development of organic chemical synthe-
sis and biotechnology 
The following are two basic definitions of chemical synthesis and biotechnology 
relevant for the exploration that follows: 
The chemical synthesis combines chemical elements or simple chemical com-
pounds to produce complex substances. 
Biotechnology is the application of scientific and engineering principles to the  
 
                                                
36  The chapter does not include the qualitative company case studies carried out for the 
analysis. It presents only the main qualitative findings and the empirical results. The 
qualitative case studies are included in annex I. 
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processing of materials by biological agents to provide goods and services (Bull 
et al. 1982).37 
According to the theoretical discussion in the previous chapter, a key characteristic of a 
technology is its imposed function. The technologies we are considering in this 
section have a common imposed function: the production of substances which can 
provide goods and services, however, while the organic chemical synthesis draws on 
the combination of chemical elements or simple chemical compounds to produce 
complex substances, biotechnology draws on the processing of materials by biological 
agents. For our purposes, this characteristic (the processing of materials by biological 
agents) is the main feature of biotechnology. Most importantly, this is the feature 
allowing us tracing a continuous (bio-)technology trajectory during the 20th century and 
beyond. This trajectory covers a large range of techniques ranging from fermentation 
processes in the 19th century to the application of recombinant DNA techniques 
developed in the 1970s. These techniques are presented in Table 4. 
Table 4: The biotechnological trajectory.  
 
1865 1940 1960 1975
• Fermentation
• Surface culture
• Aerobic 
sewage purification
• Biomass production
• Aseptic technique
• Submerge culture
• Animal tissue culture
• Microbiological 
metabolic reactions
• Microbiological
fabrication of polymers
• Immobilisation of Enzymes 
and Cells 
• Anaerobic sewage purification
• Alcoholic fermentation
• Hybridoma
Technology
• Genetic 
Engineering 
• Penicillin and other 
Antibiotics 
• Vaccines
• Cortison
Vitamin B 12,
• Ovulation inhibitors
• Wine, Beer, Cheese, 
Sourdough, Yoghurt, 
Vinegar
• Butanol, Acetone, 
Ethanol
• Citric acid
• Yeast
• Single cell proteins (SCP)
• Enzymes
• Polysaccharide
• Biogas
• Gasohol
• Monoclonal 
antibodies 
• Recombinant 
vaccines
• Recombinant 
proteins
Processes
Products
 
Source: Adapted from Fonds der Chemischen Industrie (1989). 
                                                
37  In a broad sense biological agents can be microorganisms, enzymes or plants. The agents 
may or may not be modified by genetic engineering. Among the several definitions of 
biotechnology this one proposed by the Organisation for Economic Co-operation and 
Development (OECD) has been influential in both academic and government circles and is 
the ground for the international statistics available on the development and application of 
this technology. 
54  
An interesting aspect of biotechnology and organic chemical synthesis is the strong 
influence that advances in different scientific disciplines and in engineering have had 
on the development and diffusion of these technologies. In their origins chemical 
synthesis and biotechnology were applied without any understanding of the processes 
underlying the transformation of chemical compounds or biological agents into products 
with desired properties. Technology application was an experimental trial-and-error 
process. Scientific and engineering advances during the 19th and 20th century have 
revolutionised these technologies by providing additional knowledge that has expanded 
their possibilities and improved their control. Krimsky (1991, p. 25) points out that the 
demarcation between analytic38 and synthetic chemistry is similar to the distinction 
between pre- and post-1970 biotechnology. With the development of organic chemical 
synthesis it became possible to produce unique compounds. With modern biotech-
nology, genetic information could be transferred to produce organisms with desired 
properties. However, the time path in which new forms of knowledge have shaped the 
technologies providing them with new possibilities has been quite different, influencing 
hence the periods of their development and diffusion. 
As regard to biotechnology, at the beginning of the 20th century the application of 
traditional biotechnology was an alternative to organic chemistry in the development 
and production processes of primary products. Despite the empirical nature of biotech-
nology, a large number of biotechnological processes had already been introduced in 
the industry. Waste water treatment, distillery, brewery, vinegar production, wine 
production, creamery, tannery, fertilizers, sugar production and production of organic 
acids were some of the fields and production processes where biotechnology was first 
applied. However, biotechnology (with its strong empirical character) could not 
compete with the development of the organic chemical synthesis (already drawing on a 
strong science base) and lost importance after World War I. The advent of the new 
scientific discoveries in the field of molecular biology in the 1950s changed the de-
velopment path of biotechnology. The interdisciplinary advances in its science base 
during the 20th century have provided the technology with new possibilities that have 
promoted its application in different economic sectors. 
On the other side, already in the late 19th century the chemical synthesis was guided 
by the scientific developments in organic chemistry and started to be applied by the 
dyestuff producers who developed strong scientific capabilities in organic chemistry. 
The application of the organic chemical synthesis was not only supported by its strong 
                                                
38  Analytic chemistry is a collection of techniques that allows exact laboratory determination 
of the composition of a given sample of material. 
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science base. The development of the Haber-Bosch process in the 1910s influenced 
dramatically the application of chemical synthesis and the focus of the chemical 
industry on the application of this technology to produce complex substances. The 
organic chemical synthesis dominated the processing of materials until the last quarter 
of the 20th century. These historical stylised facts matched remarkably well with 
historical  
patent indicators presented on Figure 4. 
Figure 4: Shares of biotechnology and organic chemistry-related patent 
documents in the total patent outcome 
0%
2%
4%
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Share of  biotechnology  in total patent outcome
Share or organic chemistry in total patent outcome
 
Sources: Own calculations using data from PLUSPAT and PATDPA from the vendor Questel39 
The next sections explore in detail the influence of the science base and advances in 
complementary technologies on the development paths of these technologies. 
                                                
39  Data: 5-year moving average of German patent applications filed at the German and 
European patent offices with Germany as designation country. The database PLUSPAT 
provides the back file patent documentation used by the examiners of the European Patent 
Office (EPO) in their examination processes. This documentation is retrospectively 
reclassified according to the latest European Patent Classification's (ECLA) revision. 
Accordingly, the PLUSPAT database offers a suitable research tool to cope with the 
reclassification problems that appear in historical time series of patent indicators. For 
methodological issues on the elaboration of historical time series of patent indicators see 
Dominguez Lacasa et al. (2003). 
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3.2.1 Organic chemical synthesis  
In the 18th century the chemical synthesis practice was carried out without a theoretical 
understanding of the chemical structure of the substances produced. Moreover, by the 
late 18th century the artificial production of organic substances by means of combining 
inorganic compounds seemed impossible.40 
Advances in the elemental analysis of organic substances provided chemists with new 
insights about their composition and properties. Especially the experiments of Lavoisier 
(1743-1794) gave impetus to a systematic analysis of organic substances. Further 
experimental results suggested that the chemical laws governing the composition and 
behaviour of inorganic substances could be applied to organic substances as well.41 
With the new discoveries organic substances lost their special status of being produced 
by an “intangible life force” and became the compounds of carbon. Most importantly, 
the new understanding of the composition of organic substances set the ground for 
their artificial production through chemical synthesis (by combining the right elements, 
organic and sometimes inorganic, in the right amount and under the right conditions).  
In 1846 the German chemists Frankland and Kolbe synthesised the organic compound 
acetic acid from inorganic substances that could be prepared directly from pure 
elements. After this discovery increasingly complex organic compounds were analysed. 
Already in the second half of the 19th century the synthetic structures of fruit and lactic 
acid were identified, and a large number of natural dyes, flavouring agents and the first 
medicines had been synthesised.  
Kekulé's discovery of the ring structure of benzene in 1865, advances in physical 
chemistry (concerned with the physical properties of materials, such as their electrical 
and magnetic behaviour) together with a successive creation of new institutes with 
modern laboratories and an increasing number of skilled chemists contributed to the 
development of the organic chemistry and its application for industrial purposes.  
Organic chemistry became the theoretical basis for the production of organic 
compounds available in nature (like benzene or ethylene) and its transformation 
through subsequent processing to obtain products with desired characteristics. The 
synthesis of organic substances was first applied for the production of dyes. Instead of 
                                                
40  The distinction between organic and inorganic substances was important since chemists 
assumed that organic compounds could only be produced by an “intangible life force” 
present in plants and animals (Schorlemmer 1979). 
41  Important chemists in this phase of development of the organic chemical synthesis were 
Gay-Lussac (1778-1850), Berzelius (1779-1848) and v.Liebig (1803-1873). 
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relying on the fortunate coincidence to discover new dyes, those producers skilled in 
organic chemistry had the possibility of imitating dyes that could be found in nature (or 
even inventing new ones). As pioneers of the application of the scientific principals of 
organic chemistry for industrial purposes, the dyestuff producers performed large 
investments in research and development that would determine their competitive 
capabilities in the years after (Andersen 1996).  
During the 20th century the application of organic chemical synthesis reached most 
sub-sectors of the chemical industry in Germany like the production of nylon and 
polyester fibres, the production of plastics, pharmaceuticals, and the production of 
artificial sweeteners. A technological breakthrough in engineering in the 1910s, the 
development and application of the Haber-Bosch process for the production of 
ammonia, influenced dramatically the application of the chemical synthesis (Hughes 
1975). With the high pressure synthesis of the Haber-Bosch process, the chemical 
industry intensified its strategy of chemically synthesising natural materials or replacing 
them by chemical supplements. The starting raw material was coal and Germany had 
enough coal reserves at that time. For instance, the IG Farben decided to specialise on 
coal-based products. By shaping the technological capabilities of the German chemical 
companies this breakthrough in engineering partly determined the technological 
orientation of the chemical companies towards the application of the organic chemical 
synthesis in all their segments (including pharmaceuticals) (Buchholz 1979; Marschall 
2000). 
3.2.2 Biotechnology  
Even though biotechnology needed to wait until the 20th century to have the status of a 
science-based technology, already in the 19th century it was applied in different 
industrial activities from the biological production of fertilizers up to the production of 
rubber, fuel, lactic acids and in waste water treatment. Biotechnology had the ad-
vantage of being an inexpensive production method that relied on the availability of 
carbohydrate-based raw materials. According to Marschall (2000), despite its empirical 
nature, the years between 1900 and the World War I were of most prosperity for the 
industrial biotechnology in Germany. The data given in Figure 4 support her 
assessment. 
The development of biotechnology during the 20th century to become the technology 
with the possibilities it has today is the result of the advance in understanding biological 
processes and of the development of a variety of skills and forms of knowledge to 
control them. These advances have provided a continuously growing knowledge base 
influencing the possibilities of the processing of materials by biological agents. 
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According to Abir-Am (2003), this development has come along with transdisciplinary 
research strategies to explore and control biological processes. 42 
All along the 20th century, biology has gone through a process of progressive 
colonisation by the so called exact sciences (i. e. chemistry, physics, mathematics, and 
engineering). Furthermore, this progressive colonisation has created hybrid fields or 
transdisciplinary outcomes which have found institutional stabilisation along the 20th 
century: first biochemistry, later on molecular biology, and at in the last quarter of the 
20th century genetic engineering.  
In the 19th century biotechnology relied on a scarce science base resulting from the 
alliance of biology, physiology and chemistry to explore biological and physiological 
problems with techniques of organic chemistry. Depending on whether the emphasis 
was on chemistry or biology, this alliance took different disciplinary formulations such 
as microbiology, bacteriology or biochemistry (Bud 1993, p. 7).  
The institutionalisation of biochemical research began in the early 20th century with the 
chemical investigation and explanation at the molecular level of biological processes 
such as growth, respiration, nourishment, digestion, movement, sensation and re-
production (Kamminga 2003). The studies focused on the role of enzymes, vitamins 
and hormones in biological processes. 43 
In the 1930s the crucial role played by enzymes in regulating and coordinating 
metabolic reactions generated enormous interest in the structure of these substances. 
It was soon learned that enzymes are proteins44. Because of proteins' involvement in 
life processes, the exploration and complete resolution of their chemical and spatial 
structures seemed to be holding a key to understand the processes of life (Kamminga 
2003). Due to the proteins' complexity, the problem of protein structure posed a 
                                                
42  According to Mittelstraß (2004) given a disciplinary order and a problem, the research 
strategies to solve the problem can be transdisciplinary in the sense that different scientific 
disciplines collaborate to solve it "resulting in a lasting and systematic order that alters the 
disciplinary order itself" (Mittelstraß 2004). 
43  Enzymes are protein molecules in plant or animal that affect the speed rate of specific 
metabolic reactions without being permanently altered or destroyed. They are responsible 
for bringing about all of the biochemical reactions in living organisms. Vitamins are organic 
substances that occur in many foods. They are necessary in trace quantities for the normal 
physiologic and metabolic function of the body. Hormones are biological substances that 
are produced by a certain cell or tissue and that cause a specific biological change or acti-
vity in another cell or tissue located elsewhere in the body (Morris 1992). 
44  Proteins are complex organic compounds. They are widely distributed in plants and 
animals being responsible for every function in the living cell (Morris 1992). They are 
involved in life processes including respiration, digestion, and reproduction. 
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transdisciplinary challenge, which required, among others, physical and physico-
chemical techniques, ranging from x-ray crystallography to the ultracentrifuge, 
electrophoresis, chromatography and electron microscopy. Even though proteins were 
the research focus of biochemists, the protein structure became a research object that 
could not be explored within the boundaries of biochemistry. The research question did 
not fit in the given disciplinary order because biochemists did not have tools to solve 
the spatial structure of proteins.  
The research problems (and the strategies to solve them) reinforced in the late 1930s 
the transition from the era of biochemistry to the era of molecular biology, which 
explored the structures of viruses, proteins and nucleic acids (DNA and RNA)45. 
Between the mid 1940s and 1960s scientists discovered that the form and the function 
of a living cell derive from the information enclosed in its DNA. Furthermore, scientists 
learnt how this information was processed in the cell in order to produce proteins with a 
certain function. The transition process reached its peak in the 1960s with the 
academic stabilisation of molecular biology (Abir-Am 2003). However, as we will see in 
the next sections there were major regional differences with regard to the 
institutionalisation process of molecular biology. 
Finally, in 1974 molecular biologists made public a new technological breakthrough, the 
phenomenon of artificially controlled recombinant DNA, which enabled the direct 
manipulation of the genetic material and the formation of new forms of life.46 In 1975  
scientists reported on the hybridoma technique and the production of monoclonal 
antibodies. These scientific techniques of genetic modification opened up the era of  
modern biotechnology, revolutionising the scientific knowledge base biotechnology 
draws on and its possibilities. These developments created enormous expectations for 
the industrial applications of biotechnology.47  
                                                
45  In simple words DNA constitutes the genetic material of living organisms, which is present 
in every cell of every living organism. Each gene in the DNA contains the information for 
the composition of a particular protein and the necessary signals for the production of that 
protein. The RNA is the nucleic acid in the cell responsible for decoding the genetic 
information of the DNA for producing the proteins. 
46  Recombinant DNA is a hybrid DNA molecule created by the in vitro combination of DNA 
from different sources. The recombinant DNA technology allows separating and 
recombining segments of DNA or genes (Morris 1992). 
47  Sharp (1995) presents a short but clear overview of the applications of biotechnology. Her 
contribution focuses on the biotechnology applications after the revolutionary discoveries of 
the 1970s. 
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3.3 Technological change in the German pharmaceutical 
industry during the 20th century 
After reviewing the development of chemical synthesis and biotechnology we face the 
challenge of capturing their relevance for drug discovery and development in Germany. 
Due to the great dependence of the pharmaceutical industry on the patent system for 
the appropriation of returns from research and development, the use of patent counts 
to capture the flows of codified knowledge in this sector seems to be adequate (Levin 
et al. 1987; Santos 2003). 
Based on counts of patent documents Figure 5 presents the extent to which organic 
chemical synthesis and biotechnology have shaped the research and development 
process in drug discovery and development. Despite the relative importance of 
biotechnology in pharmaceuticals in terms of the share in the patent counts at the 
beginning of the 20th century, chemical synthesis dominated the sector in the 1950s 
and 1960s and until the last quarter of the 20th century. The scientific discoveries in the 
field of molecular biology in the 1950s seem to influence the development path of these 
technologies. According to the data, since the 1970s biotechnology plays an important 
role in pharmaceuticals. The empirical evidence speaks for the strong and increasing 
influence of biotechnology in the development of pharmaceuticals in Germany, 
especially since the 1980s. 
Figure 5: Patent documents in pharmaceuticals. Shares of biotechnology and 
organic chemistry-related patents 
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Source: Own calculations based on data from the databases PLUSPAT PATDPA of the data
   base vendor Questel48. 
                                                
48  Data: German patent applications filed at the GPO and EPO with Germany as designation 
country. For methodological issues on the elaboration of historical time series of patent 
indicators see Dominguez Lacasa et al.(2003). 
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This pattern of technological change is the output of the interaction of the development 
of the firm's extramural knowledge base, the structure and competitive forces of the 
industry and government influences. The next paragraphs explore this interaction along 
late 19th and 20th centuries. The presentation draws on contributions to the de-
velopment of the pharmaceutical industry in general, without a national focus and on 
studies concentrating on the American pharmaceutical industry. Therefore, many of the 
general aspects discussed are not specific for the German experience. However, the 
analysis aims at highlighting those aspects relevant for the German case. The aim is to 
describe the environment German drug producers were facing in terms of knowledge 
base and conditions for innovation. 
Phase I (1880s-1950s): the establishment of the modern pharmaceutical industry  
Before the formation of the modern pharmaceutical industry in Germany in the last 
decades of the 19th century the process of drug discovery and development was 
carried out by apothecaries in small traditional pharmacies. The responsibilities of 
doctors and pharmacists were clearly defined. The German state guaranteed the 
pharmacists the responsibility of producing and commercialising the medicaments 
prescribed by the doctors. Already in the first half of the 19th century the analytical 
chemistry became the tool to isolate from plants those compounds with therapeutic 
character. Nonetheless, the successful isolation of these compounds and the 
(unexplainable) therapeutic effectiveness raised the questions of how to disseminate 
the drugs to as many persons as possible and how to make sure that the medicines 
had homogenous standards. Some of the apothecaries recognised the need for large 
scale production and standardisation measures. From the technical point of view there 
were no major constraints for the large scale production of the known compounds, 
however the lack of infrastructure for transportation limited the regional area the 
pharmacists could supply with medicaments. The traditional small pharmacies 
developed into medium size companies like Schering or E. Merck, which produced 
alkaloids and medicinal chemicals extracted from animals and plants. It was the first 
impulse towards the formation of the modern pharmaceutical industry in Germany. 
The second impulse towards the formation of the modern pharmaceutical industry 
came from the chemical sector. The largest German dyestuff producers were 
established between 1863 and 1873.49 They started their activities by copying the dyes 
of French and British manufactures. However, already in 1877 half of the dyestuff world 
                                                
49 Bayer Farbenfabrik (in the city of Wuppertal, 1863); Farbwerke Meister, Lucius und Brue-
ning (in Hoechst, 1863), Aktiengesellschaft fuer Anilin-Fabrikation -Agfa- (in Berlin, 1873). 
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production had German origin (Murmann, Landau 1998).50 During the 1880s the medi-
cinal effects of dyestuffs and other organic chemicals were discovered. German 
chemical companies such as Hoechst AG and Bayer leveraged their technical 
competencies in organic chemical synthesis to manufacture drugs (Marschall 2000). 
Besides the strong competencies in organic chemistry the chemical companies 
strengthened their competencies through intensive research collaborations with 
academic scientists. 
With the impulse from the dyestuff producers the German pharmaceutical industry 
became the largest source of medicinal innovations. Dyestuff firms (such as Bayer and 
Hoechst) and traditional drug producers (such as E. Merck and Schering) built up in the 
last decades of the 19th century the modern German pharmaceutical industry, which 
dominated the world market for new chemical drugs until World War I (Murmann, 
Landau 1998).  
This prosperous period of the German pharmaceutical industry matches with the 
foundation of drug research, which found its institutional setting in the industrial 
research laboratories of the German drug producers.51 In this period drug research 
was strongly influenced by the principles of the organic chemical synthesis. By the end 
of the 19th century analytic and synthetic chemistry had reached a high degree of 
maturity and were moving hand in hand with drug discovery and development (Drews 
2003). Many examples illustrate the alliance of organic chemistry and medicine. The 
origins of chemotherapy, for instance, drew on the search for chemical compounds, 
which had the ability of destroying pathogens and could hence be used against 
infectious diseases like bacterial infections and, later on, against fungal and protozoa 
infections. Additionally, the scientific principles of organic chemistry allowed the 
synthesis of hundreds of compounds in the laboratory that could be tested for 
therapeutic effects against parasites (source of infectious diseases) in animal models 
and systematically manipulated to reach desired properties (Issekutz 1971). Even 
though this strategy for drug discovery very much relied on serendipity, this random 
                                                
50  The dyestuff industry in Germany developed from the large scale production of illuminating 
gas. This production process produced a major by-product, the “coal tar”. This black mass 
seemed at first to have no significant industrial use; however it turned out to contain 
compounds of great interest for the production of dyes. Instead of being extracted from 
animal or vegetable sources, dyes could be developed "artificially" from the coal tar. This 
was the solution to satisfy the demand for dyes in the rapid growing textile industry at that 
time. 
51  In other regions such as in the US and in the UK, formal science entered the drug factories 
in the mid-20th century after the discovery of the therapeutic properties of penicillin 
(Henderson et al. 1999). 
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screening worked very well for the German companies for many years. The 
opportunities for innovation were large since the companies faced an open field where 
most therapeutic solutions were waiting to be discovered.52 Even though this strategy 
did not provide any biological understanding of the disease, drug discovery became an 
analytical process based on the accurate variation of the structure of organic 
compounds for designing and synthesising promising drugs. With chemotherapy 
diseases like syphilis or sleeping sickness could be treated with synthetic 
substances.53 In the 1920s substances against malaria and streptococcus were 
successfully synthesised. In the 1930s the medical effects of sulphonamide to treat 
bacterial infections (streptococcus or staphylococcus infections) were discovered.54 
Again, even though organic synthesis did not provide any understanding of the 
biological process by which sulphonamide was able to achieve a bacteriological cure, 
the discovery of sulphonamide started the era of antibacterial chemotherapy.  
Based on historical sources, Achilladelis (1999) points out that between 1880 and 1930 
the modern German pharmaceutical industry was the source of more than 50 % of the 
medicinal innovations. Until the 1930s the application of synthetic organic chemistry 
had led German drug producers to innovative products that relieved the symptoms of 
diseases rather than their causes. These types of drugs were analgesics and 
antipyretics. Later on, organic chemical synthesis led to drugs that fought against the 
disease-causing agents such as protozoa or bacteria. In the 1940s the structure of a 
large range of natural substances with antiseptic characteristics to treat bacterial 
infections was discovered and synthesised in the laboratory by organic chemists. 
Phase II (1950s-1970s): From random to guided drug discovery  
Parallel to the successful synthesis of innovative drugs, biotechnology was ex-
periencing a strong development, opening possibilities to understand biological pro-
cesses of diseases and to produce medicines with microbiological methods at a large 
scale. 
                                                
52  Achilladelis and Antonakis (2001) present data on innovation counts in the pharmaceutical 
industry since the 19th  century. According to their data German corporations were until 
World War II the major introducers of innovations in the pharmaceutical sector. 
53  Important substances of this type were Atoxil and Salvarsan. Salvarsan was the first 
effective chemotherapy. It was brought to the market by the German dye manufacturer 
Hoechst, with whom the scientist Paul Ehrlich collaborated. 
54  The first marketing drug of this type was called Prontosil. It was brought to the market by 
the German dyestuff manufacturer Bayer in 1932. 
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As discussed in section 3.2.2 since the 1930s biology was being transformed by the 
exact sciences. The alliance of biology, physiology and organic chemistry (bio-
chemistry) was providing new diagnostic procedures and means of intervening in 
disease processes at the chemical level (Kamminga 2003). Moreover, between the mid 
1940s and 1960, advances in molecular biology provided the screening procedures to 
search for substances that attack biological targets with certain selectivity (Drews 2003, 
p. 80). In other words, these first advances in molecular biology set the ground for the 
understanding of the mechanisms by which drugs affect the body and allowed latter to 
developed techniques of "rational drug discovery" or "drug discovery by design" 
(Henderson 1994, pp. 14-16; Gambardella 1995, pp. 23-25). 
Additionally, regarding the application of biotechnology in production processes, in the 
mid 1940s the development of bio-reactors offered unpredictable new possibilities. It 
was the beginning of the aseptic and aeration technique for the microbiological 
production at large scale. The development of the bio-reactor made the industrial 
application of microbiological processes possible (Metz 1995). 
The German pharmaceutical industry had difficulties exploiting the technological 
opportunities offered by the new scientific advances in the disciplines emerging from 
biology (such as microbial biochemistry and enzymology). For instance, after the 
properties of penicillin to treat bacterial infections had been discovered in the late 
1930s and its production by fermentation processes optimised, American and Swiss 
drug companies started to establish departments of microbiology and fermentation 
units. However, in Germany penicillin was only known from the scientific literature. Its 
therapeutic features were not very well known. Few research institutes and companies 
were carrying out research on penicillin production (Metz 1995). While in the 1940s 
American drug producers were producing penicillin to go through clinical trials German 
chemical engineers kept trying to synthesise sulphonamides for the treatment of 
bacterial diseases (Marschall 2000).55 
Especially in the USA, pharmaceutical producers embarked on a period of massive 
investment in research and development. This period of institutionalisation of science in 
the American pharmaceutical industry was supported by strong investments of public 
research organisations in medical research in the United States (Pisano 2002). The 
penetration of biochemistry, microbiology and molecular biology into drug research was 
responsible for the drug revolution that in the 1950s and 1960s produced an 
                                                
55  For a detailed historical analysis of the reasons why German drug producers disregarded 
the changes in the knowledge base underlying drug discovery in the 1940s see Marschall 
(2000, chapter 4.2). 
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abundance of new medicines such as psycho-pharmaceuticals, beta-blockers, calcium 
antagonists, diuretics, anaesthetics and anti-inflammatory preparations (Drews 2003).  
The German pharmaceutical industry lost its leading position after the World War II. 
According to Achilladelis (1999) this was not a consequence of the war damage since 
in other sectors of the chemical industry companies such as Hoechst and Bayer re-
emerged to become world leaders in the 1970s. In the pharmaceutical sector the 
weakness was mainly technological. After World War II, German drug producers 
restarted their activities with research and development strategies that had made them 
successful in the previous period and building on their chemical capabilities. In the 
1960s they were not building up capabilities, which would have allowed them to 
conduct  medical research on the function of hormones, the cardiovascular and the 
central nervous systems, anti-inflammatory drugs or vitamins (Buchholz 1979). 
Industry’s disregard for biotechnology research and development in the 1960s was 
accompanied by a weak commitment of German public research institutions and 
universities in the biotechnology-relevant scientific fields. Zarnitz (1968, pp. 83-84) 
analysis the research activities of German research institutes and universities in the 
1960s and identifies serious gaps with regard to the process of institutionalisation of 
molecular biology in German universities. Research fields such as protein research, 
cell and virus research, immune biology or molecular genetics at that time were mainly 
concentrated on selected institutes of the Max Planck society. However, according to 
Buchholz (1979), the biotechnology-relevant scientific developments and the industrial 
application of biotechnology in the 1960s occurred mainly in the Anglo-Saxon regions, 
in Switzerland, in Japan and in Sweden. Interestingly, Nobel prices in the fields of 
medicine and physiology in the period between 1946 and 1964 were granted for 
achievements in research on molecular biology. The national origin of the scientists 
was USA (6), Sweden (2), UK (7) and Germany (1) (Zarnitz 1968, pp. 54-55).56 
The knowledge base of the industry was changing mainly beyond the German borders 
and the German corporations were not able to match the advances of their competitors 
based on the application of microbiology, biochemistry and later on, of molecular 
biology. 
                                                
56  The figures in brackets represent the number of scientists with the given nationality. In 
some years the Nobel price was granted to more than one scientist. 
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Phase III (1970s-1990s): the era of modern biotechnology in the pharmaceutical 
industry 
Since the mid 1960s and during the last quarter of the 20th century the breakthroughs 
in molecular biology and the revolutionary discoveries of recombinant DNA and 
monoclonal antibodies radically changed the drug discovery and development process. 
Their contribution to the process of drug discovery has been twofold. On the one hand 
they have helped to understand diseases and to determine the optimal molecular target 
for drug intervention. On the other, they have provided the tools for manufacturing 
proteins with known therapeutic value at a large scale, allowing their distribution as 
therapeutic agents (Gambardella 1995; Henderson 1994).  
The scientific development was accompanied by strong institutional changes as the 
new assortment of genetic and cellular techniques was transferred from academic to 
commercial laboratories.57 This institutional process motivated the use of the term 
Biotechnology to describe an emergent industry in the United States in the late 1970s 
and later on in Europe (Kenney 1986; Krimsky 1991). Moreover, due to the widespread 
expectations of the application of modern biotechnology for medicinal purposes, 
academics, consultants, industry stakeholders and government have promoted the 
term "biotech revolution" to refer to the scientific and institutional changes in the 1970s 
and 1980s. The expectations have brought about an increasing volume of research 
and development expenditures in drug discovery and development. Whether modern 
biotechnology has been able to produce the expected revolutionary improvements in 
medicines and health care services is part of a current controversial debate 
(Nightingale, Martin 2004). 
Senker (1998) and Acharya et al (1998) have studied the differences of the emergence 
and development of modern biotechnology and its commercialisation among different 
regions, especially between the US and Europe. Their contributions stress how 
Europe, maybe with the exception of the U.K., was much slower in developing and 
exploiting the biotechnology knowledge base. Besides the strength of the American 
biotechnology knowledge base, the US has traditionally had a more adequate 
institutional climate for the commercialisation of modern biotechnology than Europe. 
Patenting and regulatory issues have been identified as the most significant differences 
between the US and Europe influencing the commercial exploitation of modern 
biotechnology (Senker et al. 1998). 
                                                
57  For a detailed presentation of the interaction between industry and academia in the 
commercial exploitation of genetic engineering see McKelvey (1996, pp. 100-110). 
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For the global pharmaceutical industry, the emergent biotechnology industry in the 
USA brought about a new industrial organisation presenting (i) three type of actors: 
incumbent large diversified firms (LDFs), public research institutions (university or R&D 
Laboratories) and knowledge/science-intensive small and medium-sized enterprises 
called Biotechnology Dedicated Firms (BDFs) and (ii) constantly growing inter-
institutional collaboration agreements between the new entrants and incumbents 
(Saviotti 1998; Orsenigo 1989).  
Regarding the role of DBFs in the pharmaceutical industry, two stylised interpretations 
can be made One the one hand, DBFs can be explained in terms of a life cycle industry 
model58. There are two main reasons why an industry life cycle scenario does not 
perfectly fit to the pharmaceutical industry. Firstly, drug producers have survived the 
emergence of modern biotechnology and some of them continue to be industrial 
leaders. Furthermore, incumbents and small entrants have built a co-operative be-
haviour at various stages of R&D and production (Acharya et al. 1998, p. 89). 
An alternative explanation of the emergent industrial organisation in the pharmaceutical 
industry after the advent of modern biotechnology builds upon the strong science-
based and interdisciplinary nature of modern biotechnology. These features favour the 
collaboration between actors and the establishment of innovation networks (Orsenigo 
1989; Pisano 1991). 
Within the borders of the Federal Republic of Germany, the development of the 
biotechnology knowledge base and the creation of DBFs followed a slower pace. Buch-
holz (1979, p. 71) has pointed out the underdevelopment of the German Federal 
Republic in the 1970s in what concerned both the development of the biotechnology 
knowledge base and its industrial exploitation.  
This underdevelopment vis-à-vis the United States and the UK in the knowledge base, 
the difficulties of the German innovation system in fostering the establishment of DBFs 
together with the large investments of important German drug producers in research 
and development projects with American public research institutions59 motivated major 
political concern about Germany's technological weakness in biotechnology. Moreover, 
                                                
58   The industry life cycle model relates industrial dynamics with technological change. The 
coming up of a new technology fosters market entry for small innovative firms in terms of 
product innovation. The incumbent firms have problems in adapting to the new paradigm. 
As the technology matures market entry becomes harder. The industry settles down to a 
set of established firms where the early innovators have swept away the formal industry 
leaders.  
59  The strategy of Hoechst with research and development investments in the USA is the 
most well-known example. See annex I  for a short presentation. 
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due to the widespread expectations that biotechnology would revolutionise drug 
discovery and development, policy-makers were concerned about the possible 
negative implications of the German underdevelopment for the competitiveness of the 
German pharmaceutical industry and other industrial sectors (Giesecke 2001).  
The major conscious policy contribution to the development of biotechnology in 
Germany was probably the introduction of the Genetic Engineering Act in 1989 to set 
the legal framework for the activities involving genetic engineering. However, the 
government concern for the support of biotechnology in Germany had already began in 
the 1970s. Policy has taken several forms and tackled issues regarding the regulatory 
framework, the development of the knowledge base through direct project funding (with 
special emphasis on research that can be directly applied), the establishment of  
science-based dedicated biotechnology firms network formation between industry and 
academia and the creation of regional clusters (Buchholz 1979; Giesecke 2000; 
Dominguez Lacasa, Reiss 2004). 
Figure 6: Direct project funding for biotechnology-related research in Germany 
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60  Source: Public Promotion Catalogue of the Bundesministerium für Bildung und Forschung 
(BMBF Federal Ministry of Research and Education). The figures include only the federal 
investments classified as biotechnology activities by the German Federal Ministry of 
Research and Education and does not consider expenditures in medical, health and 
environmental research that may directly support biotechnology but do not appear in the 
ministry’s biotechnology statistics. Block grants and other types of institutional funding such 
as the biotechnology funding of the Deutsche Forschungsgemeinschaft (German Research 
Council) are not included either.  
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Figure 6 presents the public direct project funding in biotechnology since 1970. The 
figures give evidence for the increasing policy concern for biotechnology in Germany in 
terms of project funding between the years 1970 and 2000. Research and technology 
policy have explicitly targeted the development of the biotechnology science base and 
its industrial exploitation. In terms of project funding industry actors have been an 
important target of the policy measures during the entire period under consideration. At 
the beginning of the 1970s, firms beneficiated the most from public promotion 
programmes. However, since the 1980s public funding has increasingly targeted 
fundamental research by supporting public research centres who have became the 
most important target group of direct project funding followed by industry actors who 
have kept a quite large stake of public funding. According to the public budget 
allocation among actors, in 2000 companies and non-university research institutes 
received more than 75 % of the direct project funding for biotechnology. 
With regard to the development of the biotechnology industry, policy intervention in 
Germany during the 1990s supported the creation of biotechnology start-ups and a 
number of measures to promote the availability of venture capital and private 
investments were implemented. By 2000 the German biotechnology industry was 
already the largest in Europe in terms of numbers of biotechnology dedicated firms 
(Dominguez Lacasa, Reiss 2004).  
The underdevelopment of the German biotechnology science base in the 1980s 
compared to the USA and the almost inexistent German biotechnology industry have 
probably augmented the costs of recognition and exploitation of modern biotechnology 
by the German drug producers. There is strong empirical evidence for the delay of 
German drug producers in entering into the biotechnology networks (Hullman 2000, 
pp. 92-94). There have been different types of arrangements for linking up to dedicated 
biotechnology firms, ranging from research collaborations and licenses, equity 
investments and acquisitions. Moreover, as other European corporations in the 
pharmaceutical industry, German drug producers have relied mainly on American 
DBFs to access to biotechnology capabilities. Regarding the collaborations with public 
research institutions, in the early 1990s German public health research institutions 
played an important role for German companies. However, in the second half of the 
1990s the importance of North American and other European universities and public 
research institutions beyond the German borders increased (Hinze et al. 2001, pp. 58-
61).  
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3.4 The recognition and exploitation of modern biotech-
nology by 4 German drug producers 
After the study of the knowledge environment of the pharmaceutical industry in 
Germany, we go on to explore the process shaping the recognition and exploitation of 
technological opportunities. The next paragraphs concentrate on the experience of 
German drug producers in adapting to the advent of modern biotechnology after the 
1970s. 
A number of contributions to innovation studies and explorations of industry dynamics 
and processes of creative destruction have already chosen the advent of modern 
biotechnology in the 1970s to study, among other issues, the reactions of incumbents 
in the pharmaceutical industry to the shift in their knowledge environment. Pisano 
(1991), Senker and Sharp (1997), Galambos and Sturchio (1998), Rothaermel (2001) 
and Santos (2003) focus on the establishment of collaborative arrangements between 
large firms and biotechnology companies for the transfer biotechnology capabilities 
after the revolutionary discoveries of the 1970s. As a reaction to the changes in the 
knowledge environment, Zucker and Darby (1997) stress the resource mobilisations of 
pharmaceutical corporations within the firm (through hiring new scientists) and the 
access to external capabilities (through non contractual collaboration between large 
firms and academic research groups). From a different perspective, Kaplan et al. 
(2003) explore the role of management models in the recognition of the technological 
discontinuity after the 1970s.  
In general terms, these contributions do not consider explicitly the historical 
conditioning of technological change and, more specifically, the influence of firms' past 
decisions and experience in the process of recognising and exploiting technological 
opportunities. An exception may be the contribution of Henderson (1994) who explores 
the development of the competencies of pharmaceutical companies involved in drug 
discovery in the last quarter of the 20th century.  
From a historical perspective, one of the interesting aspects of the exploration of the 
adjustment by German drug producers is their successful innovative record during the 
first half of the 20th century applying synthetic organic chemistry. As we have seen, in 
the era of random screening the German drug producers dominated the 
pharmaceutical industry in terms of innovation. Among other factors their innovation 
success drew indeed on the application of organic chemical synthesis. Given the 
dynamics in the underlying knowledge base of the pharmaceutical industry, especially 
with the scientific advances in molecular biology in the 1950s and the developments 
that followed during the last quarter of the 20th century, this sections aims at deepening 
into the question whether the firm-specific technological competencies in organic 
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chemical synthesis of the German drug producers can have inhibited an adjustment to 
the external shifts in the knowledge base. 
The German corporations active in drug discovery and production facing the 
revolutionary discoveries of the 1970s come traditionally from two different sectors: the 
traditional pharmacy and the coal-tar dyestuff industry. Until the 1950’s both sub-
sectors of the pharmaceutical industry (the more traditional pharmaceutical companies 
and the pharmaceutical companies from the coal-tar sector) were different in their 
organisational capabilities, their product lines and most importantly their attitudes 
towards the application of biotechnology during the 20th century.  
The study explores the reaction to the advent of modern biotechnology by two 
diversified chemical companies coming from the coal-tar dyestuff industry (Hoechst 
AG61 and Bayer) and two representatives of the traditional pharmaceutical industry 
(Schering AG and E. Merck62), both companies with a strong tradition in the application 
of microbiology and enzymatic processes for drug development and production. The 
goal is to unfold the organisational variables and processes shaping the adjustment to 
the emergence of modern biotechnology.  
Patent indicators are used to capture the development of the technological capabilities 
of the firms in biotechnology and organic chemical synthesis. Given these results, the 
next step will be to disclose the process of perception and adoption of the possibilities 
of biotechnology after the 1970s. Guided by the theoretical framework sketched in 
chapter 2, the study focuses on the following issues and indicators: 
(i) Research traditions (in terms of science-based or empirical trial-and-error 
strategies);  
(ii) Attitudes towards the application of traditional biotechnology and focus on 
synthetic organic chemistry (to capture the technological roots of the firms);  
(iii) Research and development investments (to measure the extent to which 
firms are research-based);  
                                                
61  Since 1999, after the merger with Rhone Poulenc, the company’s name is Aventis and has 
its headquarters in Strasbourg, France. In 2003 Aventis was acquired by the French 
pharmaceutical company Sanofi-Synthelabo and is now called Sanofi-Aventis. 
62  Since 1995 and after several corporate reorganisations during the 20th century the 
company has the name Merck KGaA and is located in Darmstadt, Germany. Today Merck 
KGaA has no connection with Merck & Co. of Whitehouse Station, New Jersey. Even 
though the historical roots are the same this branch was confiscated by the US government 
during World War I and in 1917 became the independent company Merck & Co 
(Bernschneider-Reif et al. 2002). 
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(iv) Educational statistics (to capture the disciplinary profiles of the employees 
and its development);  
(v) Strategic collaborative agreements, (to capture the extent to which firms aim 
at exploiting the extramural knowledge base).  
3.4.1 Organisational technological capabilities in the second half 
of the 20th century 
Patent documents draw on research and development activities regardless of the 
innovative impact of the potential invention. Granstrand et al. (1997) or Mowery et al. 
(1996) have already successfully applied patent statistics as indicators to analyse 
organisational technological capabilities. Therefore, this indicator can unfold the extent 
to which the corporations develop and apply biotechnology and organic chemical 
synthesis in their research and development efforts.  
Figure 7: Corporate patent documents in pharmaceuticals. Share of biotech-
nology and organic chemistry-related patent documents in the phar-
maceutical corporate patent portfolio of Schering, Bayer, Hoechst and 
Merck and their main subsidiaries63 
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Sources: Annex II. 
                                                
63  Data: German patent applications filed at the German and European patent offices with 
Germany as designation country. The criteria to classify the patent documents were based 
on the European Patent Classification (EPC). 
Share of biotechnology in pharmaceuticals 
Share of organic chemistry in pharmaceuticals 
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The indicators based on patent documents are presented in Figure 7. The data 
historical time series used for our analysis has been gathered from the online 
databases PLUSPAT and PATDPA of the database vendor Questel.  
The indicators present counts of German patent applications of the four corporations 
and their main subsidiaries filed at the German and European patent offices with 
Germany as designation country. Using the European Patent Classification (ECLA), 
pharmaceutical-related patents of the corporations have been categorised in two 
groups: those involving the application of biotechnology and those involving the 
application of organic chemical synthesis.64 The results suggest a considerably better 
performance of Bayer and Hoechst than the traditional drug producers in perceiving 
and exploiting the possibilities of biotechnology in the period under consideration. For 
the period 1960s-80s Merck presents a rather similar share of biotechnology-related 
pharmaceutical patents than the best adopters, however biotechnology at Merck does 
not reach the share obtained in the pharmaceutical patents of Bayer and Hoechst. In 
the 1990s the share decreases slightly. Schering has a very low share of 
biotechnology-related patents in pharmaceuticals throughout the whole period 
considered. 
The next sections aim at exploring some of the forces driving these developments. 
3.4.2 Research traditions  
Marschall (2000) and Achilladelis (1999) point out that until the 1950’s the two sub-
sectors of the pharmaceutical industry (the traditional pharmaceutical companies and 
the pharmaceutical companies from the dyestuff sector) were quite different. As 
presented in Table 5, these differences concerned their size and their product lines65, 
the skills of the employees and most importantly their research strategies and criteria 
for technology adoption. On the one hand, the traditional pharmaceutical companies 
applied trial-and-error base principles to develop new drugs. Accordingly, the German 
traditional pharmaceutical companies (such as E. Merck, A. Knoll and Schering AG) 
were quite slow in shifting their emphasis from extraction of natural products to the 
                                                
64  The definitions of pharmaceuticals-related patent documents and those documents 
involving biotechnology and organic chemical synthesis are based on codes of the ECLA 
classification (see annex II). 
65  In general the traditional pharmaceutical companies developed organic acids with the  
application of traditional biotechnology and enzymes, vitamins and hormones, which in the 
early phases of the pharmaceutical industry were isolated from natural raw materials. On 
the other hand the dyestuff producers concentrated on the development of innovative 
synthetic products. 
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organic synthesis of drugs. On the other hand, guided by the principles of organic 
chemistry, the strategies of the dyestuff manufacturers had already became  
science-based by the 1880s (Marschall 2000).66 This science-based strategy shaped 
their learning processes, which were characterised by (i) the institutionalisation of 
industrial scale R&D activities, (ii) large supply of well-trained university chemists and 
(iii) interaction with research institutes and universities. 
Table 5: German drug producers at the beginning of the 20th century 
Coal-tar dyestuff  
companies 
Traditional pharmaceutical  
companies 
• Large diversified companies; 
 
 
• Chemists in charge of the drug 
discovery activities; 
• Science-based strategies guided 
their research and development 
activities; 
• Conscious choice of the organic 
chemical synthesis in drug 
discovery until the 1960s. 
• Small and medium enterprises 
arising from traditional 
pharmacies; 
• Pharmacists responsible for the 
drug discovery activities; 
• Empirical “trial-and-error” guided 
their research and development 
strategies; 
• Extraction of drugs from natural 
compounds and application of 
traditional biotechnology. 
Sources: Marschall (2000) and Achilladelis (1999). 
Moreover, the innovation flow (in terms of products) maintained by the German coal-tar 
dyestuff companies occurred parallel to the establishment of industrial scientific labo-
ratories to exploit the industrial application of scientific principles (Marsch 1994). The 
research and development activities that used to be carried out in laboratories at a 
small scale were then performed at large industry scale. This transition from laboratory 
to industrial scale research and development activities was possible through the 
institutionalisation of science in the industry. The enlargement of research capabilities 
                                                
66  As Marschall (2000) has put forward, in its origins the research and development practices 
of the dyestuff companies had an empirical fundament, that is trial-and-error exercises 
guided the process of developing synthetic dyes from the coal tar. The chemical structure 
of the synthetic dyes remained unknown until the advances in the structural analyses of 
organic compounds, which led to the first synthesizes of organic compounds based on the 
understanding of their molecular structure. The scientific advances in organic chemistry 
transformed the discovery of dyestuffs from an empirical into a theory driven procedure. In 
the 1880s dyestuff producers diversified into pharmaceuticals applying the same science-
based strategies that they were using in the discovery and development of dyestuffs. With 
this strategy the dyestuff companies were able to develop a large portfolio of innovative 
drugs. 
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demanded large investments in infrastructure for research and development.67 These 
corporate research activities were strongly influenced by the German university and the 
polytechnic institutes (Beer 1959).  
The dyestuff companies complemented this organisational innovation with the 
recruitment of workers with experience in scientific research. At the Bayer company for 
instance, already in 1897 all research chemists in the main laboratory held a Ph.D. in 
chemistry and the majority had research experience at the university (Meyer-Thurow 
1982, p. 376). Achilladelis (1999) and Beer (1959) also stress the ability of dyestuffs 
producers in the pharmaceutical industry to build in house R&D capabilities and to 
interact and cooperate with academic researchers, universities and polytechnic 
institutes. 
3.4.3 Attitudes towards the application of traditional biotech-
nology 
According to Marschall (2000) the traditional pharmaceutical companies applied 
traditional biotechnological methods with great success in the production of basic 
chemicals (like butyric acid, acetic acid or lactic acid). The Schering company produced 
organic acids in the early 1900s with the application of micro-organisms, Luitpold was 
active in 1931 in the biotechnological production of enzymes and Knoll in the 
production of Ephedrin since 1930. Roehm and Boehringer Ingelheim are other 
examples of early adopters of biotechnology. After World War II, Boehringer Ingelheim 
and Merck were leaders in microbial transformation technology. 
On the other hand, the companies of the coal-tar dyestuff sector were less interested in 
developing and applying biotechnology methods. The leading players in the sector 
(Bayer, BASF, and Hoechst) reacted very cautiously and sceptically (even with 
prejudice) to the possibilities offered by biotechnology. The strong innovation flow of 
the dyestuff producers at the beginning of the 20th century was rooted in the application 
of scientific principles. The successful research strategy of the dyestuff producers 
supported the establishment of implicit principles that would shape their technological 
decisions in the future by guiding their perception, assessment and selection of 
technologies. These implicit principles favoured science-based technologies and 
rejected empirical (i. e. trial-and error guided) technologies (Marschall 2000).  
                                                
67  Liebenau (1988) points out that there is little evidence that cost/benefit calculations were 
done in anything more than a rudimentary way. According to him, the decisions taken by 
German corporations leading to the creation of the industrial laboratories were not the 
result of a systematic analysis leading to the conclusion that the company would profit from 
the establishment of laboratories. 
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Only after the discovery of the therapeutic importance of penicillin, the improvement of 
microbiological production methods and their relevance after World War II, did the 
companies from the dyestuff sector start to produce penicillin under US licences 
(Buchholz 1979).  
Figure 8 sketches the main achievements of the drug producers under study in 
exploring and exploiting the technological possibilities of biotechnology. These findings 
are a result of the cases studies included in Annex I. The case studies use historical 
sources to describe the biotechnology research achievements of the firms and their 
process of building up biotechnology research capabilities. 
Figure 8: Relevant achievements with the application of biotechnology and 
biotechnology research projects of Schering, Merck, Bayer and 
Hoechst 
1940
Schering
Merck
Bayer
Hoechst
1940s -60s
• Microbiological transformation 
of steroids (Cortisone)
• Production of enzymes
1950s
• Penicillin-production 
(through licences)
• Fermentative 
extraction of 
6-APS
1970s-80s
• Single cell proteins  (SCP) Probion
• Monoclonal antibodies and genetic 
engineering research: Recombinant 
human insulin / Blood clotting 
factors: PA, AT VIII, Factor VIII
1950s
• Penicillin-production 
(through licences)
1970s-80s 
• Acarbose (to treat Diabetes)
• Genetic engineering for the production 
of blood clotting factor  VIII
• After 1937
• Research on the 
microbiological 
transformation of 
steroids
1890-1940s
• Anaerobic and aerobic 
processes for the 
production of acids and 
vitamin C
1960 1970
Since 1987 research on:
• Genetic engineering for 
contraception methods 
• Control of the 
coagulation system
Late 1980s
Immunological research 
with monoclonal 
antibodies
1950s-1960s
• Penicillin-Production 
(through licenses)
• Microbiological  
transformation of steroids, 
enzymes, aminoacids
19801950
 
Source: Annex I 
The corporations present a different profile in the exploitation of biotechnology in the 
20th century. While the representatives of the traditional pharmaceutical industry had 
accumulated experience with the application of what we have defined as traditional 
biotechnology, the dyestuff producers started its application using licences for the 
production of penicillin.  
However, according to the findings, traditional pharmaceutical companies did not 
further develop their capabilities. In the 1970s dyestuff producers started their activities 
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in modern biotechnology while the traditional pharmaceutical companies waited until 
the late 1980s. Surprisingly dyestuff producers had been faster in recognising the 
possibilities of the technology after the revolutionary scientific discoveries of the 1970s. 
3.4.4 Investment in research and development 
To capture the extent to which firms are research-based and engage in creating and 
accumulating knowledge and in developing their absorptive capacity, data on research 
and development expenditures in pharmaceuticals for the period 1955-1995 are 
presented in Table 6. The historical data have been gathered from the corporate 
historical archives using annual reports and relevant documents covering the 
pharmaceutical segment of the corporations. The internationalisation of corporations in 
the pharmaceutical industry during the 20th century makes the consistent analysis of 
trends in financial data over long periods of time quite difficult. The data for the period 
1955-1970 refer to pharmaceutical research and development of the corporation 
(Mutterkonzern). For the period 1975-1995 the data refer to the global group (Welt oder 
Gruppe). 
Table 6: Investment volume in research and development in pharmaceuticals 
(in million German Mark and as a percentage of pharmaceutical sales) 
 Merck Schering Hoechst Bayer 
 mio DM % mio DM % mio DM % mio DM % 
1955       12 9 % 1955 
1960     21 7 % 23 10 % 1960 
1965   27.3 6 % 43 9 % 37 11 % 1965 
1970  13 % 60.4 10 % 109 11 % 61 10 % 1970 
1975 55 8 %   352 10 %   1975 
1980 67 8 % 194 14 % 503 10 % 290 6 % 1980 
1985   380 18 % 972 14 %   1985 
1990 205 12 % 543 17 % 1182 13 % 986 12 % 1990 
1995 439 13 % 845 18 % 2018 18 % 1517 14 % 1995 
Source: Material from the historical corporative archives other sources (see annex II). 
The data presented in Table 6 show that the differences between the companies in 
terms of size remained in the 20th century. As in the period of establishment of the 
pharmaceutical industry, in 1980 (about 100 years later) Merck and Schering were 
much smaller than their competitors Hoechst and Bayer in terms of investment volume 
in pharmaceutical research and development. Economies of scale in research seem to 
play a role in the adjustment to the external shift in the knowledge base. This result is 
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consistent with Kaplan et al. (2003) who find evidence for the hypothesis that the 
adjustment process is also driven by economies of scale. In terms of investment ratio 
however, the differences are not as clear. All 4 corporations are very research intensive 
and until 1995 they seem to have quite stable R&D investment behaviour. According to 
the data available, in the last quarter of the 20th century Schering was investing the 
largest share of its pharmaceutical sales in R&D activities, but the differences are not 
significant. 
3.4.5 Internal capabilities  
To explore the internal capabilities of the firms we use educational statistics. 
Jacobsson and Oskarsson (1995) put forward the educational statistics approach to 
trace the technological base of firms. The analysis in this section explores educational 
background of the staff before the advent of modern biotechnology to capture the 
extent to which the internal capabilities of the companies were appropriate to recognise 
the possibilities of modern biotechnology and adopt it.  
Figure 9 presents the data for the corporations we are considering. Subsidiary-
companies have not been included in the analysis. Again the data have been gathered 
from the historical corporate archives using historical material from the corporate staff 
departments on employee qualification. Due to problems of data availability, building up 
consistent time series for the 4 corporations for the same period was a challenging 
exercise. The raw data are structured in academic groups with a classification from 
company to company presenting different degrees of aggregation. For the purposes of 
the analysis five academic groups have been built for each firm: 
• Biologists and microbiologists; 
• Physicians and pharmacists; 
• Chemists; 
• Engineers and physicists; 
• other disciplines (which include disciplines such as psychologist, mathematics, law, 
or business administration). 
Unfortunately the data available do not allow making an accurate comparison between 
the corporations. However, an interesting observation can be drawn. In terms of the 
employee qualification the companies in the 1970s seem to maintain the profile of the 
beginning of the 20th century presented in Table 5. Chemists are the most important 
group of employees with an academic degree in the dye-stuff companies Hoechst and 
Bayer. At Merck chemists and the group integrating pharmacists and physicians, are 
comparable in size while at Schering chemists do not play a leading role at all. 
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Figure 9: Human capital at Schering, Merck, Hoechst and Bayer: Qualification of 
the employees holding an academic degree 
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Source: Historical corporative archives68. 
According to employee qualifications, by the 1970s the employees of the German 
corporations under consideration had weak skills to develop understanding on the 
biological processes of diseases. While Schering and Merck seemed to have strong 
skills on pharmacology and medicine, Hoechst and Bayer had mostly competencies in 
chemistry. The profile of employee qualifications seems to be quite persistent. Even in 
the era of modern biotechnology, skills in biology either play a secondary role or were 
clearly underrepresented among the employees with an academic degree of the 
corporations we are considering (for Bayer we have no evidence to make an 
assessment of the development of employee qualification). 
Considering that the data refer to the whole corporations (and not just to the 
pharmaceutical business units) the differences in the employees' academic profiles 
                                                
68  Comments to the data: For Schering in the year 1970 the data refer to the pharmaceutical 
activities only. Data for Hoechst in the years 1981 and 1993 refer to the Hoechst AG, for 
the other years the data refers to the Hoechst Group. The data for Bayer refers to Bayer 
Farbenfabrik. For detail see annex II. 
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could be explained by the fact that the dye-stuff producers were very much diversified 
in the chemical sector while the traditional pharmaceutical companies mainly focused 
on pharmaceuticals. However, according to the corporate annual reports, in 1975 
Merck and Schering had developed into diversified chemical companies reaching 55 % 
and 45 % of their sales, respectively, in industries of the chemical sector other than 
pharmaceuticals. Accordingly, the differences in the scientific skills of the employees  
(measured in terms of share of academic degrees in selected disciplines) and their 
persistence demonstrate to a large extent different paths in the accumulation of internal 
(i. e. firm-specific) technological capabilities. 
3.4.6 Strategic collaboration 
To explore the strategies of the corporation to access extramural knowledge and skills 
outside the firms, we examine the strategic collaborative agreements of the firms. 
Figure 10 presents the biotechnology-related contractual agreements of the companies 
(and their major subsidiaries). These include equity and non equity inter-firm 
agreements (except for licensing activities) and major strategic collaborative 
arrangements between the firm under consideration and public research institutions 
aiming at enhancing the technological capabilities of the firms. To control for the size of 
the companies the data have been related to the number of patent applications in 
pharmaceuticals. 
Figure 10: Number of biotechnology-related strategic agreements per patent 
application in pharmaceuticals 
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Source: Peter (2002) and own desk research using annual reports, secondary literature and 
   firm information (see annex II). 
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In the 1980s the corporations present a similar collaborative intensity in terms of 
agreements per patent application in pharmaceuticals. In the 1990s all companies 
increase the collaboration rate; however Schering seems to rely largely on its internal 
firm-specific assets to develop research and development capabilities in the new 
knowledge environment. 
3.4.7 Discussion 
As presented in previous sections the emergence of modern biotechnology in the 
1970s has changed the institutional and knowledge environment of the pharmaceutical 
industry. The industry incumbents have faced the challenge of adjusting to the new 
conditions for innovation in drug discovery and development. Drawing on the 
theoretical framework of the organisational capabilities of the firm (or knowledge-based 
approach to the firm) this section has aimed at describing the knowledge bases of the 
German drug producers, at characterising their strategies for the acquirement and 
development of capabilities and most importantly, at exploring their adjustment to the 
shift in their knowledge environment after the emergence of modern biotechnology.  
Table 7: The exploitation of biotechnology by German drug producers and in-
dicators to capture the adjustment to the advent of modern biotech-
nology 
 Merck Schering Hoechst Bayer 
Research tradition in the early 
20th century 
empirical (trial-and-
error) strategies 
empirical (trial-and-
error) strategies 
science-based 
strategies 
science-based 
strategies 
Biotechnology in drug 
development and production 
before the 1970s 
successful 
applications of BT 
since the 19th 
century  
successful 
applications of BT 
since the 1930s 
focus on chemical 
synthesis 
applications of BT 
after 1950 (through 
licensing)   
focus on chemical 
synthesis 
applications of BT 
after 1950 
(through 
licensing)   
R&D investment in 
pharmaceuticals in % of pharm. 
sales (average 1970-95) 
11 % 15 % 13 % 11 % 
Disciplinary orientation of 
employees' qualification by the 
1970s 
Medicine / 
Pharmacology 
Medicine / 
Pharmacology 
Chemistry Chemistry 
Biotech. strategic agreements 
per pharmaceutical patent 
(average 1980-99) 
0.48 0.23  0.41 0.34 
Modern biotechnology 
Biotechnology in drug 
discovery and development 
after the 1970s 
research starts in 
the late 1980s 
research starts in 
the late 1980s 
first applications in 
the early 1980s 
first applications 
in the early 1980s
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The analysis has tried to be consistent with the historical conditioning of technological 
change and the fact that the decisions of firms on technology adoption and 
development are not independent from the history of the organisations in which 
corporate strategies and capabilities develop. 
By considering the organisational factors shaping the innovation activities of the 4 firms 
and their experience with the application of biotechnology in the first half of the 20th 
century we have explored the exploitation of modern biotechnology by the 4 German 
drug producers in the second half of the 20th century. The overall results of the analysis 
are given in Table 7. A key aspect of the study is the different heritage of the 
corporations: Merck and Schering are representatives of the traditional pharmaceutical 
industry while Hoechst and Bayer are rooted in the coal tar dyestuff industry. 
With regard to their research tradition, the representatives of the traditional 
pharmaceutical industry were characterised by empirical (trial-and-error-based) 
strategies. On the other hand, the coal tar dyestuff producers followed a science-based 
strategy characterised by a large supply of well trained university chemists and strong 
collaboration patterns with research institutes and universities.  
Contributions to the history of technology and to the exploration of the pharmaceutical 
industry have pointed out that these research traditions influenced the application of 
biotechnology in the first half of the 20th century. As shown in Table 7, the empirical 
character of biotechnology (compared with the science-base character of organic 
chemical synthesis) prevented the coal tar dyestuff companies from applying it in drug 
development. They did not apply biotechnology until the sterile technique for the 
production of penicillin in the 1950s had been developed and successfully applied by 
their American and Swiss counterparts. At this time the progressive colonisation of 
biology by the exact sciences was providing biotechnology with a continuously growing 
scientific knowledge base. According to the empirical analysis of technological 
capabilities through patent counts presented in Figure 7, during the second half of the 
20th century the accumulation of biotechnological capabilities at Hoechst and Bayer 
went hand in hand with the transformation of biotechnology into a science-based 
technology. The values and norms shaping the technology adoption of drug producers 
may have played a role in this development.  
In terms of share of investment in research and development the companies behave 
quite similarly. Schering, which is probably the largest investor in this group in relative 
terms, does not exploit the new technological opportunities of biotechnology in the  
second half of the 20th century. However, the total volume of research and 
development investments given in Table 6 discloses considerable differences in size 
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between the corporations. Interestingly the largest firms (Bayer and Hoechst) seem to 
have been faster in recognising and exploiting the new technological opportunities after 
the emergence of modern biotechnology. Economies of scale in research seem to play 
a role in the adjustment to the external shift in the knowledge base.  
The companies maintain a constant profile of in-house scientific skills suggesting that 
(in the absence of mergers, acquisitions or buyouts) changes in the internal capabilities 
of the firms do not occur rapidly. Additionally, the data on employee qualification  
suggest that, before the emergence of modern biotechnology the dyestuff companies 
did not have the skills to develop capabilities for understanding the biological process 
of diseases.  
As for the strategies to access the extramural knowledge base through the interaction 
with dedicated biotechnology firms, the relatively large share of contractual agreements 
of Bayer and Hoechst demonstrates their engagement aiming at identifying and 
accumulating additional capabilities in biotechnology. Merck presents a similar profile in 
terms of collaboration, even though according to the patent indicators presented in 
Figure 10 the exploitation of biotechnology is not as strong as at Bayer and Hoechst. 
Moreover, its reaction to the advent of modern biotechnology is slower (see Figure 8). 
As for Schering, its engagement in biotechnological research and development during 
the first half of the 20th century, its relatively large share of investment in research and 
development in pharmaceuticals and its firm-specific capabilities in medicine and 
pharmacology (which seem more appropriate for the rational model of drug discovery 
enhanced by the emergence of modern biotechnology) have not resulted in the 
adoption of the new technological opportunities. The interactions to accumulate 
external capabilities seem to be missing. 
The existence of research and development activities, the science-based research 
tradition together with interactions to access the extramural knowledge base of the 
firms seem to have been crucial in the perception and adoption of the new 
technological possibilities of biotechnology after the 1970s, rather than prior 
competence in biotechnology or the employees with the skills to develop the 
capabilities to exploit it. 
3.5 Issues for a history-friendly model of technological 
change and technology adoption in the German phar-
maceutical industry 
In the previous sections we have introduced important facts to develop an appreciative 
theory of technological change in the German pharmaceutical industry by focusing the 
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development and diffusion of the organic chemical synthesis and the biotechnology 
during the 20th century. For this purpose we have taken three perspectives: the know-
ledge environment, the industrial and the organisational perspective. 
From the perspective of the knowledge environment underpinning firms' activities and 
technological change we have focused on the development of two technologies: 
organic chemical synthesis and biotechnology. The stylised facts introduced in the 
previous sections suggest that the scientific advances in the knowledge bases 
underlying these two technologies have very much influenced their diffusion in the 
pharmaceutical industry. However, the development of the scientific knowledge bases 
of these technologies has followed different paces. The scientific base of the organic 
chemical synthesis was developed in the second half of 19th century, providing 
scientific theories (codified knowledge) about how to manipulate compounds to create 
new substances. The complexity of analytical chemistry and the principles guiding 
organic chemical synthesis (in terms of scientific disciplines contributing to its 
development) were moderate.  
The development of biotechnology presents a different profile. While at the end of the 
19th century the application of biotechnology was mainly a handcraft activity and its 
scientific base still in its infancy, during the 20th century scientific advances have 
changed the nature of the biotechnology-relevant science base. This process started 
already in the 1950s with the development of molecular biology and culminated in the 
1970s with the revolutionary discoveries of rDNA and the production of monoclonal 
antibodies. With scientific development the knowledge base underlying biotechnology 
has gradually gain in complexity and the technology has become less tacit (easier to 
articulate).  
The exploration of the influences of these developments for the pharmaceutical 
industry reveals three different phases in the pharmaceutical industry. The stylised 
facts identified in the 3 phases of development of the German pharmaceutical industry 
together with the changes in the development of organic chemical synthesis and 
biotechnology allow us to identify the parameters describing the technological regimes 
shaping technological change in the industry. As put forward in section 2.5.2, according 
to Malerba and Orsenigo (1993) the relevant parameters are (i) the level of opportunity 
conditions, (ii) the appropriability conditions, and (iii) the degrees of cumulativeness of 
technological knowledge and (iv) the characteristics of the knowledge base. The 
estimations are given in Table 8. 
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Table 8: Relevant parameters for the characterisation of the conditions for 
technological change in the different phases of the German pharma-
ceutical industry 
Description Phase (I) Phase (II) Phase (III) 
Innovation opportunity conditions high high very high 
Appropriability conditions middle middle low 
Cumulativeness of the knowledge base middle large large 
Volume of scientific knowledge provided by public sector 
research institutions relevant for the organic chemical 
synthesis 
large large large 
Degree of tacitness of the chemical synthesis low low low 
Degree of complexity of chemical synthesis middle middle middle 
Volume of scientific knowledge provided by public sector 
research institutions relevant for biotechnology 
low large large 
Degree of tacitness of biotechnology high middle low 
Degree of complexity of  biotechnology middle high very high 
Phase I covers the establishment of the modern pharmaceutical industry from the 
1880s until World War II. In this period both biotechnology and organic chemical 
synthesis competed in the processing of materials until World War I. The dominance of 
the dyestuff companies in the German pharmaceutical industry supported the 
technological option for the organic chemical synthesis in the drug discovery and 
development processes. However, at this point drug discovery did not draw on the 
understanding of the biological processes of diseases. Drug discovery was based on 
random experimentation with the application or principles of organic chemistry. The 
degree of cumulativeness of the knowledge base was moderate since, even though 
successful innovation was based on the accumulation of capabilities in organic 
chemistry, the capabilities for innovation were embedded in large in-house research 
and development infrastructures to complete screening procedures. The innovation 
opportunity conditions were high since most diseases were waiting for a therapeutic 
treatment and the incentives to carry out research and development were large. The 
need of random experimentation provided the innovation environment with possibilities 
to appropriate the profits from innovation. Accordingly, even though in Germany patent 
law did not protect medicines and their therapeutic until the 1960s, appropriability 
conditions were moderate. Serependity in drug discovery made innovation around well 
known chemical compounds with therapeutic properties difficult, since the light 
variation of a compound did not guarantee therapeutic effects.  
Phase II in the development of the pharmaceutical industry in Germany began with the 
termination of World War II. This phase saw the transition from random towards guided 
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drug discovery). After Wold War II biotechnology gradually becomes the key for 
innovation in the drug discovery and development processes. The understanding of 
biological process starts influencing drug discovery. even though innovation continues 
to draw on the accumulation of knowledge, capabilities in organic chemical synthesis 
are not enough for successful innovations. Microbiology, biochemistry, physiology and 
pharmacology become key disciplines for drug discovery and development. The 
innovation opportunity conditions were still large, and the development of the 
knowledge opened up gradually new areas of therapeutic application. However, with 
this gradual transformation of the knowledge environment German drug producers lost 
their innovative strength in the second half of the 20th century. Imitation was not 
straightforward since even though the knowledge underpinning biotechnology was 
becoming gradually codified, its transfer and was still very much based on observing 
interacting and training. The appropriability conditions were moderate. 
Finally, Phase III starts with the advent of modern biotechnology in the 1970s, the 
emergence of a biotechnology industry in the United States and the strategic 
orientation of German drug producers towards this region in what concerned research 
and development activities. Scholars have already referred to the emergence of 
modern biotechnology in the pharmaceutical industry as a competence destroying 
technological advance in the sense of Tushman and Anderson69, a new technological 
trajectory in Nelson and Winter's sense70 or a new paradigm in Dosi's sense71. The 
stylised facts provide evidence for a transformation of the knowledge environment 
shaping drug discovery and development and its industry structure with the entrance of 
biotechnology dedicate firms ant the creation of networks of innovation. The innovation 
opportunity conditions increase since modern biotechnology brings about enormous 
expectations for drug discovery with regard to the understanding of diseases and the 
manufacturing of proteins. Regarding the appropriability conditions, the private 
appropriation of the profits deriving from innovation was however difficult 
(appropriability conditions were low). On the one side, and particularly in the early 
stages, the relevant knowledge base could in principle be codified and was hence 
easily transferable. Moreover, there was great confusion in what concerned the 
patentability of biotechnology-related novel technological advances. Regarding the 
cumulativeness of the knowledge base, drug discovery became even more research 
and development intensive. The scientific discoveries underpinning modern 
                                                
69  See for example Freeman (1995, p. 14) or Pisano (1991, p. 239). 
70  See for example Nelson et al. (1982). 
71  See for example Dosi (1988a). 
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biotechnology forced German drug producers to acquire and develop new capabilities 
which were largely being developed beyond the German innovation system. During the 
last two decades of the 20th century strong policy engagement was directed towards 
the promotion of the industrial application of biotechnology, the creation of 
biotechnology companies and the interaction between industry and academia within 
the German borders. 
All in all, the emergence of modern biotechnology and the increasing importance of the 
role of understanding diseases for innovation have transformed the knowledge 
environment and the research and development activities; however, the 
pharmaceutical industry in Germany and in other regions is still largely based on the 
application of chemical principals. It seems that, in the sense of De Liso and Metcalfe 
(1996, pp. 79-80.) biotechnology has not replace or overcome the chemical paradigm 
in the pharmaceutical industry, both paradigms coexist. Regarding the radical 
dimension of modern biotechnology, we concur with Nightingale and Martin (2004) in 
that even though the developments at the level of the knowledge base in the 1970s 
were rather radical than incremental, the articulation of these scientific advances into 
innovative products with therapeutic properties has not fulfilled jet the expectations 
created in the 1970s. While the knowledge dimension of the technology has 
experienced radical improvement, the artefact dimension of the technology (in terms of 
medicines and therapies) seems to be following an incremental path of change.  
Given this development of the knowledge environment of the pharmaceutical industry, 
the analysis has tried to disclose, at the level of the firm, the process of recognition and 
adoption of the technological possibilities of modern biotechnology after the 1970s by 
German drug producers. The empirical exercise has considered the theoretical 
discussion on the role of the firm in the process of technological change and the main 
concepts developed by the knowledge-based view of the firm identified in section 2.5: 
firm heterogeneity, absence of maximising behaviour in their decision processes, 
historical conditioning of firm behaviour, the contribution of internal and external 
learning to knowledge accumulation and the importance of being able to 
reconfigure firm capabilities to survive in dynamic knowledge environments. 
Given that the companies hold a similar share of R&D investments per pharmaceutical 
sales, the qualitative and quantitative innovation indicators used have tried to identify: 
(i) the research traditions (in terms of science-based versus empirical research 
strategies),  
(ii) the technological roots of the firms (in terms of previous experience with 
biotechnology and focus on the application of organic chemical synthesis),  
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(iii) the availability of internal skills to develop capabilities in biotechnology (in 
terms of the academic profile of the employees), and 
(iv) the interaction to access the extramural knowledge base of the firms (in 
terms of number of strategic cooperations per patent application). 
Science-based research strategies together with interactions to access the extramural 
knowledge base of the firms (learning external to the firm) have been crucial in the 
perception and adoption of the new technological possibilities of biotechnology after the 
1970s.  
These results suggest that in dynamic environments it is not enough for entrepreneurs 
to manage their internal knowledge bases and allocate their resources effectively. 
Additionally, to be aware of the changes in their knowledge environments and adapt 
adequately, entrepreneurs seem to be forced to manage their interface between 
internal and external knowledge bases.  
This analysis of the German pharmaceutical industry has identified variables and 
depicted causal relationships to unfold the process of technological change and tech-
nology adoption. The argumentation has been developed in a verbal way. As 
discussed in section 2.6.4, the next step is to asses the logic of the argumentation by 
formalising the processes and variables identified in a formal model and explore the 
conditions for technological change and technology adoption running simulation 
experiments, i. e. varying selected parameters and observing the results. 
The following issues could be explored with a history-friendly model: 
Firstly, the development of the knowledge base, especially after World War II, seems to 
play an important role in the diffusion of biotechnology in the German pharmaceutical 
industry. The historical stylised facts speak for a development of the knowledge base 
and the industrial exploitation especially in the US. This geographical dimension of the 
knowledge base (i. e. the access for German drug producers was more difficult than for 
other actors), together with its increasing complexity has probably played a role in the 
application of biotechnology in the German pharmaceutical industry. Accordingly, a 
simulation model could serve as platform to test technological change and technology 
adoption under different characteristics of the knowledge base.  
Moreover, the barriers for industrial exploitation of biotechnology in Germany have 
probably augmented the costs of perceiving and adopting the new technological 
opportunities by the German pharmaceutical industry. A history-friendly model can 
explore the influence of adoption costs in the adoption and development of 
biotechnology in the German pharmaceutical industry. 
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Additionally, given their technological traditions, firms' learning strategies (in terms of 
internal and external learning) seem to have been determinant to perceive and adopt 
the new technological opportunities, especially after the 1970s, when the biotechnology 
science base experienced a radical change in terms of complexity. Given the 
development of the knowledge base and the set of factors determining the level of 
adoption costs, a history-friendly model can serve as artificial environment to test the 
influence of firms' strategies on technological change and technology adoption. 
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4 A history-friendly model of technological change 
and technology adoption in the German pharma-
ceutical industry 
4.1 Introduction 
Guided by the appreciative theory introduced in the previous chapter, the history-
friendly model put forward in the next sections intends to draw the process of 
technological change in the German pharmaceutical industry driven by the scientific 
advances of molecular biology in the mid 20th century and the emergence of modern 
biotechnology in the 1970s.  
The aim of this exercise is to create an artificial environment to explore technological 
change in a science-based industry by focusing on the nature of the science base (in 
terms of volume and complexity), on the conditions for technology adoption, on firms' 
strategies to build up technological capabilities and, finally, on the influence of 
collaboration as mechanism for knowledge transfer. 
At the micro level the model specifies (i) the activities of heterogeneous firms nested in 
the competitive dynamics of drug discovery and development, (ii) firms' decision-
making process regarding research and technology development and (iii) the evolution 
of firms' technological capabilities. Additionally, the science-based character of the 
industry is explicitly modelled by defining technology development at the firm level as a 
function of the ability of firms to perceive, develop and articulate scientific results 
available in their knowledge environment. However, the interesting phenomenon the 
model aims at exploring is at the industry level, i. e. at a higher level of aggregation 
than the level of the firm. The development of technologies at the industry level is 
simulated by modelling the creation and development of technological capabilities at 
the firm level. As discussed in section 2.6.2, the model presents micro-macro 
relationships and technological change is hence the collective result of the individual 
actions of firms.  
Figure 11 presents the basic structure of the model with an artificial drug industry 
where companies compete to find the best drug candidates and to develop them into 
drug products.  
Drawing on the neo-Schumpeterian tradition the model involves heterogeneous firms 
with bounded rationality, search and selection processes and a knowledge 
environment firms can draw on to improve their routines.  
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Figure 11: Artificial pharmaceutical industry: the basic structure of the model 
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Based on the appreciative theory the model presents three types of companies: 
Traditional Pharmaceutical companies (Firm Type TP), Dyestuff companies (Firm Type 
DC) and Dedicated Biotechnology Firms (DBFs). However, DBFs enter the industry at 
a later stage, after a discontinuity in the knowledge environment bringing about new 
technological opportunities. Therefore, firms of type TP and DC are considered 
incumbent firms in the industry while DBFs are considered new entrants with the 
capabilities to exploit the new technological opportunities. 
Search processes 
Firms face a search space of potential medicines which may have therapeutic 
properties (drug candidates on the right side in figure 11). Their goal is to find the best 
potential drug candidates, develop them into drug products and bring them to the 
market (on the left side in figure 11). Therefore firms compete (i) to search for drug 
candidates and (ii) to develop them into products. In their search and development 
processes firms can apply two technologies: technology B and technology S (which 
represent biotechnology and organic chemical synthesis, respectively). The imposed 
function of these technologies is to ease the search and development processes. 
Effectiveness of the search process depends on the level of technological capabilities 
of the firms. 
Selection processes 
Firms face additionally a selection environment which represents the market for 
medicines. Success is specified according to ability of firms to market the products 
developed (discoveries or imitations). Therefore, firms' adaptability to the selection 
environment (firms' fitness in an evolutionary sense) is determined according to the 
relative performance of their products vis-à-vis the product portfolio of their 
competitors. Good performance provides best adaptors with relatively higher rewards 
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that can be used to develop their capabilities and search modes further and improve 
adaptability, while bad adaptors are forced to constraint their development due to lower 
rewards. 
The knowledge environment 
Firms interact in their knowledge environment carrying out learning processes external 
and/or internal to the firm to accumulate technological capabilities. The model 
emphasises the knowledge dimension of technologies by assuming that technology 
development draws on the accumulation of technological capabilities. Technological 
capabilities are the main assets of firms (since they determine the effectiveness of the 
search and development processes of products and, consequently, firm's adaptability 
to the competitive environment). Moreover, firm's performance in the selection 
environment will influence the extent to which firms are able to develop their 
technological capabilities further, applying their superior search modes and learning 
strategies. Therefore, if the conditions for innovation do not change (i. e. the conditions 
in the selection environment), adaptability of firms at time t depends on the extent to 
which they were able to adapt to the environment and obtain rewards in the past. 
Figure 12: Firm's decisions and its interactions within the system 
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The model presents the following major simplifications: 
• Two technologies: technology B and technology S; 
• Three types of firms: Traditional Pharmaceutical Companies (Firm Type TP), 
Dyestuff Companies (Firm Type DC) and Dedicated Biotechnology Firms (DBFs); 
• The selection environment with a constant budget to reward firms represents the 
market dynamics; 
• Firms' knowledge environment involves two knowledge bases (one for each 
technology) which are independent from each other and to some extent exogenous. 
The knowledge bases develop with the input of public research institutions 
(exogenously) and with intra-industry spill-overs (endogenously); 
• Absence of firm exit in the industry. 
Figure 12 outlines the main decisions, variables and processes shaping the activities of 
a sample firm and its interactions with the knowledge environment. The next sections 
elaborate on the main issues. 
4.1.1 The search space 
To specify the process of drug discovery in the model a search space is modelled 
where firms look for potential medicines (or drug candidates) i . As given in Eq 1, in the 
search space each potential medicine i  is defined by a parameter iq  (representing its 
quality) and a variable itp  indicating whether the potential drug is still waiting to be 
discovered, it has already been developed or is available for imitation. Imitation of pro-
ducts is only possible if the patent protection has expired (20 periods after the dis-
covery of the drug).  
Eq 1 ( ) { };1, Nipqi iti K=≡  
iq := Quality of the potential drug i; 
itp := Intellectual property rights variable; 
⎪⎩
⎪⎨
⎧
=
over.isimitation  from protectionfor   period the if2
 imitation; from protected is and  developedbeen  has drug the if1
jet; discoveredbeen not  has drug the if0
itp  
The number of potential drugs N  is exogenously given. The quality iq assigned to 
each potential drug i in the search space is determined in the first period of the 
simulation trough a random process as given in Eq 2: 
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Eq 2 ).,(~ baNqi  
Figure 13 presents the search space of potential products that the companies face in 
the process of drug discovery. 
The firms search and compete for potential drugs with the highest quality in the search 
space. The goal is to discover or imitate drug candidates with a high therapeutic  
quality. The selection environment only accepts products with a therapeutic quality 
level over a given standard *q . In the search and selection process firms have 
bounded rationality which prevents them from accessing the entire search space and 
from recognising the true quality of the drug candidates. The accuracy of their search 
process depends on their technological capabilities. Additionally, the area of the search 
space they have access to is also a function of their technological capabilities. 
Figure 13: The search space of drug candidates 
i
N(a,b)
a
iq
q
 
4.1.2 The technologies 
Technologies ease the search process by allowing firms to approach the search space 
in a more effective way. The search process involves the application of two 
technologies: technology "S" (which represents organic chemical synthesis and 
determines the extension of the landscape of compounds a firm can access) and 
technology "B", given by jtσ  in Eq 3, (which represents biotechnology and determines 
the observation error of the companies in the search process). Technology 
effectiveness is firm specific. In other words, firms have different level of technological 
capabilities, which determine firm's technological achievements and the extent to which 
they are able to exploit technologies effectively. Therefore, firms are heterogeneous 
since the conditions under which they access the search space are not the same for 
every firm. Figure 14 presents a graphic representation of technology specification in 
the formal model. 
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Figure 14: Technologies to explore the search space. Technology B determines 
the firm's error of observation ( jtσ ). Technology S determines the 
range of search space the firm can explore ( jtS ). 
q
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Given the true quality of a drug candidate iq  and the error of observation of firm j in 
the search process (technological level reached by the firm in period t in technology B 
jtσ , Eq 3 gives the quality of the drug candidate perceived by firm j:  
Eq 3  ( )jtiijt qNq σ,' = . 
Given the starting position within the search space where firms start searching in each 
period, the achievement in technology S ( jtS ) gives the scope of the search space 
firms have access to. The starting point in every period is given by a uniform probability 
distribution. 
The maximum effectiveness a technology can reach is given by its technological 
frontier. Technological frontiers in each technology SF  and BF  are exogenous and 
determine firm's technological gaps SjtG  and 
B
jtG , which are defined by the distance of 
firm's technological performance in each technology jtS  and jtσ  to the respective 
technological frontiers and given in Eq 4: 
Eq 4 jt
S
t
S
jt SFG −=  with  jtSt SF ≥ ; 
B
tjt
B
jt FG −= σ  with  Bjtjt F≤σ . 
The model stresses the knowledge dimension of technologies, which implies that in 
order to make a technology work, knowledge is needed. The larger the capabilities 
available to make a technology work are, the nearest the technological achievements 
of the firm to the technological frontier. Accordingly, technology development at the firm 
level draws on learning processes that yield to the accumulation of capabilities.  
Drawing on Malerba et al. (2002), the rates of technological change jtr  are firm specific 
and depend on the stock of technological capabilities of the company jtK  and on its 
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technological gap jtG  (i. e. distance of the technological achievement of the firm to the 
technological frontier F ) in each technology, respectively. As firm's performance nears 
the technological frontier, technical improvement requires more capabilities. Moreover, 
this process is not totally deterministic. To stress the uncertain character of 
technological change, a stochastic term e  is included in the equations giving the rates 
of technological development jtr .  
The rates of technological change at the firm level are given in equations Eq 5 and Eq 
6: 
Eq 5 Sjtjtjt rSS =− −1       with 0jS the initial technological level of firm j; [ ] [ ] ;21 eKGr aSjtaSjtSSjt ⋅⋅⋅= θ  
Sθ := Scaling parameter; ( )2.1,8.0~ Ue ; 1a < 2a <1; 
Eq 6  Bjtjtjt r−=− −1σσ       with 0jσ  the initial technological level of firm j; [ ] [ ] eKGr bBjtbBjtBBjt ⋅⋅⋅= 21θ  
Bθ := Scaling parameter; ( )2.1,8.0~Ue ; 1b < 2b <1. 
Technological improvements in technology S enlarge the area of the search space jtS  
a firm has access to. Technological improvements in technology B reduce the error of 
observation of the firm jtσ  in the selection of drug candidates with high therapeutic 
qualities. 
4.1.3 The knowledge environment 
In their learning processes firms can access the knowledge environment. The model 
specifies two knowledge bases external to the firm (i. e. two extramural knowledge 
bases). These are brought about (i) by the effort of public research organisations 
conducting scientific research driven by the incentive of understanding processes and 
disseminating their research results, (ii) by the volume of knowledge firms are willing to 
share through cooperative research or licensing activities and (iii) by knowledge and 
technology intra-industry spill-overs (since normally the conditions of the technological 
regimes can not guarantee the technicians’ appropriation of his or her technological 
advances).  
As given in Eq. 7, the model includes two extramural knowledge bases (one per 
technology) involving the action of public research institutions z , the intra-industry 
knowledge spill-overs (determined by the rate of spill-overs φ ) and the knowledge 
available through collaborative activities jtΩ : 
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Eq 7 ∑
≠
Ω++=Ζ
jJ
J
S
jt
S
Jt
SS
jt Kz ;φ  
∑
≠
Ω++=Ζ
jJ
J
B
jt
B
Jt
BB
jt Kz .φ  
The scientific knowledge provided by public sector research institutions is exogenous 
and constant in every period. The knowledge available through collaborative 
arrangements is endogenous, firm specific and depends on the collaborative activities 
of the firm (see Eq 21 below). Moreover, the ability to access the extramural knowledge 
bases depends on the absorptive capacity of the firms (see Eq 11 bellow). These two 
last characteristics of the model regarding firms' extramural knowledge base 
emphasise the evolutionary perspective of the firm according to which firms are 
heterogeneous and, even if firms are embedded in the same knowledge environment, 
their ability to exploit it varies across firms.  
4.1.4 Characterisation of the firm 
As given in Figure 12 at the beginning of the chapter, the model includes firms con-
centrating on two activities: learning and marketing. The aim of firm's learning is to 
create technological capabilities that enable them the effective search for products in 
the search space. Learning processes can be external or internal to the firm (Malerba, 
Orsenigo 1993; Santos 2003). External learning enables, on the one side, awareness 
of existence of new technological opportunities through the exploration of the science 
base and, on the other side, collaboration and knowledge transfer between the firm and 
actors shaping the articulation of the science base into useful technological processes 
(see Figure 12). Firm's marketing activities, on the other hand, aim at promoting the 
image of the firm's product portfolio.  
The extent to which a firm engages in learning or in marketing activities is the result of 
firm's decision-making process determined by the strategic paradigms of the firms. 
From an evolutionary perspective this is considered a path dependant process in the 
sense that firms can not change their strategic paradigms easily or at no cost (see 
section 2.5.2.3). 
Firm's strategic paradigms shape hence its learning strategy and determine its pre-
ference for a technological trajectory. 
Firm's learning strategy 
Firm's learning strategy is given by the variables 1≤jtβ  and 1≤jtλ , which determine the 
budget invested in learning ( jtjt B⋅β ) and the share of the learning budget directed to 
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external learning ( jtjtjt B⋅⋅ βλ ). The budget invested in external learning serves to 
accumulate capabilities for exploring the science base, for collaborating with other 
companies or public research organisations and for acquiring licences. The budget that 
is not invested in learning )1( jtβ− is planned for marketing activities. 
Eq 8 gives the budgets invested in internal and external learning in every period ( WjtL  
and EjtL ), where jtB represents the total budget available to finance firm's activities. 
Eq 8 ;)1( jtjtjt
W
jt BL ⋅⋅−= βλ  
.jtjtjt
E
tj BL ⋅⋅= βλ  
Firm's technological trajectory 
In the model proposed firms develop a technological strategy determined in every 
period by the variable jtα , which represents the firm's bet on the technology being 
worth developing in-house (Malerba et al. 1999). The larger jtα , the greater the budget 
share invested in technology S. The budget share invested din technology B is hence 
jtα−1 . 
To capture bounded rationality in decision-making the variables jtβ , jtλ  and jtα  are 
uniform randomly distributed. To capture firm heterogeneity and path dependence the 
upper and lower bounds of the uniform distributions ),( 21 jjU ββ , ),( 21 jjU λλ  and 
),( 21 jjU αα are firm specific and constant.72 
To sum up, firm's technological capabilities in every period are created through internal 
and external learning: New technological capabilities in each technology developed in 
every period by firm's internal learning Wjtl  are given by Eq 9. The variable jtα  
determines firm's technological focus. The logarithmic function implies decreasing 
returns of investment in learning in the short term: 
                                                
72  For reasons of simplicity, the specification of the investment decisions does not follow the 
satisficing behaviour rules put forward by Nelson and Winter (Nelson, Winter 1982). In their 
history-friendly models Malerba et al. (Malerba et al. 1999, p. 13) also choose this strategy 
of simplifying the investment decisions and model investment decisions with constant 
investment rates. 
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Eq 9 ( ) ;1log, WjtjtSWjt Ll ⋅+= α  ( ).)1(1log, WjtjtPWjt Ll ⋅−+= α  
On the other side, firm's investment in external learning EjtL  contributes to the 
accumulation of organisational capabilities Ejtl  to exploit extramural knowledge. This 
stock of organisational capabilities is accumulated according to the expression given in 
Eq 10: 
Eq 10 ( )EjtEjtEjt Lll +⋅+= −11log ω  with 1<ω . 
This stock of organisational capabilities shape the “absorptive capacity” jtγ  of the firm, 
which determines the extent to which firm j is able to integrate and exploit its 
extramural knowledge base (Cohen, Levinthal 1989). The model uses the functional 
specification of absorptive capacity put forward by Llerena and Oltra (2002) given in 
Eq 11, where ϕ stands for the degree of complexity of the extramural knowledge 
base: 
Eq 11 ⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛ ⋅−=
E
jt
jt
l´
21 ϕγ with ∞≤≤ Ejtl24ϕ . 
Accordingly, besides the creation of technological capabilities through internal learning 
given by Eq 9, external learning provides the firm in every period with the technological 
capabilities Ejtl  in each technology as given by Eq 12. These are a function of the 
absorptive capacity ( jtγ ) of the firm and firm's extramural knowledge base jtΖ  in each 
technology: 
Eq 12 ;, Sjt
SE
jt Zl ⋅= γ  
., Bjtjt
BE
jt Zl ⋅= γ  
4.1.5 Accumulation of technological capabilities 
The technological capabilities created in every period can be accumulated over time. 
Both, capabilities created through external and internal learning Wjt
E
jt landl  contribute 
to this accumulation process. However, capabilities in both technologies depreciate 
over time at a rate δ ; so that in order to maintain an adequate level of technological 
capabilities firms need to invest constantly in learning activities. The capabilities 
accumulation processes in technology S and technology B of firm j at time t are given 
 101 
in Eq 13. Both stocks of capabilities determine the total stock of technological 
capabilities in drug discovery and development jtK  of firm j at time t: 
Eq 13 ( ) ;1 ,,1 SEjtSWjtSjtSSjt llKK ++⋅−= −δ  ( ) ;1 ,,1 BEjtBWjtBjtBBjt llKK ++⋅−= −δ  
B
jt
S
jtjt KKK += . 
Technology development at industry level is given by the simple aggregation of the 
stock of technological capabilities of the firms in the industry (which includes only those 
firms holding a drug portfolio)73 in every period as given in Eq 14 and Eq 15: 
Eq 14 ;∑=
j
S
jt
S
t KI  
S
tI := Stock of capabilities in technology S at industry level in period t; 
S
jtK :=Stock of capabilities of firm j in technology S in period t; 
Eq 15 ;∑=
j
B
jt
B
t KI  
B
tI := Industrial stock of capabilities in technology B in period t; 
B
jtK :=Industrial stock of capabilities of  firm j in technology B in period t. 
 
4.1.6 Firm's perception of discontinuities in the knowledge en-
vironment and adoption of the new technological oppor-
tunities 
The knowledge environment can experiment discontinuities brought about by scientific 
advances. Due to the science-based character of the industry, scientific advances 
contribute to technological change. However, the model presents firms as the carriers 
of technology and, therefore, technology development draws on firms exploiting and 
developing the new technological opportunities offered by scientific discontinuities. 
Consequently firms need to become aware of scientific discontinuities and decide 
                                                
73  Firms make part of the industry (and hence contribute to the accumulation of capabilities at 
the industry level) as long as they are able to successfully develop products and compete 
in the selection environment. Other wise their capabilities are not considered in the 
aggregation process of the industry since they are not consider as "pharmaceutical 
companies". 
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whether or not integrate them in their technology development processes. In the 
tradition of Nelson and Winter (1982) this decision is implemented as a stochastic 
process with probability AjtW  given by the Eq 16: 
Eq 16 ;exp1
2
⎟⎟⎠
⎞
⎜⎜⎝
⎛ ⋅−−= υ
η EjtA
jt
l
W  with η :=Scaling parameter. 
The probability AjtW  of perceiving and adopting the discontinuities in the knowledge 
environment is a function of the stock of organisational capabilities of the firm for 
external learning Ejtl  and the expected additional costs of integrating the new scientific 
discoveries υ . Figure 15 illustrates how these factors and the parameter influence the 
probability. 
Figure 15: Probability to perceive and adopt new technological opportunities 
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Again, the process is stochastic. The firm accesses an adoption "lottery" where the 
adoption decision is taken as long as the probability is larger than the so called 
"adoption draw" ( )1,0~Ubt  and the level of capabilities of the firm for external learning 
in period t Ejtl  is larger enough than the adoption costs υ . 
Eq 17 ⎪⎩
⎪⎨
⎧
<
>≥=
.0
;21
t
A
jt
E
jtt
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jt
jt bWifdisregard
landbWifadoption
A
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Due to the specificities of the discontinuity in the knowledge base (in terms of the 
complexity for instance) and the novelty of the underlying scientific results, the adoption 
and integration of the scientific advances available imply additional costs υ  for the firm. 
These costs burden the firm (by diminishing its profits) for a certain number of periods. 
The burden decreases in every period at rate θ , after the firm has started to explore 
the new technological opportunities offered by the discontinuity. 
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4.1.7 Collaboration 
Scientific advances may bring about radical technological change. According to the 
appreciative theory previously discussed, in the case of the pharmaceutical industry, 
the revolutionary discoveries of recombinant DNA for instance provoked the 
emergence of modern biotechnology and the entrance of new firms mastering the new 
technological opportunities offered by biotechnology (DBFs). Incumbent firms entered 
into collaborative arrangements with the new entrants.  
Accordingly, the model specifies the possibility for incumbent firms having perceived 
technological discontinuity of entering into collaborative arrangements with the new 
entrants. The process of entering into collaborative arrangement is modelled as a 
stochastic process. The probability AjztW  that two firms (an incumbent j and a new 
entrant z) achieve a collaborative agreement is a function of the stock of capabilities for 
external learning of the incumbent firm Ejtl  (which captures the extent to which the 
research strategy of the firm considers the active interaction with the actors involve in 
shaping its knowledge environment) and the distance between the two firms in the 
search space of potential drugs jztπ  (which represents the extent to which the potential 
partners may have the same research objectives). The probability is given by Eq 18: 
Eq 18 ;exp1
2
⎟⎟⎠
⎞
⎜⎜⎝
⎛ ⋅−−=
jzt
E
jtC
jzt
l
W π
ν
 with ν representing a scaling parameter. 
Again, the firms enter into a "collaboration lottery" given in Eq 19 to determine whether 
the collaboration occurs or not. 
Eq 20 ⎪⎩
⎪⎨
⎧
<
≥=
;0
;1
t
C
jzt
t
C
jzt
jzt dWif
dWifioncollaborat
C  
jztC := result at time t of the process of collaboration between firm j and z; 
( )1,0~Udt . 
After two periods the termination of a collaboration agreement is considered by 
activating the same stochastic process, (after updating two variables: the location of 
the firms in the search space and the engagement of the incumbent firm in interacting 
with its environment). For reasons of simplicity the model specification does not allow a 
DBF to hold more than a collaborative agreement simultaneously. Incumbent firms 
however, can have several collaboration partners. 
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A collaborative arrangement between incumbent firm j and a DBF z has two main 
implications. Firstly, the incumbent firm has access to a share of the technological 
capabilities BztKϑ  of its collaboration partner. Given that the incumbent firm may have 
many collaboration partners, the technological capabilities that add up to the extra 
mural knowledge of incumbent firm  j in every period BjtΩ  are given by Eq 21: 
Eq 21 ∑=Ω
z
B
zt
B
jt K .ϑ  
As part of the firm extramural knowledge, the extent to which firm j is able to absorb the 
capabilities of its collaboration partners and integrate them in its search and 
development activities depends on its absorptive capacity.74 Moreover, incumbent 
firms have the possibility to licence the potential drug candidate of highest quality within 
the portfolio of drug candidates of the DBF partner. Moreover, after a licensing 
agreement incumbent firms can exploit the drug candidate even after the collaboration 
has been terminated. Accordingly, after successful development, licensed products 
enlarge the product portfolio of incumbent firms in the selection environment as their 
own products. Drugs of DBFs can be licensed only once.  
4.1.8 The innovation process 
Firms innovate when they are able to develop drug candidates (new discoveries, 
imitations or licensed drug candidates of their partners) that are not included jet in their 
product portfolio and reach the quality standards required by the selection environment. 
In every period firms move in the search space looking for an attractive drug candidate 
as given in Figure 12 (or by collaborating with new entrants if a technological transition 
has taken place). The selection is based on the quality of the potential drug (which is 
unknown and can only be estimated by the application of technology B). These drugs 
might be totally new for the selection environment or imitations. New products are 
protected from imitation for 20 simulation periods. The extent to which the innovation 
process succeeds depends on the stock of technological capabilities accumulated by 
the firm. However, the result of the innovation process remains a stochastic process 
(Nelson, Winter 1982). By accumulating capabilities in drug discovery and development 
jtK  firms can increase the probability of successful innovation/imitation 
I
jtW  which is 
given by Eq 22 and sketched in Figure 16: 
                                                
74  See Eq 7 and Eq 12 for related equations giving the extramural knowledge base of the firm 
and the extent to which this on is integrated in the technological capabilities of the firm. 
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Eq 22  ( );exp1 jtIjt KW ⋅−−= µ  with µ := Scaling parameter. 
Figure 16: Probability to innovate IjW  
I
jW
jK  
Accordingly, the model specifies the cumulative character of technology in the 
innovation process since the accumulated stock of technological capabilities (and not 
the new technological capabilities created in every period) influence the probability to 
successfully develop new products or imitate them.  
With this probability to successfully develop potential drugs selected from the search 
space or licensed into products, firm j accesses in each period the so called "innovation 
lottery" which determines the success of the innovation process ijtI . The random draw 
in the innovation lottery of firm j at time t is given by a uniform random distribution ( )1,0~ Ua jt .  
Eq 23 ⎪⎩
⎪⎨
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I  
with ijtI := result of the process of developing the drug candidate i by the firm j at period t. 
A successful innovation implies that the firm's portfolio of products increases in one 
drug and the selection environment has an additional product against diseases. This 
happens only if the novel drug selected (or the generic developed) reaches the 
minimum quality determined by the standards *q in the selection environment.  
Once a product is accepted by the selection environment the firm supports it with 
marketing campaigns to improve the product's image. The aim of the firm's marketing 
campaign is to increase the "merit" of the product which determines the reward the firm 
obtains from the selection environment. This volume of marketing efforts jtM  to reach 
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a desirable product image is given in equation Eq 24, where jβ  stands for the 
investment share for learning activities and jtΒ  for firm’s budget. 
Eq 24 .)1( jtjtjt BM ⋅−= β  
4.1.9 The selection environment 
Drawing on the evolutionary tradition firms face a selection environment that evaluates 
the products (drugs) they develop and commercialise. In each period companies 
approach the selection environment with their portfolio of products developed so far. 
Accordingly, the products available in the selection environment are those discovered 
and developed by all the firms in the industry. The selection environment only accepts 
products that reach certain quality standards. In other words, as in the pharmaceutical 
industry is the case, products can be introduced in the selection environment as long 
as they reach a minimum level of quality set by the system. 
Firms are rewarded by the selection environment according to the “aggregate merit” of 
their product portfolio compared to the aggregate merit reached by the industry. For 
this purpose the selection environment has a budget ψ .The reward from the selection 
environment is used to finance firm's activities.  
The products in the selection environment are evaluated and given a certain "merit". 
Drawing on Malerba and Orsenigo (2002) in every period the merit of product de-
veloped by the firm j tijU  depends on three factors: 
(i) the true quality of the product ijq , 
(ii) its expected return on investment ir , which is higher for novel products than for 
generics and  
(iii) its image ijtc , which in turn depends on the marketing investment of the firm for 
that particular drug )( ijj tM . 
The relevant expressions concerning these variables are given in Eq 25 and Eq 26:  
Eq 25 ( ) ;/10 cba mijtmimijtji crqmU ⋅⋅⋅=  with 0m :=scaling parameter and am < bm < cm . 
Eq 26 { } ;)(exp)(
0
⎪⎩
⎪⎨
⎧
≥−⋅⋅
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tji ttiftttM
ttif
c ρ  
where ρ  represents the rate of erosion of the image of a product. 
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The merit share reached by firm j in each period jtF  is given by the aggregated merit 
of the products developed by firm j related to the aggregated merit of the products in 
the selection environment.  
Eq 27 ∑
∑
=
ji
tji
i
tji
tj U
U
F ; 
As given in Eq 28, the budget to reward firms ψ  and the merit share of the firm j jtF  
determine firm’s revenue in period t. 
Eq 28 .ψ⋅= tjtj FR  
Finally, the profit jtπ  of firm j in each period is determined by the sum of the non 
expended budget (after considering the current investment research and technology 
development jtL , the marketing investments for launching a new product jtM  in the 
periods where a medicine is offered to the health system and the costs of adopting new 
technological opportunities jtT in the periods where these activities take place) and the 
revenue tjR . Eq 29 gives the relevant expression: 
Eq 29 ;jtjtjtjtjtjt RTMLB +−−−=π  
The profit is reinvested in the activities of drug discovery and development and 
marketing. The budget of a firm is given by Eq 30:  
 
Eq 30 ⎪⎩
⎪⎨⎧ >
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− ;0
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jtB := Budget for drug discovery, drug development and marketing activities; 
jtπ :=Profit of firm j at time t. 
4.1.10 The transition dynamics 
The model is dynamic. Accordingly the specification defines the transition from stage t 
to stage t+1 as given in Figure 17. 
The transition dynamics include stochastic processes. These are represented in 
Figure 17 with circles. In the spirit of the Nelson and Winter models, the state of the 
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industry in any period determines the probability distribution of the state of the industry 
in the next period. The specification of the transition from the state at time t to the state 
at time t+1 has the character of a stochastic Markov process. However, inspired by 
Llerena and Oltra (2002), probabilities do not depend on current variables (such as in 
the Nelson and Winter models). In the model put forward in this contribution, the 
probability to innovate, to perceive discontinuities in the knowledge environment and to 
collaborate depend on the stock of accumulated capabilities rather than on current 
investment.  
Figure 17: Transition dynamics in the model  
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4.2 Simulation experiments 
According to Malerba (1999), to test the logic of an appreciative theory as the one 
presented in chapter 3 it is necessary to demonstrate that a stylised formal model 
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incorporating the appreciative theory is able to reproduce the observed historical 
patterns.  
The first step is to implement the model described in the previous section in a 
numerical simulation model. The implementation of the simulation model has been 
done using object-oriented programming. This approach allows building models with a 
structure made of a set of objects. Objects are abstract entities, referred to with a name 
or label, which can contain either other objects or numerical variables. Objects are 
devoted to present entities of the reality the model aims at simulating like, for example, 
market, firms, capabilities, products etc. Stochastic and deterministic functions and 
numerical parameters specify initial conditions, object interaction and transition 
dynamics from one stage to the next (Valente 1998).75  
Next, to replicate the pattern of technological change of the industry described in 
chapter 3, a parameter setting will be specified capturing the key stylised facts given in 
the appreciative theory. Additionally, the simulation environment allows building 
counterfactual scenarios by specifying alternative parameter settings that might 
contradict the main assumptions of the appreciative theory. This procedure enables, on 
the one side, to prove the logic of the theory developed. If the logic is coherent, a 
parameter setting that does not correspond to the basic stylised facts of the 
appreciative theory should produce history divergent results. Finally, the results can 
have relevant policy implications.  
Section 4.2.1 discusses the specification of the history-friendly scenario and presents 
the results of the simulation runs replicating the pattern of technological change in the 
German pharmaceutical industry in the 20th century driven by the development of 
biotechnology and synthetic organic chemistry and discussed in chapter 3. The 
counterfactual analysis is presented in section 4.2.2 
4.2.1 The history-friendly scenario 
The history-friendly scenario aims at reproducing the historical patterns of technological 
change presented in chapter 3. The empirical analysis carried out from the industrial 
and organisational perspectives (sections 3.3 and 3.4) constitute the basis for the 
parameter setting of the model. More specifically, the value of the parameters related 
to the technological regimes, such as complexity of the scientific knowledge base,  
                                                
75  The software used has been the Laboratory for Simulation Development (LSD), freely 
available at http://www.business.aau.dk/lsd/lsd.html. The parameters and important parts 
of the programming code are included in annex III and IV. 
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appropriability conditions (spill-overs) or the cumulativeness of technological 
capabilities in terms of level (high or low) draw on the analysis carried out in 
section 3.5. On the other hand, the selection of the parameters related to the 
characterisation of the firms draw on the organisational analysis carried out in 
section 3.4.7. 
An important aspect of the parameter setting of history-friendly models is the fact that 
the level of the parameters is not grounded on econometric or statistical analysis. The 
values of the parameters need to be numerically coherent with the model specification 
and match the stylised facts of the appreciative theory. However, the numerical values 
themselves do not represent an accurate empirical result in absolut terms.76  
A simulation run includes 100 periods. In each period the cycle specified in Figure 17 
updates the stage of the industry in terms of level of technological capabilities (Eq 14 
and Eq 15). This process includes the update of variables at the organisational level 
such as firms' investment decisions and research, learning and marketing activities as 
specified in the previous sections, as well as their performance regarding collaboration 
and innovation. It is assumed that firms in their real managerial activities revise such 
decisions yearly. Accordingly, a simulation period corresponds to a year. 
The next section presents the main assumptions concerning the parameter setting re-
plicating the historical pattern of technological change given in the appreciative theory 
and summarised in section 3.5. The discussion of the parameter setting starts with a 
general description of the main exogenous events introduced in the simulation 
concerning the knowledge environment and firm entry. Next, a detail specification of 
the parameters determining firm's strategic paradigms is presented. Moreover, the 
arguments behind the parameters influencing the technological regimes and their 
changes are discussed in detail.  
                                                
76  For instance, to capture the stylised fact based on the empirical analysis that the revolution 
of molecular biology in the 1950s brought about a change in the nature of biotechnology's 
science base and moreover, that the emergence of modern biotechnology involved 
revolutionary scientific advances, two exogenous discontinuities specified in the simulation 
increase the degree of complexity of the firms’ extramural biotechnology knowledge base 
Bϕ (see Eq 11). The appreciative theory developed in chapter 3 does not allow us to 
assign an accurate value to the parameter Bϕ  (degree of complexity of the knowledge 
base) after the discontinuities occur, but it does allow us to put forward an increase of 
complexity after the scientific advances. 
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4.2.1.1 Exogenous discontinuities, firm entry and collaboration 
The stylised facts distinguished 3 phases in the evolution of the German 
pharmaceutical industry from the 1880s to the end of the 20th century. The history-
friendly model introduced in this chapter covers the three phases and involves 2 main 
exogenous discontinuities in the knowledge environment. Accordingly, in a simulation 
run (100 periods) exogenous discontinuities are introduced in the periods t=50 and 
t=75. The discontinuity at t=75 allows for firm entry and the establishment of 
collaborative agreements between industry incumbents and new entrants. 
 
First discontinuity (t=50) 
This event tries to capture the effects of the revolution of molecular biology in the 
1950s in the German pharmaceutical industry. It involves the following changes in the 
knowledge environment: 
• The knowledge base related to technology B expands due to novel scientific 
advances and to an increase in the volume of research results from foreign public 
research organisations (see Eq 7); 
• The technological frontier of technology B moves to allow for further 
improvements of the firms in this technology (see Eq 4 and Eq 6). Additionally, 
the scientific knowledge base of technology B becomes more complex (see 
Eq 11); 
• Only those firms perceiving the novel scientific advances exploit the new 
technological opportunities (depending on their level of absorptive capacity) and 
start trying to reach the new technological frontier (see section 4.1.6).  
Second discontinuity (t=75) 
This event represents the advent of modern biotechnology in the 1970s, the 
establishment of the biotechnology industry and innovation networks. This transition is 
specified as follows: 
• The opportunity conditions for innovation increase. The landscape of molecules 
changes to include more potential drugs with higher therapeutic quality. 
However, again only those firms perceiving the new scientific advances and 
integrating them have access to additional drug candidates in the landscape of 
molecules. The opportunities for innovation increase hence only for these 
companies; 
• The novel scientific advances turn the scientific knowledge base of technology B 
more complex. At the same time the technological frontier of technology B 
moves further to allow for additional technological improvements of the firms in 
this technology; 
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• The transition is to some extent competence destroying in the sense that it 
challenges the ability of incumbent firms to accumulate technological capabilities 
in technology B given the new conditions in the knowledge environment. The 
maintenance of the level of capabilities in technology B requires more effort 
since, due to novel scientific advances, in every period the share of capabilities 
in technology B becoming obsolete is larger than in the past (see Eq 13); 
• Dedicated Biotechnology Firms (DBFs) enter the industry. 
Firm entry and collaboration (t=75) 
DBFs are characterised by their exclusive engagement in the development and 
application of technology B. Accordingly, the companies have no marketing 
capabilities. This handicap prevents them from bringing in potential drug candidates 
they have discovered into the selection environment and obtaining a reward. However, 
they have access to a fix budget in every period (capturing the access to venture 
capital or public subsidies of Dedicated Biotechnology Firms), which is the financial 
basis of their learning activities to develop technology B.  
Regarding their technological performance in the application of technology B, DBFs 
enter the industry with a technological performance that equals the technological 
frontier. In other words, DBFs are able to fully exploit the technological opportunities 
offered by technology B when they enter the industry. In what concerns their 
technological achievement in technology S, they are far away from the technological 
frontier and therefore, compared to incumbent firms, they have access to a relatively 
narrow scope of the search space. Due to their exclusive engagement in the 
development of technology B they do not develop any capabilities in technology S and 
therefore, they do not experience any improvement in what concerns the application 
and development of this technology.  
The simulation allows for the establishment of collaborative arrangements (i. e. the 
model specification allows for collaboration only after t=75). Incumbent firms have the 
possibility of entering collaborative arrangements with the new entrants (see 
section 4.1.7).  
According to the model specification, t he role of DBFs is twofold. On the one hand, 
they act as potential collaboration partners for incumbent firms (firms of type DC and 
TP). For incumbent firms a collaboration agreement entails the possibility of acquiring 
additional knowledge to develop biotechnology capabilities (technology B). Therefore, 
DBFs can be considered as a source of knowledge in incumbents' extramural 
knowledge base. On the other hand, due to the excellence of DBFs in technology B, 
these may be able to develop products of higher therapeutic quality than incumbent 
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firms. Collaborative arrangements involve the possibility for incumbent firms of 
obtaining the rights for the commercial exploitation of products developed by DBFs. 
4.2.1.2 Parameter setting regarding firms' strategic paradigms 
With regard to the number of firms, at the beginning of the simulation the model 
presents an industry with 4 firms: two of firm type DC (representing dyestuff 
companies) and the other two firms of type TP (representing traditional pharmaceutical 
companies). In period t=75 the specification of the model allows for the entry of 14 
firms of type DBF. Table 9 gives the relevant variables specifying firms' strategic 
paradigms and its values.77 
Table 9: Firms' strategic paradigms: Variables for the characterisation of the 
firms in history-friendly simulation runs 
 Firm Type 
Variables and description TP DC DBFs 
jtβ := Investment share directed to learning U (0.5 , 0.7) U (0.5 , 0.7) 1 
jtλ := Investment share directed to external 
learning 
U (0.1 , 0.2) U (0.3 , 0.4) 1 
jtα := Company's bet on the technology being 
worth developing 
U (0.3 , 0.5) U (0.6 , 0.8) 0 
This parameter setting at the level of the organisation aims at capturing, in an extreme 
form, the strategic paradigms of the firms, i. e. the different research traditions and 
technological roots of the firms in the industry.  
As given in Table 9, three variables determine the behavioural and cognitive 
characteristics of a firm. On the one side, the variables jtβ  and jtλ  determine its 
learning strategies. As introduced in section 4.1.4, firms' learning strategies aim at 
creating and accumulating technological capabilities to carry out search and 
development activities.  
Companies of type TP and DC are assigned parameter values according to which the 
share of their budgets invested in learning in every period jtβ  is uniformly distributed 
between 0.5 and 0.7. Even though the probabilistic distribution and its limits remain 
constant, the variable is updated in every period. The fact that the probability 
distribution and the limits of the stochastic parameters are time invariant is a strong 
simplification of the model.  
                                                
77  The complete list of parameters and their values are included in annex III. 
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The learning budget can be invested in internal and external learning. The share of 
investment for external learning jtλ  (which determines the share of the learning budget 
to finance activities promoting learning by searching and learning by interacting in the 
sense of Malerba (1993)) differs among companies. In accordance with the stylised 
facts discussed in section 3.4.7, the engagement of firms of type DC in external 
learning is stronger than in the case firms of type TP.78 Again, the variable is uniformly 
distributed and is updated in every period even though the probabilistic distribution and 
its limits remain constant.  
The variable jtα  captures companies’ technological strategy (i. e. companies' bet on 
the technology being worth developing in-house). Firms of type DC have a preference 
for technology S while firms of type TP have a slight preference towards the 
development and application of technology B.  
With regard to DBFs, this type of companies appears in the simulation at t=75. DBFs 
invest their entire budget in learning, which implicates that no resources are invested 
for marketing activities. Moreover, DBFs are exclusively engaged to external learning. 
Therefore, they are characterised by a deterministic parameter jλ  equal to 1. 
Additionally, to capture their exclusive engagement in technology B, jα  is deterministic 
and equal to zero.  
4.2.1.3 Parameter setting regarding the technological regimes  
The history-friendly model aims at replicating the stylised facts discussed after the 
establishment of the modern pharmaceutical industry. In this phase already two 
technological trajectories (biotechnology and synthetic organic chemistry) shaped drug 
discovery and development processes. Accordingly, the exploration does not cover the 
emergence of technologies. It focuses in their development and relative importance for 
the pharmaceutical industry over time. 
                                                
78  According to the stylised facts, the differences between dyestuff companies and traditional 
pharmaceutical companies in terms of R&D expenditures as share of their sales have not 
been significant. However, dyestuff companies were characterised by strong interaction 
with the knowledge environment in terms of collaboration and by following science-based 
research strategies. Traditional pharmaceutical companies, on the other hand, have 
traditionally empirical (trial-and error or learning by doing) research strategies and, to some 
extent, do not interact as much as their counterparts with the actors in their knowledge 
environment. Moreover, dyestuff companies were very much focused on the application of 
the organic chemical synthesis, while the representatives of the traditional pharmaceutical 
industry had positive attitudes towards the application of biotechnology, and had applied it 
and developed it in the first half of the 20th century. 
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To set the parameters characterising the dimensions of the technological regimes 
shaping the different phases of the pharmaceutical industry the analysis draws on the 
stylised facts elaborated in sections 3.3 and 3.4 of chapter 0. The relevant parameters 
capturing the staring situation and their changes have been discussed in the previous 
chapter and given in Table 8.  
In the parameter setting of the history-friendly scenario given in Table 8 the changes in 
the technological regimes are driven by the development of the knowledge base 
underpinning the application and development of technology B. The main change 
corresponds to the volume of scientific knowledge provided in every period by public 
sector research institutions Bz  after t=50. Additionally, the degree of complexity of the 
extramural knowledge base relevant for technology B Bϕ  increases. This effect aims to 
capture the changes in the nature of the knowledge base in terms of the number of 
disciplines contributing to its development. Moreover, the depreciation rate of 
technological capabilities in technology B Bδ  increases to capture the difficulty of firms 
in keeping up with the intensive scientific development in technology B. 
Table 10: Relevant parameters for the characterisation of the technological 
regimes in the different phases of the industry in the history-friendly 
scenario 
Parameter and description 
Phase (I) 
0 <t<49 
Phase (II) 
50<t<74 
Phase (III)
75<t 
BF := Technological frontier of technology B (min. search error) 1200 700 300 
Bz := Scientific knowledge underpinning technology B provided in every 
period by public sector research institutions 
1.5 5 5 
Bϕ := Degree of complexity of technology B extramural knowledge base 0.22 0.24 0.28 
Bφ := Rate of intra-industry knowledge spill-overs in technology B 0.01 0.01 0.01 
Bδ := Depreciation rate of technological capabilities in  technology B 0.04 0.04 0.045 
SF := Technological frontier of technology S (max. search scope) 400 400 400 
Sz := Scientific knowledge underpinning technology S provided in every 
period by public sector research institutions 
3 3 3 
Sϕ := Degree of complexity of technology S extramural knowledge base 0.22 0.22 0.22 
Sφ := Rate of intra-industry knowledge spill-overs in technology S 0.01 0.01 0.01 
Sδ := Depreciation rate of technological capabilities in  technology S 0.04 0.04 0.04 
An important contribution of the advent of modern biotechnology for the pharmaceutical 
industry (technology B in our model) was the enlargement of the opportunity conditions 
for innovation. In the simulation model this changes is specified by giving firms 
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adopting and developing the new technological opportunities in technology B the 
possibility to discover new products with higher quality that were not available before. 
Accordingly, the search space varies for incumbent firms adopting the new 
technological opportunities available after t=75. 
4.2.1.4 History-friendly simulation results 
The next paragraphs and charts present the results of the history-friendly simulation 
runs. These match quite well the historical pattern of technological change described in 
chapter 3.  
The discussion of the results will be carried out at two levels of aggregation: the level of 
the industry and the level of the organisation. As for the industry level, the analysis 
focuses on technological change in terms of the relative importance of technology B 
and technology S and the rate of development of industrial capabilities in these 
technologies. As for the organisational level, the results consider the differences in the 
types of firm (TP, DC or DBF) and analyse the following aspects of firm behaviour:  
• Development of firms' technological capabilities  
• Firms' reaction to changes in the knowledge environment  
• Firms' collaborative behaviour  
• Quality level reached by the best products (i. e. firm's superior products) developed 
by each firm  
• Development of firms' product portfolio (in terms of number of products) 
• Reward obtained by firms from the selection environment in each period 
Figure 18 gives the results in terms of technological capabilities of the industry.79 
Technology S (representing the organic chemical synthesis) dominates the capabilities 
of the industry during the entire simulation. However, after the first discontinuity in the 
knowledge environment (t=50) technology S slows its development rate while the rate 
at which the industry develops capabilities in technology B increases. Next, after period 
t=75, the industry is not able to maintain the rate of development in creating capabilities 
in technology B. According to the specification of the model, the absorptive capacity of 
incumbent firms is weaken by the increased complexity of the extramural knowledge 
base relevant for technology B. However, the industry keeps developing capabilities in 
                                                
79  At this point it is most important to note that the values in the Y-axis standing for the 
technological capabilities of the industry deserve only a qualitative interpretation (in terms 
of low of high). In neo-Schumpeterian evolutionary models data are the numerical results of 
the simulation and do not aim at capturing the absolute volume of capabilities of the 
industry. The pattern of change is of relevance, not the aboslute values per se. This holds 
for all the data presented in the next sections. 
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technology B at a larger rate than capabilities in technology S. The results match 
remarkably well the stylised facts presented in section 3.5 and speak for a forthcoming 
change in the dominance of technologies in the industry.  
Figure 18: History-friendly scenario: Technological change in the industry (100 
simulation runs and average) 80 
Technology S Technology B
0
100
200
300
400
500
0 20 40 60 80 100
Time periodsT
ec
hn
ol
og
ic
al
 c
ap
ab
ili
tie
s 
of
th
e 
in
du
st
ry
(I) (II) (III)
 
Figure 19 gives the level of technological capabilities of the 4 incumbent firms specified 
in the simulation. Drawing on the stylised facts, the initialisation of the simulation 
specifies firms of type TP with a higher level of capabilities in technology B than 
capabilities in technology S while firms of type DC are larger and hold a relatively larger 
share of capabilities in technology S (see annex III for details on the initialisation of 
these variables). 
While the relative importance of the technological capabilities remains unchanged in 
the case of firms of type DC, firms of type TP experience a transformation in their 
technological identity. Even though the companies start the simulation with a large 
share of capabilities in technology B, already in period t=30 technology S dominates 
the capabilities for product search and development. Both types of companies 
accelerate the rate of development of technology B capabilities after t=50, even though 
in the case of firms of type TP the acceleration is weaker and it starts latter than in the 
case of firms of type DC.  
                                                
80  A simulation run includes stochastic processes based on computer-generated random 
numbers. An algorithm produces the random numbers, so they are not really random. The 
algorithm needs a number to start with (the so called seed). Simulation runs with the same 
parameter setting drawing on different seeds produce different random numbers and hence 
different simulation results so that the simulation's result depends on the seed chosen. To 
eliminate this deterministic bias the simulation results given in the tables present the 
average results of 100 simulations each with a different seed. 
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Figure 19: History-friendly scenario: Technological capabilities of the incumbent 
firms (average 100 simulation runs) 
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Table 11 gives detailed insight to the reaction of firms to discontinuities in the know-
ledge environment. Firms of type DC perceive the first technological discontinuity at a 
rate of 99 % and 98 %, respectively, while firms of type TP present lower average 
perception and adoption rates. The reactions to the next discontinuity are quite similar. 
Firms of type DC are better able to perceive and adopt the new technological 
opportunities. Adoption occurs in both cases often and faster in the case of the firms of 
type DC. These results are coherent with the specification of the model and with the 
logic of the appreciative theory. Commitment to external learning (as in the case of 
firms of type DC) enables perception and adoption of technological opportunities. 
Table 11: History-friendly scenario: Firms' reaction to discontinuities in the  
knowledge environment (average over 100 simulation runs)81 
 
 
Firm Type TP Firm Type DC 
  Firm 1 Firm 2 Firm 3 Firm 4 
Perception / Adoption rate 81 % 83 % 99 % 98 % 
t=50 
 
Average adoption period 69 67 60 61 
Perception / Adoption rate 51 % 53 % 92 % 86 % t=75 
 Average adoption period 86 85 82 84 
                                                
81  A perception / Adoption rate of 81 % in the case of firm 1 after the discontinuity at t=50 
means that firm 1 has perceived and adopted the technological opportunities given by the 
discontinuity in the knowledge environment in 81 out of 100 simulation runs. In average, 
adoption took place in period t=69. 
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After the discontinuity at t=75, Dedicated Biotechnology Firms (DBFs) introduce 
changes in the structure of the industry. Firms of type TP and DC have now the 
opportunity of cooperating with the DBFs and herewith the access to additional sources 
of knowledge related to technology B. Figure 20 gives the number of collaborations of 
incumbent firms (firms of type TP and DC) with the new entrants after the second 
discontinuity in t=75. Compared to their counterparts, firms of type DC interact more 
with DBFs.  
Figure 20: History-friendly scenario: Number of collaborations of incumbent firms 
(average 100 simulation runs) 
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Again, the results are coherent with the appreciative theory. Engagement in external 
learning (as in the case of firms of type DC) implicates larger number of collaborations 
with DBFs.  
Figure 21 gives the quality of firms' superior product candidates. After period  t=75, 
DBFs hold the drug candidates with the highest quality. Due to the fact that DBFs are 
at the technological frontier (that is, they carry out the search and selection process of 
product candidates in the search space with the lowest error of observation allowed) 
they are able to discover and (if already patented) imitate the potential drugs with the 
highest quality. However, these innovations remain drug candidates because DBFs 
have no marketing resources and hence they are not able to build up a drug portfolio 
and compete with incumbent firms.  
As given in Figure 21, firms of type DC are able to increase continually the quality of 
their best product candidate. In phase III the maximum quality reached improves more 
radically. In the case of firms of type TP this improvement is more incremental. 
Regarding the capacity of firms to develop products and add them up to the product 
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portfolio provided to the selection environment Figure 22 gives the size of firm's drug 
portfolio.  
Figure 21: History-friendly scenario: Quality of firm's superior product candidates 
(average 100 simulation runs) 
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Figure 22: History-friendly scenario: Size of firm's product portfolio (average 100 
simulation runs) 
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The results suggest that firms of type DC are more successful in bringing products to 
the selection environment. Their success is more evident in phase III. Even though 
firms of type DC start the simulation with a larger volume of capabilities, the results 
suggest that firms of type TP are able to follow them by introducing innovations at the 
same pace. In phase III the differences of performance are clearer. These results are 
consistent with the results regarding the reward that firms obtain from the selection 
environment presented in Figure 23.  
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Figure 23: History-friendly scenario: Firm's reward from the selection environment 
(average 100 simulation runs) 
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As discussed in section 4.1.9, in each period the companies provide the selection 
environment with their product portfolio. The selection environment rewards product 
developers according to the relative "merit" of the company's product portfolio (see Eq 
27 and Eq 28). The results confirm that firms of type DC are able to collect the largest 
reward during almost the entire simulation. In phase III the dominance of firms of type 
DC is clear. In phase I industrial leadership seems to be related to technological 
strength in applying technology S. Moreover, engagement in external learning 
reinforces the ability to recognise discontinuities in the knowledge environment and to 
develop absorptive capacity in phase III. Therefore, firms of type DC enhance their 
performance by exploiting the possibilities provided by their knowledge environment 
and adapting to the selection environment. These results at the organisational level are 
coherent with the appreciative theory.  
4.2.2 Counterfactuals: history-divergent scenarios 
In this section we test the logic of the appreciative theory by running the simulation with 
parameter settings that contradict the appreciative theory. The results should be 
history-divergent, or in other words, they should not replicate the empirical stylised 
facts of technological change in the pharmaceutical industry. 
Counterfactual analysis can be carried out to explore technological change in the 
industry from many different perspectives. This contribution chooses focusing on the 
influence of the conditions for knowledge accumulation and the role of the strategic 
paradigms of the firms on technological change. Figure 24 presents the selected 
research issues for counterfactual analysis. 
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Figure 24: Selected research issues for counterfactual analysis 
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The following scenarios are specified: 
• Scenario 1: Absence of discontinuities in the biotechnology knowledge base  
At t=50 (1950s) and t=75 (1970s) the parameter setting does not include discontinuities 
in the scientific knowledge base related to technology B ( Bz ). Accordingly, the scenario 
does not allow for the entry of DBFs at t=75 either. 
• Scenario 2: Firms' strategic paradigms focus on one type of learning 
Two parameter settings define alternative firms' learning strategies to the ones 
specified in the history-friendly scenario by modifying the limits of the probability 
distribution of the parameter controlling for external learning (see jtλ  in Eq 8 and 
Table 9). 
• Scenario 3: Absence of adoption costs versus high level of adoption costs 
Two parameter settings define alternative levels of technology adoption costs (υ ) that 
firms need to cover if they aim at exploiting the new technological opportunities offered 
by major discontinuities in the firms' knowledge environment (see Eq 16 ). 
• Scenario 4: Absence of firm entry 
The parameter setting includes the discontinuities in the knowledge environment 
concerning technology B. However, the scenario does not allow for firm entry at t=75 
(1970s). Incumbent firms can not enter into collaborative arrangements with DBFs. 
The counterfactual analysis that follows in each scenario is carried out at two levels of 
aggregation: the level of the industry and the level of the organisation. As for the 
industry level, the analysis focuses again on technological change in terms of the 
relative importance of technology B and technology S and the rate of development of 
these technologies. As for the organisational level, the following aspects of firm 
performance in the different scenarios are analysed: development of firm's 
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technological capabilities, the quality level reached by the best products developed by 
each firm, firms' reaction to the changes in their knowledge environment and the 
reward obtained by the firms from the selection environment in each period. 
4.2.2.1 Scenario 1: Absence of discontinuities in the biotechnology 
knowledge base  
To explore the influence of changes in the scientific knowledge base relevant for 
technology B a scenario is implemented where the knowledge environment develops 
without experiencing major discontinuities. The parameter setting maintains constant 
the starting values of the parameters given in Table 10 referring to the scientific 
knowledge provided by public sector research institutions relevant for technology B Bz , 
the degree of complexity of technology B extramural knowledge base Bϕ , the rate of 
depreciation of capabilities of technology B Bφ  and the depreciation rate of 
technological capabilities in technology B Bδ .  
With regard to the appreciative theory, this scenario represents a situation where the 
two main scientific impulses for the development of biotechnology (technology B), the 
scientific advances of molecular biology between the 1940s and 1960s and the de-
velopment of genetic engineering, do not occur. Furthermore, by preventing the 
scenario from allowing firm entry, it is assumed that major institutional changes 
enabling the transfer of scientific results from academia to the industry do not take 
place.  
Figure 25 gives the average results of 100 simulation runs in terms of the level 
technological capabilities of the industry in technology B and in technology S. 
Figure 25: Counterfactual scenario 1: Technological change in the industry (100 
simulation runs and average) 
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Phase I in Figure 25 presents the same pattern than the history-friendly scenario 
(Figure 18). However, due to the counterfactual parameter setting (based on 
assumptions that do not correspond with the stylised facts identified) a different 
(history-divergent) pattern of technological change emerges. Contradicting the ob-
served pattern of technological change explored in chapter 3 and the history-friendly 
scenario, the industry does not change the rate of development of capabilities in 
technology B during phases II and III.  
As for the results at the organisational level, the analysis starts with the accumulation 
of technological capabilities.  
Figure 26 gives the average results of 100 simulation runs under scenario 1. As in the 
history-friendly scenario (Figure 19), firms of type TP change their technological identity 
at about period t=30 and herewith technology S becomes the dominant technology for 
both types of firms. However, technology development in phases II and III occurs 
differently than in the history-friendly scenario. While in the history-friendly scenario the 
development rate of capabilities in technology B increases in phases II and III, in this 
scenario the rate of development of technology B remains quite stable for both types of 
firms. 
Figure 26: Counterfactual scenario 1: Technological capabilities of incumbent 
firms (average 100 simulation runs) 
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In what concerns product development, as given in Figure 27 the absence of 
discontinuities in the knowledge environment seems to have a strong influence on the 
quality level of the products developed and accepted by the selection environment. In 
phase I firms are able to increase incrementally the quality of their products. However, 
they do not reach the levels of the history-friendly scenario given in Figure 21 in 
phase III. 
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Figure 27: Counterfactual scenario 1: Quality of firm's superior product candidates 
(average 100 simulation runs) 
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Accordingly, the absence of scientific development in disciplines contributing to the 
development of technology B influences product quality in the industry. This is in line 
with the results in terms of the size of the product portfolio. In the absence of scientific 
advances firms' innovation performance in terms of number of new products is slightly 
weaker. However, the differences with the history-friendly scenario (Figure 22) are not 
as strong as in the case of product quality. These findings suggest that the changes in 
the knowledge environment do not result in radical change in the number of new pro-
ducts. 
Figure 28: Counterfactual scenario 1: Size of firm's product portfolio (average 100 
simulation runs) 
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Due to the absence of discontinuities in firms' knowledge environment, the study of this 
scenario skips the analysis of firms' reactions to these events. 
An additional aspect to be considered is firms' performance in terms of reward from the 
selection environment in each period. Figure 29 presents the average results of 100 
simulation runs. As in the history-friendly scenario (Figure 23), in phase I firms of type 
DC are the best adaptors and receive the largest rewards. The reward levels do not 
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experience much variation after period t=30. The industrial leadership in terms of firm 
reward remains stable in phase II and phase III. 
Figure 29: Counterfactual scenario 1: Firm's reward from the selection 
environment (average 100 simulation runs) 
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The results of the first counterfactual scenario are coherent with the assumption of the 
central role of the development of the science base in shaping and driving 
technological change in a science-based industry (in terms of knowledge underpinning 
search and innovation activities). However, as for the effects in the knowledge 
environment on the innovation rate of the industry, the results suggest that in a 
scenario without radical scientific advances in the knowledge environment, the inno-
vative performance of the companies in terms of number of products brought to the 
market doesn't experience any remarkable differences compared to the history-friendly 
scenario. Nonetheless, in the scenario without discontinuities in the knowledge 
environment product quality is much lower. 
As far as the experience of the German pharmaceutical industry, the development of 
the science base can explain the pattern of technological change in the pharmaceutical 
industry. The difficulties of German drug producers in developing biotechnology 
capabilities compared to the achievements to their American and European counter-
parts already in the 1960s (and in the 1980s after the advent of modern biotechnology) 
can be explained by the regional differences in the development of the knowledge 
base.  
All in all, the results support the pattern of technological change according to which the 
development of biotechnology has brought about radical changes in the knowledge 
underlying search and innovation in the pharmaceutical industry. However, in terms of 
number of product innovations the discontinuity is more incremental. 
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4.2.2.2 Scenario 2: Firms focus on one type of learning 
The next counterfactual analysis explores the influence of firms’ learning strategies on 
the development of technological capabilities of the industry. In the model proposed, 
firms' learning strategies are specified (i) through investment decisions in learning 
activities and (ii) through the extent to which learning is internal or external. Drawing on 
the results presented in section 3.4.7, the history-friendly scenario has assumed that 
incumbent firms (firms of type DC and TP) implement different learning strategies in 
what concerns the balance between internal and external learning. As given in Table 9, 
in the history-friendly scenario firms of type DC present a higher commitment in 
external learning (i. e. learning from advances in science and spill-overs and learning 
by interacting) than their counterparts (firms of type TP).  
In this section two alternative scenarios are implemented. Firstly, the parameter setting 
assumes weak commitment in external learning by all incumbent firms (the uniform 
distribution specifying variable jtλ  in each period is given the limits (0.10 , 0.15)). 
Alternatively, in a second scenario the parameter setting reflects strong commitment in 
external learning by all incumbent firms (the uniform distribution specifying variable jtλ  
in each period is given the limits (0.40 , 0.50)). The analysis focuses firstly on the 
development of capabilities at the level of the industry. Figure 30 gives the results of 
100 simulation runs and the average. 
Figure 30: Counterfactual scenario 2: Technological change in the industry (100 
simulation runs and average)  
 Low investment share in external learning Large investment share in external learning 
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The results suggest that firms' commitment to external learning influence the 
aggregated pattern of technological change at the industry level. On the right hand side 
figure, the pattern of technological change is similar to the history-friendly scenario 
(Figure 18) in the sense that in phases II and III (characterised by changes in the 
extramural knowledge base) the level of technological capabilities in technology B 
grows in average at a faster rate than the level of capabilities in technology S. 
However, the rate of development of technology B in the last periods is higher in this 
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scenario. Accordingly in phase III technology B outperforms technology S in terms of 
relative importance leading to a paradigmatic change in the industry. This result is 
history divergent. While both technologies complement each other, their relative im-
portance changes giving advantage to technology B. The figure in the left hand side 
gives the results of choosing a parameter setting assuming weak commitment in exter-
nal learning by all incumbent firms. In this case, the level of technological capabilities of 
the industry is lower than the history-friendly scenario for both technologies.  
As for the results at the firm level, Figure 31 gives the level of technological capabilities 
of firms of type DC and TP in both scenarios: low and large investment share in 
external learning. 
Figure 31: Counterfactual scenario 2: Technological capabilities of the incumbent 
firms (average 100 simulation runs) 
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Again, the results suggest that large investment share in external learning (on the lower 
part of the figure) enhances the development of capabilities in technology B after the 
scientific advances at t=50 and t=75. Differently from the history-friendly scenario 
(Figure 19), firms of type TP (on the left side) invest more in external learning. This 
leads to a change in their technological identity in phases I and III, in the sense that the 
relative importance of the technologies in their volume of technological capabilities 
changes. As in the history-friendly scenario, firms of type DC also adapt the de-
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velopment of technological capabilities to the changes in their knowledge environment. 
In case of firms of type DC, however, compared with the history-friendly scenario  the 
parameter setting has not varied much. 
Table 12: Counterfactual scenario 2: Firms' reaction to discontinuities in the  
knowledge environment (100 simulation runs) 
Low investment share in external learning 
 
  Firm Type TP Firm Type DC 
  Firm 1 Firm 2 Firm 3 Firm 4 
Perception / Adoption rate 85 % 84 % 86 % 87 % t=50 
Average adoption period 69 67 67 69 
Perception / Adoption rate 56 % 61 % 58 % 64 % t=75 
Average adoption period 85 85 85 85 
Large investment share in external learning 
 
  Firm Type TP Firm Type DC 
  Firm 1 Firm 2 Firm 3 Firm 4 
Perception / Adoption rate 96 % 100 % 100 % 97 % t=50 
Average adoption period 61 60 60 61 
Perception / Adoption rate 83 % 88 % 89 % 84 % t=75 
Average adoption period 83 84 82 84 
The results presented in Table 12 confirm the role of external learning in firms' reaction 
to changes in the knowledge environment. In the scenario with large share of 
investment in external learning incumbent firms perceive the discontinuity at t=50 in at 
least 96 % of the simulation runs. The average period of adoption of the new tech-
nological opportunities after t=50 lies between period t=60 and t=61. As for the dis-
continuity at t=75, the perception rates are again much higher (and adoption takes 
place faster) than in the low investment share scenario. 
Figure 32: Counterfactual scenario 2: Quality of firm's superior product candidates 
(average 100 simulation runs) 
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With regard to product quality, this scenario suggests that external learning has strong 
effects on the quality of the products developed by incumbent firms. In Figure 32, in the 
case of large investments in external learning, the best product candidates of 
incumbent firms match the quality of the best products discovered by DBFs. This is 
also the case for firms of type TP, which are not able to reach such high levels of 
quality in the history-friendly scenario (Figure 21). Considering that DBFs are located at 
the frontier of technology B (in other words, DBFs are able to exploit all technological 
opportunists offered by technology B in the search process) the achievement of 
incumbent firms by engaging in external learning is remarkable. 
Figure 33: Counterfactual scenario 2: Firm's reward from the selection environ-
ment (average 100 simulation runs) 
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As shown in Figure 33, and compared with the history-friendly scenario in Figure 23, 
both scenarios present a similar profile in terms of firms' rewards in the selection 
environment. Especially, in the parameter setting specifying large investment in ex-
ternal learning by all incumbent firms (on the right hand side), performance in the 
selection environment converges among firms. In other words, in a dynamic en-
vironment, if all firms behave similarly (in terms of balance between external and 
internal learning) firm performance is not affected by discontinuities in the knowledge 
environment. Accordingly, the decision "internal versus external learning" seems to 
have a big influence in the adaptation of firms to the conditions of the selection 
environment and in the rewards they obtain from it.. 
An important implication of these results is that the development of technological 
capabilities in a science-based industry is not independent from the ability of firms to 
access their extramural knowledge base. As shown in scenario 1, the development of 
the scientific knowledge base is a necessary condition for technological change in the 
science-based industry. Additionally, this scenario suggests that, the extent to which 
industry actors are able to articulate scientific advances into technological innovations 
depends on the ability of firms to perceive changes in their extramural knowledge base 
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and exploit them. This ability depends on their engagement in external learning (i. e. 
learning from advances in science and technology, learning from industry spill-overs 
and learning by interacting). Moreover, in the presence of changes in the knowledge 
environment, this ability influences the quality improvement of the products they 
develop. Finally, similar firm behaviour in terms of strong commitment to external 
learning diminishes the differences in the performance of incumbent firms in the 
selection environment. A comparison of the results with the history-friendly scenario 
suggests that in a dynamic environment, differences in firm performance seem to be 
related to differences in their learning strategies with regard to the balance between 
internal and external learning. 
As for the stylised facts in the German pharmaceutical industry the results confirm the 
appreciative theory: difficulties of the traditional pharmaceutical companies 
(represented by firms of type TP) in exploiting the technological opportunities after the 
advent of modern biotechnology can be explained through their learning strategies. 
Even though their technological tradition and internal technological capabilities in terms 
of human capital were better qualified to develop capabilities in modern biotechnology, 
their commitment to external learning was not strong enough to exploit the changes in 
the knowledge environment. On the other side, dyestuff companies committed 
traditionally to external learning have been better able to exploit the knowledge 
environment, despite their disadvantage in terms of internal core competences and 
technological tradition. 
4.2.2.3 Scenario 3: Absence of adoption costs versus high level of 
adoption costs 
Given the specification of the model as presented in section 4.1.6, firms do not have 
free access to the extramural knowledge base. Exploitation of scientific advances 
requires firstly the ability to perceive scientific advances or technological opportunities 
from the extramural knowledge base and additionally, covering an extra cost υ  repre-
senting the effort of exploiting new technological opportunities (see Eq 16).  
In the history-friendly scenario the parameter setting specifies the adoption costs with 
υ =1. This section introduces a scenario with low adoption costs (υ =0.01) and a 
scenario with high adoption costs (υ =2). The parameters characterising the knowledge 
environment and firms' behaviour correspond to the history-friendly scenario given in 
Table 9 and Table 10. Figure 34 gives the average results of 100 simulation runs 
regarding the technological capabilities of the industry under low (in the left hand side 
figure) and high adoption costs (in the right hand side figure). 
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The results given in the right hand side figure confirm that high adoption costs for firms 
imply a lower level of industrial capabilities in technology B after 100 periods. Despite 
the strong increase in the volume of scientific knowledge provided by public research 
institutions after t=50, the industry in phases II and III is not able to developed the level 
of technological capabilities reached in the history-friendly scenario (Figure 18). In the 
presence of high adoption costs for firms, the rate of development of technology B is 
slower than in the history-friendly scenario and the industry remains under strong 
influence of technology S. In the left hand side figure, the parameter setting assumes 
lower adoption costs than the history-friendly scenario. The pattern of technological 
change presents a change in the relative importance of technologies in phase III. The 
industrial level of capabilities in technology B develops faster in phase I and phase II 
than in the history-friendly scenario. 
Figure 34: Counterfactual scenario 3: Technological change in the industry (100 
simulation runs and average) 
 Low adoption costs  High adoption costs 
Technology S Technology B Technology S Technology B
0
100
2 00
3 00
4 00
500
6 00
0 20 40 60 80 100
Time period
T
ec
hn
ol
og
ic
al
 c
ap
ab
ili
tie
s 
M
M
of
 t
he
 in
du
st
ry
(I) (II) (III)
0
100
2 00
3 00
4 00
500
6 00
0 20 40 60 80 100
Time period
T
ec
hn
ol
og
ic
al
 c
ap
ab
ili
tie
s 
m
m
of
 t
he
 in
du
st
ry
(I) (II) (III)
 
 
The results at the level of the firm given in Figure 35 suggest that adoption costs 
influence the extent to which firms react to the changes in their knowledge en-
vironment. In the case of low adoption costs both types of firms (TP in the left and DC 
in the right) develop capabilities in technology B to the extent that in phase III all firms 
present a higher absolute level of capabilities in technology B than in technology S. In 
this case search and innovation become processes mainly guided by technology B. 
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Figure 35: Counterfactual scenario 3: Technological capabilities of the incumbent 
firms (average 100 simulation runs) 
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Table 13: Counterfactual scenario 3: Firms' reaction to discontinuities in the  
knowledge environment (100 simulation runs) 
Low adoption costs 
 
  Firm Type TP Firm Type DC 
  Firm 1 Firm 2 Firm 3 Firm 4 
Perception / Adoption rate 100 % 100 % 100 % 100 % t=50 
Average adoption period 51 51 51 51 
Perception / Adoption rate 100 % 100 % 100 % 100 % t=75 
Average adoption period 76 76 76 76 
High adoption costs 
 
  Firm Type TP Firm Type DC 
  Firm 1 Firm 2 Firm 3 Firm 4 
Perception / Adoption rate 48 % 53 % 82 % 83 % t=50 
Average adoption period 72 73 64 68 
Perception / Adoption rate 24 % 33 % 60 % 59 % t=75 
Average adoption period 83 86 86 84 
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As given in Table 13, the rates of perception and adoption of technological oppor-
tunities by firms after the development of novel scientific advances underpinning tech-
nology B at t=50 and t=75 are extremely high in the low adoption costs scenario. These 
results are coherent with he logic of the model. 
The results in Figure 36 regarding the quality of firms' superior products suggest that 
the development of capabilities in technology B by incumbent firms in the low adoption 
costs scenario allows all of them (independently of the type of firm TP or DC) to 
discover and develop products that outperform the product candidates of DBFs in 
terms of quality. DBFs count only with capabilities in technology B. Despite their 
superior technological achievement for the selection of products with high quality in the 
search space, the low adoption costs for incumbents prevent DBFs for maintaining the 
leading position in terms of quality of product candidates. In the low adoption cost 
scenario incumbents are able to develop large levels of capabilities of technology B 
which seem to complement their capabilities in technology S in the search process for 
potential products. The combination of capabilities enables them to outperform DBFs in 
terms of quality. 
Figure 36: Counterfactual scenario 3: Quality of firm's superior product candidates 
(average 100 simulation runs) 
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Moreover, the results provide insights into the competitive advantage of firms engaging 
in external learning. In the case of discontinuities in the knowledge environment with 
high adoptions costs (on the right hand side in Figure 36) firms of type DC reach higher  
levels of quality in their potential products than firms of type TP. Even though in-
cumbent firms are not able to outperform DBFs, those engaging in external learning 
are more effective in their search process.  
As for the results concerning firm performance in the selection environment, Figure 37 
presents the rewards obtained by firms. In the presence of low adoption costs learning 
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strategies do not seem to influence firm performance and the relative position of firms 
in the selection environment does not change. In the case of large adoption costs, firms 
of type DC are better able to adapt than their competitors. This effect is quite 
remarkable in phase III. Accordingly, in the presence of high adoption costs, firms 
engaging in external learning adapt better to the selection environment. 
Figure 37: Counterfactual scenario 3: Firm's reward from the selection environ-
ment (average 100 simulation runs) 
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Again, the counterfactuals explored in this section are coherent with the verbal logic of 
the appreciative theory of technological change in the German pharmaceutical industry. 
The costs of developing capabilities to exploit technological opportunities offered by 
novel scientific advances (i. e. adoption costs at the firm level) influence the pattern of 
technological change at the industry level. Apart from the knowledge required to exploit 
new technological opportunities, adoption costs may be reinforced by uncertainty about 
the possibilities of exploiting the new technological opportunities, by barriers to access 
the novel scientific results or by the costs of adapting firm's processes and in-
frastructure to the requirements of exploiting the new technological opportunities. 
Therefore, in the presence of high adoption costs for firms, the industry does not exploit 
new opportunities given by the knowledge environment. At the organisational level, 
firms engaging in external learning are better prepared to deal with barriers to adoption.  
In the German case, the geographical dimension of scientific advances and public 
research in scientific disciplines relevant for the development of biotechnology (which 
took place beyond the German borders until the 1980s) increased the adoptions costs 
of German drug producers in relation to those of their American counterparts. 
Moreover, the institutional framework did not contribute to decrease adoption costs. 
Regarding the differences between German drug producers, in the presence of these 
high adoption costs, the engagement of dyestuff companies in external learning has 
given them an advantage in the adoption process. 
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4.2.2.4 Scenario 4: Absence of firm entry 
In this section a history-divergent scenario is introduced by assuming that the advent of 
modern biotechnology in the mid 1970s (t=75), which opens phase III in the history-
friendly scenario, did not involve the emergence of a biotechnology industry enhancing 
the transfer of the new scientific results from the academic to the industrial laboratories. 
The goal is to explore the role of Dedicated Biotechnology Firms (DBFs) in transferring 
capabilities to incumbent firms through collaborative agreements and industry spill-
overs. 
Figure 38 gives the average results of 100 simulation runs of the path of technological 
change of the industry. The results in terms of capabilities of the industry in technology 
B present a slightly different pattern of technological change than the history-friendly 
scenario (Figure 18).82 In phase III the industry does not increase the level of 
capabilities in technology B as much as in the history-friendly scenario. 
Figure 38: Counterfactual scenario 4: Technological change in the industry (100 
simulation runs and average) 
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At the level of the firm (Figure 39), in the absence of DBFs and collaborative 
arrangements those firms engaging in external learning are not able to reach the level 
of capabilities of the history-friendly scenario (Figure 19). It seems that with the 
absence of DBFs the access to additional knowledge in technology B is limited to the 
existence of spill-overs and the rate of development of capabilities in incumbent firms is 
now lower. The pattern of development of technological capabilities in the case of firms 
of type TP does not vary much. Since the number of collaborative arrangements in the 
                                                
82  Note that the history freindly scenario does not include the capabilities of DBFs in the  
aggregate level of technological capabilities of the industry. Only those actors reaching the 
selection environment are considered as industry members. DBFs discover products, 
however,, they never reach the selection environment due to their lack of marketing 
capabilities (see footnote 73). 
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history-friendly scenario was also lower (see Figure 20), the absence of DBFs has not 
a great impact for them and their engagement in learning from their spill-overs (external 
learning) is also weak. 
Figure 39: Counterfactual scenario 4: technological capabilities of the incumbent 
firms (average 100 simulation runs) 
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The results presented in Figure 40 regarding the quality of the best product candidates 
of incumbent firms suggest that product quality does not suffer from the absence of 
DBFs in the industry. Superior products of incumbent firms are able to reach the levels 
of quality of the history-friendly scenario (Figure 21) at the end of the simulation run.  
Figure 40: Counterfactual scenario 4: Quality of firm’s superior product candi-
dates (average 100 simulation runs) 
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Moreover, in the absence of DBFs and collaborative arrangements, incumbent firms 
continue to enlarge their product portfolios (see Figure 41) without drawing on the extra 
volume of capabilities being transferred from DBFs. The innovation rate in terms of 
products increases incrementally as in the history-friendly model. 
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Figure 41: Counterfactual scenario 4: Size of firm's product portfolio (average 100 
simulation runs) 
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Finally, rewards from the selection environment given in Figure 41 behave as in the 
history-friendly scenario (Figure 23). Firms of type TP clearly deteriorate their position 
in phase III and firms of type DC improve it. These findings are not surprisingly since 
reward depends on product quality. As seen above the absence of DBFs doesn't have 
large influence on product quality reach by incumbents. 
Figure 42: Counterfactual scenario 4: Firm's reward from the selection environ-
ment (average 100 simulation runs) 
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Considering that technology B represents biotechnology, these results are consistent 
with the assumption of the appreciative theory according to which the historical pattern 
of technological change in the pharmaceutical industry after the 1970s drew on the 
institutional changes enhancing biotechnology knowledge transfer in the pharma-
ceutical industry. An important policy implication is hence the central role of firm entry 
for technology transfer science-based industries. However, in the history-friendly model 
specified, firm entry enhances knowledge transfer rather than product development. To 
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sum up, the absence of DBFs and collaborations seems to have strong impact in the 
development pattern of technological capabilities of the industry. However, the effect 
on product development is not as convincing. 
The findings support the merit of DBFs in transferring knowledge and technology from 
the knowledge environment to the industry. Accordingly, DBFs play a role in the 
transformation of the technological capabilities of the industry. However, in terms of 
enabling product innovation to incumbent firms, DBFs aren't decisive. In the absence of 
DBFs incumbent firms do reach the quality level of the history-friendly scenario and 
continue to develop new products. The results suggest that the knowledge transfer 
carried out by DBFs is not articulated into products to the extent that it would be 
expected. These findings support the position discussed in section 3.5 according to 
which, the advent of modern biotechnology and the new institutional setting for 
innovation in the pharmaceutical industry has resulted into a transformation of the 
knowledge base underpinning drug discovery and development. However, the 
discontinuity in terms of products has a much incremental character. 
With the regard to the German experience, the results can support the scenario of a 
delay in the German industry vis-à-vis the US in exploiting modern biotechnology due 
to the different framework conditions for firm creation and entry. However, due to the 
differences in the developments of the knowledge environment in both regions, the 
explanation does not allow to identify the institutional setting promoting firm creation as 
the only reason for this delay.  
Nonetheless, the German experience shows how firm entry can be strongly promoted 
by policy intervention. In the few years between 1995 and 2000 Germany became the 
European country with the largest biotechnology industry in terms of DBFs. These firms 
entered the industry mainly through public support. Their problems in bringing products 
to the market made many of them unprofitable. Policy instruments were not designed 
to sustain the growth of these actors. Accordingly many of them disappeared or have 
been acquired by incumbents after a few years of activity. 
Due to the role of DBFs for knowledge and technology transfer, an interesting issue for 
policy research is whether other measures than subsidised entry of DBFs exist to 
promote the transfer of knowledge from the academic to the industrial laboratory as 
effectively as the creation of small technology-based companies, but in a sustainable 
manner. 
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5 Summary and conclusions 
This contribution explores technological change from an evolutionary perspective. The 
aim is to unfold the processes underpinning the changes in the relative importance of 
technologies in industries, the mechanisms driving these transitions and the conse-
quences for industry incumbents.  
The analysis concentrates on the experience of the German pharmaceutical industry 
and the changes in the relative importance of biotechnology and synthetic chemical 
synthesis in shaping drug discovery and production processes along the 20th century. 
The role played by German drug producers in this process, and the extent to which 
they have been able to perceive and contribute to these changes, are the main issues 
of study. 
The theoretical framework 
The evolutionary framework provides an adequate toolbox to explore the interrelation 
between the macro and micro-levels of the process of technological change since, from 
an evolutionary perspective, firms are the carriers of technology and, consequently, 
patterns of change at the level of the industry are the result of the collective interaction 
of firms. Moreover, in the last 30 years, a large body of literature has contributed to 
define firm behaviour in this context, even though the theoretical framework is still 
developing.  
Evolutionary theorists consider firms as heterogeneous agents with bounded rationality 
in the sense that the constraints of their computational abilities prevent them from 
conducting any type of optimisation decision processes. In addition, firms in the same 
environment and facing the same type of market signals may interpret information 
differently and/or react in dissimilar ways. The main factors making firms different are 
their specific knowledge base, the conditions in which they have accumulated it and 
their strategies to articulate the knowledge into useful products or processes.  
A further important aspect stressed by the evolutionary approach is that firms do not 
act in isolation. Thus, firms' decision-making is a process embedded in an institutional 
matrix in which institutions and firms' behavioural patterns coevolve. Evolutionary 
theorists use the concept of technological regimes or paradigms to refer to the set of 
institutions influencing firms' behaviour and firms' assessments about the technological 
options being worth taken, or about the superior strategies that should be applied and 
developed to solve managerial and technical problems. Accordingly, technological 
regimes or paradigms act as focusing devices for firms, tracing possible patterns of 
development and blinding out potential alternatives. Consequently, these influences 
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depict so called technological trajectories that underpin industrial activity. Technological 
trajectories may coexist, complement each other or compete.  
Moreover, the evolutionary perspective imposes the recognition of the process of 
technological change in industries as a dynamic process. From this view, and in 
analogy to biological evolution, variety creation and selection (in the sense that firms 
may enter the industry but may be forced to disappear) lead to changes in the 
composition of the industry and in its aggregate patterns. Accordingly, taking into 
consideration that firms are the carriers of technologies, which technological 
trajectories shape an industry depends, to a large extent, on the performance of the 
firms developing and applying them in the selection environment. The technologies 
developed and applied by the best performers will hence outperformed alternative 
technologies in terms of importance. In this endogenous competition, process 
externalities and dynamic increasing returns may influence firms' behaviour, thus 
reinforcing the development of a technological trajectory or preventing experimentation 
in other directions.  
All in all, changes in the relative importance of technological trajectories bring about 
technological change in terms of the technological capabilities underpinning industrial 
activity. These changes can have incremental or radical dimensions and impact 
incumbent firms by enhancing their competences or destroying them. In some cases 
they may lead to paradigmatic transitions within the industry turning the capabilities of 
incumbent firms inadequate for the new framework conditions and fostering the en-
trance of new firms. The knowledge-based theory of the firm explores the mechanisms 
enabling incumbent firms to adjust to these transitions. The approach puts forward 
concepts such as "absorptive capacity", "combinative capabilities" and "dynamic capa-
bilities" to define the type of firms' capabilities enabling adjustment to discontinuities in 
the knowledge environment. 
Simulation as a tool  
Drawing on this theoretical toolbox, one strand of evolutionary economic theory has 
explored economic growth and technological change using simulation models inspired 
by the seminal work of Nelson and Winter (1982). The usefulness of simulation models 
builds mainly on their ability to deal with the fundamental uncertainty and the re-
quirement to consider heterogeneity between firms. Moreover, computer simulation 
models enable the study of complex processes were macroeconomic properties are 
considered phenomena flowing from the interaction of microeconomic agents. 
Evolutionary simulation models have been able to generate plausible patterns of 
economic growth or changes in the concentration of industries. However, evolutionary 
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scholars have concentrated on the exploration of these processes without testing the 
models' outcomes against historical experience in a rigorous manner. On the other 
hand, embracing institutional economics, a strand of neo-Schumpeterian research has 
elaborated a large body of empirical and historical case studies without mathematical 
abstraction, exploring explicitly the role of institutions in shaping technological change, 
economic growth and the differences between regions, countries and industries. 
To reconcile formal modelling to build general theories with empirical analysis of 
specific cases, a group of scholars with a large record of contributions to the de-
velopment of neo-Schumpeterian economics (including Nelson and Winter) have 
developed so called "evolutionary history-friendly models". In this framework, simu-
lation models attempt at reproducing observed patterns of socio-economic change. The 
theory underpinning the models draws on stylised facts and verbal causal relationships 
(i. e. on an appreciative theory) considering the role of institutions in shaping the phe-
nomena under exploration. Thus, in the history-friendly framework, formal modelling 
should be considered as an attempt to asses the consistency of the verbal arguments 
that constitute the appreciative theory explaining dynamic phenomena. History friendly 
models include (i) a set of stylised facts characterising the phenomenon to be explored, 
(ii) verbal logic on how the processes occur, (ii) formal representation of the verbal 
logic in a model and (iii) the implementation of a numerical computer simulation 
replicating the phenomenon explored.  
A history-friendly model 
This contribution chooses the approach of evolutionary history-friendly modelling to 
study technological change in the German pharmaceutical industry during the 20th 
century and the ability of German drug producers to adjust to the discontinuities in their 
knowledge environment. Empirical findings are the ground to develop an appreciative 
theory that explains verbally the phenomenon under consideration. Next, the appre-
ciative theory has been specified in a formal model and implemented in a simulation to 
test the logic of the verbal explanations. 
From an evolutionary perspective this endeavour demands the specification of an 
argument to explain technological change that deals with the complex interaction of (i) 
the knowledge environment shaping the conditions for technology emergence and 
development, (ii) a selection environment evaluating the technologies upon a unit of 
selection and determining the conditions for innovation, and finally (iii) firm's strategies 
in developing technologies to ease their risk-taking activities. 
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The stylised facts  
Consequently, the efforts concentrate firstly on the empirical exploration of the changes 
in the knowledge environment, on the development of the industry, and on firms' 
strategies in adopting and developing new technologies.  
From the perspective of the scientific knowledge environment shaping technology 
development, the study focuses on the knowledge bases of organic chemical synthesis 
and biotechnology. The stylised facts suggest that the scientific advances underlying 
these two technologies have very much influenced their application and diffusion in the 
pharmaceutical industry. However, the scientific development has followed different 
paces. While the scientific base of the organic chemical synthesis was developed in the 
second half of the 19th century, the scientific base of biotechnology at that time was still 
in its infancy. Along the 20th century, scientific advances have provided biotechnology 
with strong scientific base. This process started already in the 1950s with the de-
velopment of molecular biology and was enhanced in the 1970s with the revolutionary 
discoveries of rDNA and the production of monoclonal antibodies. 
At the level of the pharmaceutical industry both technologies competed in the pro-
cessing of materials until the World War I. The dominance of the dyestuff companies in 
the German pharmaceutical industry supported the technological option for the organic 
chemical synthesis in the drug discovery and development processes. However, after 
Wold War II (especially after the 1970s) biotechnology has gradually become the key 
for innovation in the drug discovery and development processes. With this 
development, German drug producers lost their innovative strength in the second half 
of the 20th century. The path breaking discoveries in molecular biology in the 1950s, 
the advent of modern biotechnology in the 1970s together with the emergence of a 
biotechnology industry in the United States changed the knowledge environment of the 
industry and the institutional conditions for knowledge diffusion, especially in what 
concerned the transfer of knowledge from academic to industrial laboratories. 
Nonetheless, this development was at first very much localised in the USA. The 
strategic orientation of German drug producers towards this region in what concerned 
their research and development activities alarmed the German government. During the 
last two decades of the 20th century strong policy engagement was directed towards 
the promotion of the industrial application of biotechnology, the creation of 
biotechnology companies and the interaction between industry and academia within 
the German borders. 
Given these processes at the level of the industry, we have explored the processes of 
technology adoption and development at the level of the firm. Specially, the ability of 
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German large firms to develop and exploit organic chemical synthesis and 
biotechnology. German drug producers can be classified in two different types of firms 
according to their technological traditions: the traditional pharmaceutical companies 
and the dyestuff producers. The strategies of these companies to build up capabilities 
for drug discovery and development along the 20th century seem to differ. To put it in 
an extreme way, traditional pharmaceutical companies have been more engaged in 
understanding the biological processes behind the diseases and in using biological 
products to treat them while dyestuff corporations were very much focused on the 
synthesis of potential drugs. The advent of modern biotechnology in the 1970s had a 
competence destroying character and forced the German drug producers to adopt new 
ways of drug discovery and development. In this process, the companies that tra-
ditionally came from the coal-tar dyestuff industry were faster in adjusting to the new 
framework conditions.  
These empirical findings allow us to identify the following processes as key 
determinants of technological change in the German pharmaceutical industry: 
Firstly, the entry of the dyestuff producers at the end of the 19th century with 
capabilities in organic chemical synthesis and the strength of the firms' knowledge 
environment supporting this technology determined the technological dominance of the 
organic chemical synthesis in the first half of the 20th century. However, the de-
velopment of the knowledge environment after World War II, as the organic chemistry 
reached maturity and biotechnology developed further, contribute to the change in the 
relative importance of both technologies. By the last quarter of the 20th century drug 
discovery and development was increasingly being guided by biological principles.  
The historical stylised facts speak for a strong development of the biotechnology 
knowledge base and its industrial exploitation especially in the USA. This geographical 
dimension of the knowledge base (together with its increasing complexity) has probably 
played a role in the industrial application of biotechnology in the German pharma-
ceutical industry by slowing the process of technological change compared to the USA. 
Moreover, the barriers for industrial exploitation of biotechnology in Germany in the 
early 1980s have probably prevented drug producers from perceiving and adopting the 
new technological opportunities of biotechnology. 
Regarding the role of firms in this process, the leaders of the German pharmaceutical 
industry in the first half of the 20th century (the dyestuff producers) were embedded in 
the technological regime of the organic chemical synthesis. Their technological regime 
favoured science-based research strategies, where interaction with the knowledge 
environment (by learning from scientific advances and from interacting) played a 
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central role in technology development. Despite the exclusion of biotechnology until the 
1950s, their ability to perceive the discontinuity in the knowledge environment allowed 
them to adjust faster to the emergence of modern biotechnology. On the other side, 
traditional pharmaceutical companies, with a historical record in the application of 
biotechnology and empirical (trial-and-error) guided research and development strate-
gies have been much slower in the adoption process, even though the competence 
destroying nature of the discontinuity should have been less drastic for these type of 
firms. 
The evolutionary model  
These stylised facts have been used to specify an evolutionary history-friendly model 
which intends to draw the patterns of technological change observed.  
In the neo-Schumpeterian tradition, the history-friendly model put forward specifies 
firms as the carriers of technology. Hence, technological change at the industry level is 
the result of firms' interaction in a selection environment. The aggregated pattern of 
mechanisms of technology adoption and development at the firm level determined the 
technological development of the industry. In this sense, technological change is the 
collective result of the individual actions of firms. 
The formal model presents an artificial industry with companies searching and 
developing drugs in a knowledge environment. Firms face a search space of potential 
medicines which may have therapeutic properties (product candidates). The goal of 
firms is to find and develop best potential product candidates and offer them to the 
selection environment (which is a simplification of the health system or the market for 
pharmaceuticals). Firms are heterogeneous and are rewarded by the selection 
environment according to the “merit” (which is largely based on quality) of the products 
they have developed. Accordingly, firms' have different strategies aim at improving their 
technological capabilities to improve the merit of their products. 
Two technologies enable the search process by reducing the observation error in the 
search process (technology B) and by expanding the range of possible drug candidates 
the can handle (technology S).The knowledge dimension of these technologies and its 
cumulative character are essential aspects of the model. Knowledge accumulation  
allows firms improving the merit of their products by enhancing technological achieve-
ments and by easing firms' problem solving activity.  
Moreover, innovation is specified as a stochastic process where the stock of accu-
mulated knowledge can increase the chances of innovating. Knowledge accumulation 
stands on learning processes which can be internal to the firm (by learning by doing for 
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instance) and external to the firm (learning by searching and interacting in the know-
ledge environment and from spill-overs).  
Finally, the model is dynamic and the transition dynamics can be described with a 
Markov process where the stage of the industry at t influences the stage of the industry 
at t+1. Most importantly the specification of the accumulated stock of knowledge as a 
variable influencing the stochastic processes grants the model with "historicity" in the 
sense that the stage at t captures the results of the learning process in the past.  
The simulation experiments try first to replicate the observed pattern of technological 
change in the pharmaceutical industry (the history-friendly scenario). For this purpose, 
the parameter settings aim at capturing in a extreme form the key stylised facts of the 
appreciative theory regarding (i) the nature of the knowledge environment shaping the 
different phases of the pharmaceutical industry and (ii) the characterisation of the firms. 
To capture the nature of the knowledge environment the dimensions of the 
technological regimes have been specified (i. e. technological frontier of technologies, 
volume of scientific knowledge, degree of complexity of knowledge, appropriability 
conditions in terms of spill-overs, and depreciation rate of technological capabilities). 
Additionally, the characterisation of the firms specifies 3 types of companies: Com-
panies of firm type DC (representing the dyestuff companies), firm type TP (repre-
senting the traditional pharmaceutical companies) and firm type DBF (representing the 
dedicated biotechnology firms entering the industry a la later stage). These firms are 
different with regard to (i) the technology they believe is worth developing, (ii) in their 
engagement in learning and (iii) in their balance between internal and external learning.  
In addition, the simulation environment has been used to experiment with alternative 
parameter settings that contradict the stylised facts of the appreciative theory. Apart 
from testing the logic of the appreciative theory and the stylised facts, the approach has 
led to the identification of relevant policy implications at the level of the industry and 
provided insights about firms' strategies in dynamic environments. The mechanisms 
and effects identified in the simulation experiments concern the level of the industry 
and the level of the firm. 
Model results: Patterns of technological change at the level of the industry 
The results in terms of technological capabilities of the industry in the history-friendly 
experiments match remarkably well the stylised facts. The origins of the industry are 
shaped by the dominance of firms of type DC (dyestuff producers) and the estab-
lishment of search and innovation processes drawing on technology S (organic 
chemical synthesis). Changes in the knowledge environment of the firms in two time 
periods (t=50) and (t=75) bring about an incremental application of technology B 
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(biotechnology). The exogenous specification of these changes is based on the stylised 
facts identified in chapter 3. These changes refer to the parameters describing the 
technological regime of the industry including the specific characteristics of the 
knowledge dimension of technology B (biotechnology) (innovation opportunity con-
ditions, volume of scientific knowledge from the public sector, degree of complexity of 
knowledge, depreciation rate of technological capabilities) and entry of DBFs. After the 
discontinuities in the knowledge environment providing new technological oppor-
tunities, firms increase the accumulation of technology B. Accordingly the aggregate 
pattern of technological capabilities in the industry varies while technology B 
challenges the relative importance of technology S. Nonetheless, both technologies 
coexist.  
With regard to the implications for the pharmaceutical industry in Germany, which is the 
ground of the empirical analysis, the pattern of development of technological 
capabilities described by the history-friendly scenario speaks for a forthcoming change 
in the dominance of organic chemical synthesis in the industry. The results suggest 
that the industry is still dominated by an organic chemical paradigm, however the 
application of biological principles in drug discovery and development play an in-
creasingly important role and may displace chemical synthesis in the future.  
The simulation experiments explore the role of developments in the knowledge 
environment in driving technological change of the industry. Considering that firms are 
the carriers of technology, and that technological opportunities have to be recognised 
and exploited by firms, the results support the central role of firms' knowledge 
environment in the pattern of technological change of the industry. Accordingly, the 
nature of the science base in terms of the complexity of knowledge, the speed of 
scientific development and the volume of research results available from public 
institutions can explain the pattern of technological change in the pharmaceutical 
industry and differences across regions. As far as the experience of the German 
pharmaceutical industry, the development of the science base can explain the pattern 
of technological change. Thus, the difficulties of German drug producers in developing 
biotechnology capabilities compared to the achievements to their American and 
European counterparts already in the 1960s (and in the 1980s after the advent of 
modern biotechnology) can be the result of the differences in the development of the 
national scientific knowledge bases.  
The influence of firms' strategic paradigms (Metcalfe, Boden 1992) and the relevance 
of the dynamic capabilities of the firms (Teece et al. 1997) for technological change at 
the industry level has been analysed in the second counterfactual analysis (scenario 
2). The results suggest that the development of technological capabilities in a science 
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base industry is not independent from the ability of firms to access their extramural 
knowledge base. The extent to which the industry is able to articulate scientific 
advances in technological solutions depends on the ability of firms to perceive changes 
in their extramural knowledge base and exploit them.  
As for the role of technology adoption costs at the level of the firm, the results suggest 
that the investment firms need to undertake to integrate new scientific advances from 
the knowledge environment and to exploit new technological opportunities influence the 
development pattern of technological capabilities of the industry. Adoption costs involve 
the efforts to understand information from the knowledge environment and integrate it 
in the corporate research and development processes. Moreover, institutional and 
geographical barriers to access the novel scientific results can reinforce barriers to 
adoption. In the case of the German pharmaceutical industry, the geographical 
dimension of scientific advances and public research in scientific disciplines relevant 
for the development of biotechnology (which took place beyond the German borders 
until the 1980s) probably increased the adoptions costs of German drug producers in 
relation to those of their American counterparts.  
Finally, the experiments analyse the role of mechanisms for knowledge and technology 
transfer. The findings support the merit of Dedicated Biotechnology Firms (DBFs) in 
transferring knowledge and technology from the knowledge environment to the 
industry. However, in terms of easing product innovation to incumbent firms, DBFs 
aren't so influential. These findings support the position discussed in section 3.5 
according to which the advent of modern biotechnology and the new institutional 
setting for innovation in the pharmaceutical industry has resulted into a transformation 
of the knowledge base underpinning drug discovery and development. However, the 
discontinuity in terms of products has a much incremental character. 
With the regard to the German experience, the results can support the scenario of a 
delay in the German industry vis-à-vis the US in exploiting modern biotechnology due 
to the different framework conditions for firm creation and entry. However, due to the 
differences in the developments of the knowledge environment in both regions, the 
explanation does not allow to identify the institutional setting promoting firm creation as 
the only reason for this delay. 
Model results: The firm in the process of technological change 
At the organisational level, the history-friendly scenario is able to reproduce the 
historical experience. Accordingly, firms of type TP (representing traditional phar-
maceutical companies such as Merck KGaA and Schering AG with traditional 
technological experience with the application of technology B) have experienced a 
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transformation in their technological identity towards the accumulation of capabilities in 
technology S (organic chemicals synthesis). Regarding the perception and adoption of 
technological opportunities, firms of type DC (representing dyestuff companies such as 
Hoechst and Bayer) are better able to perceive and adopt the new technological 
opportunities from the knowledge environment. Moreover, compared to their 
counterparts, firms of type DC interact more with Dedicated Biotechnology Firms 
(DBFs). This ability is enhanced by their commitment to external learning (i. e. learning 
from advances in science and technology, learning from industry spill-overs and in 
learning by interacting). Moreover, in dynamic environments, differences in firms' 
performance seem to be related to differences in firms' learning strategies with regard 
to the balance between internal and external learning.  
Therefore, regarding the experience of German drug producers, the findings put 
forward that the balance between internal and external learning can explain the 
difficulties of traditional pharmaceutical companies in exploiting technological 
opportunities after the advent of modern biotechnology. Despite their technological 
tradition in biotechnology and internal technological capabilities in pharmacology, 
biology and medicine in terms of human capital, their weak commitment to external 
learning seems to prevent them from perceiving and exploiting the changes in the 
knowledge environment. On the other hand, the dyestuff companies, with their tech-
nological roots in the synthetic organic chemistry but a long tradition in the application 
of science-based strategies and in collaboration, have been faster in reacting to the 
discontinuities in the knowledge environment. External learning seems to have com-
pensated for the disadvantage of the corporations in terms of large firm-specific assets 
in organic chemistry (due to their traditional focus on this technology), which could 
have caused inertia in the adoption process.  
The results are coherent with the notion of absorptive capacity (Cohen, Levinthal 1990) 
in that firms balancing external and internal learning appropriately are better prepared 
to deal with barriers to knowledge and technology adoption. Regarding the different 
reactions among German drug producers to the advent of modern biotechnology, in the 
presence of the high adoption costs characterising the German pharmaceutical 
industry, the companies with science-based research strategies have been better able 
to exploit the new technological opportunities. 
Methodological issues 
The study has deepened into the process of technological change in a science-based 
industry. The challenge has been to select a research phenomenon, generate 
hypothesis about the variables and mechanisms shaping it using qualitative and 
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quantitative empirical facts and verbal reasoning and finally, specified the logic in a 
formal model to test the outcome against the historical experience. 
The task of formalising verbal explanations demands extraordinary diligence forcing the 
scientist to elaborate thoughts in a precise way, defining feed back mechanisms and 
complex relationships. Therefore, the formalisation of the logic followed by the 
implementation of the simulation experiments have lead to a better understanding of 
the process of technological change and technology adoption observed in the German 
pharmaceutical industry. Formal theory has contributed to the identification of gaps or 
mistakes in the verbal explanation, since the outcomes did not match the observed 
patter of change. In these cases, the empirical analysis had to be rethought. 
Additionally, simulation has provided an experimentation tool to test alternative 
hypothesis.  
On the other side, the specification of the model regarding the parameter set to run the 
simulation remains a dangerous issue. As in the other history-friendly models put 
forward so far, the parameters draw on qualitative estimations and are coherent with 
the stylised facts. However, the values themselves do not represent a quantitative 
empirical result, neither are grounded on econometric or statistical analysis. For this 
reason, the justification of why to choose a model specification instead of other isn't 
straight forward.  
In the case of this contribution, the function and parameter specification builds a 
numerically consistent model matching the stylised facts of the appreciative theory. The 
process of setting parameters has been diligently discussed in sections 3.5 and 4.2.1. 
Moreover, the results of the history-friendly scenario match the historical experienced, 
the counterfactuals are coherent with the verbal logic and account for the sensitivity of 
the results. Additionally, the results concern general trends rather than the forecasting 
of precise values. Nonetheless, a criticism is easily found to any argument supporting 
the given specification and not an alternative one.  
Recent methodological contributions deal with this general problem of empirically 
based simulation-models and proposed a methodology to cope with specific 
characteristics of models in heterodox economics (Werker, Brenner 2004, 2005). 
These approaches are based on Critical Realism83 as a methodology to infer models. 
The approach combines data on assumptions and implications based on empirical 
                                                
83  According to Werker and Brenner ( 2005) Critical Realism sustains "that reality is the result 
of processes at a deeper level. Therefore it is not sufficiently to describe the relationships 
on the observed level. We need to understand these relationships on the basis of the 
processes of the underlying level". 
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findings to create classes of systems. Hence the approach leads beyond the common 
use of simulation models. Contributions of this kind give evidence on the increasing 
importance of simulation models in socio-economic analysis and the methodological 
gaps still needed to be filled. All in all, the results support the value of combining 
empirical work and formal modelling in order to understand socio-economic processes.  
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Introduction 
The case studies concentrate on four corporations of the German pharmaceutical in-
dustry. The corporations have been chosen among a list of German corporations re-
present two types of drug producers: diversified chemical companies coming from the 
coal-tar dyestuff industry and traditional pharmaceutical companies. After contacting 
the different corporations and their historical archives the selection of the four 
corporations depended on the extent to which qualitative and quantitative material to 
conduct the case studies seemed to be available. Accordingly the firms that could be 
considered for the case studies were Hoechst AG, Bayer, Schering AG and E. Merck.  
The case studies concentrate on the biotechnology related activities of the cor-
porations, their achievements in biotechnology research and development and on the 
biotechnology capabilities they accumulated in second half of the 20th century. The 
data presented in annex 2 on patent publications, corporate expenditures in research 
and development, human capital and collaborations complement the qualitative case 
studies that follow. 
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Case study 1: Hoechst 
The case study focuses on the activities of the company in the second half of the 20th 
century.  
The company's first activities began in 1863 with the setting up of a factory for coal tar 
dyes "Meister, Lucius & Co" at Höchst near Frankfurt am Main. In 1883 pharma-
ceuticals became part of the product portfolio supplied by the company. The small 
dyeworks factory grew to become a modern stock chemical corporation in the 1880s. 
After the devastating effects of World War I together with other German chemical 
companies the corporation created a larger community of interests in 1915/16 and 
finally merged in 1925 into the I.G Farbenindustrie AG84. With the break up of the I.G. 
Farbenindustrie AG after World War II the company was refunded as an independent 
chemical corporation in 1951 under the name "Farbwerke Hoechst AG vormals Meister 
Lucius & Brüning".85 
Farbwerke Hoechst AG restarted its activities in 1951 with 5 business fields: Dyes, 
solvents, pharmaceuticals, organic chemicals and chemical preliminary products and 
other chemical products. However, the annual reports of the decade of the 1950s 
announced activities in all types of chemical products distributed in different 
organisational structures. Even though the corporation was quite diversified the 
management was very much centralised and had a clear strategic preference for the 
development of the business dealing with chemical gross products. Accordingly, in the 
1950s the corporation focused on the production of chemical products such as plastics, 
solvents, fibre, and foils. The segments pharmaceuticals and dye stuffs lost 
progressively their importance in terms of sales and investments (Bartmann 2003, pp. 
237-239). 
The strong chemical focus of the corporation remained along the second half of the 
20th century. However, the pharmaceutical segment gained progressively importance 
within the company in terms of sales. In the 1960s the management started focusing 
                                                
84  The I.G. Farbenindustrie AG was funded in 1925. Its headquarters where in Frankfurt am 
Main. The corporation was the result of the merger of the 8 largest chemical companies in 
Germany. After World War II the Allies forced the corporation to go through a 
dismemberment process giving rise to entirely new and organisationally independent 
companies.  
85  In 1974 the corporate name changed again to "Hoechst Aktiengesellschaft". Since 1999, 
after the merger with Rhone Poulenc, the company’s name is Aventis and has its 
headquarters in Strasbourg, France. In 2003 Aventis was acquired by the French 
pharmaceutical company Sanofi-Synthelabo and is now called Sanofi-Aventis. 
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on the pharmaceutical segment and supporting its expansion with acquisitions and 
investments.  
Despite the strong chemical tradition of the corporation, the responsible for drug 
discovery and development were aware of the existence of different strategies that 
could be followed in the process of drug discovery. The annual report of the year 1969 
discusses the presence of two alternative research strategies in drug discovery. On the 
one side it refers to the "screening strategy" on the other to the "biological strategy": 
"In the screening strategy 30 compounds out of 4000 new synthetic 
compounds have qualified for further drug development and will go 
through the quality and security tests. Of these 30 compounds only 10 
reached the stage of clinical trials and only one reaches the market. In 
the cancer research, for instance, hundreds of synthetic substances are 
screened each year. Apart from this screening strategy the company 
follows a biological research approach. However, results from the 
biological research approach are expected only in the long term" (Annual 
Report 1969, p. 36). 
Despite the strong chemical research tradition, drug discovery responsibles at Hoechst 
in the 1970s seemed to be aware of the possibilities of applying other scientific 
principles than the organic chemical synthesis. 
On the base of notes from interviews with researchers at Hoechst conducted for the 
purposes of an internal project of the company, we can put forward that in 1960s 
pharmaceutical research was still guided by chemical principles. These provided the 
tools for varying the structure of known medicines to synthesis new compounds which 
were tested for therapeutic properties. In the 1970s and 1980s the understanding of the 
biological mechanisms behind the effectiveness of medicines increased and the 
research tasks in drug discovery changed accordingly. Instead of "vary the structure" 
the slogan in drug discovery became "do beta-blockers" (Wicenec 1996). 
Biotechnology research and achievements at Hoechst 
The first relevant application of biotechnology for drug development was the penicillin 
production through microbiological processes. Already after World War II, Hoechst 
recognises the importance of strategic collaborations with companies in order to 
accomplish successful biotechnology-related projects. In 1947 started the first ne-
gotiations with the company Merck Rahway (USA ) for the licensing of the penicillin 
production method (Hoechst 1985a; Schreier, Wex 1990). The license contract 
included the intensive collaborative activities with Merck including personal exchange. 
2 employees from Merck spent 2 years in Germany to help building up the necessary 
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technological capabilities in house (Hoechst 1985b). A bio-reactor plant for the 
penicillin production was built at Hoechst in 1955 (Hoechst 1985b).  
With the penicillin production researchers at Hoechst faced a challenging exercise 
since the production mainly drew on the control of biological process, which required 
different skills than the application of organic chemical synthesis. The activities de-
manded experience and some times also "a bit of luck" in order to obtain the expected 
results since the outcome of biological processes could not be forecasted and the 
secrets of the growth of fungus had not been disclosed. After this first step Hoechst 
continued in 1968 the next biotechnology-related activities with the production of 
Cephalosporine (an antibiotic) through enzymatic biotransformation processes in 
collaboration with Roussel-Uclaf (France) (Hoechst 1985b). 
In the 1970s Hoechst restraint the line of chemotherapy-based cancer research. The 
serendipity-based screening strategy followed to developed chemotherapy treatments 
against cancer resulted quite ineffective. However, biological research activities on 
cancer were continued at the Behringwerke. In 1981 Hoechst was carrying out re-
search in this location on the production of monoclonal antibodies for therapeutic and 
diagnostic purposes against cancer (Hoechst 1985b, pp. 46-48). 
In the field of plant biotechnology Hoechst also seemed to be aware of the possibilities 
of applying biological principles in the production processes. In the annual report of 
1975 Hoechst notifies that, apart from working on the traditional chemical pest control, 
the company also works on biological and biochemical applications for plant protection 
(such as the breeding and reproduction of virus, which attack exclusively harmful 
insects). These research activities were carried out with public support and in 
collaboration with universities.  
In the 1970s different biotechnology applications were developed. In 1971 Hoechst had 
already achieved the production of single cell proteins (SCP) with the Probion 
(Kretzschmar et al. 1997). The research activities in the field of antibiotics were 
successful. In the family of the Cephalosporin (a highly effective antibiotic) a new semi-
synthetic compound was produced together with Roussel Uclaf (Annual Report 1977). 
In 1979 hybridoma-cell lines were developed for the in vitro production of monoclonal 
antibodies at Behringwerke (Hoechst 1985b). Additionally, Hoechst produced large 
scale industrial production of ethanol from starch and sugary substances (Kretzschmar 
et al. 1997). 
In the early 1980s annual reports announced optimistic perspectives for genetic 
research in different types of substances. Insulin, the vaccine therapy for viral diseases 
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Interferone, antibiotics and coagulants were some of the potential applications for 
genetic engineering in the pharmaceutical sector.86  
The era of insulin at Hoechst had begun in 1971 with the peptide chemical modification 
of insulin. In the 1970s insulin research continued. However, the research work 
focused on the extraction of human insulin through the enzymatic transformation of 
animal insulin (pig insulin). In 1984 the research work results into the expression of a 
fusion protein reach in insulin (recombinant human insulin) (Hoechst 1985b; Obermeier 
1997). The same year an application for the establishment of a production plant is sub-
mitted. In 1985 began the planning and establishment of a pilot plant for the production 
of recombinant human insulin (Obermeier 1997). 
Regarding the application of genetic engineering for the development of coagulants, a 
number of research projects focused on genetic production of substances which could 
only be isolated from blood (blood-clotting Factor VIII und XIII and Antithrombin). In 
1985 began the cultivation of genetically modified mammal animal cells for the 
production of blood-clotting factors. In 1991 biotechnological production of blood-
clotting factor Hyrundin in large scale was successful and clinical trials started. 
According to the annual report of that year, the substance was produced through 
infiltration of the gene for Hyrundin in yeast cells. 
Further achievements involving genetic engineering were the Recombinant Tissue 
Plasminogen Activator (or rTPA, commonly used in patients with myocardial infarction), 
which was successfully completed in 1985 at Behringwerke, the expression of 
Angiogenin at laboratory scale (completed in 1986 and produced at large scale in 
collaboration with the Harvard Medical School) and the production of recombinant 
human Erythropoietin. In 1988 Behringwerke requested a building-licence for the 
production plant of recombinant human Erythropoietin (rhu-EPO). 
Biotechnology capabilities at Hoechst 
The process of building up biotechnology capabilities at Hoechst has been shaped by a 
combination of accumulation of internal capabilities in German research locations, 
collaborative activities and internationalisation. 
Already in 1970 foreign research locations of Hoechst were located in France, in the 
UK, in the US, in Japan, in India and in Egypt (Hoechst 1985b). At a first glance the 
internationalisation process of the company seems in the 1970s seems to follow the 
                                                
86  Plant protection is also presented as a field of application for genetic engineering. 
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aim of building up biotechnology capabilities. However, at that point, inter-
nationalisation was not the result of an innovation strategy to search for capabilities 
and research infrastructure abroad. In 1981, 72 % of the pharmaceutical research and 
development costs were invested in the Germany.87 As in the case of Bayer AG, the 
establishment of foreign locations in the 1950s and 1960s aimed at supporting the 
access to foreign markets (Bartmann 2003). 
The pharmaceutical research capabilities of the corporation in Germany were 
distributed in 4 locations: Hoechst, Behringwerke, Cassella and Albert. However, the 
biotechnology capabilities were mostly located at Hoechst in Frankfurt and at the 
Behringwerke (in Marburg). Hoechst in Frankfurt was the home of the biochemical and 
microbiological departments. In 1977 research in the field of gene-technology was 
established as an integral part of research and development in this location (Obermeier 
1997). Between 1979 and 1981 a research group on monoclonal antibodies and a 
gene technology group were established at Behringwerke (Hoechst 1985b). The 
research domains at Behringwerke focused on diagnostics, vaccines, growth and 
differentiation factors of the immune system, production processes for plasma proteins, 
blood-clotting factors and gene technology (Hoechst 1985b).  
In the early 1980s the annual reports present gene technology as a new research 
focus. In 1983, 9 % of research investments in pharmaceuticals worldwide were 
directed to gene-technology activities (Hoechst 1985b, p. 54). 
The internationalisation process in search for biotechnology capabilities began in the 
1980s as the pharmaceutical business tried to strengthen its research capabilities in 
biotechnology abroad. An important step was the 10-years-collaboration agreement 
with the Molecular Biological Institute of the Massachusetts General Hospital, which 
received in 1981 37 million DM (5 % of the total R&D costs) (Hoechst 1985b, p. 55). 
According to the annual report of 1981, 5 million DM per year were planed to finance 
the research activities of the research group. It was the most important collaborative 
research project with a public research institution in terms of investment and length. In 
1981 a 10 years collaboration agreement was signed (Hoechst 1985b; Schreier, Wex 
1990).  
Similarly, in 1984 Roussel Uclaf (which had been acquired by Hoechst) established a 
research institute for genetics and complex chemical synthesis. The institute was 
                                                
87  This figure excludes the costs of the clinical trials and the R&D investment of Roussel Uclaf 
(in 1981 Hoechst was the largest share holder of the French company). 
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meant to be a platform for collaboration with the public research organisation CNRS 
(Schreier, Wex 1990). 
In the 1990s the expansion of biotechnology capabilities abroad continues. In 1995 the 
establishment of a Drug Development Centre In Bridgewater/USA is planed. In 1997 a 
research centre for applied genome research was established together with ARIAD 
Pharmaceuticals in Cambridge (USA). Collaboration with the Harvard Medical School 
continued in the 1990s. In 1997 Hoechst announced a five-´years (16 million US$) 
joint-research-agreement to carry out research on bio-information engineering, cellular 
cycle regulation, cellular regeneration and bioinformatics. The same year an institute 
was established in Martinsried (Munich).  
Important collaborators of Hoechst along the last quarter of the 20th century were the 
company Ciba (latter on with Ciba-Geigy AG until 1984) in the field arteriosclerosis and 
metabolic disorders, Roussel-Uclaf S.A. in the field of hormone research, Boehringer 
Mannheim in the field of antidiabetics and the Bayer AG in AIDS research together with 
the Georg-Speyer-Haus. Collaborative research and development with companies was 
intensified in the 1990s. In 1997 the annual report announces running cooperative 
projects in the pharmaceutical business with 12 different companies88. 
Acquisitions and Joint Ventures relevant for Hoechst's biotech-
nology activities 
In the internationalisation process that started in the 1960s the management considers 
the acquisition of an American company with the aim of establishing a pharmaceutical 
location in USA. The company Lloid Brothers Pharmaceuticals Inc. was acquired. 
However, the acquisition did not bring the expected results. The successful acquisition 
for the pharmaceutical business took place in the 1990s with the incorporation of 
Marion Merrell (Bartmann 2003, p. 270). 
Already in the 1960s the French company Roussel-Uclaf S.A. was an important 
research and business collaborator of Hoechst in the pharmaceutical business. In 1967 
Hoechst acquires 20 % of the company and in 1972 increases its shares to obtain the 
majority of the shares (Hoechst 1985b). The expansion of the pharmaceutical business 
of Hoechst continues in 1995/1996 with the acquisition of Marion Merrel Dow (US). The 
American company was incorporated together with Roussel Uclaf and the 
                                                
88  An important joint venture in plant biotechnology was AgrEvo-Joint Venture with the 
German company Schering. 
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pharmaceutical business of Hoechst into the new pharmaceutical company Hoechst 
Marion Roussel, which integrated the pharmaceutical activities of Hoechst AG. 
Parallel to this development, relatively smaller acquisitions took place to reinforce the 
diagnostic business: in 1977 an American producer of enzyme-based diagnostics 
(Calbiochem, US) and in 1995 Syva (USA) also focused on the field of diagnostics. In 
1997 a joint venture was planned with the American diagnostic producers Dade 
International of which Hoechst held a 32 % participation. 
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Case study 2: Bayer 
The case study reviews achievements of the company in biotechnology research and 
the development of capabilities in this field in the second half of the 20th century. 
Similar to Hoechst, Bayer's origins are rooted in the production of dyes from coal-tar 
derivatives. In 1863 a partnership between two chemists was established with the aim 
of manufacturing and saling synthetic dyestuffs. As Hoechst, Bayer was able to 
develop strong capabilities in the production of dyes for the textile industry experi-
menting impressive growth in its early years. The partnership became a stock company 
called "Farbenfabriken vorm. Friedr. Bayer & Co." in 1881. Even though dyestuffs 
remained the company's largest division, between 1881 and 1913 new business fields 
built up a strong multinational with a world wide organisation and major research 
capabilities in Wuppertal-Elberfeld. 
Together with Hoechst and other German chemical companies, Bayer created a larger 
community of interests in 1915/16 and finally merged in 1925 into the I.G 
Farbenindustrie AG89 until the end of World War II. 
As one of the successors of IG-Farben, Bayer was newly established in 1951. The 
management was strongly conditioned from the IG tradition and in the first years the 
chemical segments remained the focus of the corporate investments. Between 1948 
and 1960 only 7.2 % of the investments in research laboratories and infrastructure for 
product development were directed towards the pharmaceuticals' segment (Bartmann 
2003, pp. 299-300). 
Both, the relatively manageable war-damages and the high reputation of the company 
allowed Bayer to restart its business without major problems. In the period from 1950 to 
1960 Bayer had tripled its sales. However the discovery of the therapeutic properties of 
the penicillin (and its production and marketing by Bayer's competitors) drastically 
changed the innovative performance of the company. Bayer, which belonged to the 
pioneers of the industrial pharmaceutical synthesis, could not compete with its foreign 
competitors in microbiological production methods.  
After World War II the pharmaceutical business of Bayer focused on the development 
of chemotherapeutics. Until the 1970s the sales programme included mainly licensed 
                                                
89  The I.G. Farbenindustrie AG was funded in 1925. Its headquarters where in Frankfurt am 
Main. The corporation was the result of the merger of the 8 largest chemical companies in 
Germany. After World War II the Allies forced the corporation to go through a 
dismemberment process giving rise to entirely new and organisationally independent 
companies.  
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products or own innovations introduced before the war. New drug developments were 
carried out and products such as Adalat (launched in 1972), Canesten (launched in 
1974) and the penicillin derivatives (launched in 1977) turned to be strong block buster 
contributing to strengthen the pharmaceutical business (Bartmann 2003, p. 350). 
Biotechnology research and achievements at Bayer 
The first important project in which Bayer gets involved with the application of 
biotechnological methods was the production of penicillin after World War II. With 
American licences Bayer was able to apply microbiological methods for penicillin 
production in its location in Elberfeld. In the decades after Bayer intensified its work to 
develop own microbial and enzymatic processes for drug development (Benz et al. 
1996). In the 1950s Bayer begins research to develop an enzymatic process for the 
extraction of the 6-APS, the basic compound of all derivatives of penicillin. The efforts 
took several years and in 1975 Bayer accomplished this research. At the end of the 
1960s the experts in the field of metabolism entered upon a new research direction for 
the treatment of diabetes: the isolation and microbiological production of enzyme 
inhibitors (Alstaedter 1988). This research direction proved to be successful a decade 
latter when the development of "Acarbose" was completed. Biotechnological appli-
cations received increasing attention. For instance, in an internal report of 1979 the 
management of pharmaceutical research recognises the need of allocating resources 
for research exploring the biological processes dealing with the transfer of genetic 
information, especially for its application in the production of microbial agents. An 
important candidate to explore the possibilities of genetic engineering was the insulin 
production. The first research activities on the insulin synthesis had been carried 
together with Schering. Even though the collaboration did not succeed and the 
production of human insulin with recombinant DNA technology at Bayer was not 
completed, the management supports the strategy of building up progressively the 
necessary infrastructure to explore the applications of genetic engineering (Schütz 
1977, p. 8). 
In the first phase of research in genetic engineering at Bayer a quite important number 
of projects were carried out simultaneously. In July 1983 the research activities include 
11 projects in Genetic Engineering including recombinant blood-clotting factors, the 
biological characterisation of the tissue plasminogen activator (t-PA) for the treatment 
of acute ischemic stroke and the enzyme inhibitor Val-15-Aprotinin (Auerswald 1983, p. 
16). The activities were located mainly in American research locations of Bayer in 
Elkehart (location of Miles) and at the University of Rochester. Only 3 projects (among 
them the t-PA and Val-15-Aprotinin projects) were carried out in the German locations. 
The company realises that competitors already hold a technological advantage in all 
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products except for the Val-15-Aprotinin. The management tries to concentrate the 
activities on two main projects Val-15-Aprotinin und Factor VIIIc. The projects should 
be carried out together with other companies and institutions. In 1984 Bayer acquires a 
licence from Genentech for the production and marketing of the blood-clotting factor 
VIII. The company works on the improvement of the production of Factor VIII trough 
recombinant DNA technology.  
In the second half of the 1980s and in the early 1990s Bayer is able to produce the first 
research results in the field of genetic engineering and bring them to the market. In 
1986 the annual report announces important progress in the production of monoclonal 
antibodies for the targeted treatment of Pseudomonas-Infection. Another relevant 
achievement was the submission of the application to obtain the marketing approval in 
the US for the enzyme inhibitor Prolastin (Alpha-AT), a substance extracted from blood 
plasma to prevent pulmonary emphysema. In 1987 the product receives the marketing 
approval. In 1993 a blood clotting recombinant Factor VIII for the treatment of haemo-
philia is approved for marketing in the US. The brand name was Kogenate. Its de-
velopment had taken 10 years of research activities and 300 million DM investment 
costs (Dolata 1994 p. 36). 
In the 1990s Bayer advances towards the enrolment in the field of immunology and 
immunodiagnostics. These fields draw on molecular biology principals to develop 
treatments and diagnostic systems for disorders that involve the immune system (e. g., 
cancer, HIV disease, autoimmune diseases). In 1992 Bayer completes an important 
step in this field with the development of the analysis device Immuno 1. The annual 
report in 1991 announces the first positive results in the clinical trials of monoclonal 
antibodies against the tumour necrosefactor (TNF) causing arthritis. 
Biotechnology capabilities at Bayer 
The beginning of biotechnology research and development at Bayer was only possible 
though licensing and collaborative agreements with companies and research insti-
tutions. In 1949 Bayer entered into collaboration with the company Schenley to develop 
a modern plant for the production of penicillin G (Benz et al. 1996).  
In order to grasp the state-of-the art in the applications of molecular biology and gene-
technology for drug discovery and development Bayer held contacts at the beginning of 
the 1970s with the company Cetus and with Prof. Weil (from the University of Geneva) 
(Schütz 1977). 
The process of building up in house capabilities to explore the applications of genetic 
engineering in drug discovery and development starts in the second half of 1970s with 
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the establishment of two research laboratories for the stem manipulation. The goal was 
to start building up an infrastructure which should be progressively enlarge latter on 
(Schütz 1977). The acquisition of Miles Corporation (US) in 1977 was a strong impulse 
in this direction. In 1979 Bayer expands the research facilities at Miles and upgrades its 
citric-acid production plant (Hauser 2004). In the German research facilities a research 
group for genetic engineering is established with 2 senior scientists and 4 technicians. 
Additionally the construction of a laboratory with approximately 300 square meters was 
planed for 1980 (Truscheit, Frommer 1979). The biotechnology-related research 
activities were concentrated in Elberfeld and in Elkhardt, the location of Miles 
Corporation (Hauser 2004). In 1983 fifteen PhDs were involved in genetic engineering 
within the pharmaceutical business unit, five in Germany and ten in the USA. The 
management admits not having enough intern capabilities to carry out the running 
projects in the new field of genetic engineering on their own (Auerswald 1983). 
In the 1980s Bayer recognises that only the intensive contacts to external research 
institution and collaborative activities connected with the extension of intern screening 
capabilities and the appropriate expansion of the internal infrastructure for molecular 
biology research will enable Bayer the identification of promising products, its patent 
protection and its production with the application genetic engineering (Auerswald 
1983). 
In 1982 the annual report points out the importance of collaboration activities in the 
field of genetic engineering with academic institutions and research institutes in 
Germany and in the US. The report refers to the Max Planck Institute for Plant 
Breeding Research in Köln, the Genetic Institute at Köln University, the University of 
Rochester in NY and the Massachusetts Institute of Technology (MIT) in the US. 
Especially the University of Rochester in New York and the Yale University in New 
Heaven (Connecticut) were important research institutions for Bayer. In 1983 the 
company had 5 of its 11 projects in the field of genetic engineering being carried out to 
a large extent in the facilities of the University of Rochester (Auerswald 1983). The 
collaboration activities with the University of New Heaven were mainly motivated by the 
acquisition of Miles, which had research facilities in the same region. 
Important collaborations with companies include the licensing contract with Genentech 
Inc. (US) in 1984. According to the Bayer's annual report of 1986 the companies 
worked together in the biosynthetic production of the blood-clotting Factor VIII. In this 
period Bayer and Hoechst AG cooperate in AIDS research. 
The efforts to build up the necessary infrastructure continue in the years after. In 1988 
a new research centre is established in West Haven (a location of Miles). According to 
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the annual report of 1987 the new research centre integrates 3 research units: 
Molecular Diagnostics Unit (specialised on diagnostic systems based on monoclonal 
antibodies), Molecular Therapeutics Unit (specialised on the treatment of immu-
nological diseases such as Alzheimer and AIDS), and the Institute for autoimmune 
diseases (specialised on research on the therapy of rheumatic diseases). 
In 1995 an additional research centre is established in Japan, in the Kasai Science City 
near Kyoto. Collaboration and licensing activities continue to be essential for the com-
pany in the 1990s. The main role of collaboration and research activities is the 
systemic search for chances of collaborative research with companies (Alsraedter, 
Foltin 1992). 
Acquisitions and joint ventures relevant for Bayer's biotechnology 
activities 
The process of building up internal capabilities of biotechnology research and 
development after World War II and, especially, since the 1970s was supported by a 
number of important acquisitions and joint ventures.  
The first acquisition took place in 1974 with the integration of the activities of Cutter 
(US). The company was specialised in the production and sales of blood plasma-based 
products and veterinary products and most importantly, Cutter was carrying out pioneer 
research work in the field of blood fractionation. Hauser (2004) sustains that this 
acquisition was not the result of an strategic decision the expand the R&D activities but 
much more the logical consequence of Bayer business strategy of diversification of the 
sales programme to complement the products for human medicine with veterinary, 
dental and biomedical products. The acquisition of Cutter indented to reinforce the 
activities in the veterinary business. 
In 1978 the purpose of acquiring a company located in the US was quite different. With 
the acquisition of Miles Laboratories, (USA) Bayer integrated a broad diversified 
company in the chemical-pharmaceutical sector. The business focus of Miles was the 
biological production of citric acid and enzymes. The acquisition of Miles was a clear 
attempt to build up own research capabilities in the US. According to Hauser (2004), 
the plans to secure the pharmaceutical business in Germany faced a few problems 
such as the high costs and the lack of qualified staff. The pharmaceutical research 
needed a second strong base and this should be located in the US. Accordingly by 
1980 Bayer had 2 important research locations in the US: Elkhard (Indiana) which was 
the location of Miles and the research facilities of Cutter located in Berkley (California). 
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In the 1980s the strategy of expanding the research facilities towards the US continued 
with the establishment of two joint ventures in the West Haven: Molecular Diagnostics 
(in 1982) and Molecular Therapeutics (in 1985). The trend continued with the inte-
gration of Chiron Diagnostics in Bayer Diagnostics in 1987. Chiron Diagnostics pro-
vided Bayer with proprietary molecular diagnostics technology to be applied in the field 
of immunological diagnostics. 
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Case study 3: Merck 
The case study reviews achievements of the company in biotechnology research and 
the development of capabilities in this field in the second half of the 20th century. 
The beginning of Merck is rooted in a family owned pharmacy in Darmstadt (Germany), 
which gradually reached industrial dimensions in the last quarter of the 19th century. By 
1904 Merck's assortment included almost 50 specialties; about one half of these were 
preparations manufactured from animal organs and a wide variety of sera 
(Bernschneider-Reif et al. 2002, pp.52-54). 
Even though Merck KGaA has became a diversified chemical company, with regard to 
its technological roots and research tradition it can be considered within the group of 
traditional pharmaceutical companies that started their activities exclusively in the 
pharmaceutical sector. There is large evidence for the identification of the company 
with the traditional pharmaceutical companies rather than with the diversified chemical 
corporations. For instance, at the beginning of the 20th century Merck established a 
community of interests (so called "Interessengemeinschaft") together with other tradi-
tional pharmaceutical companies. According to Bernschneider-Reif et al (2002, pp. 76)  
the idea behind this collaboration was to establish a counterbalance to the growing 
influence of the coal-tar dye factories, which themselves had joined forces to build two 
different community of interests years earlier". With the war the community of interests 
ended. However, in 1915 the companies Merck, Boehringer Mannheim and Knoll 
established a company officially called MBK to jointly produce a range of frequently 
prescribed tablets and ampoules. This community of interests continued to exist until 
1971 (Bernschneider-Reif et al. 2002, p. 86). 
Biotechnology research and achievements at Merck 
Metz (1995) presents the application of traditional biotechnology along three phases. 
First, biotechnology was applied between 1893 and 1939 for the anaerobic 
bacteriological production of butyric and lactic acids. It was the integration of bio-
technology in the drug development and production processes at Merck. Next, 
after1939 Merck focused on the synthesis of the ascorbic acid (vitamin C). In order to 
improve the yield of the basic substances involved in the synthesis, Merck developed a 
chemical process which integrated a step involving the bacteriological oxidation of 
sorbit into sorbose (the aerobic-sorbose-process). According to Metz, these first 
biotechnology production processes have to be considered more as empirical and 
handcraft-based work than as industrial. They required quite unique development and 
production strategies. The situation changed with the development of the bioreactor. 
The last phase of traditional biotechnology at Merck started with the establishment of a 
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bioreactor in 1956, which played a key role in the microbiological transformation of 
steroids.90 Merck ventured into the cortisone business in 1953/1954 by buying 
manufacturing and marketing licenses (Bernschneider-Reif et al. 2002). The bioreactor 
allowed for the introduction of a microbiological transformation of steroids in the 
synthesis of Cortisone and Hydrocortisone, which made the process much more 
effective by reducing the synthesis from 32 to 13 steps. This technique (which had 
been discovered by Schering and further developed in the US) was integrated in 
Merck's development processes. Even though the company had a long tradition in the 
microbiological dehydrogenation of Sorbit to produce Sorbose, the process with 
Cortisone and Hydrocortisone required sterile reaction conditions. According to 
Brückner, who was responsible for carrying out this task, the technique was new for 
him and for the company (Brückner 1985). 
In the following years the application of microbiological reactions was very successful. 
Until 1965 the microbiological transformation of steroids was a main focus of the 
development activities (Metz 1991). Almost all microbiological reactions known and 
needed were applied. Between 1956 and 1976 the company implemented more than 
200 steroid and semi-finished steroid substances. The biotechnology capabilities built 
in this period were used for the applications in other fields and projects such as the 
sorbose process for the synthesis of the ascorbic acid, the vitamine B12, cell cultures 
and specially, during the third quarter of the 20th century, in the extraction of enzymes 
for diagnostic applications (Metz 1991, p. 44). 
After 1972 the preparative biochemistry worked in the extraction of organ-specific iso-
enzymes from the heart, brain and liver. The creation of antigen in animals as well as 
and the purification of antiserum for immunological use were additional projects 
demanding the further development of biotechnology capabilities in the company. It 
was the beginning of the immunological research at Merck. The work of the analytical 
biochemistry department complemented the activities of the diagnostic research 
programs. The microbiological group (apart from working o the production of GDH) 
worked primarily on the search for antibiotics out of staphylococci and through the 
specific selection of the microorganisms. The results in this research line were not very 
successful. 
In the second half of the 1980s the company considers the possibility of broadening its 
indication portfolio to include immunological products for tumour therapy and tumour 
                                                
90  Luitgard Marshall (2000) pp. 305-340 presents a detailed case study on the application of 
biotechnology in the production of vitamin C and the application of the bioreactor (i. e. the 
sterile technique) for production purposes at Merck. 
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diagnostics. The management had many doubts about undertaking research and 
allocating resources in this direction. On the one hand these activities were considered 
very risky and additionally, the available capabilities in immunological basic research 
and modern biotechnology were very narrow. Further more, issues of patent protection 
in this field were unclear. None the less the management saw strong innovation 
potential in this business line. New capabilities had to be built up for both research and 
development in the field of immunology (Merck 1987).  
In 1993 three immunological research programs were pursued: the therapy of certain 
types of cancer using monoclonal antibodies, active immunisation and the prevention 
of metastases using adhesion receptors. Other biotechnology-related activities in the 
early 1990s involved the processing of thrombolytic proteins produced and the supply 
of reagents for molecular biology and biochemical purposes (such as gel material for 
nucleic acid electrophoresis or special enzymes for the isolation and purification of 
DNA and RNA) (Bernschneider-Reif et al. 2002). 
Biotechnology capabilities at Merck 
Merck set up its bacteriological department in 1895. Besides the production of 
antidiphteric serum and smallpox vaccine, the department carried out experiments to 
explore the possibilities of manufacturing additional biological-therapeutic products. 
This department grew rapidly and in 1902 a second location with a bacteriological 
department was established in Halle on the Saale (Germany). Animals were kept to 
guarantee the resources for the active constituents of the vaccines (Bernschneider-Reif 
et al. 2002). 
The available sources do not provide with any evidence of establishment or expansion 
of research infrastructure to promote biotechnology-related activities in the first half of 
the 20th century. 
The reestablishment of the research activities at Merck after World War II was slower 
than at other firms such as the successors of the IG-Farben, Bayer and Hoechst. That 
the annual reports of the company did not report any information on the research 
activities until 1957 could be a confirmation of the lack of interest on research and 
development activities from the management side (Brückner 1985).  
In the 1950s professional contacts to research institutes in Germany in the 
microbiological field were very unusual. Microbiology and Biochemistry institutes in the 
German Universities were first created in the 1960s. Industrial problems were not of 
interest for the few University professors in the field at that time (Metz 1991). 
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At the end of the 1950s the research and development activities were distributed in 
three segments: the chemical research, the medical research (which included the 
pharmacological research department) and the biological station. 
The microbiological capabilities were integrated in the pharmaceutical research 
segment. The work in the microbiological transformation of steroids demanded strong 
efforts in building up state-of-the-art in-house bacteriological capabilities to conduct the 
steroid-synthesis. In 1955 Merck built a bioreactor and microbiological laboratories for 
the application of microbiological processes in the steroid synthesis (Metz 1995).  
The 1960s began with the establishment of a biochemical department by Dr. Hermann 
Lang after a visit in the US. The biochemical department was subordinated to the 
chemical research segment. In 1964 the technical microbiology group joined the bio-
chemical department. The research focused on the exclusively microbiological 
synthesis of vitamin C and other projects on the microbiological production of enzymes. 
Already in 1967 the biochemical department was large enough to establish an inde-
pendent biochemistry research unit with two departments: preparative biochemistry 
and analytical biochemistry. The microbiology research group belonged to the pre-
parative biochemistry (Brückner 1985).  
In 1975 the infrastructure for the development of microbiological production processes 
was modernised. The bioreactor was renovated to integrate a computerised data 
processor (Metz 1995). 
Marshall points out the subordination of the microbiological research group to the 
exploration of chemical problems (Marschall 2000).91 According to her, despite the 
critical mass in biotechnology capabilities at Merck and the successful achievements in 
the 1960s and the broad microbiological research portfolio, the company's activities in 
the 1960s and 1970s were mainly driven by chemical principles. 
However available sources point out that in 1970 the importance of the screening 
activities for successful drug discovery was questioned by the management. Even 
though screening-based chemical strategy had led to a large number of more or less 
effective substances, only few of them had turned up to be really valuable for medical 
purposes. Screening activities had a strong weight in the drug discovery process and 
the probability to find a new substance with new therapeutic value was relatively low. 
                                                
91  Her argument draws on the one side on the promising biotechnology-based products and 
processes that were not developed because they did not belong to the core business of 
steroids and enzymes and on the other, on the organisational structure of the research and 
development activities at Merck. 
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Additionally, the search process was quite superficial, leading to preliminary products 
that had trouble going through the required quality and safety controls. The logical 
consequence for the company management was to reorient drug discovery much more 
towards the diseases against which new therapeutic solutions should be developed, 
rather than focusing it on the synthesis of potential drug candidates. In an internal 
report the management pointed out the successful results of a "disease-oriented 
strategy" in liver-research and the need to allocate resources for drug discovery main-
taining the resources for drug screening at a level not higher than the absolutely 
necessary (Merck 1970). The management seemed to be aware of the chances of 
understanding the biological causes of diseases for the discovery and development of 
appropriate therapies. In the mid 1980s biotechnology research and development was 
institutionalised.  
In the 1970s professional contacts to research institutes were intensified. According to 
Metz (1991) after the strong political support of biotechnology in the 1970s there was 
an increasing number of university research institutes willing to cooperate with the 
industry92. Especially in the field of molecular genetics collaboration was very 
successful in different enzyme projects. For instance in the project invertase (yeast 
derived enzyme) and for genetic modifications of glucose-dehydrogenase the Merck 
worked together with Prof. Esser from the University of Bochum and Prof. Gassen.  
In 1984 a biotechnology department was established by merging microbiology and the 
biochemistry research groups (Metz 1991). In 1986 the research activities included the 
development of monoclonal antibodies through animal cell cultures (Marschall 2000). 
Already in the 1970s and 1980s the company considered the option of collaboration in 
the molecular genetic field with private companies. Metz (1991, p. 166) describes how 
in each case an assessment was necessary to decide whether to build in-house 
capabilities or to outsource research and development tasks. 
In 1992 Merck bought an interest in the American company Biosite to strengthen its 
activities in the area of immunodiagnostics. In 1998 followed the joint venture BioMet 
Inc. USA and the acquisition of CN Biosciences, both in the USA. In 1999 the acquisition 
of Lexigen aimed at the expansion of biotechnology research, especially in order to 
secure the patent position of the company.  
                                                
92  Metz describes how the framework conditions to carry out collaborative research changed. 
Apart from the increasing number of academic institutes, there was also a growing interest 
on working with problems arising from the industrial application of the scientific principals. 
Metz (1991, p. 164) sustains that this change in the willingness to cooperate had probably 
a lot to do with the criteria for the allocation of public funds in research. 
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Case study 4: Schering  
The case study reviews achievements of the company in biotechnology research and 
the development of capabilities in this field in the second half of the 20th century. 
E. Schering was established in 1851 as family-owned pharmacy in Berlin. The pharma-
cy produced medicines and chemical products. The gradual conversion from a tra-
ditional pharmacy with a small laboratory into a pharmaceutical and chemical company 
led in 1871 to the change of corporate form to become a public limited company, the 
"Chemische Fabrik auf Aktien (vorm. E. Schering)". Even though the roots of the 
company were in a small pharmacy, along the first half of the 20th century the 
pharmaceutical business of Schering became a small part of a large conglomerate of 
business units (Bartmann 2003, pp. 384-386). In 1922 the company was acquired by a 
chemical corporation. The new mother company (with the stock market name 
Oberkoks) after a reorganisation of the holding company over took the name of one of 
its companies to become the Schering AG in 1937. Similar to the case of Bayer and 
Hoechst, the pharmaceutical business was a small unit of the corporation. In 1938 the 
pharmaceutical sales amounted less than the 15 % of the corporative sales. However, 
according to Bartmann (2003, p. 387), unlike the organisations of Bayer and Hoechst, 
the only large research infrastructure established at Schering was the pharmaceutical 
research department. The pharmaceutical research remained quite uninfluenced from 
the management, which was not interested in research and development. The research 
program focused since the early 1920s on physiological problems.  
After World War II, Schering had lost a large part of its factories and infrastructure. 
Apart from the tremendous war damage, locations were lost with the new political 
frontiers established after the war. The reconstruction of the business drew on the de-
velopment of the pharmaceutical activities93. 
Biotechnology research and achievements at Schering 
Initial biotechnology-related activities at Schering were carried out in the bacteriological 
department. During the first decade of the 20th century the intensive research work in 
this department lead to patents for the production of prophylactics and remedies 
against tuberculosis (Scheringianum 1997a). 
                                                
93  In the next paragraphs, unless otherwise indicated, the name Schering refers to the 
pharmaceutical activities of the current Schering AG . 
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In the first half of the 20th century pharmaceutical research at Schering focused on 
hormone research, especially on steroid hormones94. The work of the scientific 
research laboratory combined the efforts of understanding the functions of steroid 
hormones and their isolation with efforts of producing them through chemical synthesis.  
In 1925 Schering applies the Allen-Dosi-Test for the assessment of hormones' effects. 
The first hormone products that were taken onto the market demanded expensive 
production processes. For instance, to produce the first hormone preparation for 
climacteric complaints the hormones had to be extracted from a placenta. To reduce 
the costs, the search for rational production processes by means of organic chemical 
synthesis was intensified. Chemists from university institutes were engaged in the late 
1920s and mid 1930s to find the structural form of the hormones, which was the key to 
their synthesis in the laboratory (Berghausen et al. 1991, pp. 21-31). 
In the late 1930s an alternative technique was explored by Schering to obtain sexual 
hormones: the microbiological transformation of hormones. In 1937 Schering patents a 
hydrogenation technique to produce testosterone drawing on the application of 
backer's yeast to the steroid hormone androstendion. This patent was the first 
description of a microbiological transformation of steroid hormones. However, at the 
time the process did not reach any relevance within the company since the production 
at industrial scale was not feasible. This discovery gave impulse to further activities 
involving the application of microbiology. A series of simple microbiological reactions 
with steroid hormones were described. This line of research and production was more 
or less disregarded until the end of the World War II. Schering did consider them 
economically attractive enough for their industrial application (Witzel 1983, pp.1-3). 
Schering's experience with microbiological process was not an advantage for the 
company in the challenging penicillin production. Like most German drug producers 
after the 2nd WW, Schering was not able to produce antibiotics in an autonomous basis. 
In 1954 Schering brings onto the market the Antibiotic Erycinum, a preparation of Eli 
Lilly (Witzel 1983). 
The management board member Dr. Clerc (mentor of the reconstruction of the 
company after the 2nd WW) promoted the research on projects combining techniques of 
                                                
94  In 1905 the chief of the physiological research laboratory recognizes the effects of extracts 
from pancreas and sustains that patients of diabetes could be provided with this extract by 
a subcutaneous injection to activate the functions lost. Further research in this direction did 
not take place. Eighteen years later Canadian scientists developed insulin (Berghausen et 
al. 1991, p. 16). 
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organic chemical synthesis and microbiology to try to economise the production 
processes of steroids. After 1955 a small group of 3 scientists built up a first fermentor, 
which latter on would serve as pilot model for a bigger fermentation plant. In the 1960s 
the application of microbiology for steroids' processing had won recognition within the 
firm. These techniques were well established in drug production processes. The 
application of microbiology was not limited to the production of steroids, also enzymes, 
amino acids, and alkaloids were developed with the application microbiological 
principles (Ott 1994; Witzel 1983). 
In 1987 the company considered exploring the possibilities of molecular biology, cell-
biology and protein-chemistry. Schering announced the strategic decision of building 
up this line of research by further developing the available capabilities in microbiology 
and biochemistry (Scheringianum 1991, p. 3 year 1987).  
The research work in biotechnology at this time focused on three main projects, one of 
them was the microbiological synthesis of steroids. In 1987 a project for the production 
of appropriate streams of bacteria to improve the microbiological steroid synthesis was 
launched. Additionally, Schering explored the application of genetic engineering for 
contraception methods and therapies against infertility. Finally, applications to improve 
the control of the coagulation system were part of the research program as well 
(Scheringianum 1990). 
In the 1990s Schering makes important acquisitions to provide the company with 
additional capabilities. For instance, with the acquisition of the American biotechnology 
company Triton Biosciences Inc. in 1990 Schering incorporated strong biotechnology 
capabilities. In 1993 Betaferon, the first biotechnology product of the company was 
launched onto the market. The research work on the interferon-beta1 (Betaferon) had 
been carried out by Triton in the 1980s. The product became the block buster of 
Schering for the treatment of multiple sclerosis. 
In 1997 the biotechnology-based product-pipeline included 5 projects. Only one of 
them was being carried out outside the US. In the field of cardiovascular diseases a 
project investigated the development of a recombinant product for the treatment of 
heart attacks. Additionally, the company worked in the Angiogenic Gene Therapy for 
cardiovascular diseases since 1996. For the treatment of Multiple Sclerosis (MS) 
Schering explored Glial Growth factors and lymphocyte / monocyte interactions. 
Finally, in the field of cancer therapy Schering carried out a project on ribosomes 
(Scheringianum 1997b). 
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Biotechnology capabilities at Schering 
An analytical laboratory was built in 1883 and 10 years later the bacteriological 
department was established. However, the era of continuous research and de-
velopment started in 1902, as the chemist and physiologist Max Dohrn became head of 
the new physiological laboratory. From the beginning Dohrn focused the research work 
on biological processes such as metabolism, hormone research and preparations 
extracted from animal’s organs (Berghausen et al. 1991, p. 16).  
The activities carried out at Schering in 1920s and 1930s in hormone research and in 
the microbiological transformation of steroids were supported by Prof. Butenandt and 
his student Luigi Mamolli who worked in the department of biological chemistry at the 
University of Göttingen and latter on at the University of Berlin and at Max Planck 
Institute for Biochemistry, Berlin-Dahlem (Ott 1994). 
In penicillin production the American pharmaceutical company Squibb provided 
Schering with technological support in the early 1950s. In return Squibb was interested 
in the provision with steroid preliminary products from Schering for its activities in the 
steroid fermentation (Ott 1994; Wicenec 1996). In this period Schering built up the 
necessary in house capabilities to develop microbiological applications for production 
processes at large scale. Besides the establishment of a department for biochemistry 
in the pharmaceutical-chemical research unit, a microbiology department and a plant 
for the manufacture of corticoids were set up in the Charlottenburg works 
(Scheringianum 1971; Scheringianum 1983, p.3). In 1961 a large fermentor was built in 
Bergkamen. Two years later the company started the production with fermentation 
technique. In 1967 the capacity was enlarged. The plant was used for research and 
development (Witzel 1983). 
In 1962 the research structure in the pharmaceutical unit explicitly distinguished 
between biological and chemical-pharmaceutical research. In the 1960s biological 
research plays an important role focusing on the exploration of biological processes. 
Issues of chemical physiology received special attention. The goal of this line of 
research was to increase the possibilities of the other research units involved in   
pharmaceutical research by providing orientation for a targeted development of 
therapies. In 1962 and 1963 this field experienced strong expansion in terms of 
personnel and capital investments (Scheringianum 1983, pp.24-25 and pp.44-45). 
Even though Schering integrated biological research in the drug discovery and 
development processes, the capabilities for exploring the possibilities of modern 
biotechnology in the mid 1970s were quite short. The company waited until 1986 to 
build up capabilities in modern biotechnology and to consider the application of genetic 
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engineering for industrial purposes. In 1972 the company had began molecular genetic 
research. However, 1986 the capabilities for this activities integrated 5 scientists and 
10 technical workers (Scheringianum 1986). 
Since 1975 and almost without interruption Schering becomes public support from the 
Ministry of Research and Technology for research projects in the field of biotechnology. 
In the period between 1974 and 1985 the volume of public support amounted 4 mil-
lion DM, covering 23 % of the total investments in microbiological and biochemical 
research95 (Scheringianum 1986).  
In the mid 1980s Schering undertakes organisational changes to impulse the activities 
in genetic engineering. Before 1986 biotechnology-related research was not sub-
ordinated to any business sector within the firm. This line of research was integrated in 
the area of fundamental research. Between 1986 and 1987 a research group called 
plant biotechnology was incorporated into the plant protection business unit. 
Additionally, another research group for fundamental research in biotechnology was 
integrated in the pharmaceutical business. This was the institute for biochemistry, 
which became in 1992 the institute for cell and molecular biology. Both institutes (in the 
plant and pharmaceutical business units) were established with the intention of 
promoting them to reach an adequate research infrastructure (Scheringianum 1992). 
To build up capabilities in the field of genetic engineering Schering established in the 
mid 1980s two research institutes as platforms of access to the research results of 
public research institutions (Scheringianum 1993). In the period 1984-86 Schering 
established (and partly financed) the Institute for Gene-Biological Research in Berlin. It 
was created as an independent institution integrated in the location of the Max Planck 
Institute for Molecular Genetic in Berlin. The institute was connected with the University 
of Berlin (FU Berlin) through a collaboration contract and focused its work on cell 
biology research. Schering held a first refusal right on all research results. 
The Institute of Diagnostic Research GmbH in Berlin was established in 1985 as a 
100 % company of Schering. The institute worked as a normal profit center in the 
University Clinic in Charlottenburg (Berlin) and had direct contact to clinical research. 
The institute held a contract with the Berlin University (FU Berlin). The focus of the 
institute was applied research in the diagnostic field. Both Schering and the university 
held the first refusal rights on the research results. 
                                                
95  The investments do not include personnel costs.  
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In 1991 Schering launches an industry research consortium and establishes the clinic 
of the Albrecht-Ludwig University in Freiburg. In the project 3 companies were involved: 
Asta-Chemie (Frankfurt), Ciba Geigy (Basel) and Schering (Berlin). The goal of the 
clinic was the development and test of new methods for Tumour Diagnostics. The 
innovative aspect was the integration of oncology research, a clinic and a rehabilitation 
unit in one institution. 
A further step towards the expansion of the biotechnology capabilities in Germany was 
the establishment in 1998 of the metaGen Gesellschaft für Genomforschung mbH in 
Berlin focusing on research on the human genome. The foundation was preceded by 
cooperation in 1996 between Schering and the Californian company Incyte Pharma-
ceuticals, which provided Schering with access to large DNA databases.  
Acquisitions and joint ventures relevant for Schering's biotech-
nology activities 
Schering's biotechnology activities at the end of the 1990s were mostly concentrated in 
the US. This situation was the result of the intensive acquisitive strategy followed by 
the corporation in the last quarter of the 20th century.  
With the acquisition in 1979 of the internal medicine division of Cooper Laboratories in 
Palo Alto, Schering established Berlex Inc., a company with expertise in cardiovascular 
disease in the US.  
The strategy of Schering in the 1990s was the incorporation of companies and 
research infrastructure to build up Berlex capabilities in the field of genetic engineering. 
To facilitate the acquisitions Schering establishes in the USA the Schering Berlin 
Venture Inc (New Jersey) with the aim of acquiring shares in companies conducting 
particularly innovative technologically research (Scheringianum 1971). 
In 1990 Berlex Inc. acquired from the Schell Oil Company (Texas) the pharmaceutical 
research activities of Triton Biosciences Inc. (California). Experts estimate that the 
transaction reached the 100 million US$ value. Even though Triton did not have any 
product in the market at the time, the company had a research portfolio with very 
promising products (Lippold 2004). Additionally, Berlex expanded into biotechnology 
with the acquisition of Codon, also in the area of San Francisco. Both acquisitions 
added 250 employees working on biotechnology research. 
In 1992 Berlex acquired for 85 million DM the research facilities of Chevron (US) in 
Richmond, California. This location involved 25 scientists working in the fields of 
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tumour therapy, cardiovascular diseases and the central nerve system. By 1993, all 
Berlex research was consolidated in Richmond, California (Lippold 2004). 
The industrial Chemicals and Natural Substances Divisions were sold to the US 
American company Witco Corporation in New York (US) and the electroplating division 
was sold to the French company Elf Atochem SA, Paris (France).  In 1994 the 
agrochemicals division is integrated in the joint venture AgreVo together with the 
Hoechst AG Schering held 40 % shares in this joint venture. With these operations in 
the first half of the 1990s  Schering has set the ground for the future of Schering as a 
pharmaceutical company (Scheringianum 1971). 
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Patent publications 
Methodological issues 
The patent data presents counts of the first publications of patent applications filed at 
the German patent office or European Patent Office with Germany as designation 
countries. The data until 1967 include all (foreign and German) published documents. 
From 1967 on, the time series include German documents only. 
The data was gathered through online databases EDOC, PLUSPAT and PATDPA from 
the vendor Questel96.  
To deal with the problems of building historical time series of patent indicators the 
patent searches considered the approach put forward by Dominguez Lacasa et al. 
(2003)97. These problems concern the changes in the patent legislation and the 
publication rules, the use of consistent patent classifications over time and the limited 
comprehensive bibliographical information available in electronic form for patent docu-
ments published before 1968. Table A 1 gives the patent classes of the international 
patent classification (IPC) used for the sector and technology definitions. Regarding the 
counting of corporate patents, patent documents were recognised as pertaining to one 
of the corporations under consideration as long as the corporations' name, or the name 
of a major subsidiary, appeared as patent applicant. Changes in the corporations' 
name and possible errors due to companies with similar names in the US (for the case 
of Schering and Merck) were taken into account. 
Table A 1:  Patent classes for sector and technology definition 
Sector / Technology Patent Classes 
Pharmaceuticals A61K (except for A61K-007/EC), A61P  
Organic chemistry C07 
Biotechnology C12M; C12N, C12P, C12Q, C12S, A61K-039,  
A61K-048, C02F-003, G01N-033/48, G01N-
033/49, G01N-033/5, G01N-033/6, G01N-033/7, 
G01N-033/8, G01N-033/9 
                                                
96  www.questel.orbit.fr 
97  Dominguez Lacasa, I.; Grupp, H.; Schmoch, U. (2003): Tracing technological change over 
long periods in Germany in chemicals using patent statistics. In: Scientometrics, 57 (2), 
pp. 175-195. 
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Patent data 
Table A 2: Patent data 
Total % Total % Total % Total % Total %
1895-1905 73747 128 0.2% 101 0.1% 1131 1.5% 8 6.3% 11 8.6%
1905-1915 107423 258 0.2% 180 0.2% 1612 1.5% 46 17.8% 11 4.3%
1950s 227060 1123 0.5% 467 0.2% 9065 4.0% 87 7.7% 102 9.1%
1960s 283639 2157 0.8% 1246 0.4% 17918 6.3% 248 11.5% 846 39.2%
1970s 652679 6228 1.0% 5469 0.8% 36350 5.6% 1566 25.1% 1431 23.0%
1980s 861802 14764 1.7% 13842 1.6% 49899 5.8% 4462 30.2% 2504 17.0%
1990s 1242769 16672 1.3% 14618 1.2% 42972 3.5% 4260 25.6% 2598 15.6%
Total % Total % Total % Total % Total %
1950s 2533 62 2.4% 15 0.6% 777 30.7% 0 0.0% 13 21%
1960s 3985 49 1.2% 41 1.0% 1588 39.8% 11 22.4% 15 31%
1970s 7416 190 2.6% 173 2.3% 2669 36.0% 60 31.6% 48 25%
1980s 12011 567 4.7% 474 3.9% 4821 40.1% 198 34.9% 123 22%
1990s 11314 423 3.7% 344 3.0% 3993 35.3% 177 41.8% 95 22%
Total % Total % Total % Total % Total %
1950s 1708 33 2% 15 1% 570 33.4% 3 9.1% 5 15%
1960s 2341 74 3% 37 2% 829 35.4% 22 29.7% 30 41%
1970s 5083 223 4% 137 3% 1790 35.2% 92 41.3% 58 26%
1980s 9475 625 7% 783 8% 3689 38.9% 288 46.1% 151 24%
1990s 9896 594 6% 572 6% 3282 33.2% 223 37.5% 114 19%
Total % Total % Total % Total % Total %
1950s 297 33 11.1% 3 1.0% 207 69.7% 1 3.0% 10 30.3%
1960s 370 62 16.8% 12 3.2% 224 60.5% 2 3.2% 41 66.1%
1970s 781 67 8.6% 51 6.5% 452 57.9% 5 7.5% 22 32.8%
1980s 1757 214 12.2% 118 6.7% 984 56.0% 17 7.9% 55 25.7%
1990s 2115 275 13.0% 76 3.6% 677 32.0% 14 5.1% 86 31.3%
Merck
Total % Total % Total % Total % Total %
1950 217 19 8.8% 12 5.5% 115 53.0% 0 0.0% 2 10.5%
1960 548 71 13.0% 39 7.1% 384 70.1% 16 22.5% 30 42.3%
1970 745 117 15.7% 61 8.2% 456 61.2% 31 26.5% 29 24.8%
1980 1150 96 8.3% 76 6.6% 508 44.2% 35 36.5% 17 17.7%
Organic chemical 
synthesis in 
Pharmaceuticals
Pharmaceuticals  Biotechnology
Organic chemical 
synthesis
Biotechnology in 
pharmaceuticals
Organic chemical 
synthesis in 
Pharmaceuticals
Pharmaceuticals  Biotechnology
Organic chemical 
synthesis
Biotechnology in 
pharmaceuticals
Organic chemical 
synthesis in 
Pharmaceuticals
Pharmaceuticals  Biotechnology
Organic chemical 
synthesis
Biotechnology in 
pharmaceuticals
Organic chemical 
synthesis in 
Pharmaceuticals
Pharmaceuticals  Biotechnology
Organic chemical 
synthesis
Biotechnology in 
pharmaceuticals
Schering and main subsidiaries
Pharmaceuticals  Biotechnology
Organic chemical 
synthesis
Biotechnology in 
pharmaceuticals
Merck and main subsidiaries
Organic chemical 
synthesis in 
Pharmaceuticals
German Patent Ofice and European Patent office with Germany as designation country
Total number of 
patent documents 
published
Total number of 
patent documents 
published
Total number of 
patent documents 
published
Total number of 
patent documents 
published
Total number of 
patent documents 
published
Bayer and main subsidiaries
Hoechst and main subsidiaries
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Corporate expenditures in research and development 
Data sources 
The historical data have been gathered from the corporate historical archives using 
annual reports and relevant documents covering the pharmaceutical segment of the 
corporations. The data for the period 1955-1970 refer to pharmaceutical research and 
development of the corporation (Mutterkonzern). For the period 1975-1995 the data 
refer to the global group (Welt oder Gruppe). 
Sources Hoechst 
Annual reports (several years) 
Bartmann, W. (2003): Zwischen Tradition und Fortschritt - Aus der Geschichte der 
Pharmabereiche von Bayer, Hoechst und Schering von 1935-1975, Stuttgart: 
Franz Steiner Verlag. 
Hoechst (1985a): Chronik des Geschätsbereichs Pharma der Hoechst AG. Band III, 
Hoechst Aktiengesellscahft (ed.) (unpublished work). 
Hoechst (1985b): Chronik des Geschätsbereichs Pharma der Hoechst AG. Band IV 
1867-1983, Hoechst Aktiengesellschaft (ed.) (unpublished work). 
Archive Hö Foge 22 Materialsammlung: Geschichte der Forschung bei Hoechst.  
Sources Schering 
Annual reports (several years) 
Archive Sch FuE Kennzahlen Grüne Mappe (1970-2002) 
Archive Sch B01-0116/1, Archive Sch B01-263, Archive Sch B01-263 / 392 
Archive Sch B01-520/2, Archive Sch B01-0268 
Archive Sch B03 70-80-1025, Archive Sch Annex 1 70 80 1022 
Sources Bayer: 
Annual reports (several years) 
Archive Ba 26 5/1.2 
Bartmann, W. (2003): Zwischen Tradition und Fortschritt - Aus der Geschichte der 
Pharmabereiche von Bayer, Hoechst und Schering von 1935-1975, Stuttgart: 
Franz Steiner Verlag. 
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Hauser, A. (2004): Geschichte der Pharma nach dem Zweiten Weltkrieg (1951-
1980) (unpublished work). 
Sources Merck:  
Annual reports (several years) 
Archive Me J10 98 
Archive Me J10 50 
Archive Me J10 63, F1/1 
Data 
Table A 3: Investment volume in research and development (in million German 
Mark and as a percentage of the total sales). 
 Merck Schering Hoechst Bayer 
 mio DM % mio DM % mio DM % mio DM % 
1955 n.a. n.a. 0.3 0 % 69 5 % 62 4 % 1955 
1960 10 5 % 12 7 % 113 4 % 125 4 % 1960 
1965 22 7 % 33 9 % 204 4 % 193 5 % 1965 
1970 50 9 % 69 11 % 420 6 % 355 6 % 1970 
1975 105 7 % 163 9 % 930 4 % 803 5 % 1975 
1980 134 7 % 281 9 % 1302 4 % 1241 4 % 1980 
1985 208 6 % 575 11 % 2083 5 % 2134 5 % 1985 
1990 303 9 % 802 14 % 2687 6 % 2738 7 % 1990 
1995 565 9 % 845 18 % 3479 7 % 3258 7 % 1995 
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Human capital 
Data sources and data 
Human capital data gathering had the goal of building educational statistics as 
indicators of firm's internal capabilities. This approach allowing the identification of 
companies' core capabilities and their development has been put forward by 
Jacobsson and Oskarsson (1995)98. 
The data used in the analysis cover the educational background of the staff holding an 
academic degree according to their academic qualification. In order to capture the 
extent to which internal capabilities vary over time it is necessary to collect data at 
different points in time. Due to the historical perspective of the study, the data need to 
cover a time frame of at least 30 years. This means that in the case of for diversified 
companies the data is not differentiated according to the business segment.  
The data have been collected from the corporative historical archives and, in some 
cases, directly from the personal departments of the companies under consideration. 
Annual reports and public corporate information do not give any relevant information for 
this purpose. Moreover, the personal departments of the 4 corporations have used, in 
most cases, different levels of aggregation to classify the academic disciplines. 
Accordingly, to obtain comparable data, the analysis has demanded a re-classification 
of the data available. 
The data are given in Table A 4 For Schering in the year 1970 the data refer to the 
pharmaceutical activities only. Data for Hoechst in the years 1981 and 1993 refer to the 
Hoechst AG, for the other years the data refers to the Hoechst Group. The data for 
Bayer refers to Bayer Farbenfabrik. 
The sources for the data are given bellow: 
 
Schering 
Scheringianum 3.1.2 "Belegschaftszahlen SA - Grüne Mappe". Personal Statistik / 
Anzahl Akademiker nach Fachrichtungen 
Merck 
Year  Source  
1970  Archive file J10 98 "Akademische Berufe nach Fachrichtungen" 
1982  Archive file: J10 565 "Akademische Berufe nach Fachrichtungen" 
1990 Data from the personal department 
1995 Data from the personal department 
2000 Data from the personal department 
                                                
98  Jacobsson, S.; Oskarsson, C. (1995): Educational statistics as indicators of technological 
activity. In: Research Policy, 25, pp. 127-136. 
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Hoechst 
Year  Source  
1955 Archive file 52 20 / 121110 Direktionsabteilung T Akademiker der Farbwerke 
 Hoechst AG  
1966 Jahresbericht 1966 Personal und Sozialbestand 
1972 Archive file KPS 8  / 1972-1983 Veränderung des Stammpersonales . Stand 
 nach Naturwissenschaftlern und Bestand nach Berufsgruppen. 
1981 Personal und Sozialwessen Akademiker. Hoechst AG Naturwissenschaftler 
 1958-1981 (Graphik) 
1993  Archive file. Akte R. Personalabteilung AT. Referat Naturwissenschaftler  
 Einstellung von Akademikern. Beschäftigte Akademiker 1993 
 
Bayer 
Year  Source 
1950 215/5.2 "Akademiker Stand 1.6.1950" 
1959 215/5.2 "Beruflicher Gliederung akademischer Angestellten" 
1966 265/8 "Zusammenstellung der akademischen Angestellten nach Berufsgruppen" 
1975 Personalabteilung LA Personal "Bewegung der Akademiker mit naturw. und  
 technische Ausbildung einschließlich Juristen" 
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Table A 4: Human capital profile: Employees holding an academic degree according to their academic qualification (disciplines) 
1970 1980 1985 1995 1955 1960 1966 1972 1981 1993
Physicians / Pharmacists 42% 32% 27% 31% Physicians / Pharmacists 12% 12% 10% 19% 12% 12%
Biologists / Microbiologists 3% 6% 7% 8% Biologists / Microbiologists 1% 1% 2% 4% n.a. 6%
Chemists 30% 30% 28% 25% Chemists 58% 55% 51% 50% 54% 39%
Engineers /Physicists 0% 8% 15% 17% Engineers /Physicists 22% 23% 26% 26% 19% 17%
Other 25% 30% 30% 27% Other 8% 10% 14% 6% 15% 31%
1970 1982 1990 2000 1950 1959 1966 1975
Physicians / Pharmacists 43% 29% 27% 23% Physicians / Pharmacists 8% 3% 13% 13%
Biologists / Microbiologists 4% 13% 6% 12% Biologists / Microbiologists 1% 1% 2% 3%
Chemists 39% 46% 40% 33% Chemists 67% 56% 53% 54%
Engineers /Physicists 7% 6% 11% 23% Engineers /Physicists 21% 26% 26% 28%
Other 12% 18% 23% 22% Other 4% 14% 8% 5%
Merck
Hoechst 
Bayer
Schering
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Strategic collaborative arrangements 
Type of collaborative arrangements and data sources 
Data gathering has concentrated on counting strategic collaborative arrangements of 
the corporations Bayer AG, Merck KGaA, Schering Aktiengesellschaft and Hoechst. In 
the case of Hoechst, due to the continuous corporative restructure processes, the data 
includes collaborative activities of the following companies and subsidiaries: Hoechst 
Marion Roussel (HMR), HMR Behringwerke, HMR Celanese, HMR Chiron Behring, 
HMR Hoechst Japan, HMR Hoechst Schering AgrEvo GmbH, Hoechst-Roussel, 
Marion Merrell Dow GmbH, HMR Roussel-Uclaf, Hoechst Schering AgrEVO, Hoechst-
Ariad Genomics Center. 
The strategic collaborative arrangements involve biotechnology-related activities of the 
following types: 
• Research: unilateral transfer of fundamental research results  
• Development: unilateral technology and product development services 
• Co-development: joint development  
• Collaboration: joint research 
• Manufacturing 
• Marketing 
• Licensing 
• Acquisition 
• Share holding investment 
• Joint Venture 
• Other 
The main sources for data gathering have been: 
Lippold, M. (2004): Die Schaffung und Nutzung von Property Rights an Informationen: 
Zum Zusammenhang von Recht und Akteurshandeln im Bereich Biotechnologie. 
Online: http://www.biotechpropertyrights.uni-bremen.de/ (Accessed: 2004-05-01). 
Peter, V. (2002): Institutionen im Innovationsprozess - Eine Analyse anhand der 
biotechnologischen Innovationssysteme in Deutschland und Japan, Heidelberg: 
Physica-Verl. 
Material from the corporative archives of the corporations under consideration. 
Desk research and literature review using corporate information (Internet and Annual 
Reports). 
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Strategic collaborative arrangements per year and type 
Table A 5: Strategic collaborative arrangements per year and type 
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1974 1 1 1 1977 1 1 1
1978 1 1 1 1980 1 1 1
1980 1 1 1 1 1981 1 1 1
1982 1 1 1 2 2 1982 1 1 1
1983 3 3 3 3 1984 1 1 1 1 0
1984 2 1 3 1 1985 3 4 1 2 1 6 4
1986 3 2 1 1 1 2 5 3 1986 3 3 1 3 1 2 6 5
1987 1 1 1 1 1987 2 2 1 1 1 3 2
1988 1 1 1 1 0 1988 2 3 3 1 1 7 4
1989 1 2 1 1 5 4 1989 2 1 1 2 1 4 2
1991 2 1 1 1 1 4 4 1990 1 3 2 1 6 4 3 7 1
1992 3 2 3 4 1 8 4 1991 2 2 2 2 4 2 7 3
1993 1 4 3 4 6 2 1992 1 4 1 2 2 7 3 3 11 4
1994 3 1 2 4 4 3 1 2 3 10 7 1993 3 9 3 1 4 12 1 2 1 22 10
1995 2 3 1 3 6 3 2 9 3 1994 2 2 1 5 8 1 1 15 7
1996 3 7 2 2 1 6 1 1 1 11 5 1995 2 6 2 1 3 9 3 4 1 3 16 7
1997 2 2 2 1 2 4 8 4 1996 2 3 2 7 1 2 1 3 15 8
1998 7 7 1 4 5 3 8 2 2 3 2 23 15 1997 8 8 1 1 1 3 12 7 5 5 28 16
1999 1 2 1 1 1998 2 7 3 1 2 6 9 6 2 1 4 32 23
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1988 1 1 1 1 0 1973 1 1 1
1990 2 3 2 4 2 4 0 1977 4 4 4 4
1991 1 1 1 1 3 3 1978 0 0
1992 1 2 2 1 1 2 1 1 1 6 4 1979 1 1 1
1993 1 1 1 1 1982 3 2 1 3 2
1994 1 1 1 1 1 1 1984 1 1 1 1
1995 1 1 2 2 1989 2 1 3 3
1996 1 2 1 2 3 1 1 5 2 1990 1 1 1
1997 2 1 1 3 2 1991 1 1 0
1998 1 1 1 2 1 1 13 11 1993 3 2 1 2 4 3 8 4
1994 1 1 1 2 2 3 1
1995 2 4 1 3 6 3 1 7 1
1996 2 2 2 1 1 5 4
1997 1 1 3 3 2 1 5 2
1998 3 2 1 2 2 5 1 2 1 10 5
1999 1 1 0
Hoechst Bayer AG
Merck KGaA Schering AG
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Research partners per year 
Bayer 
Table A 6: Research partners Bayer 
Year entering 
collaboration 
Partner's name 
  
1974 Cutter Laboratories 
1978 Miles Laboratories 
1980 Rochester University 
1982 Molecular Diagnostics 
1982 Synbiotics 
1983 Genetic Systems, US 
1983 Massachusetts Institute 
of Technology MIT 
1983 Institut für Genetik der 
Universität Köln 
1984 Genentech  
1984 Standford University  
1984 Molecular Therapeutics 
1986 GBF Braunschweig 
1986 Hoechst und Georg-
Speyer-Haus  
1986 Chiron Diagnostics 
1986 Hygeia Pharmaceuticals
1986 Mast Immunosystems 
1987 Yale University 
1988 Hoechst 
1988 Mitsubishi 
1989 Calgene 
1989 Technicon 
1989 Chiron 
1989 Elan 
1989 Scios 
1990 California Biotechnology
1991 Iterex Pharmaceuticals 
1991 California Biotechnology
1991 ImClone Systems 
1991 Trega Biosciences 
1992 Celltech 
1992 Kyoto Daiichi Kagaku 
1992 Pharmaceutical Proteins
1992 Robert Pharmaceutical 
1992 Saitex Pharmaceuticals 
Year entering
collaboration 
Partner's name 
  
1992 Syntro 
1992 Viagene 
1992 Zeneca 
1993 Bioprojet 
1993 Centocor 
1993 Eisai 
1993 Fujirebio 
1993 NABI 
1993 Eisai  
1994 Arris Pharmaceuticals 
Inc.  
1994 Serologicals Corp. 
1994 Axys Pharmaceuticals 
1994 Heska 
1994 Hycor Biomedical 
1994 Onyx 
1994 Schein Pharmaceutical 
1994 SKB SmithKline 
1994 Urgo 
1994 Zeneca 
1995 North American 
Biologicals 
1995 Inex Pharmaceuticals 
1995 Matritech 
1995 Metra Biosystems 
1995 Myriad Genetics 
1995 NABI 
1995 Pall 
1995 Pharmacopeia 
1995 Shaman 
Pharmaceuticals 
1996 Pharmazia 
1996 Oncogene Sciences 
1996 Alza Corporation 
1996 CV Therapeutics 
1996 Fuisz Technologies 
1996 Hoffmann-LaRoche 
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Year entering 
collaboration 
Partner's name 
  
1996 Immune Response 
1996 MDL Information 
Systems 
1996 OSI Pharmaceuticals 
1996 Quidel 
1996 Zeneca 
1997 Alza Corporation 
1997 Barr Laboratories 
1997 Biomatrix 
1997 Genome Therapeutics 
1997 Genzyme 
1997 Molecular Simulations 
1997 Myriad Genetics 
1997 Sequus 
1998 Centeon 
1998 Chiron Diagnostics 
1998 Crompton & Knowles  
1998 Exelixis 
Pharmaceuticals 
1998 Fuisz Technologies 
  
  
  
Year entering
collaboration 
Partner's name 
  
1998 Incyte Pharmaceuticals 
1998 Lion bioscience 
1998 Matritech 
1998 Microtek International 
1998 Microtek International 
1998 Millennium 
Pharmaceuticals 
1998 Molecular Simulations 
1998 NicOx S.A. 
1998 Novalon 
1998 Oxford Asymmetry 
International 
1998 Paradigm Genetics 
1998 Proteomix (sub of 
NovaDX int, Vancouver)
1998 Sangamo BioSciences 
1998 Scios 
1998 Serologicals 
1998 Symyx Technologies 
1998 Stanford University 
1998 Roche 
1999 Cambridge 
NeuroScience 
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Hoechst 
Table A 7: Research partners Hoechst 
Year entering 
collaboration 
Partner's name 
  
1977 Callbiochem 
1980 Cetus 
1891 Massachusetts Hospital  
1982 Biogen 
1984 Scios 
1985 Immunex 
1985 Genex 
1985 Citus 
1985 Elan 
1985 Nova Pharmaceutical 
1985 Calgene 
1986 Bayer und Georg-
Speyer-Haus  
1986 Synbiotics 
1986 Chiron 
1986 Celgene 
1986 Codon 
1986 Nova Pharmaceutical 
1987 Integrated genetics 
1987 IG Laboratories 
1987 Cortech 
1988 Calon 
1988 Bayer AG 
1988 Biomatrix 
1988 Alza 
1988 Creative BioMolecules 
1988 Controlled Therapeutics 
1989 Nippon Kayaku 
1989 Genex 
1989 Therion Biologics 
1989 US Bioscience 
1990 Transkaryotic Therapies 
1990 Genzyme Transnational 
1990 Sumitomo Metal 
1990 Alteon 
1990 Gensia Sicor 
1990 DNARD 
1990 ImmunoGen 
1991 Bradley Pharmaceuticals
Year entering
collaboration 
Partner's name 
  
1991 Chiron 
1991 Syntro 
1991 Affymax 
1991 Columbia Labs 
1991 Ecogen 
1991 EcoScience 
1992 PGS International 
1992 Polfa 
1992 Triplex 
1992 NABI 
1992 Chapin Medical 
1992 RPR 
1992 Syntro 
1992 ImmuLogic 
1992 OSI Pharmaceuticals 
1992 Scios 
1992 Schering AG 
1993 Oncogene Sciences 
1993 Copley Pharmaceuticals 
1993 Cortecs 
1993 HMR 
1993 HMR 
1993 OSI Pharmaceuticals 
1993 Kaketsuken-Mochida 
1993 Roussel-Uclaf 
1993 SKB 
1993 Toyobo 
1993 Biovail 
1993 OSI Pharmaceuticals 
1993 Bio-Imaging 
Technologies 
1993 Mitsubishi Chemical 
1993 Novopharm 
1993 Rugby Group 
1993 Sepracor 
1993 SKB 
1993 Synthelabo 
1993 ABC Pharma 
1993 Vertex 
 215 
Year entering 
collaboration 
Partner's name 
  
1993 Toyobo 
1994 Biopharm AG 
1994 Deprenyl Animal Health 
1994 Kyorin Pharmaceutical 
1994 North China 
Pharmaceuticals 
1994 Biomira 
1994 Ixsys 
1994 Biovail 
1994 KV Pharmaceuticals 
1994 Astra Merck 
1994 Ostex International 
1994 SKB 
1994 Synthelabo 
1994 Transkaryotic Therapies 
1994 Suntory 
1995 Transkaryotic Therapies 
1995 Allelix 
Biopharmaceuticals 
1995 Cell Genesys 
1995 Incyte Pharmaceuticals 
1995 Lynx Therapeutics 
1995 MMD 
1995 MPG 
1995 ProScript 
1995 Teva Pharmaceutical 
1995 Zynaxis 
1995 Syva 
1995 Armour 
1995 Ilex Oncology 
1995 Pierre Fabre 
1995 Selectide 
1995 Ariad Pharmaceuticals 
1996 Alza Corporation  
1996 Transkaryotic Therapies 
1996 Oncogene Sciences 
1996 Alliance Pharmaceuticals
1996 BMS 
1996 Cell Genesys 
1996 Chiron 
1996 Novartis Ciba-Geigy 
1996 PGS International 
1996 Pharmacyclis 
Year entering
collaboration 
Partner's name 
  
1996 RPR 
1996 Shire Pharmaceuticals 
1996 Titan Pharmaceuticals 
1996 Tripos 
1996 North American Vaccine 
1997 Fuisz Technologies Ltd 
1997 Bayer Corporation 
1997 Genentech 
1997 VIA Medical Corporation 
1997 Chiron Corporation 
1997 SmithKline Beecham 
1997 Incyte Pharmaceuticals  
1997 Amgen 
1997 Oncogene Science Inc 
1997 Incyte Pharmaceuticals  
1997 Dade International  
1997 Cell Genesys 
1997 Bavarian Science 
Foundation 
1997 Cell Control GmbH 
1997 MediGene Ag 
1997 Alza 
1997 Amylin Pharmaceuticals 
1997 Ariad Pharmaceuticals 
1997 Harvard University 
1997 Kimeragen 
1997 MediGene 
1997 Nanogen 
1997 OSI Pharmaceuticals 
1997 Procter & Gamble 
1997 Scriptgen 
1997 Sugen 
1997 Symyx Technologies 
1997 Watson Pharmaceuticals
1998 Transgene 
1998 3M Pharmaceuticals 
1998 Advanta B.V. 
1998 Cell Genesys 
1998 Transkaryotic Therapies 
1998 Amersham Pharmacia 
Biotech 
1998 Ariad Pharmaceuticals 
1998 Alza 
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Year entering 
collaboration 
Partner's name 
  
1998 Ariad Pharmaceuticals 
1998 Harvard School of Public 
Health 
1998 Procter & Gamble 
1998 Chiron 
1998 OSI Pharmaceuticals 
1998 ProScript 
1998 Quintiles Transnational 
1998 Rhone-Poulenc 
1998 Inhale Therapeutic 
Systems 
1998 Pfizer 
1998 Chiron 
1998 Chiron Behring 
1998 Genome Therapeutics 
1998 Immunex 
1998 Matrix 
1998 Phylos 
1998 Roberts Pharmaceutical 
1998 Rugby Group 
1998 Glaxo Wellcome 
1998 Cargill 
1998 Sapharco 
1998 Cargill 
1998 Gene Logic 
1998 Pangea Systems 
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Merck 
Table A 8: Research partners Merck 
Year entering 
collaboration 
Partner's name 
  
1988 ImmunoGen 
1990 Cygnus 
1990 Dura Pharmaceuticals 
1990 ImClone Systems 
1990 Scios 
1991 British Glaxo Group 
Ltd. 
1991 Lipha 
1991 Environmental 
Diagnostic 
1992 Scripps Clinic, San 
Diego 
1992 Strategic Diagnostics 
1992 Biotrol 
1992 Biosite Diagnostics 
1992 Ligand 
Pharmaceuticals 
1992 MGI Pharma 
1993 Medical Research 
Council at Mill Hill.  
1994 Medarex 
1995 Amersham 
International 
1995 Nycomed Amersham 
1996 3-Dimensional 
Pharmaceuticals 
1996 Etex 
1996 Human Genome 
Sciences 
1996 Neogen 
1996 SKB SmithKline 
1997 Biomet 
1997 ImClone Systems 
1997 Solvay 
1998 CN Biosciences 
1998 Argonaut Technologies
1998 ImClone Systems 
1998 Lexigen 
Pharmaceuticals 
1998 Abbott 
1998 Argonaut Technologies
1998 Ariad Pharmaceuticals 
Year entering
collaboration
Partner's name 
  
1998 Astra AB 
1998 DuPont 
1998 Genetics Institute 
1998 Merck Sharp and Dom 
1998 RPR 
1998 Sumitomo Pharma 
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Schering 
Table A 9: Research partners Schering 
Year entering 
collaboration 
Partner's name 
  
1973 Cetus 
1974 Pfizer 
1974 Hoffmann-La Roche 
1974 World Health 
Organisation 
1974 American National 
Institute of Health 
1979 Cooper Laboratories 
1982 FU Berlin 
1982 Max Plank Gesellschaft  
1982 Genex 
1984 FU Berlin und MPG 
1989 Condon 
1989 Triton Bioscience 
1989 Unigene Labs 
1990 Liposome Company 
1991 Molecular Biosystems 
1993 Chiron 
1993 Mallinckrodt 
1993 NeXStar 
1993 Nycomed Amersham 
1993 Siemens 
1993 Zonagen 
1993 Bradley Pharmaceuticals
1993 PCS Health Systems 
1994 Bioject 
1994 Dr. Rentschler 
1994 Novartis Ciba-Geigy 
1995 3M 
1995 Anthra Pharmaceuticals 
1995 Ethical Holdings 
1995 ImmuLogic 
1995 Advanced Magnetics 
1995 Argonaut Technologies 
1995 Pharmacopeia 
1996 Collateral Therapeutics 
1996 Incyte Pharmaceuticals 
1996 Jenapharm 
1996 MDL Information 
Systems 
Year entering
collaboration 
Partner’s name 
  
1996 Novo Nordisk 
1997 Alliance Pharmaceutical 
1997 Kimeragen 
1997 Ribozyme 
Pharmaceuticals 
1997 Metra Biosystems 
1997 Norland Medical 
Systems 
1998 Cargill 
1998 Cargill 
1998 Gene Logic 
1998 IntroGene B.V. 
1998 Medarex 
1998 Myriad Genetics 
1998 Pharmacopeia 
1998 Ribozyme 
Pharmaceuticals 
1998 Vertex 
1998 Cytogen 
 Annex 3: 
Parameter setting in the  
history-friendly scenario 
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Table A 10: Parameter values history-friendly scenario 
 Parameter Description Value 
 t* Revolution of molecular biology period 50 
 t** Emergence of modern biotech. period 75 
Search Space    
 N in Eq. 1 Size (number of potential drugs) 1200 
  Patent duration 20 
before t** a in Eq. 2 Drugs' quality average 1000 
before t** b in Eq. 2 Drugs' quality stand. dev. 200 
after t** a in Eq. 2 Drugs' quality average 2500 
after t** b in Eq. 2 Drugs' quality stand. dev 200 
Technology adoption   η in Eq. 16 Scaling parameter 0.05 
υ in Eq. 16 Max. adoption costs 1  
θ  Decreasing rate of υ  after adoption 0.9 
Collaboration (after t**)   
 ϑ in Eq. 20 Rate of knowledge flow 0.05 
 ν in Eq. 18 Scaling parameter  10 
Innovation    
 µ in Eq. 21 Scaling parameter 0.08 
Organisational capabilities   
for external learning ω in Eq. 10 Degree of depreciation 0.8 
Technology B  Technology diminishing firm's error of observation in the search process 
 Bθ in Eq. 6 Scaling parameter  1 
 b1 in Eq. 6 Growth rate parameter 0.1 
 b2 in Eq. 6 Growth rate parameter 0.5 
before t* 
BF1 in Eq. 4 Technological frontier (min. error) 1200 
after t* 
BF2 in Eq. 4 Technological frontier (min. error) 700 
after t** 
BF3 in Eq. 4 Technological frontier (min. error) 300 
before t* 
B
1ϕ in Eq. 11 Complexity of knowledge base 0.22 
after t* 
B
2ϕ in Eq. 11 Complexity of knowledge base 0.24 
after t** 
B
3ϕ in Eq. 11 Complexity of knowledge base 0.28 
before t** 
B
1δ in Eq. 13 Degree of depreciation (tec. capb) 0.03 
after t** 
B
2δ in Eq. 13 Degree of depreciation (tec. capb) 0.045 
 
Bφ in Eq. 7 Intra-industry spill-over rate 0.01 
before t* 
Bz1 in Eq. 7 Volume of public research 1.5 
after t* 
Bz2 in Eq. 7 Volume of public research 5 
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Table A 10 continued 
 Parameter Description Value 
Technology S Technology increasing firm's scope in the search process 
Sθ in Eq. 5 Scaling parameter  0.3 
a1in Eq. 5 TC function's parameter 0.1 
a2in Eq. 5 TC function's parameter 0.5 
SF in Eq. 4 Technological frontier (max. scope) 400 
Sϕ in Eq. 11 Complexity of knowledge base 0.22 
Sδ in Eq. 13 Degree of depreciation (tec. capb) 0.04 
 
Sz in Eq. 7 Volume of public research 3 
Products    
 0m in Eq. 24 Scaling parameter in the merit function 0.001 
 am in Eq. 24 Parameter in the merit function 1.4 
 bm in Eq. 24 Parameter in the merit function 1 
 cm in Eq. 24 Parameter in the merit function 0.2 
 ir in Eq. 24 Expected return on investment (imitation) 0.7 
 ir in Eq. 24 Expected return on investment (innovation) 0.8 
 ρ in Eq. 25 Product's image erosion rate 0.01 
Selection environment   
 tψ in Eq. 26 Budget of the health system to reward firms 30 
 *q in Eq. 22 Quality standard of the health system 1100 
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Table A 11 : Initial values of variables that need to be initialised 
Variable Description Value 
Search Space 
 Firm's search start position in the search 
space 
U (1,1200)   
Firm's investment decisions Firm Type 
  TP DC DBF 
jtβ  in Eq. 8 Share of investment in learning U(0.5,0.7) U(0.5,0.7) 1 
jtλ  in Eq. 8 Share of investment in external learning U(0.1,0.2) U(0.3,0.4) 1 
jtα  in Eq. 9 Technological trajectory U(0.3,0.5) U(0.6,0.8) 0 
Firm's level of capabilities Firm Type 
  TP DC DBF 
S
jtoK  in Eq. 13 in chemical synthesis at t=0 10 40 0 
B
jtoK  in Eq. 13 in biotechnology at t=0 30 15 25 
E
jtol  in Eq. 10 in external learning at t=0 1 1 1 
Firm's technological position at entry Firm Type 
  TP DC DBF 
0jtσ  in Eq. 6  Technological level in biotechnology at t=0 1200 1500 300 
0jtS  in Eq. 5 Technological level in chemical synthesis  at t=0 100 300 50 
  
 Annex 4: 
Model's source code  
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Lsd Model: History-Friendly Model German Pharma-
ceutical Industry Version 2.1 
 
 
 
   
 
 
Summary 
 
Object Structure 
Root->Root2->World->Industry->Firm->Portfolio->Drug 
                  |               |                 
                  |               ->Scope_Tech 
                  |               |            
                  |               ->Precision_Tech 
                  |               |                
                  |               ->Network->col 
                  |                              
                  ->Space->Mol 
                  |            
                  ->Knowledge_Base 
                                   
List of Variables:    
Abs_P(0), Abs_S(0), Adoption_Draw(0), Alpha(0), B(1), beta(0), col_Knowl(0), 
Collaboration(0), Delete(0), Divorce(0), DK(0), DP(1), DP_SO(0), DS(1), 
DS_SO(0), Entry_DBF(0), Ex(0), F(0), Fi(0), Generics(0), I(0), Image(0), Init2(0), 
Innovation_Draw(0), K(0), KP(1), KP_Share(0), KS(1), KS_Share(0), 
L_Budget(0), lambda(0), LB_Invest(1), LB_KK(1), LB_KP(0), LB_KS(0), 
LC_KP(0), LW_Invest(1), LW_KP(0), LW_KS(0), M_Expend(0), Max_Drug_q(0), 
Max_Drug_q_Industry(0), Merit(0), P_Adoption_De_1(0), P_Adoption_De_2(0), 
P_Knowl(0), P_SO(0), Precision(1), Precision_Gap(0), Precision_r(1), 
Precision_TP(0), Precision_V(1), Precision_WA(0), R(0), 
Rational_Phase_Industry(0), Rational_Phase_Knowlbase(0), 
S_Adoption_De(0), S_Knowl(0), S_SO(0), Scope(1), Scope_Gap(0), 
Scope_New_Knowlbase(0), Scope_r(1), Scope_TP(0), Scope_V(1), 
Scope_WA(0), Search(0), Start(1), U_Firm(0), U_Industry(0), V(0), WI(0) 
 
List of Parameters:    
a1, a2, a_u, Alpha_dbf, Alpha_f, ap, Approval, b1, b2, b_u, beta_f, c_u, col_date, 
col_DBF, col_divorce, col_divorce_date, col_j, col_knowl_r, col_KP, col_LF, 
col_number, cp, CW, DBF_Number, distance, DP_SO_p, Drug_C, Drug_d, 
Drug_del, Drug_i, Drug_l, Drug_lp, Drug_M, Drug_phase, Drug_q, Drug_qo, 
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Drug_Type, DS_SO_p, DW, fda, Firm_Type, HSB, i, Ip, ip, j, lambda_dbf, 
lambda_f, Mode, Mol_d, Mol_phase, o_u, Oligopol_size, P_complex, 
P_complex_2, P_complex_3, P_F1, P_F2, P_F3, P_Knowl_firm, P_PR_1, 
P_PR_2, P_sc, P_sc_2, P_SO_r, P_SO_r_2, P_td_1, P_td_2, Pd, 
Portfolio_Size, Precision_Adoption_1, Precision_Adoption_1_Date, 
Precision_Adoption_2, Precision_Adoption_2_Date, Precision_Max, 
Precision_Theta, pwa_power, q, q_average1, q_average2, q_st_dv1, q_st_dv2, 
qo, rho, S_complex, S_complex_2, S_F1, S_F2, S_PR_1, S_PR_2, S_sc, 
S_sc_2, S_SO_r, S_td, Scope_Adoption, Scope_Adoption_Date, Scope_Min, 
Scope_Theta, Size, t_entry_DBF, U, v, v_decr_rate, VentCap 
 
Equation File:  fun_HFM_2.1.cpp 
  
 
 
Object Root 
Containing Objects:   Root2 
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
    
 
 
Object Root2 
Contained in Object:  Root 
Containing Objects:   World 
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
Description 
This Object has been created to be able to build averages of 100 simulation runs. The 
implementation includes 100 Worlds and the main variables are analysed by creating 
average results of the 100 Worlds 
 
'Root2' appears in the equation for: (Never Used). 
  
 
 
Object World 
Contained in Object:  Root->Root2 
Containing Objects:   Industry, Space, Knowledge_Base 
List of Variables:  (no Variables) 
 229 
List of Parameters:  (no Parameters) 
Description 
This is the largest object in the model. 
 
'World' appears in the equation for: (Never Used). 
  
 
 
Object Industry 
Contained in Object:  Root->Root2->World 
Containing Objects:   Firm 
List of Variables:  Alpha(0), beta(0), Collaboration(0), Delete(0), Divorce(0), DK(0), 
DP(1), DS(1), Entry_DBF(0), Fi(0), Image(0), lambda(0), 
Max_Drug_q_Industry(0), Merit(0), Rational_Phase_Industry(0), Search(0), 
U_Industry(0) 
List of Parameters:  Alpha_dbf, col_knowl_r, DBF_Number, HSB, lambda_dbf, 
Mode, Oligopol_size, P_SO_r, P_SO_r_2, rho, S_SO_r, t_entry_DBF, VentCap 
Description 
The object industry includes incumbent companies developing products with therepeu-
tic properties (drugs). The industry presents different types of firms according to their 
learning strategies (in terms of learning within the firm and beyond the firm), size and 
their technological strategies. 
 
'Industry' appears in the equation for: (Never Used). 
Object Label Comment 
Industry  Mode (P)  'Mode' appears in the equation for: I. 
Innovation can be deterministic (Mode=0) or 
the result of a random process (Mode=1) 
Init. values   If Mode=0 innovation is a 
draw which depends on the level of capabili-
ties of the firms. If Mode=1 all innovate. 
Industry  Search (0)  Search is an equation at the level of the sys-
tem activitated in every period. It concerns 
every firm and activates the marketing and 
discovery and development processes of the 
firms. The firms, by appliying their tech-
nologies Scope and Precision, explore the 
search space of molecules to find the mole-
cule with the best characteristics (highest 
quality) to develop a drug. If a drug is de-
veloped, marketing expenditures take place.
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'Search' appears in the equation for: (Never 
Used). 
Industry  Fi (0)  Budget of the health system to reward firms
 
'Fi' appears in the equation for: R. 
Industry  HSB (P)  Budget of the health system to reward firms
'HSB' appears in the equation for: Fi. 
Init. values   The value is set to 30. This 
parameter is a huge simplification of the 
demand side of the system 
Industry  DS (1)  Scope capabilities (Technology S) at indus-
try level. The capabilities of the DBFs are 
not computed. Only the capabilities og in-
cumbent firms. 
 
'DS' appears in the equation for: DK. 
Init. values    
Industry  DP (1)  Precision capabilities (Technology B) at 
industry level. The capabilities of the DBFs 
are not computed. Only the capabilities og 
incumbent firms. 
 
'DP' appears in the equation for: DK. 
Init. values    
Industry  U_Industry (0)   
Total drug merit in the industry 
 
'U_Industry' appears in the equation for: F. 
Industry  rho (P)  Rate of erotion of the image of the drug. 
 
'rho' appears in the equation for: Image. 
Init. values    
Industry  Merit (0)   
This action update of the merit values of the 
drugs. The Merit function is a simplified 
version of Malerba & Orseniigo (2002), 
p.681 
 
Merit= (TrueQual-
ity)^a*(1/roi)^b*(MarkInvest)^c 
a=(1.2;1.4) like in Malerba (2002) 
b=(1.0;1.2) 
c=(0.1;0.2) 
roi=0.8 (in Malerba 0.2) for innovative 
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products 
roi=0.7 (in Malerba 0.1) for immitative 
products  
 
roi is desired return of investment. Other 
things beeing equal,  
the higher ri, the will be the price and the 
lower the demand 
Annual Marketing invest-
ment=LaunchCamp/20  
 
'Merit' appears in the equation for: Search. 
Industry  Image (0)   
This variable updates the image values of 
the drugs 
 
'Image' appears in the equation for: Search. 
Industry  S_SO_r (P)  Spillover rate (Technology S) 
 
'S_SO_r' appears in the equation for: S_SO.
Init. values    
Industry  P_SO_r (P)  Spillover rate (Technology B) 
 
'P_SO_r' appears in the equation for: P_SO.
Init. values    
Industry  DK (0)   
Capabilities at industry level 
 
'DK' appears in the equation for: (Never 
Used). 
Industry  Oligopol_size (P)  Number of DBFs that enter the industry in 
the second discontinuity (emergence of 
modern biotechnology) 
 
'Oligopol_size' appears in the equation for: 
Entry_DBF. 
Init. values    
Industry  Rational_Phase_Industry (0) The technological discontinuity (emergence 
of modern biotechnology) changes the 
cummulativeness of the capabilities. 
 
'Rational_Phase_Industry' appears in the 
equation for: (Never Used). 
Industry  P_SO_r_2 (P)  Spillover rate after the second discontinuity 
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in technology B. 
In this version of the model the spillover rate 
does not change after the discontinuity. The 
parameter has strong inflluence on the re-
sults. 
 
'P_SO_r_2' appears in the equation for: 
(Never Used). 
Init. values   All 50 instances equal to 0.02. 
Industry  Entry_DBF (0)  Entry of biotech companies. The function is 
computed only once and then it is trans-
formed in a parameter and never computed 
again. This equation sets the search space of 
molecules availiable for the drug producers 
to discover and develop drugs. 
 
'Entry_DBF' appears in the equation for: 
(Never Used). 
Industry  DBF_Number (P)  Number of Dedicated Biotechnology Firms 
 
'DBF_Number' appears in the equation for: 
Entry_DBF. 
Init. values    
Industry  lambda_dbf (P)  Investment share dedicated to external learn-
ing by DBFs 
 
'lambda_dbf' appears in the equation for: 
Entry_DBF. 
Init. values    
Industry  Alpha_dbf (P)  Company's bet on the technology being 
worth developing 
 
'Alpha_dbf' appears in the equation for: En-
try_DBF. 
Init. values    
Industry  t_entry_DBF (P)  Period of entry of DBF 
 
't_entry_DBF' appears in the equation for: 
Entry_DBF, LC_KP, col_Knowl, Collabora-
tion, Divorce. 
Init. values   All 100 instances equal to 75. 
Industry  VentCap (P)  Amount of venture capital availiable for 
DBFs in every period 
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'VentCap' appears in the equation for: B. 
Init. values    
Industry  Delete (0)  This equation deletes the drugs of the DBFs 
after they have been added to the structure 
of the model. The variable has been included 
because the entry of firms in the model is 
implemented by selecting a firm that already 
exists and creating similar objects. However, 
new firms do not have products when they 
enter the industry. 
 
'Delete' appears in the equation for: 
Entry_DBF. 
Industry  Collaboration (0)  Activates the search of LFs (Firm Type 1 or 
2) for collaborative partners (Firm type 3). 
The search starts after the discontinuity at 
t=70 has taken place. 
 
'Collaboration' appears in the equation for: 
Search. 
Industry  Divorce (0)  Evaluates the possibility of a collaboration 
to terminate. 
The termination of collaboration is a sto-
chastic process after updating the location of 
the frims in the search space and the en-
gagement of the incumbent firm in interact-
ing with its environment. 
'Divorce' appears in the equation for: (Never 
Used). 
Industry  col_knowl_r (P)  Rate of capabilities that are transferred from 
the DBF to the incumbent firm in every pe-
riod if a collaboration takes place 
 
'col_knowl_r' appears in the equation for: 
Collaboration, Divorce. 
Init. values   All 100 instances equal to 
0.05. 
Industry  beta (0)  Investment share directed to learning 
 
'beta' appears in the equation for: 
M_Expend, L_Budget. 
Industry  Alpha (0)  Company's bet on the technology being de-
veloped 
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'Alpha' appears in the equation for: LW_KS, 
LW_KP, Abs_S, Abs_P. 
Industry  lambda (0)  Company's investment share in the technol-
ogy being developed 
 
'lambda' appears in the equation for: 
LW_Invest, LB_Invest. 
Industry  Max_Drug_q_Industry (0)  Max drug quality in the industry 
 
'Max_Drug_q_Industry' appears in the equa-
tion for: (Never Used). 
   
 
 
Object Firm 
Contained in Object:  Root->Root2->World->Industry 
Containing Objects:   Portfolio, Scope_Tech, Precision_Tech, Network 
List of Variables:  Abs_P(0), Abs_S(0), Adoption_Draw(0), B(1), col_Knowl(0), 
DP_SO(0), DS_SO(0), Ex(0), F(0), I(0), Innovation_Draw(0), K(0), KP(1), 
KP_Share(0), KS(1), KS_Share(0), L_Budget(0), LB_Invest(1), LB_KK(1), 
LB_KP(0), LB_KS(0), LC_KP(0), LW_Invest(1), LW_KP(0), LW_KS(0), 
M_Expend(0), Max_Drug_q(0), P_Adoption_De_1(0), P_Adoption_De_2(0), 
P_SO(0), R(0), S_Adoption_De(0), S_SO(0), Start(1), U_Firm(0), V(0), WI(0) 
List of Parameters:  a_u, Alpha_f, ap, Approval, b_u, beta_f, c_u, col_number, cp, 
CW, distance, DP_SO_p, DS_SO_p, Firm_Type, ip, j, lambda_f, o_u, 
P_Knowl_firm, Portfolio_Size, v, v_decr_rate 
Description 
The Firms are the actors in the industry and the carriers of technology. 
Firms are heterogenous and have bounded rationality. 
 
'Firm' appears in the equation for: Entry_DBF, Delete, Search, Image, Merit, DS_SO, 
DP_SO, DS, DP, Collaboration, Divorce. 
Object Label Comment 
Firm  R (0)  Reward of the company in each period. It depends on 
the quality reached by the molecule of the company 
and on the budget of the health system. 
 
'R' appears in the equation for: Entry_DBF, B. 
Firm  Start (1)  Action that determines in each period the location in 
the search space to start the search for the molecule 
with the highest quality. 
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'Start' appears in the equation for: Entry_DBF, Search, 
Start, Collaboration, Divorce. 
Init. values   All 4 instances set to integer random 
values drawn from a uniform in the range [200,1200]. 
Firm  LW_Invest (1)  Investment in learning within the firm.  
 
'LW_Invest' appears in the equation for: Entry_DBF, 
LW_KS, LW_KP. 
Init. values   All 4 instances equal to 3. 
Firm  LB_Invest (1)  Investment in learning beyond the firm 
 
'LB_Invest' appears in the equation for: Entry_DBF, 
LB_K, LB_KK. 
Init. values   All 4 instances equal to 3. 
Firm  LB_KK (1)  Stock of capabilities for learning beyond the firm 
 
'LB_KK' appears in the equation for: Entry_DBF, 
LB_KK, Abs_S, Abs_P, Scope_WA, Precision_WA, 
Collaboration, Divorce. 
Init. values   All 8 instances equal to 1. 
Firm  LW_KS (0)  Internal research investment in the Scope technology 
(Technology S) 
 
'LW_KS' appears in the equation for: Entry_DBF, KS.
Firm  LW_KP (0)  Internal research investment in the Precision Technol-
ogy (Technology B) 
 
'LW_KP' appears in the equation for: Entry_DBF, KP.
Firm  LB_KS (0)  Capabilities in the scope technology through learning 
outside the firm in the scope technology. 
 
'LB_KS' appears in the equation for: Entry_DBF, KS. 
Firm  LB_KP (0)  Capabilities in the precision technology through learn-
ing outside  
the firm in the precision technology.  
 
'LB_KP' appears in the equation for: Entry_DBF, KP. 
Firm  KS (1)  Capabilities in the scope technology (Technology S). 
Inspired by Lerena & Oltra p. 9.The acummulation of 
capabilities is a weighted average of past and new 
capabilities. 
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'KS' appears in the equation for: Entry_DBF, DS_SO, 
DS, KS, K, KS_Share, Scope_r. 
Init. values   All 4 instances equal to 0. 
Firm  KP (1)  Accumulation of Capabilities in the Precision Tech-
nology (Technology B) 
Inspired by Llerena et Oltra p. 9.The acummulation of 
capabilities is a weighted average of past and new 
capabilities. 
 
'KP' appears in the equation for: Entry_DBF, DP_SO, 
DP, KP, K, KP_Share, Collaboration, Divorce, Preci-
sion_r. 
Init. values   All 4 instances equal to 0. 
Firm  K (0)  Accumulation of Capabilities in both technologies.  
 
'K' appears in the equation for: Entry_DBF, KS_Share, 
KP_Share, WI. 
Firm  KS_Share (0)  Share of scope capabilities (Technology S) within the 
firm 
 
'KS_Share' appears in the equation for: Entry_DBF. 
Firm  KP_Share (0)  Share of precision capabilities (Technology B) within 
tne firm 
 
'KP_Share' appears in the equation for: Entry_DBF. 
Firm  I (0)  Innovation can be dterministic (Mode 0) or the result 
of a random process (Mode 1). 
 
'I' appears in the equation for: Entry_DBF, Search. 
Firm  WI (0)  Probability to Innovate. Different options to model 
this function. 
 
'WI' appears in the equation for: Entry_DBF, I. 
Firm  Portfolio_Size (P)  Number of products in the product portfolio. The pa-
rameter is updated every period according to the per-
formance of every firm. 
 
'Portfolio_Size' appears in the equation for: En-
try_DBF, Search. 
Init. values   All 4 instances equal to 1. 
Firm  U_Firm (0)   
Quality of the drug portfolio (by adding up product 
quality). 
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'U_Firm' appears in the equation for: Entry_DBF, 
U_Industry, F. 
Firm  F (0)  Merit share of the firm. This equation is used as per-
formance indicator and  
is used to compute the reward of the firm from the 
system. 
 
'F' appears in the equation for: Entry_DBF, R. 
Firm  ap (P)  Scalling parameter in the stochastic adoption decition 
 
'ap' appears in the equation for: Scope_WA, Preci-
sion_WA. 
Init. values   All 8 instances equal to 0.05. 
Firm  ip (P)  Scalling parameter in the stochastic innovation process
 
'ip' appears in the equation for: WI. 
Init. values   All 4 instances equal to 0.005. 
Firm  v (P)  Initial Adoption Cost 
 
'v' appears in the equation for: S_Adoption_De, 
P_Adoption_De_1, P_Adoption_De_2, Scope_WA, 
Precision_WA, Precision_V, Scope_V. 
Init. values   All 8 instances equal to 1. 
Firm  B (1)  Budget for the activities of the firm 
 
'B' appears in the equation for: Entry_DBF, B, 
M_Expend, L_Budget, S_Adoption_De. 
Init. values   All 4 instances equal to 10. 
Firm  M_Expend (0)  Expenditures in marketing activities 
 
'M_Expend' appears in the equation for: Entry_DBF, 
Search, Ex. 
Firm  a_u (P)  Parameter weigting Quality in the "Merit" function of 
a product 
 
'a_u' appears in the equation for: Merit. 
Init. values   All 4 instances equal to 1.4. 
Firm  b_u (P)  Parameter weigting return on investment (roi) in the 
"Merit" function of a product 
 
'b_u' appears in the equation for: Merit. 
Init. values   All 4 instances equal to 1. 
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Firm  c_u (P)  Parameter weighting Image in the Merit function 
 
'c_u' appears in the equation for: Merit. 
Init. values   All 4 instances equal to 0.2. 
Firm  o_u (P)  Scalling parameter in the Merit function 
 
'o_u' appears in the equation for: Merit. 
Init. values   All 4 instances equal to 0.001. 
Firm  Abs_P (0)  Absorptive capacity for knowledge in technology P 
(precision) 
 
'Abs_P' appears in the equation for: Entry_DBF, 
LB_KP, LC_KP. 
Firm  Abs_S (0)  Absorptive capacity for knowledge in technology B 
(Scope) 
 
'Abs_S' appears in the equation for: Entry_DBF, 
LB_KS. 
Firm  Approval (P)  The parameter is set to one if the development of a 
drug in the previous period has been accepted in the 
selection environment 
 
'Approval' appears in the equation for: Search, Ex. 
Init. values   All 4 instances equal to 1. 
Firm  Ex (0)  Expenditures. Part of the budget that has been spent 
 
'Ex' appears in the equation for: Entry_DBF, B. 
Firm  V (0)  Total adoption costs 
v[1]=p->cal("Scope_V",0); In the version of the 
model without "Entry of firms  
of type 2" make sure that this is included in the costs 
 
'V' appears in the equation for: Entry_DBF, Ex. 
Firm  Adoption_Draw (0)  The adoption draw determines the adoption succes of 
the firm. It is the same for  
all the firms. It is located at the industry level. 
 
'Adoption_Draw' appears in the equation for: En-
try_DBF, S_Adoption_De, P_Adoption_De_1, 
P_Adoption_De_2. 
Firm  S_Adoption_De (0)  Scope Adoption Decition. This function determines 
whether a firm adopts 
new echnological opportunities after a discontinuity in 
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the knolwedge base has taken place. 
This function is located at the level of the firm. 
 
'S_Adoption_De' appears in the equation for: (Never 
Used). 
Firm  P_Adoption_De_1 (0) Precision Adoption Decition. This function determines 
whether a firm adopts new technological opportunities 
after a technological discontinuity (the transition from 
random to rational search 
has taken place. This function is located at the firm 
level. 
 
'P_Adoption_De_1' appears in the equation for: 
(Never Used). 
Firm  j (P)  Firm identification number 
 
'j' appears in the equation for: Entry_DBF, DS_SO, 
DP_SO, Scope_V, Collaboration, Divorce. 
Init. values    
Firm  v_decr_rate (P)  Decreasing rate of adoption costs.  
After adoption has take place adoption costs decrease 
with time.  
 
'v_decr_rate' appears in the equation for: Precision_V, 
Scope_V. 
Init. values    
Firm  Innovation_Draw (0)  The innovation draw determines the innovation succes 
of the firm.  
It is the same for all the firms. It is located at the in-
dustry level. 
 
'Innovation_Draw' appears in the equation for: En-
try_DBF, I. 
Firm  L_Budget (0)  Amount of buget dedicated to learning 
 
'L_Budget' appears in the equation for: Entry_DBF, 
Ex, LW_Invest, LB_Invest, P_Adoption_De_1, 
P_Adoption_De_2. 
Firm  Firm_Type (P)  Firms can be large incumbent firms (of type 1 and 2) 
and Dedicated Biotechnology firms (of type 3) 
 
'Firm_Type' appears in the equation for: Entry_DBF, 
Delete, DS_SO, DP_SO, DS, DP, B, beta, lambda, 
Alpha, LW_KP, Abs_P, col_Knowl, V, Collaboration, 
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Divorce. 
Init. values    
Firm  col_number (P)  Number of collaborations an incumbent firm has enter 
into. 
DBFs can have one collaboration partner only. 
 
'col_number' appears in the equation for: col_Knowl, 
Collaboration, Divorce. 
Init. values   All 4 instances equal to 0. 
Firm  cp (P)  Scalling parameter in the collaboration and divorce 
stochastic functions 
 
'cp' appears in the equation for: Collaboration, Di-
vorce. 
Init. values   All 4 instances equal to 10. 
Firm  LC_KP (0)  Capabilities in the precision technology develop 
through collaboration 
 
 
'LC_KP' appears in the equation for: KP. 
Firm  CW (P)  Probability to collaborate. Collaboration is an stochas-
tic decition. 
 
'CW' appears in the equation for: Collaboration. 
Init. values   All 4 instances equal to 0. 
Firm  distance (P)  Distance between the incumbent firm and the DBF. 
Collaboration decition pf incumbent firms considers 
the distance of the firms in the search space.  
 
'distance' appears in the equation for: Collaboration. 
Init. values   All 4 instances equal to 0. 
Firm  col_Knowl (0)  Addition of firm's capabilities in the precision tech-
nology acquired through colaboration  
 
'col_Knowl' appears in the equation for: LC_KP. 
Firm  Max_Drug_q (0)  Quality reached by the best product  
 
'Max_Drug_q' appears in the equation for: En-
try_DBF, Max_Drug_q_Industry. 
Firm  P_Knowl_firm (P)  Part of the knowledge base a firm has access to. The 
knolwedge base is firm specific. 
 
'P_Knowl_firm' appears in the equation for: P_Knowl, 
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Entry_DBF. 
Init. values   All 4 instances equal to 0. 
Firm  Alpha_f (P)  Parameter of DBF. 
Bet on the technology being worth developing. 
 
'Alpha_f' appears in the equation for: Entry_DBF, 
Alpha. 
Init. values   All 4 instances equal to 0. 
Firm  beta_f (P)  Parameter of DBF 
Investment share directed to learning 
 
'beta_f' appears in the equation for: Entry_DBF, beta. 
Init. values   All 4 instances equal to 0. 
Firm  lambda_f (P)  Parameter of DBF 
Investment share directed to external learning 
 
'lambda_f' appears in the equation for: Entry_DBF, 
lambda. 
Init. values   All 4 instances equal to 0. 
Firm  DP_SO_p (P)  Knowledge freely avaliable in technology B (Preci-
sion) 
 
'DP_SO_p' appears in the equation for: DP_SO, P_SO.
Init. values   All 8 instances equal to 0. 
Firm  DS_SO_p (P)  Knowledge freely avaliable in technology S (Scope) 
 
'DS_SO_p' appears in the equation for: DS_SO, S_SO.
Init. values   All 8 instances equal to 0. 
Firm  DS_SO (0)  Precision capabilities at industry level without the 
capabilities of the DBFs. 
This variable updates the level of Technology S 
(Scope) spillovers each firm may have access to 
"DP_SO_p". These do not consider capabilities of the 
DBFs. 
 
'DS_SO' appears in the equation for: (Never Used). 
Firm  DP_SO (0)  Precision capabilities at industry level without the 
capabilities of the DBFs. 
This variable updates the level of Technology B (Pre-
cision) spillovers each firm may have access to 
"DP_SO_p". These do not consider capabilities of the 
DBFs. 
 
'DP_SO' appears in the equation for: (Never Used). 
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Firm  P_SO (0)  Spilovers in the Precision Technolgy a firm receives in 
each period. 
These depend on the knowledge freely avaliable and 
on the rate of spillovers 
 
'P_SO' appears in the equation for: P_Knowl. 
Firm  S_SO (0)  Spilovers in the Scope Technolgy a firm receives in 
each period. 
These depend on the knowledge freely avaliable and 
on the rate of spillovers 
 
'S_SO' appears in the equation for: S_Knowl. 
Firm  P_Adoption_De_2 (0)  Precision Adoption Decition. This function determines 
whether the firm adopt  
a new form of technology after a technological discon-
tinuity (the transition from random to rational search 
has taken place. This function is located at the firm 
level. 
 
'P_Adoption_De_2' appears in the equation for: 
(Never Used). 
   
 
 
Object Portfolio 
Contained in Object:  Root->Root2->World->Industry->Firm 
Containing Objects:   Drug 
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
Description 
This object includes the products developed by the firm. It inludes object "Drug" which 
are added to the object according to the innovation , immitation and development per-
formance of the firm. 
 
'Portfolio' appears in the equation for: Search, Image, Merit. 
   
 
 
Object Drug 
Contained in Object:  Root->Root2->World->Industry->Firm->Portfolio 
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List of Variables:  (no Variables) 
List of Parameters:  Drug_C, Drug_d, Drug_del, Drug_i, Drug_l, Drug_lp, Drug_M, 
Drug_phase, Drug_q, Drug_qo, Drug_Type, U 
Description 
Drug is the product of the firm. 
 
'Drug' appears in the equation for: Entry_DBF, Delete, Search, Image, Merit. 
Object Label Comment 
Drug  Drug_q (P)  Quality of the drug 
 
'Drug_q' appears in the equation for: Entry_DBF, Search, 
Merit, Max_Drug_q, Collaboration. 
Init. values   All 4 instances set to integer random values 
drawn from a uniform in the range [1200,1400]. 
Drug  Drug_i (P)  Drug's identification parameter 
 
'Drug_i' appears in the equation for: Search. 
Init. values   All 4 instances equal to 0. 
Drug  Drug_qo (P)  Observed quality of the drug 
 
'Drug_qo' appears in the equation for: Search. 
Init. values   All 4 instances equal to 500. 
Drug  Drug_d (P)  Period of launching the drug 
 
'Drug_d' appears in the equation for: Entry_DBF, Search, 
Image, Merit, Collaboration. 
Init. values   All 4 instances equal to 0. 
Drug  Drug_Type (P)  'Type of Drug (= 1 new drug, =2 imitation) 
 
Drug_Type' appears in the equation for: Entry_DBF, Search, 
Merit. 
Init. values   All 4 instances equal to 1. 
Drug  U (P)  Merit of the drug. The parameter is updated in every period 
according to the image, the expected return on investment 
and the quality 
 
'U' appears in the equation for: Entry_DBF, Merit, U_Firm. 
Init. values   All 4 instances set to random values drawn 
from a uniform in the range [35,40]. 
Drug  Drug_phase (P)  After the second discontinuity in technology B (Precision) 
the search space changes and new drugs are avaliable for 
discovery. This parameter gives the phase in which the drug 
can be discovered.  
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'Drug_phase' appears in the equation for: Search. 
Init. values    
Drug  Drug_C (P)  Image of the drug once developed 
 
'Drug_C' appears in the equation for: Entry_DBF, Image, 
Merit. 
Init. values   All 4 instances equal to 4. 
Drug  Drug_M (P)  Marketing Budget of the drug in the period of launching 
 
'Drug_M' appears in the equation for: Entry_DBF, Search, 
Image. 
Init. values   All 4 instances equal to 4. 
Drug  Drug_del (P)  Parameter to allow objects to be deleted if needed 
 
'Drug_del' appears in the equation for: Delete, Search. 
Init. values    
Drug  Drug_l (P)  Drug liscensed parameter. A drug can only be liscensed 
once. If ==1 the drug is already liscenced. 
 
'Drug_l' appears in the equation for: Collaboration. 
Init. values   All 4 instances equal to 0. 
Drug  Drug_lp (P)  Licensing partner parameter in the object drug 
 
'Drug_lp' appears in the equation for: Collaboration. 
Init. values   All 4 instances equal to 0. 
   
 
 
Object Scope_Tech 
Contained in Object:  Root->Root2->World->Industry->Firm 
List of Variables:  Scope(1), Scope_Gap(0), Scope_r(1), Scope_TP(0), 
Scope_V(1), Scope_WA(0) 
List of Parameters:  a1, a2, Scope_Adoption, Scope_Adoption_Date, 
Scope_Theta 
Description 
Firms are the carriers of technologies. 
technologies ease the search process by allowing firms to approach the search space in a 
more effective way. The Scope technology (or technology S) represents organic chemi-
cal synthesis and determines the extension of the landscape of compounds a firm can 
access). 
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'Scope_Tech' appears in the equation for: S_Adoption_De. 
Object Label Comment 
Scope_Tech  Scope (1)  Technological achievement of the firm in 
the scope technology. Time and firm spe-
cific 
 
'Scope' appears in the equation for: En-
try_DBF, Search, Scope, Scope_TP, 
Scope_Gap. 
Init. values   All 4 instances equal to 15. 
Scope_Tech  Scope_Gap (0)  Technological Gap. Distance of the tech-
nological level of the firm to the  
technological frontier. 
 
'Scope_Gap' appears in the equation for: 
Scope_r. 
Scope_Tech  Scope_Theta (P)  Scalling Parameter 
 
'Scope_Theta' appears in the equation for: 
Scope_r. 
Init. values   All 4 instances equal to 
0.01. 
Scope_Tech  Scope_r (1)  Rate of technological change of the scope 
technology. The variable is time and  
firm specific. Log linear function.  
 
'Scope_r' appears in the equation for: En-
try_DBF, Scope. 
Init. values   All 4 instances equal to 0. 
Scope_Tech  a1 (P)  Parameter in the technological change 
function of Technology S (Scope). Weight 
of technological Gap 
 
'a1' appears in the equation for: Scope_r. 
Init. values   All 4 instances equal to 0.1. 
Scope_Tech  a2 (P)  Parameter in the technological change 
function of Technology S (Scope). Weight 
of capabilities 
 
'a2' appears in the equation for: Scope_r. 
Init. values   All 4 instances equal to 0.4. 
Scope_Tech  Scope_TP (0)  Fraction of the distance to the technologi-
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cal frontier cover by the firm 
 
'Scope_TP' appears in the equation for: 
Scope_WA. 
Scope_Tech  Scope_WA (0)  Fraction of the distance to the technologi-
cal frontier cover by the firm 
 
'Scope_WA' appears in the equation for: 
S_Adoption_De. 
Scope_Tech  Scope_Adoption (P)  Parameter signalling that the firm has per-
ceived and adopted the technological op-
portunities offered by the discontinuity in 
the Scope technology. NOTE: This ver-
sion of the model does not include any 
discontinuity in technology S 
 
'Scope_Adoption' appears in the equation 
for: S_Knowl, Entry_DBF, 
S_Adoption_De, Scope_V, Scope, 
Scope_TP, Scope_Gap. 
Init. values    
Scope_Tech  Scope_V (1)  The adoption expenditures for adopting 
advances in the scope technology. 
NOTE: This version of the model does not 
include any discontinuity in the Scope 
technology 
 
'Scope_V' appears in the equation for: 
Scope_V. 
Init. values   All 4 instances equal to 0. 
Scope_Tech  Scope_Adoption_Date (P) Date of adoption of the new technological 
opportunities in technology S 
 
'Scope_Adoption_Date' appears in the 
equation for: S_Adoption_De, Scope_V. 
Init. values   All 8 instances equal to 150.
   
 
 
Object Precision_Tech 
Contained in Object:  Root->Root2->World->Industry->Firm 
List of Variables:  Precision(1), Precision_Gap(0), Precision_r(1), 
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Precision_TP(0), Precision_V(1), Precision_WA(0) 
List of Parameters:  b1, b2, Precision_Adoption_1, Precision_Adoption_1_Date, 
Precision_Adoption_2, Precision_Adoption_2_Date, Precision_Theta, 
pwa_power 
Description 
'Precision_Tech' appears in the equation for: P_Adoption_De_1, P_Adoption_De_2. 
Object Label Comment 
Precision_Tech Precision (1)  Technological Level of the firm 
in technology B (Precision). 
Firm and time specific 
 
'Precision' appears in the equa-
tion for: Entry_DBF, Search, 
Precision, Precision_TP, Preci-
sion_Gap. 
Init. values   All 4 instances 
equal to 1001. 
Precision_Tech Precision_Gap (0)  Precision Technological Gap. 
Distance to the technological 
frontier of  
the technology B. 
 
'Precision_Gap' appears in the 
equation for: Precision_r. 
Precision_Tech Precision_Theta (P)  Scalling parameter in the func-
tion of technological change of 
technology B 
 
'Precision_Theta' appears in the 
equation for: Precision_r. 
Init. values   All 12 instances 
equal to 0.1. 
Precision_Tech Precision_r (1)  Rate of technological change in 
the precision technology. The 
variable is  
time and firm specific. Log lin-
ear function. If the min Precision 
is 1000  
and the simulation has 100 runs I 
need a change of about 1% 
(0.01) a 
nd 2% (0.02)per period. 
 
'Precision_r' appears in the equa-
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tion for: Entry_DBF, Precision. 
Init. values   All 4 instances 
equal to 0. 
Precision_Tech  b1 (P)  Parameter in the technological 
change function 
 
'b1' appears in the equation for: 
Precision_r. 
Init. values   All 4 instances 
equal to 0.3. 
Precision_Tech  b2 (P)  Parameter in the technological 
change function 
 
'b2' appears in the equation for: 
Precision_r. 
Init. values   All 4 instances 
equal to 0.5. 
Precision_Tech  Precision_TP (0)  Fraction of the distance to the 
frontier cover by the firm 
 
'Precision_TP' appears in the 
equation for: Entry_DBF, Preci-
sion_WA. 
Precision_Tech  Precision_WA (0)  The probability of adopting a 
technology after a technological 
discontinuity is a  
function of the level of capabili-
ties in external learning, the 
technological position  
of the firm in the technology 
applied  
 
'Precision_WA' appears in the 
equation for: Entry_DBF, 
P_Adoption_De_1, 
P_Adoption_De_2. 
Precision_Tech  Precision_Adoption_1 (P)  Parameter signalling that the 
firm has perceived and adopted 
the technological opportunities 
offered by the discontinuity in 
technology B.  
 
'Precision_Adoption_1' appears 
in the equation for: P_Knowl, 
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Entry_DBF, P_Adoption_De_1, 
Precision_V, Precision, Preci-
sion_TP, Precision_Gap. 
Init. values   All 8 instances 
equal to 0. 
Precision_Tech Precision_V (1)  The adoption expenditures for 
adopting advances in the preci-
sion technology 
 
'Precision_V' appears in the 
equation for: Precision_V, V. 
Init. values    
Precision_Tech pwa_power (P)  Parameter in the stochastic adop-
tion function. 
 
'pwa_power' appears in the equa-
tion for: Precision_WA. 
Init. values   All 4 instances 
equal to 2. 
Precision_Tech Precision_Adoption_1_Date (P) Period for the first technological 
discontinuity in technolohy B 
 
'Precision_Adoption_1_Date' 
appears in the equation for: 
P_Adoption_De_1, Precision_V.
Init. values   All 8 instances 
equal to 0. 
Precision_Tech Precision_Adoption_2 (P)  Parameter signalling that the 
firm has perceived and adopted 
the technological opportunities 
offered by the discontinuity in 
technology B.  
 
'Precision_Adoption_2' appears 
in the equation for: Entry_DBF, 
Search, P_Adoption_De_2, Col-
laboration, Precision, Preci-
sion_TP, Precision_Gap. 
Init. values   All 8 instances 
equal to 0. 
Precision_Tech Precision_Adoption_2_Date (P) Period adopting the new techno-
logical opportunities after the 
second technological discontinu-
ity. 
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'Precision_Adoption_2_Date' 
appears in the equation for: 
P_Adoption_De_2. 
Init. values   All 8 instances 
equal to 0. 
   
 
 
Object Network 
Contained in Object:  Root->Root2->World->Industry->Firm 
Containing Objects:   col 
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
Description 
'Network' appears in the equation for: Collaboration, Divorce. 
   
 
 
Object col 
Contained in Object:  Root->Root2->World->Industry->Firm->Network 
List of Variables:  (no Variables) 
List of Parameters:  col_date, col_DBF, col_divorce, col_divorce_date, col_j, 
col_KP, col_LF, DW 
Description 
'col' appears in the equation for: Collaboration, Divorce. 
Object Label Comment 
col  col_LF (P)  Id of the LF in the collaboration 
 
'col_LF' appears in the equation for: Collaboration. 
Init. values   All 40 instances equal to 0. 
col  col_date (P)  Period the collaboration begins 
 
'col_date' appears in the equation for: Collaboration, 
Divorce. 
Init. values   All 40 instances equal to -1. 
col  col_KP (P)  Capabilities in technology B (precision) transferred 
from the DBF to the LF in a collaboration 
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'col_KP' appears in the equation for: col_Knowl, Col-
laboration, Divorce. 
Init. values   All 40 instances equal to 0. 
col  col_j (P)  'col_j' appears in the equation for: (Never Used). 
Init. values   All 40 instances equal to 0. 
col  col_DBF (P)  Id of the DBF in the collaboration 
 
'col_DBF' appears in the equation for: Collaboration, 
Divorce. 
Init. values   All 40 instances equal to 0. 
col  col_divorce_date (P)  Period the collaboration ends 
 
'col_divorce_date' appears in the equation for: Divorce.
Init. values   All 40 instances equal to 0. 
col  DW (P)  The termination of a collaboration is a stochastic proc-
ess. 
This is the probability that a collaboration terminates. 
Divorce is proofed every period. 
 
'DW' appears in the equation for: Divorce. 
Init. values   All 40 instances equal to 0. 
col  col_divorce (P)  Parameter updated if the collaboration has elready 
ended up 
 
'col_divorce' appears in the equation for: Divorce. 
Init. values   All 40 instances equal to 0. 
   
 
 
Object Space 
Contained in Object:  Root->Root2->World 
Containing Objects:   Mol 
List of Variables:  Generics(0), Init2(0) 
List of Parameters:  fda, Pd, Size 
Description 
Firms face a search space where they search for molecules to imitate or discover and 
develop into drugs.  
 
'Space' appears in the equation for: (Never Used). 
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Object Label Comment 
Space  Init2 (0)  Technical initialization function. It is computed only once and 
then it is transformed in a parameter and never computed again. 
This equation sets the search space of molecules availiable for 
the drug producers to discover and develop drugs. 
 
'Init2' appears in the equation for: (Never Used). 
Space  Size (P)  Number of incumbent firms in the industry 
 
'Size' appears in the equation for: Init2, Search, Start. 
Init. values   All 1 instances equal to 0. 
Space  Pd (P)  Patent duration. This parameter determines the number of period 
a potential drug remains protected after discovery. 
 
'Pd' appears in the equation for: Generics. 
Init. values    
Space  Generics (0)  This action explores the search space every time is activated in 
order to vary the parameter Ip according to the statuts of the 
molecule (discovered or not) and if appropiate (according to the 
patent duration parameter) transform it into a drug that can be 
imitated. 
 
'Generics' appears in the equation for: Search. 
Space  fda (P)  Minimum quality level that a product needs to reach in order to 
be introduced in the market. 
 
'fda' appears in the equation for: Search. 
Init. values    
   
 
 
Object Mol 
Contained in Object:  Root->Root2->World->Space 
List of Variables:  (no Variables) 
List of Parameters:  i, Ip, Mol_d, Mol_phase, q, q_average1, q_average2, 
q_st_dv1, q_st_dv2, qo 
Description 
This object represents the molecules in the search space the firms move in. Molecules 
can be discovered or picked up for imitation. 
 
'Mol' appears in the equation for: Init2, Generics, Search. 
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Object Label Comment 
Mol  Ip (P)  The parameter gives statuts of the molecule (discovered or 
not)  
'Ip' appears in the equation for: Init2, Generics, Search. 
Init. values    
Mol  i (P)  Identification Parameter of the Molecule 
'i' appears in the equation for: Init2, Search. 
Init. values    
Mol  q_average1 (P)  Average quality of the molecules in phases 1 and 2 of the 
industry 
'q_average1' appears in the equation for: Init2. 
Init. values    
Mol  q_st_dv1 (P)  Standard deviation of the quality of the molecules in phases 1 
and 2 of the industry 
'q_st_dv1' appears in the equation for: Init2. 
Init. values   All 100 instances equal to 500. 
Mol  q (P)  Quality of the molecules asigned through an stochastic 
porcess at the beginning of the simulation 
'q' appears in the equation for: Init2, Search. 
Init. values    
Mol  qo (P)  Observed quality of the molecules (frim specific) 
'qo' appears in the equation for: Search. 
Init. values    
Mol  Mol_d (P)  Date of discovers of the molecule (relevant for the patent 
protection) 
'Mol_d' appears in the equation for: Init2, Generics, Search. 
Init. values    
Mol  Mol_phase (P)  Phase in which the molecule can be discovered (After the 
second discontinuity in the Precision Technology new mole-
cules are avaliable) 
'Mol_phase' appears in the equation for: Init2, Search. 
Init. values    
Mol  q_average2 (P)  Average quality of the molecules in phase 3 of the industry 
'q_average2' appears in the equation for: Init2. 
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Init. values    
Mol  q_st_dv2 (P)  Standard deviation of the quality of the molecules in phase 3 
of the industry 
'q_st_dv2' appears in the equation for: Init2. 
Init. values    
   
 
 
Object Knowledge_Base 
Contained in Object:  Root->Root2->World 
List of Variables:  P_Knowl(0), Rational_Phase_Knowlbase(0), S_Knowl(0), 
Scope_New_Knowlbase(0) 
List of Parameters:  P_complex, P_complex_2, P_complex_3, P_F1, P_F2, P_F3, 
P_PR_1, P_PR_2, P_sc, P_sc_2, P_td_1, P_td_2, Precision_Max, S_complex, 
S_complex_2, S_F1, S_F2, S_PR_1, S_PR_2, S_sc, S_sc_2, S_td, Scope_Min 
Description 
The knolwedge base represents knowledge underlying technological development. Each 
technology has a specific knowledge base, which develops with the intra-industry spill-
overs and the contributions from science and technology 
 
of the firms 'Knowledge_Base' appears in the equation for: (Never Used). 
Object Label Comment 
Knowledge_Base  S_PR_1 (P)  Contribution to the knowledge 
base of technology S of public 
research before a discontinuity
 
'S_PR_1' appears in the equa-
tion for: S_Knowl. 
Init. values    
Knowledge_Base  P_PR_1 (P)  Contribution to the knowledge 
base of technology B of public 
research before the discontinu-
ity 
 
'P_PR_1' appears in the equa-
tion for: P_Knowl. 
Init. values    
Knowledge_Base  S_PR_2 (P)  Contribution to the knowledge 
base of technology S of public 
research after a discontinuity 
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'S_PR_2' appears in the equa-
tion for: S_Knowl. 
Init. values    
Knowledge_Base  P_PR_2 (P)  Contribution to the knowledge 
base of technology B of public 
research after the discontinuity
 
'P_PR_2' appears in the equa-
tion for: P_Knowl. 
Init. values    
Knowledge_Base  S_F1 (P)  Technological Frontier of 
technology S after the first 
technological discontinuity. 
NOTE: This version of the 
model doea not include any 
discontinuities in technology S
 
'S_F1' appears in the equation 
for: Scope, Scope_TP, 
Scope_Gap. 
Init. values    
Knowledge_Base  S_F2 (P)  Technological Frontier of 
technology S after the second 
technological discontinuity. 
NOTE: This version of the 
model doea not include any 
discontinuities in technology S
 
'S_F2' appears in the equation 
for: Scope, Scope_TP, 
Scope_Gap. 
Init. values    
Knowledge_Base  P_F1 (P)  Technological Frontier of 
technology B after the first 
technological discontinuity 
 
'P_F1' appears in the equation 
for: Precision, Precision_TP, 
Precision_Gap. 
Init. values   All 1 instances 
equal to 998. 
Knowledge_Base  P_F2 (P)  Technological Frontier of 
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technology B after the second 
technological discontinuity 
 
'P_F2' appears in the equation 
for: Precision, Precision_TP, 
Precision_Gap. 
Init. values   All 2 instances 
equal to 500. 
Knowledge_Base  S_td (P)  Period of the discontinuity in 
technology S. NOTE: This 
version of the model does not 
include any discontinuities in 
this technologies. 
'S_td' appears in the equation 
for: Scope_New_Knowlbase, 
S_Adoption_De 
Init. values   All 1 instances 
equal to 250. 
Knowledge_Base  P_td_2 (P)  Period of the second disconti-
nuity in technology P.  
'P_td_2' appears in the equa-
tion for: Ra-
tional_Phase_Knowlbase, Ra-
tional_Phase_Industry, Search, 
P_Adoption_De_2. 
Init. values   All 2 instances 
equal to 75. 
Knowledge_Base  P_td_1 (P)  Period of the first discontinu-
ity in technology P.  
'P_td_1' appears in the equa-
tion for: Ra-
tional_Phase_Knowlbase, 
P_Adoption_De_1, Precision.
Init. values   All 1 instances 
equal to 250. 
Knowledge_Base  Rational_Phase_Knowlbase (0) The technological discontinu-
ity with the revolution of mo-
lecular biology in the 1950s. 
Transition to rational drug 
discovery. 
 
'Rational_Phase_Knowlbase' 
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appears in the equation for: 
(Never Used). 
Knowledge_Base  Scope_New_Knowlbase (0)  The technological discontinu-
ity in the scope technology 
produces changes in the 
knowledge base. 
 
'Scope_New_Knowlbase' ap-
pears in the equation for: 
(Never Used). 
Knowledge_Base  Scope_Min (P)  Minimum level of technologi-
cal achievement in technology 
S.  
'Scope_Min' appears in the 
equation for: Scope_TP. 
Init. values   
Knowledge_Base  Precision_Max (P)  Minimum level of technologi-
cal achievement in technology 
P.  
'Precision_Max' appears in the 
equation for: Precision_TP. 
Init. values   
Knowledge_Base  S_Knowl (0)  Knowledge base underlying 
the scope technology. It is firm 
specific in the sense that 
it depends on whether the 
companies have perceived 
scientific advances or not.  
 
'S_Knowl' appears in the equa-
tion for: LB_KS. 
Knowledge_Base  P_Knowl (0)  Knowledge base underlying 
the precision technology. It is 
firm specific in the sense that 
it depends on whether the 
companies have perceived 
scientific advances or not.  
 
'P_Knowl' appears in the equa-
tion for: LB_KP. 
Knowledge_Base  S_complex (P)  Complexity of the knolwedge 
base underlying technology S 
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'S_complex' appears in the 
equation for: 
Scope_New_Knowlbase, 
Abs_S. 
Init. values    
Knowledge_Base  S_complex_2 (P)  Complexity of the knowledeg 
base underlying technology S 
after the technological discon-
tinuity 
 
'S_complex_2' appears in the 
equation for: 
Scope_New_Knowlbase. 
Init. values    
Knowledge_Base  P_complex (P)  Complexity of the knolwedge 
base underlying technology B
 
'P_complex' appears in the 
equation for: Ra-
tional_Phase_Knowlbase, 
Abs_P. 
Init. values   All 100 instan-
ces equal to 0.22. 
Knowledge_Base  P_complex_2 (P)  Complexity of the knowledeg 
base underlying technology B 
after the technological discon-
tinuity 
 
'P_complex_2' appears in the 
equation for: Ra-
tional_Phase_Knowlbase. 
Init. values   All 100 instan-
ces equal to 0.24. 
Knowledge_Base  S_sc (P)  Speed of change (due to scien-
tific advances) of the knowl-
edge base underlying Tech-
nology S 
 
'S_sc' appears in the equation 
for: Scope_New_Knowlbase, 
KS. 
Init. values    
Knowledge_Base  S_sc_2 (P)  Speed of change (due to scien-
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tific advances) of the knowl-
edge base underlying Tech-
nology S after the technologi-
cal discontinuity 
 
'S_sc_2' appears in the equa-
tion for: 
Scope_New_Knowlbase. 
Init. values    
Knowledge_Base  P_sc (P)  Speed of change (due to scien-
tific advances) of the 
knolwedge base underlying 
technology B 
 
'P_sc' appears in the equation 
for: Rational_Phase_Industry, 
KP. 
Init. values    
Knowledge_Base  P_sc_2 (P)  Speed of change (due to scien-
tific advances) of the knowle-
deg base underlying Technol-
ogy B after the technological 
discontinuity 
 
'P_sc_2' appears in the equa-
tion for: Ra-
tional_Phase_Knowlbase, Ra-
tional_Phase_Industry. 
Init. values    
Knowledge_Base  P_F3 (P)  Technological Frontier of 
technology B after the second 
technological discontinuity.  
 
'P_F3' appears in the equation 
for: Precision, Precision_TP, 
Precision_Gap. 
Init. values   All 2 instances 
equal to 300. 
Knowledge_Base  P_complex_3 (P)  Complexity of the knowledeg 
base underlying technology B 
after the second technological 
discontinuity 
'P_complex_3' appears in the 
equation for: Ra-
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tional_Phase_Knowlbase. 
Init. values   All 50 instances 
equal to 0.28. 
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Initial Values 
 
Object Structure 
Root->Root2->World->Industry->Firm->Portfolio->Drug 
                  |               |                 
                  |               ->Scope_Tech 
                  |               |            
                  |               ->Precision_Tech 
                  |               |                
                  |               ->Network->col 
                  |                              
                  ->Space->Mol 
                  |            
                  ->Knowledge_Base 
                                   
List of Variables:    
B(1), DP(1), DS(1), KP(1), KS(1), LB_Invest(1), LB_KK(1), LW_Invest(1), 
Precision(1), Precision_r(1), Precision_V(1), Scope(1), Scope_r(1), Scope_V(1), 
Start(1) 
 
List of Parameters:    
a1, a2, a_u, Alpha_dbf, Alpha_f, ap, Approval, b1, b2, b_u, beta_f, c_u, col_date, 
col_DBF, col_divorce, col_divorce_date, col_j, col_knowl_r, col_KP, col_LF, 
col_number, cp, CW, DBF_Number, distance, DP_SO_p, Drug_C, Drug_d, 
Drug_del, Drug_i, Drug_l, Drug_lp, Drug_M, Drug_phase, Drug_q, Drug_qo, 
Drug_Type, DS_SO_p, DW, fda, Firm_Type, HSB, i, Ip, ip, j, lambda_dbf, 
lambda_f, Mode, Mol_d, Mol_phase, o_u, Oligopol_size, P_complex, 
P_complex_2, P_complex_3, P_F1, P_F2, P_F3, P_Knowl_firm, P_PR_1, 
P_PR_2, P_sc, P_sc_2, P_SO_r, P_SO_r_2, P_td_1, P_td_2, Pd, 
Portfolio_Size, Precision_Adoption_1, Precision_Adoption_1_Date, 
Precision_Adoption_2, Precision_Adoption_2_Date, Precision_Max, 
Precision_Theta, pwa_power, q, q_average1, q_average2, q_st_dv1, q_st_dv2, 
qo, rho, S_complex, S_complex_2, S_F1, S_F2, S_PR_1, S_PR_2, S_sc, 
S_sc_2, S_SO_r, S_td, Scope_Adoption, Scope_Adoption_Date, Scope_Min, 
Scope_Theta, Size, t_entry_DBF, U, v, v_decr_rate, VentCap 
 
 
Object Industry Total instances = 1 
Label Initial values
Mode (P)  0 
HSB (P)  30 
DS   Lag(1)    0 
DP   Lag(1)    0 
rho (P)  0.01 
S_SO_r (P)  0.01 
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P_SO_r (P)  0.01 
Oligopol_size (P)  4 
P_SO_r_2 (P)  0.01 
DBF_Number (P)  10 
lambda_dbf (P)  1 
Alpha_dbf (P)  0 
t_entry_DBF (P)  75 
VentCap (P)  0.1 
col_knowl_r (P)  0.05 
 
 
Object Firm Total instances = 4 
Label Initial values 
Start   Lag(1)    616 292 957 730 
LW_Invest   Lag(1)  3 3 3 3 
LB_Invest   Lag(1)   3 3 3 3 
LB_KK   Lag(1)    1 1 1 1 
KS   Lag(1)    10 10 40 40 
KP   Lag(1)    30 30 15 15 
Portfolio_Size (P)  1 1 1 1 
ap (P)  0.05 0.05 0.05 0.05 
ip (P)  0.005 0.005 0.005 0.005
v (P)  1 1 1 1 
B   Lag(1)    10 10 10 10 
a_u (P)  1.4 1.4 1.4 1.4 
b_u (P)  1 1 1 1 
c_u (P)  0.2 0.2 0.2 0.2 
o_u (P)  0.001 0.001 0.001 0.001
Approval (P)  1 1 1 1 
j (P)  1 2 3 4 
v_decr_rate (P)  0.9 0.9 0.9 0.9 
Firm_Type (P)  1 1 2 2 
col_number (P)  0 0 0 0 
cp (P)  10 10 10 10 
CW (P)  0 0 0 0 
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distance (P)  0 0 0 0 
P_Knowl_firm (P)  0 0 0 0 
Alpha_f (P)  0 0 0 0 
beta_f (P)  0 0 0 0 
lambda_f (P)  0 0 0 0 
DP_SO_p (P)  0 0 0 0 
DS_SO_p (P)  0 0 0 0 
 
 
Object Drug Total instances = 4 
Label Initial values 
Drug_q (P)  1205 1327 1296 1245 
Drug_i (P)  1 1 1 1 
Drug_qo (P)  500 500 500 500 
Drug_d (P)  0 0 0 0 
Drug_Type (P)  1 1 1 1 
U (P)  37.0113 37.7765 38.3254 37.5898
Drug_phase (P) 0 0 0 0 
Drug_C (P)  4 4 4 4 
Drug_M (P)  4 4 4 4 
Drug_del (P)  0 0 0 0 
Drug_l (P)  0 0 0 0 
Drug_lp (P)  0 0 0 0 
 
 
Object Scope_Tech Total instances = 4 
Label Initial values 
Scope   Lag(1)    100 100 300 300
Scope_Theta (P)  0.3 0.3 0.3 0.3 
Scope_r   Lag(1)    0 0 0 0 
a1 (P)  0.1 0.1 0.1 0.1 
a2 (P)  0.5 0.5 0.5 0.5 
Scope_Adoption (P)  1 1 1 1 
Scope_V   Lag(1)    0 0 0 0 
Scope_Adoption_Date (P)  150 150 150 150
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Object Precision_Tech Total instances = 4 
Label Initial values 
Precision   Lag(1)    1200 1200 1500 1500
Precision_Theta (P)  0.1 0.1 0.1 0.1 
Precision_r   Lag(1)    0 0 0 0 
b1 (P)  0.3 0.3 0.3 0.3 
b2 (P)  0.5 0.5 0.5 0.5 
Precision_Adoption_1 (P)  0 0 0 0 
Precision_V   Lag(1)    0 0 0 0 
pwa_power (P)  2 2 2 2 
Precision_Adoption_1_Date (P) 0 0 0 0 
Precision_Adoption_2 (P)  0 0 0 0 
Precision_Adoption_2_Date (P) 0 0 0 0 
 
 
Object col Total instances = 4 
Label Initial values
col_LF (P)  0 0 0 0 
col_date (P)  -1 -1 -1 -1 
col_KP (P)  0 0 0 0 
col_j (P)  0 0 0 0 
col_DBF (P)  0 0 0 0 
col_divorce_date (P)  0 0 0 0 
DW (P)  0 0 0 0 
col_divorce (P)  0 0 0 0 
 
 
Object Space Total instances = 1 
Label Initial values 
Size (P)  1200 
Pd (P)  20 
fda (P)  1100 
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Object Mol Total instances = 1 
Label Initial values
Ip (P)  0 
i (P)  1 
q_average1 (P) 1000 
q_st_dv1 (P)  500 
q (P)  0 
qo (P)  0 
Mol_d (P)  1000 
Mol_phase (P)  1 
q_average2 (P) 2500 
q_st_dv2 (P)  500 
 
 
Object Knowledge_Base Total instances = 1 
Label Initial values
S_PR_1 (P)  2 
P_PR_1 (P)  2 
S_PR_2 (P)  3 
P_PR_2 (P)  5 
S_F1 (P)  400 
S_F2 (P)  800 
P_F1 (P)  1200 
P_F2 (P)  700 
S_td (P)  0 
P_td_2 (P)  75 
P_td_1 (P)  50 
Scope_Min (P)  3 
Precision_Max (P)  1500 
S_complex (P)  0.22 
S_complex_2 (P)  0.22 
P_complex (P)  0.22 
P_complex_2 (P)  0.24 
S_sc (P)  0.04 
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S_sc_2 (P)  0.04 
P_sc (P)  0.04 
P_sc_2 (P)  0.045 
P_F3 (P)  300 
P_complex_3 (P)  0.26 
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Detailed Description 
 
Object Structure 
Root->Root2->World->Industry->Firm->Portfolio->Drug 
                  |               |                 
                  |               ->Scope_Tech 
                  |               |            
                  |               ->Precision_Tech 
                  |               |                
                  |               ->Network->col 
                  |                              
                  ->Space->Mol 
                  |            
                  ->Knowledge_Base 
                                   
List of Variables:    
Abs_P(0), Abs_S(0), Adoption_Draw(0), Alpha(0), B(1), beta(0), col_Knowl(0), 
Collaboration(0), Delete(0), Divorce(0), DK(0), DP(1), DP_SO(0), DS(1), 
DS_SO(0), Entry_DBF(0), Ex(0), F(0), Fi(0), Generics(0), I(0), Image(0), Init2(0), 
Innovation_Draw(0), K(0), KP(1), KP_Share(0), KS(1), KS_Share(0), 
L_Budget(0), lambda(0), LB_Invest(1), LB_KK(1), LB_KP(0), LB_KS(0), 
LC_KP(0), LW_Invest(1), LW_KP(0), LW_KS(0), M_Expend(0), Max_Drug_q(0), 
Max_Drug_q_Industry(0), Merit(0), P_Adoption_De_1(0), P_Adoption_De_2(0), 
P_Knowl(0), P_SO(0), Precision(1), Precision_Gap(0), Precision_r(1), 
Precision_TP(0), Precision_V(1), Precision_WA(0), R(0), 
Rational_Phase_Industry(0), Rational_Phase_Knowlbase(0), 
S_Adoption_De(0), S_Knowl(0), S_SO(0), Scope(1), Scope_Gap(0), 
Scope_New_Knowlbase(0), Scope_r(1), Scope_TP(0), Scope_V(1), 
Scope_WA(0), Search(0), Start(1), U_Firm(0), U_Industry(0), V(0), WI(0) 
 
List of Parameters:    
a1, a2, a_u, Alpha_dbf, Alpha_f, ap, Approval, b1, b2, b_u, beta_f, c_u, col_date, 
col_DBF, col_divorce, col_divorce_date, col_j, col_knowl_r, col_KP, col_LF, 
col_number, cp, CW, DBF_Number, distance, DP_SO_p, Drug_C, Drug_d, 
Drug_del, Drug_i, Drug_l, Drug_lp, Drug_M, Drug_phase, Drug_q, Drug_qo, 
Drug_Type, DS_SO_p, DW, fda, Firm_Type, HSB, i, Ip, ip, j, lambda_dbf, 
lambda_f, Mode, Mol_d, Mol_phase, o_u, Oligopol_size, P_complex, 
P_complex_2, P_complex_3, P_F1, P_F2, P_F3, P_Knowl_firm, P_PR_1, 
P_PR_2, P_sc, P_sc_2, P_SO_r, P_SO_r_2, P_td_1, P_td_2, Pd, 
Portfolio_Size, Precision_Adoption_1, Precision_Adoption_1_Date, 
Precision_Adoption_2, Precision_Adoption_2_Date, Precision_Max, 
Precision_Theta, pwa_power, q, q_average1, q_average2, q_st_dv1, q_st_dv2, 
qo, rho, S_complex, S_complex_2, S_F1, S_F2, S_PR_1, S_PR_2, S_sc, 
S_sc_2, S_SO_r, S_td, Scope_Adoption, Scope_Adoption_Date, Scope_Min, 
Scope_Theta, Size, t_entry_DBF, U, v, v_decr_rate, VentCap 
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Object Root 
 
Containing: Root2  
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
   
 
Object Root2 
 
Contained in Object: Root 
Containing: World  
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
   
 
Object World 
 
Contained in Object: Root->Root2 
Containing: Industry Space Knowledge_Base  
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
   
 
Object Industry 
 
Contained in Object: Root->Root2->World 
Containing: Firm  
List of Variables:  Alpha(0), beta(0), Collaboration(0), Delete(0), Divorce(0), DK(0), 
DP(1), DS(1), Entry_DBF(0), Fi(0), Image(0), lambda(0), 
Max_Drug_q_Industry(0), Merit(0), Rational_Phase_Industry(0), Search(0), 
U_Industry(0) 
List of Parameters:  Alpha_dbf, col_knowl_r, DBF_Number, HSB, lambda_dbf, 
Mode, Oligopol_size, P_SO_r, P_SO_r_2, rho, S_SO_r, t_entry_DBF, VentCap 
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Parameter Mode 
In Object  Industry  
Used in: I  
Go to: Description,  Initial values,  Model Structure 
Variable Search 
In Object  Industry  
Used in: (never used) 
Using: Merit Image Collaboration Start I Portfolio_Size M_Expend Approval 
Drug_q Drug_i Drug_qo Drug_d Drug_Type Drug_phase Drug_M Drug_del 
Scope Precision Precision_Adoption_2 Size Generics fda Ip i q qo Mol_d 
Mol_phase P_td_2  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Search"))  
{  
   
/*  
Search is an equation at the level of the system activitated in every 
period.  
It concerns every firm and activates the marketing and discovery and 
development processes of the firms.  
The firms, by appliying their technologies S (Scope) and B (Preci-
sion), explore the search space of  
molecules to find the molecule with the best characteristics (highest 
quality) to  
develop a drug. If a drug is developed, marketing expenditures take 
place.  
*/  
 
v[60]=p->cal("Generics",0);//Activates the process of revision of pat-
ent protection.  
v[300]=p->cal("P_td_2",0);//biotech revolution period where the tech-
nological discontinuity affects the opportunities  
CYCLE(cur3, "Firm")  
 {  
 cur3->write("Approval",0,0);//Setting the approval parameter to zero  
 /* This parameter activates the planed marketing expenditures.  
 If the approval is not sucessfull the planed marketing expenditures 
can be reinvested in the next period.  
 If in the previous period a drug has been approved the parameter has 
been set to 1.  
 BUT the parameter has to be reset to cero in every period in order to 
make sure that the parameter  
 varies according to the action of the firm in every period.  
 */  
   
 /*  
 The next lines refer to the marketing activities of the firm  
 */  
 v[50]=cur3->cal("M_Expend",0);//Marketing budget for the potential 
drug that can be developed.This budget is used only in the case the 
drug is developed.  
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 /*  
 Which are the search tools of the firm? Which is the achievement in 
both technologies?  
 Has the firm perceived and adopted the new technology?  
 For every object "Firm" in the industry the area of the search space 
to be explored  
 is determined by the capabilities in Technology S , the start-point 
in the  
 search space and whether or not the firm has adopted the new Technol-
ogy B  
 */  
   
 v[0]=cur3->cal("Scope",0);//Technological achievement in the Technol-
ogy S  
 v[1]=cur3->cal("Start",0);//Where does the search start?  
 v[40]=cur3->son->cal("Precision_Adoption_2",1);  
 // Has the firm perceived and adopted the new technology? f yes, the 
search conditions change.  
   
 /*  
 The following lines make sure that the complete scope of exploration 
of the  
 firm is within the existing search space  
 */  
   
 v[29]=p->cal("Size",0);  
 v[30]=v[0]+v[1];// Id of the last molecule of the field of explora-
tion  
 v[31]=v[30]-v[29];//Differ. betw. the last Id of explor. and the last 
Id  
 if (v[31] > 0) //if outside of the search space  
 v[32]= v[1]-v[31]; //the start point changes accordingly  
 else //if within the search space  
 v[32]=v[1];//nothing changes  
 /*  
 With the given part of the search space that can be explored the 
search process  
 for the molecule with the highest to develop the drug beginns  
 */  
 
 CYCLES(cur3,cur2,"Portfolio")  
   {  
    double maxQ = 0;  
    cur1 = NULL;  
    CYCLES(p->next,cur,"Mol")  
    {  
   
      v[3]=cur->cal("i",0);//Id of the molecule  
      v[5]=cur->cal("Ip", 0);//Protection state of the molecule  
      v[41]=cur->cal("Mol_phase",0);//Phase in which the molecule is 
availiable.  
      //1==random search 2==rational search  
      v[21]=cur->cal("q",0);//True quality of the molecule  
      v[20]=cur3->cal("Precision",0);  
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      v[22]=norm(v[21],v[20]);  
      v[4]=round(v[22]);  
      if (v[4]>0)  
      cur->write("qo",v[4],0);  
      else  
      cur->write("qo",0,0);  
      /*Be Carefull when controlling if the simulation works: Note 
that at the end of the simulation the parameter 
     "ObsQ" of the molecules in the search space will have the value 
of the ObsQ of the molecule as observed by the 
      last firm*/  
        
      if (v[40]==0)  
        //If the firm has not adopted the new perception technology  
         {  
           if(v[3] >= v[32] && v[3] < v[0] + v[32])  
           /* This line determines the part of the search space to be 
explored according  
            to the technology S capabilities of the firm*/  
            {  
             if(v[4] >= maxQ && v[5] != 1 && v[41]==1) //Random search  
             //The v[41] determines the type of molecules the firm has 
acces to.  
              {  
               maxQ = v[4];  
               cur1 = cur;  
              }  
            }  
           v[3] = v[3] + 1;  
         }  
       
      if (v[40]==1 && t>v[300])//rational search and modern biotech 
revolution  
           //If the firm has adopted the new perception technology the 
firm has  
             //access to more molecules  
          {  
            if(v[3] >= v[32] && v[3] < v[0] + v[32])  
            //This line determines the part of the search space to be 
explored  
            {  
             if(v[4] >= maxQ && v[5] != 1 && v[41]!=0) 
             //in this phase firms have access to both types of drugs 
if they have adopted!  
              {  
                 maxQ = v[4];  
                 cur1 = cur;  
              }  
            }  
            v[3] = v[3] + 1;  
          }  
          
          //I have included this part to make a difference between DNA 
revol (1950s) 
           //and "modern biotech" with rDNA 1970s.  
           
         if (v[40]==1 && t<v[300]) //rational search no modern biotech  
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           //If the firm has adopted the new perception technology but 
the  
             //time is bellow P_td_2(no modern biotech)  
          {  
            if(v[3] >= v[32] && v[3] < v[0] + v[32])  
            //This line determines the part of the search space to be 
explored  
             according to the technology S capabilities of the firm  
             {  
              if(v[4] >= maxQ && v[5] != 1 && v[41]==1)  
              //The v[41] determines the type of molecules the firm 
has acces to.  
              {  
               maxQ = v[4];  
               cur1 = cur;  
              }  
             }  
            v[3] = v[3] + 1;  
          }  
        
    }  
    v[51]=cur3->cal("I",0);  
    /*  
    v[51] activates the innovation function (see below) which deter-
mines whether the discovery  
    and development processes are succesfull.  
    */  
      
    if(cur1 != NULL && v[51]==1)  
      {  
        v[7]=cur1->cal("q",0);  
        // True quality of the selected object "Mol" with the maximum 
observed quality  
        v[200]=p->cal("fda",0);  
        //Minimum Quality required for a drug to be launched into the 
market  
        if (v[7]>v[200])  
        /*  
        If an object Mol is selected wich satisfies the quality re-
striction determined by  
        the minmum quality required:  
        1) The approval parameter is updated accordingly activating 
the marketing costs  
        2) a new object "Drug" is added to the portfolio of the firm  
        3) the parameters of the new drug are updated accordingly  
        */  
          {  
            cur4=cur2->add_an_object("Drug", cur2->search("Drug"));  
            cur3->write("Approval",1,0);  
            cur3->increment("Portfolio_Size",1);  
            cur1->write("Mol_d",(double)t,0);  
            v[6]=cur1->cal("i",0); // Id of selected object "Mol" with 
the maximum observed quality  
            v[8]=cur1->cal("qo",0); // Observed quality of the se-
lected "Mol"  
            v[9]=cur1->cal("Ip",0);  
            // Type of molecule. If Ip==2, the molecule is an imita-
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tion, if Ip==0 the molecule is  
            //a new discovery  
            v[10]=cur1->cal("Mol_phase",0);  
            /*  
            In the next lines the parameters of the new object "Drug" 
of each firm are updated according  
            to the results of "search" in the time step.  
            */  
            cur4->write("Drug_del",1,0);//Parameter to allow objects 
to be deleted if needed.  
            cur4->write("Drug_d",(double)t,0);//Period of launching 
the drug  
            cur4->write("Drug_i",v[6],0);//Identification parameter  
            cur4->write("Drug_q",v[7],0);//Quality of the drug  
            cur4->write("Drug_qo", v[8],0);//Observed quality of the 
drug (implemented only for control purposes)  
            cur4->write("Drug_phase", v[10],0);//Phase (1 or 2) in 
which the drug was discovered  
            cur4->write("Drug_M", v[50],0);//Marketing Budget for the 
drug  
              
            if (v[9]==0) //The molecule has been selected for the 
first time.  
            {  
            cur1->write("Ip", 1, 0);  
            //The discovered molecule will be protected from imitation 
for the nex 20 periods.  
            cur4->write("Drug_Type", 1, 0);//The drug is a new drug.  
            }  
              
            if (v[9]==2) //The selection is an imitation.  
            cur4->write("Drug_Type", 2,0);//Generic drug  
   
          }  
      }  
   }  
 }  
v[100]=p->cal("Image",0);//Activates the process of updating the image 
value of each drug  
v[101]=p->cal("Merit",0);//Activates the process of updating the merit 
value of each drug  
v[301]=p->cal("Collaboration",0);//Activates the process of updating 
the merit value of each drug  
 
res=1;  
goto end;  
}  
Return 
Variable Fi 
In Object  Industry  
Used in: R  
Using: HSB  
Go to: Description,  Model Structure 
Equation Code:  
274  
if(!strcmp(label,"Fi"))  
{  
/*  
Budget of the health system to reward firms  
*/  
v[0]=p->cal("HSB",0);  
res=v[0];  
goto end;  
}  
Return 
Parameter HSB 
In Object  Industry  
Used in: Fi  
Go to: Description,  Initial values,  Model Structure 
Variable DS 
In Object  Industry  
Used in: DK  
Using: KS Firm_Type  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"DS"))  
{  
/*  
Technology S capabilities at industry level without the capabilities 
of the DBFs  
*/  
 
  v[0]=0;  
  for(cur1=p->search("Firm"); cur1!=NULL; cur1=go_brother(cur1) )  
     {  
      v[6]=cur1->cal("Firm_Type",0);  
      if (v[6]==3)  
            v[1]=0;  
                  else  
      v[1]=cur1->cal("KS",0);  
                 v[0]=v[0]+v[1];  
     }  
res=v[0];  
goto end;  
}  
Return 
Variable DP 
In Object  Industry  
Used in: DK  
Using: KP Firm_Type  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"DP"))  
{  
/*  
 275 
Technology B capabilities at industry level without the capabilities 
of the DBFs  
*/  
 
  v[0]=0;  
  for(cur1=p->search("Firm"); cur1!=NULL; cur1=go_brother(cur1) )  
     {  
      v[6]=cur1->cal("Firm_Type",0);  
      if (v[6]==3)  
      v[1]=0;  
      else  
      v[1]=cur1->cal("KP",0);  
   
 
    v[0]=v[0]+v[1];  
     }  
res=v[0];  
goto end;  
}  
Return 
Variable U_Industry 
In Object  Industry  
Used in: F  
Using: U_Firm  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"U_Industry"))  
{  
/*  
Total drug merit in the industry  
*/  
 
v[0]=p->sum("U_Firm",0);//Merit of the firms  
 
res=v[0];  
goto end;  
}  
Return 
Parameter rho 
In Object  Industry  
Used in: Image  
Go to: Description,  Initial values,  Model Structure 
Variable Merit 
In Object  Industry  
Used in: Search  
Using: a_u b_u c_u o_u Drug_q Drug_d Drug_Type U Drug_C  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Merit"))  
276  
{  
/*  
This action update of the merit values of the drugs.  
The Merit function is a simplified version of Malerba and Orsenigo 
(2002), p.681  
*/  
CYCLE(cur,"Firm")  
  {  
    // The relevant parameters are at the firm level  
    v[0]=cur->cal("a_u",0);//parameter for Quality  
    v[10]=cur->cal("b_u",0);//parameter for roi  
    v[100]=cur->cal("c_u",0);//parameter for Image  
    v[101]=cur->cal("o_u",0);//scaling parameter  
      
    CYCLES(cur,cur1, "Portfolio")  
     {  
      CYCLES(cur1,cur2,"Drug")  
        {  
          v[2]=cur2->cal("Drug_d",0);//date  
          v[3]=cur2->cal("Drug_C",0);//Image  
          v[4]=cur2->cal("Drug_q",0);//Quality  
          v[5]=cur2->cal("Drug_Type",0);//Generic(2) or New(1)  
            
          v[6]=v[101]*pow(v[4],v[0])*pow((1/0.8),v[10])*pow(v[3],v[100
]);  
          v[7]=v[101]*pow(v[4],v[0])*pow((1/0.7),v[10])*pow(v[3],v[100
]);  
            
          if (v[5]==1)//If new drug  
          cur2->write("U", v[6],0);//Updating of the parameter Merit!  
          if (v[5]==2)//If generic drug  
          cur2->write("U", v[7],0);//Updating of the parameter Merit!  
        }  
    }  
  }  
res=1;  
goto end;  
}  
Return 
Variable Image 
In Object  Industry  
Used in: Search  
Using: rho Drug_d Drug_C Drug_M  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Image"))  
{  
/*  
Updating of the image values of the drugs  
*/  
CYCLE(cur,"Firm")  
 {  
  CYCLES(cur,cur1,"Portfolio")  
  {  
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    CYCLES(cur1,cur2,"Drug")  
    {  
      v[6]=cur2->cal("Drug_M",0);//Marketing Budget of the drug in the 
period of launching  
      v[8]=cur2->cal("Drug_d",0);//Date of launch of the drug  
      v[9]=p->cal("rho",0);//Rate of erotion of the image of the drug  
      v[10]=cur2->cal("Drug_C",1);//Image of the drug  
        
      if (t == v[8])  
      cur2->write("Drug_C", v[6],0);//Drug image at time of launch  
        
      if (t>v[8])  
       {  
        v[11]=v[10]*(1-v[9]);  
        //Drug image after launching. It decreases according to the 
rate of image erotion  
        if (v[11]>0)  
        cur2->write("Drug_C", v[11],0);  
        else  
        cur2->write("Drug_C", 0,0);//0.1  
       }  
    }  
  }  
 }  
res=1;  
goto end;  
}  
Return 
Parameter S_SO_r 
In Object  Industry  
Used in: S_SO  
Go to: Description,  Initial values,  Model Structure 
Parameter P_SO_r 
In Object  Industry  
Used in: P_SO  
Go to: Description,  Initial values,  Model Structure 
Variable DK 
In Object  Industry  
Used in: (never used) 
Using: DS DP  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"DK"))  
{  
/*  
Capabilities at industry level  
*/  
v[0]=p->cal("DP",0);  
v[1]=p->cal("DS",0);  
res=v[1]+v[0];  
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goto end;  
}  
Return 
Parameter Oligopol_size 
In Object  Industry  
Used in: Entry_DBF  
Go to: Description,  Initial values,  Model Structure 
Variable Rational_Phase_Industry 
In Object  Industry  
Used in: (never used) 
Using: P_td_2 P_sc P_sc_2  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Rational_Phase_Industry"))  
{  
/*  
The technological discontinuity changes the cummulativeness of the ca-
pabilities.  
*/  
v[0]=t;  
v[2]=p->cal("P_td_2",0);  
v[3]=p->next->next->cal("P_sc_2",0);  
 
if (v[0] >= v[2])  
p->next->next->write("P_sc",v[3], 0);  
   
res=1;  
goto end;  
}  
Return 
Parameter P_SO_r_2 
In Object  Industry  
Used in: (never used) 
Go to: Description,  Initial values,  Model Structure 
Variable Entry_DBF 
In Object  Industry  
Used in: (never used) 
Using: Oligopol_size DBF_Number lambda_dbf Alpha_dbf t_entry_DBF Delete 
R Start LW_Invest LB_Invest LB_KK LW_KS LW_KP LB_KS LB_KP KS KP K 
KS_Share KP_Share I WI Portfolio_Size U_Firm F B M_Expend Abs_P Abs_S 
Ex V Adoption_Draw j Innovation_Draw L_Budget Firm_Type Max_Drug_q 
P_Knowl_firm Alpha_f beta_f lambda_f Drug_q Drug_d Drug_Type U Drug_C 
Drug_M Scope Scope_r Scope_Adoption Precision Precision_r Precision_TP 
Precision_WA Precision_Adoption_1 Precision_Adoption_2  
Go to: Description,  Model Structure 
Equation Code:  
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if(!strcmp(label,"Entry_DBF"))  
{  
 
 /*  
  Entry of biotech companies. The function is computed only once and 
then it is transformed in a parameter and never computed again. This 
equation sets the search space of molecules availiable for the drug 
producers to discover and develop drugs.  
 */  
   
v[0]=p->cal("t_entry_DBF",0);  
if (t==v[0])  
{  
 v[3]=p->overall_max("j", 0);//highest Firm Id  
 v[2]=p->cal("Oligopol_size",0);//Size of the oligopol  
 v[21]=v[3]-v[2];//To make sure that we start at 0.  
 v[1]=p->cal("DBF_Number",0);//Number of biotech companies  
 cur=p->search_var_cond("j", v[3], 0);//Firm with the highest Firm Id  
 v[6]=p->cal("lambda_dbf",0);//  
 v[7]=p->cal("Alpha_dbf",0);//  
   
 while (v[21]<v[1])  
 {  
  cur1=p->add_an_object("Firm",cur);  
  cur1->write("Firm_Type", 3, v[0]);  
  cur1->write("j", v[21]+v[2]+1, v[0]);  
  cur1->write("Start",rnd_integer(1, 1200), v[0]-1);  
  cur1->write("Portfolio_Size", 1, v[0]);  
    
  cur1->write("lambda_f", v[6], v[0]);  
  cur1->write("Alpha_f", v[7], v[0]);  
  cur1->write("beta_f", 1, v[0]);  
 
  cur1->write("WI", 0, v[0]);  
  cur1->write("Adoption_Draw", 0, v[0]);  
  cur1->write("Innovation_Draw", 0, v[0]);  
  cur1->write("B", 0.1, v[0]);//no v[0]-1  
  cur1->write("P_Knowl_firm", 0, v[0]);  
 
  cur1->write("I", 0, v[0]);//no v[0]-1  
  cur1->write("F", 0, v[0]);//no v[0]-1  
    
  cur1->write("LB_KK", 1, v[0]);//no 1 and no v[0]-1  
  cur1->write("K", 0, v[0]);//no v[0]-1  
  cur1->write("KS_Share", 0, v[0]);//no v[0]-1  
  cur1->write("KP_Share", 0, v[0]);//no v[0]-1  
    
  cur1->write("KP", 25, v[0]-1);  
  cur1->write("LW_KP", 0, v[0]);  
  cur1->write("LB_KP", 0, v[0]);  
  cur1->write("Abs_P", 0, v[0]);//no v[0]-1  
 
  cur1->write("KS", 0, v[0]);//no v[0]-1  
  cur1->write("LW_KS", 0, v[0]);//no v[0]-1  
  cur1->write("LB_KS", 0, v[0]);//no v[0]-1  
  cur1->write("Abs_S", 0, v[0]);//no v[0]-1  
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  cur1->write("Ex", 0, v[0]);  
  cur1->write("M_Expend", 0, v[0]);  
  cur1->write("L_Budget", 0, v[0]);  
  cur1->write("LB_Invest", 0, v[0]);  
  cur1->write("LW_Invest", 0, v[0]);  
  cur1->write("R", 0, v[0]);  
    
    
  cur1->son->next->next->write("Precision_Adoption_1", 1, v[0]-1);  
    cur1->son->next->next->write("Precision_Adoption_2", 1, v[0]-1);  
  cur1->write("V", 0, v[0]-1);  
  cur1->son->next->write("Scope_Adoption", 1, v[0]-1);  
  cur1->son->next->write("Scope", 100, v[0]); // no 50 //no v[0]-1  
  cur1->son->next->write("Scope_r", 0, v[0]);//no v[0]-1  
  cur1->son->next->next->write("Precision_r", 0, v[0]-1);  
  cur1->son->next->next->write("Precision", 300, v[0]-1);  
  cur1->son->next->next->write("Precision_TP", 0, v[0]);  
  cur1->son->next->next->write("Precision_WA", 0, v[0]);  
    
 
  cur1->write("U_Firm", 0, v[0]);//no v[0]-1  
  cur1->write("Max_Drug_q", 0, v[0]);//no v[0]-1  
  for(cur2=cur1->search("Drug"); cur2!=NULL; )  
   {  
   cur3=go_brother(cur2);  
   cur2->write("Drug_q",rnd_integer(1500, 3000) , v[0]);  
   cur2->write("Drug_d",v[0] ,v[0] );  
   cur2->write("Drug_Type", 1, v[0]);  
   cur2->write("Drug_C", 0, v[0]);//no 0.5  
   cur2->write("Drug_d", v[0], v[0]);  
   cur2->write("Drug_M", 1, v[0]);  
   cur2->write("U",0, v[0]); // no rnd_integer(75, 100)  
   cur2=cur3;  
   }  
 
     
  v[21]=v[21]+1;  
 }  
  v[11]=p->cal("Delete",0);  
    
            
res=1;  
param=1;  
}  
 
else  
res=0;  
 goto end;  
}  
Return 
Parameter DBF_Number 
In Object  Industry  
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Used in: Entry_DBF  
Go to: Description,  Initial values,  Model Structure 
Parameter lambda_dbf 
In Object  Industry  
Used in: Entry_DBF  
Go to: Description,  Initial values,  Model Structure 
Parameter Alpha_dbf 
In Object  Industry  
Used in: Entry_DBF  
Go to: Description,  Initial values,  Model Structure 
Parameter t_entry_DBF 
In Object  Industry  
Used in: Entry_DBF LC_KP col_Knowl Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter VentCap 
In Object  Industry  
Used in: B  
Go to: Description,  Initial values,  Model Structure 
Variable Delete 
In Object  Industry  
Used in: Entry_DBF  
Using: Firm_Type Drug_del  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Delete"))  
{  
/*  
This equation deletes the drugs of the DBFs after they have been added 
to the structure of the model.  
*/  
last_update--;//repeat the computation any time is requested  
if(c==NULL)//Avoids to be computed when the system activates the equa-
tion  
{  
res=-1;  
goto end;  
}  
 CYCLE(cur2,"Firm")  
   {  
    v[4]=cur2->cal("Firm_Type",0);  
    if (v[4]==3)  
     {  
 
       for(cur=cur2->search("Drug"); cur!=NULL; )  
       {  
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       v[1]=cur->cal("Drug_del",0);  
       cur1=go_brother(cur);  
       if (v[1]==1)  
       cur->delete_obj();  
       cur=cur1;  
       }  
 
     }  
   }  
 v[3]=1;  
 
 
res=v[3];  
goto end;  
}  
Return 
Variable Collaboration 
In Object  Industry  
Used in: Search  
Using: t_entry_DBF col_knowl_r Start LB_KK KP j Firm_Type col_number cp 
CW distance Drug_q Drug_d Drug_l Drug_lp Precision_Adoption_2 col_LF 
col_date col_KP col_DBF  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Collaboration"))  
{  
/*  
This function activates the search of LFs (Firm Type 1 or 2) for col-
laborative partners (Firm type 3).  
The search starts after the discontinuity at t=70 has taken place.  
*/  
 
v[0]=(double)t;  
v[1]=p->cal("t_entry_DBF",0);  
v[40]=p->cal("col_knowl_r",0);//rate of knowledge flow in the collabo-
rative arrangements  
if (v[0]>v[1])  
 
{  
CYCLE (cur,"Firm")  
 {  
 v[2]=cur->cal("Firm_Type",0);  
 v[17]=cur->cal("j",0);//Id of the firm  
 v[3]=cur->cal("Precision_Adoption_2",0);  
 v[4]=cur->cal("Start",0);  
 v[16]=cur->cal("LB_KK",0);  
 /*  
 v[6]=cur->cal("KP_rank",0);  
 */  
   
   if (v[2] != 3 && v[3]==1)//Only incumbent firms that have adopted 
the new technological opportunities  
    {  
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   CYCLES (cur->up, cur1, "Firm")  
     {  
     v[5]=cur1->cal("Firm_Type",0);//DBF - Potential collaboration 
partner  
     v[14]=cur1->cal("KP",0);//DBF capabilities  
     v[41]=v[40]*v[14];//DBF capabilities that can be transferred  
     v[9]=cur1->cal("col_number",1);  
     v[7]=cur1->cal("Start",0);  
     v[15]=round(abs(v[7]-v[4]));  
       
     if (v[15]==0)  
     v[30]=0.1;  
     else  
     v[30]=v[15];  
     cur1->write("distance",v[30],0);//Distance between the incumbent 
firm and the DBF  
     v[28]=cur1->cal("j",0);//Identification Number of the DBF  
       
     v[31]=cur1->overall_max("Drug_q",0);//quality of max drug of DBF  
     cur5=cur1->search_var_cond("Drug_q",v[31],0);//drug (object)with 
highst quality of potential partner DBF  
     v[34]=cur5->cal("Drug_l",0);//Is the drug already licensed? This 
needs to be cheked  
     v[32]=cur->overall_max("Drug_d",0);//date of jungest drug of LF  
     cur6=cur->search_var_cond("Drug_d",v[32],0);//jungest drug (ob-
ject) of the incumbent LF searching for partner  
     v[33]=cur6->cal("Drug_q",0);//quality of jungest drug of LF  
       
       
     /*  
     v[8]=cur1->cal("KP_rank_par",0);  
     */  
       if (v[30]<300)//only the ones that are "close"  
        {  
         v[10]=cur1->cal("cp",0);//Scalling parameter  
         v[11]=(double)1-exp(-v[10]*pow(v[16],2)/v[30]);  
         v[18]=UNIFORM(0,1);  
         cur->write("CW",v[11],0);//Probability to collaborate  
 
          if (v[11]>v[18] && v[5]==3 && v[9]!=1)//Closing licensing 
agreement  
              
            {  
            if (v[33]<v[31] && v[34]!=1)//If the drug has not been 
liscensed jet  
            {  
            //jungest drug (object) of the LF becomes the quality of 
the best drug of   the DBF  
                        cur6->write("Drug_q",v[31],0); 
            //Updating the "drug liscenced" parameter in the portfolio 
of LF  
            cur6->write("Drug_l",1,0); 
            //Updating the licensing partner parameter in the drug 
liscensed by the incumbent  
                        cur6->write("Drug_lp",v[28],0); 
            cur5->write("Drug_l",1,0);//Updating the "drug liscenced" 
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parameter in the portfolio of the DBF  
            }  
              
            CYCLES(cur,cur2,"Network")  
             {  
             cur3=SEARCHS(cur2,"col");  
             if(VS(cur3,"col_date")!=-1)  
               cur3=cur2->add_an_object("col",cur3);  
             cur1->write("col_number",1,0);//DBF level  
             cur3->write("col_LF",v[17],0);//Id of the LF in the coll. 
updated // Col level  
             cur->increment("col_number",1);//Number of collaboration 
of the LF updated // LF Level  
             cur3->write("col_date",(double)t,0);//Date of collabora-
tion beginn updated// col level  
             cur3->write("col_KP",v[41],0);//Capabilities transferred 
from the DBF to the LF in the coll.//col level  
             cur3->write("col_DBF",v[28],0);//Id of the DBF in the 
coll. updated // Col level  
             }  
            }  
         }  
      }  
     }  
  }  
}  
res=1;  
goto end;  
}  
Return 
Variable Divorce 
In Object  Industry  
Used in: (never used) 
Using: t_entry_DBF col_knowl_r Start LB_KK KP j Firm_Type col_number cp 
col_date col_KP col_DBF col_divorce_date DW col_divorce  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Divorce"))  
{  
/*  
Termination of collaboration.  
Stochastic process after updating the location of the frims in the 
search space and the engagement of the incumbent firm in interacting 
with its environment.  
*/  
v[0]=(double)t;  
v[1]=p->cal("t_entry_DBF",0);  
v[40]=p->cal("col_knowl_r",0);  
 
 if (v[0]>v[1])  
 {  
  CYCLE(cur,"Firm")  
  {  
  v[2]=cur->cal("Firm_Type",0);  
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  v[3]=cur->cal("col_number",0);  
  v[6]=cur->cal("Start",0);  
  v[8]=cur->cal("LB_KK",0);  
  if (v[2]!=3 && v[3]>0)  
  {  
   CYCLES(cur,cur1,"Network")  
   {  
    CYCLES(cur1,cur2,"col")  
     {  
     v[4]=cur2->cal("col_DBF",0);  
     v[22]=cur2->cal("col_date",0);  
     if(v[22]==-1)  
      break; //exit the cycle if it is not a real "col"  
     cur3=cur1->up->search_var_cond("j",v[4], 0);  
     v[5]=cur3->cal("Start",0);  
     v[14]=cur3->cal("KP",0);  
     v[41]=v[14]*v[40];  
     v[7]=abs(v[5]-v[6]);  
     if (v[7]==0)  
     v[9]=0.1;  
     else  
     v[9]=v[7];  
     v[10]=cur->cal("cp",0);  
     v[11]=1-exp(-v[10]*pow(v[8],2)/v[9]);  
     cur2->write("DW",v[11],0);//col level  
     v[18]=UNIFORM(0,1);  
     v[21]=cur2->cal("col_divorce",0);  
 
     if (v[11]>v[18] && v[21]==0 && v[22]<v[0]-2)  
       cur2->write("col_KP",v[41],0);//col level  
     if (v[11]<=v[18] && v[21]==0 && v[22]<v[0]-2)  
         {  
         cur2->write("col_KP",0,0);//col level  
         cur2->write("col_divorce_date",double(t),0);//col level  
         cur3->write("col_number",0,0);  
         cur2->write("col_divorce",1,0);//col level  
        }  
    }  
  }  
 }  
}  
}  
   
res=1;  
goto end;  
}  
Return 
Parameter col_knowl_r 
In Object  Industry  
Used in: Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Variable beta 
In Object  Industry  
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Used in: M_Expend L_Budget  
Using: Firm_Type beta_f  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"beta"))  
{  
/*  
Variable capturing investment decitions in learning  
*/  
last_update--;//repeat the computation any time is requested  
if(c==NULL)//Avoids to be computed when the system activates the equa-
tion  
{  
res=-1;  
goto end;  
}  
 
v[0]=c->cal("Firm_Type",0);  
if (v[0]==1)  
v[1]=UNIFORM(0.5,0.7);  
if (v[0]==2)  
v[1]=UNIFORM(0.5,0.7);  
if (v[0]==3)  
v[1]=1;  
 
c->write("beta_f",v[1],0);  
res=v[1];  
goto end;  
}  
Return 
Variable Alpha 
In Object  Industry  
Used in: LW_KS LW_KP Abs_S Abs_P  
Using: Firm_Type Alpha_f  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Alpha"))  
{  
/*  
Variable capturing the technological bet of the firm  
*/  
last_update--;//repeat the computation any time is requested  
if(c==NULL)//Avoids to be computed when the system activates the equa-
tion  
{  
res=-1;  
goto end;  
}  
 
 
v[0]=c->cal("Firm_Type",0);  
if (v[0]==1)  
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v[1]=UNIFORM(0.3,0.5);  
 
if (v[0]==2)  
v[1]=UNIFORM(0.6,0.8);  
 
if (v[0]==3)  
v[1]=0;  
 
c->write("Alpha_f",v[1],0);  
res=v[1];  
goto end;  
}  
Return 
Variable lambda 
In Object  Industry  
Used in: LW_Invest LB_Invest  
Using: Firm_Type lambda_f  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"lambda"))  
{  
/*  
Variable capturing investment dections in external learning  
*/  
last_update--;//repeat the computation any time is requested  
if(c==NULL)//Avoids to be computed when the system activates the equa-
tion  
{  
res=-1;  
goto end;  
}  
 
v[0]=c->cal("Firm_Type",0);  
if (v[0]==1)  
 
v[1]=UNIFORM(0.10,0.15);//HFM scenario and Exp2_l scenario  
/*  
v[1]=UNIFORM(0.30,0.40);//Exp2_h scenario  
*/  
 
if (v[0]==2)  
v[1]=UNIFORM(0.30,0.40);//HFM scenario and Exp2_h scenario  
 
/*  
v[1]=UNIFORM(0.10,0.15);//Exp2_l scenario  
*/  
 
if (v[0]==3)  
v[1]=1;  
 
c->write("lambda_f",v[1],0);  
res=v[1];  
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goto end;  
}  
Return 
Variable Max_Drug_q_Industry 
In Object  Industry  
Used in: (never used) 
Using: Max_Drug_q  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Max_Drug_q_Industry"))  
{  
/*  
Max drug quality in the industry  
*/  
v[2]=p->overall_max("Max_Drug_q", 0);  
res=v[2];  
goto end;  
}  
Return 
   
 
Object Firm 
 
Contained in Object: Root->Root2->World->Industry 
Containing: Portfolio Scope_Tech Precision_Tech Network  
List of Variables:  Abs_P(0), Abs_S(0), Adoption_Draw(0), B(1), col_Knowl(0), 
DP_SO(0), DS_SO(0), Ex(0), F(0), I(0), Innovation_Draw(0), K(0), KP(1), 
KP_Share(0), KS(1), KS_Share(0), L_Budget(0), LB_Invest(1), LB_KK(1), 
LB_KP(0), LB_KS(0), LC_KP(0), LW_Invest(1), LW_KP(0), LW_KS(0), 
M_Expend(0), Max_Drug_q(0), P_Adoption_De_1(0), P_Adoption_De_2(0), 
P_SO(0), R(0), S_Adoption_De(0), S_SO(0), Start(1), U_Firm(0), V(0), WI(0) 
List of Parameters:  a_u, Alpha_f, ap, Approval, b_u, beta_f, c_u, col_number, cp, 
CW, distance, DP_SO_p, DS_SO_p, Firm_Type, ip, j, lambda_f, o_u, 
P_Knowl_firm, Portfolio_Size, v, v_decr_rate 
Variable R 
In Object  Firm  
Used in: Entry_DBF B  
Using: Fi F  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"R"))  
{  
/*  
Reward of the company in each period. It depends on the quality 
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reached by  
the molecule of the company and on the budget of the health system.  
*/  
v[1]=p->cal("F",0);  
v[2]=p->up->cal("Fi",0);  
if (v[1]>0)  
v[4]=v[1]*v[2];  
else  
v[4]=0;  
 
res=v[4];  
goto end;  
}  
Return 
Variable Start 
In Object  Firm  
Used in: Entry_DBF Search Start Collaboration Divorce  
Using: Start Size  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"Start"))  
{  
/*  
Action that determines in each period the location in the search space 
to start the  
search for the molecule with the highest quality.  
*/  
 
v[0]=(double)t;  
if (v[0]==1)  
{  
 v[4]=p->cal("Size",0);  
 v[3]=rnd_integer(0,v[4]);  
}  
else  
{  
 v[2]=rnd_integer(-50,50);  
 v[1]=p->cal("Start",1);  
 v[3]=abs(v[2]+v[1]);  
}  
res=round(v[3]);  
goto end;  
}  
Return 
Variable LW_Invest 
In Object  Firm  
Used in: Entry_DBF LW_KS LW_KP  
Using: lambda L_Budget  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"LW_Invest"))  
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{  
/*  
Investment in internal learning  
 
*/  
v[0]=p->cal("L_Budget",0);  
v[1]=p->cal("lambda",0);//Investment in learning by interacting (ex-
ternal learning)  
 
v[4]=v[0]*(1-v[1]);  
 
 
res=v[4];  
goto end;  
}  
Return 
Variable LB_Invest 
In Object  Firm  
Used in: Entry_DBF LB_KK  
Using: lambda L_Budget  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"LB_Invest"))  
{  
/*  
Investment in external learning  
*/  
 
v[0]=p->cal("lambda",0);//External learning parameter  
v[1]=p->cal("L_Budget",0);//Leraning budget  
 
v[3]=v[0]*v[1];  
 
 
res=v[3];  
goto end;  
 
}  
Return 
Variable LB_KK 
In Object  Firm  
Used in: Entry_DBF LB_KK Abs_S Abs_P Scope_WA Precision_WA 
Collaboration Divorce  
Using: LB_Invest LB_KK  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"LB_KK"))  
{  
/*  
Stock of learning beyond the firm  
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*/  
v[1]=p->cal("LB_Invest",0);  
v[2]=p->cal("LB_KK",1);  
v[3]=0.8*v[2]+v[1];//0.8 depreciation of capabilities  
v[5]=log(1+v[3]); //Abnehmende Skalenerträge or decreasing returns to 
scale  
 
res=v[5];  
goto end;  
}  
Return 
Variable LW_KS 
In Object  Firm  
Used in: Entry_DBF KS  
Using: Alpha LW_Invest  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"LW_KS"))  
{  
/*  
Internal learning investment in the technology S  
*/  
v[1]=p->cal("LW_Invest",0);//Investment in learning within the firm  
v[5]=p->cal("Alpha",0);//technological trayectory of the firm  
v[3]=v[1]*v[5];//Investment in technology S  
 
v[4]=log(1+v[3]);  
/*  
v[4]=pow(v[3],0.5);  
*/  
res=v[4];  
goto end;  
}  
Return 
Variable LW_KP 
In Object  Firm  
Used in: Entry_DBF KP  
Using: Alpha LW_Invest Firm_Type  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"LW_KP"))  
{  
/*  
Internal research investment in technology B  
*/  
v[1]=p->cal("LW_Invest",0);//Investment in learning within the firm  
v[5]=p->cal("Alpha",0);//Technological trayectory of the firm  
v[10]=p->cal("Firm_Type",0);//Firm Type  
 
if (v[10]==1)  
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{  
v[6]=1-v[5];  
v[12]=UNIFORM(0.3,v[6]);  
}  
if (v[10]==2)  
{  
v[6]=0.9-v[5];  
v[12]=UNIFORM(0.3,v[6]);  
}  
if (v[10]==3)  
v[12]=1;  
 
v[3]=v[1]*v[12];//Investment in technology B  
 
v[4]=log(1+v[3]);  
res=v[4];  
goto end;  
}  
Return 
Variable LB_KS 
In Object  Firm  
Used in: Entry_DBF KS  
Using: Abs_S S_Knowl  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"LB_KS"))  
{  
/*  
Capabilities in the technology S through external learning  
*/  
 
v[4]=p->cal("Abs_S",0);//Absorptive capacity  
v[6]=p->cal("S_Knowl",0);// Extramural knowledge base  
v[7]=v[4]*v[6];  
 
res=v[7];  
goto end;  
}  
Return 
Variable LB_KP 
In Object  Firm  
Used in: Entry_DBF KP  
Using: Abs_P P_Knowl  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"LB_KP"))  
{  
/*  
Capabilities in the technology B through external learning  
 
*/  
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v[4]=p->cal("Abs_P",0);//Absorptive capacity  
v[6]=p->cal("P_Knowl",0);  
v[7]=v[4]*v[6];  
 
res=v[7];  
goto end;  
}  
Return 
Variable KS 
In Object  Firm  
Used in: Entry_DBF DS_SO DS KS K KS_Share Scope_r  
Using: LW_KS LB_KS KS S_sc  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"KS"))  
{  
/*  
Capabilities in technology S  
Inspired by llerena et Oltra (1999)p. 9.  
*/  
 
v[0]=p->cal("KS",1);  
v[1]=p->cal("LW_KS",0);//Cummulative research  
v[2]=p->cal("LB_KS",0);//Non cummulative research  
v[3]=p->cal("S_sc",0);//Depreciation of knowledge or Degree of cummu-
lativeness  
v[4]=v[1]+v[2]+(1-v[3])*v[0];  
 
res=v[4];  
goto end;  
}  
Return 
Variable KP 
In Object  Firm  
Used in: Entry_DBF DP_SO DP KP K KP_Share Collaboration Divorce 
Precision_r  
Using: LW_KP LB_KP KP LC_KP P_sc  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"KP"))  
{  
/*  
Accumulation of Capabilities.  
Inspired by llerena et Oltra (1999)p. 9.  
The acummulation of capabilities is a weighted average of past and new  
capabilities.  
*/  
 
v[0]=p->cal("KP",1);  
v[1]=p->cal("LW_KP",0);//Learning internal to the firm  
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v[2]=p->cal("LB_KP",0);//Learning external to the firm  
v[22]=p->cal("LC_KP",0);//Learning external to the firm  
v[3]=p->cal("P_sc",0);//Depreciation of knowledge (or Degree of cummu-
lativeness)  
v[4]=v[1]+v[2]+v[22]+(1-v[3])*v[0];  
 
res=v[4];  
goto end;  
}  
Return 
Variable K 
In Object  Firm  
Used in: Entry_DBF KS_Share KP_Share WI  
Using: KS KP  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"K"))  
{  
/*  
Accumulation of Capabilities of both technologies.  
*/  
 
v[1]=p->cal("KP",0);  
v[2]=p->cal("KS",0);  
v[3]=v[1]+v[2];  
res=v[3];  
 
goto end;  
}  
Return 
Variable KS_Share 
In Object  Firm  
Used in: Entry_DBF  
Using: KS K  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"KS_Share"))  
{  
/*  
Firm's share of technology S capabilities  
*/  
 
v[0]=p->cal("KS",0);  
v[1]=p->cal("K",0);  
 
res=v[0]/v[1];  
 
goto end;  
}  
Return 
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Variable KP_Share 
In Object  Firm  
Used in: Entry_DBF  
Using: KP K  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"KP_Share"))  
{  
/*  
Firm's share of capabilities in technology B  
*/  
v[0]=p->cal("KP",0);  
v[1]=p->cal("K",0);  
 
res=v[0]/v[1];  
goto end;  
}  
Return 
Variable I 
In Object  Firm  
Used in: Entry_DBF Search  
Using: Mode WI Innovation_Draw  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"I"))  
{  
/*  
Innovation can be deterministic (Mode=0) or the result of a random 
process (Mode=1).  
*/  
v[0]=p->cal("Innovation_Draw",0);  
v[1]=p->cal("WI",0);  
v[3]=p->up->cal("Mode",0);  
/*  
It determines the version of the model (all innovate or not). If 
Mode=0 innovation is a  
draw which depends on the level of capabilities of the firms. If 
Mode=1 all innovate.  
*/  
if (v[3]==0)  
 {  
  if (v[0] < v[1])  
  v[2]=1;  
  else  
  v[2]=0;  
 }  
else  
v[2]=1;  
 
res=v[2];  
goto end;  
}  
Return 
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Variable WI 
In Object  Firm  
Used in: Entry_DBF I  
Using: K ip  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"WI"))  
{  
/*  
Probability to Innovate. Different options to model this function.  
*/  
v[0]=p->cal("K",0);//Stock of capabilities  
v[1]=p->cal("ip",0);//Scalling parameter  
v[2]=1-exp(-v[1]*v[0]);  
 
res=v[2];  
goto end;  
}  
Return 
Parameter Portfolio_Size 
In Object  Firm  
Used in: Entry_DBF Search  
Go to: Description,  Initial values,  Model Structure 
Variable U_Firm 
In Object  Firm  
Used in: Entry_DBF U_Industry F  
Using: U  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"U_Firm"))  
{  
/*  
Sum of the qualities of the drug portfolio.  
*/  
v[0]=p->son->sum("U",0);  
res=v[0];  
goto end;  
}  
Return 
Variable F 
In Object  Firm  
Used in: Entry_DBF R  
Using: U_Industry U_Firm  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"F"))  
{  
/*  
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Merit share of the firm. This equation is used as performance indica-
tor and i  
s used to operationalised the reward of the firm from the system.  
*/  
v[1]=p->cal("U_Firm",0);  
v[3]=p->up->cal("U_Industry",0);  
if (v[1]>0)  
v[4]=(v[1]/v[3]);  
else  
v[4]=0;  
 
res=v[4];  
goto end;  
}  
Return 
Parameter ap 
In Object  Firm  
Used in: Scope_WA Precision_WA  
Go to: Description,  Initial values,  Model Structure 
Parameter ip 
In Object  Firm  
Used in: WI  
Go to: Description,  Initial values,  Model Structure 
Parameter v 
In Object  Firm  
Used in: S_Adoption_De P_Adoption_De_1 P_Adoption_De_2 Scope_WA 
Precision_WA Precision_V Scope_V  
Go to: Description,  Initial values,  Model Structure 
Variable B 
In Object  Firm  
Used in: Entry_DBF B M_Expend L_Budget S_Adoption_De  
Using: VentCap R B Ex Firm_Type  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"B"))  
{  
/*  
Budget for the activities of the firm  
*/  
 
v[5]=p->cal("Firm_Type",0);  
v[0]=p->cal("B",1);//Previous budget  
v[1]=p->cal("R",0);//Reward  
v[2]=p->cal("Ex",0);//Expenditure  
v[6]=p->up->cal("VentCap",0);  
if (v[5]==3)  
/*  
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v[3]=v[6];  
*/  
v[3]=v[0]+v[1]-v[2]+v[6];  
else  
v[3]=v[0]+v[1]-v[2];  
 
 
res=v[3];  
goto end;  
}  
Return 
Variable M_Expend 
In Object  Firm  
Used in: Entry_DBF Search Ex  
Using: beta B  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"M_Expend"))  
{  
/*  
Expenditures in marketing activities  
*/  
v[0]=p->cal("beta",0);//Investment in learning  
v[2]=p->cal("B",1);  
v[3]=(1-v[0])*v[2];  
 
res=v[3];  
goto end;  
}  
Return 
Parameter a_u 
In Object  Firm  
Used in: Merit  
Go to: Description,  Initial values,  Model Structure 
Parameter b_u 
In Object  Firm  
Used in: Merit  
Go to: Description,  Initial values,  Model Structure 
Parameter c_u 
In Object  Firm  
Used in: Merit  
Go to: Description,  Initial values,  Model Structure 
Parameter o_u 
In Object  Firm  
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Used in: Merit  
Go to: Description,  Initial values,  Model Structure 
Variable Abs_P 
In Object  Firm  
Used in: Entry_DBF LB_KP LC_KP  
Using: Alpha LB_KK Firm_Type P_complex  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Abs_P"))  
{  
/*  
Absorptive capacity for knowledge in technology B  
*/  
 
v[11]=p->cal("Alpha",0);//Technological trajectory  
v[1]=p->cal("LB_KK",0);//External research level. It influences the 
absorptive capacity of the firm  
v[3]=p->cal("P_complex",0);//Complexity of technology S Knowledege 
Base  
v[10]=p->cal("Firm_Type",0);  
 
 if (v[10]==1)  
 {  
 v[6]=1-v[11];  
 v[12]=UNIFORM(0.3,v[6]);  
 }  
 if (v[10]==2)  
 {  
 v[6]=0.9-v[11];  
 v[12]=UNIFORM(0.3,v[6]);  
 }  
 if (v[10]==3)  
 v[12]=1;  
 
v[7]=v[1];  
if (v[7]<4*pow(v[3],2))  
 v[8]=4*pow(v[3],2);  
 else  
 v[8]=v[7];  
v[4]=1-(2*v[3]/sqrt(v[8]));//Absorptive capacity  
if (v[4]<0)  
 v[5]==0;  
 else  
 v[5]=v[4];  
 
res=v[5];  
goto end;  
}  
Return 
Variable Abs_S 
In Object  Firm  
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Used in: Entry_DBF LB_KS  
Using: Alpha LB_KK S_complex  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Abs_S"))  
{  
/*  
Absorptive capacity of the technology S knowledge  
s  
*/  
v[6]=p->cal("Alpha",0);//Technological trajectory  
v[1]=p->cal("LB_KK",0);//External research level. It influences the 
absorptive capacity of the firm  
v[3]=p->cal("S_complex",0);//Complexity of technology S knowledege 
Base  
/*  
v[7]=v[6]*v[1];  
*/  
 
v[7]=v[1];  
 
if (v[7]<4*pow(v[3],2))  
v[8]=4*pow(v[3],2);  
else  
v[8]=v[7];  
v[4]= 1-(2*v[3]/sqrt(v[8]));//Absorptive capacity  
if (v[4]<0)  
v[5]==0;  
else  
v[5]=v[4];  
 
res=v[5];  
goto end;  
}  
Return 
Parameter Approval 
In Object  Firm  
Used in: Search Ex  
Go to: Description,  Initial values,  Model Structure 
Variable Ex 
In Object  Firm  
Used in: Entry_DBF B  
Using: M_Expend Approval V L_Budget  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Ex"))  
{  
/*  
Expenditures. Part of the budget that has been spent  
*/  
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v[1]=p->cal("L_Budget",0);//Learning investment  
v[3]=p->cal("M_Expend",0);//Marketing Expenditures  
v[4]=p->cal("Approval",0);//Development of a drug in the previous pe-
riod has been accepted  
v[5]=p->cal("V",0);//Adoption costs  
 
 
if (v[4]==1)//If in the period a drug has been admited for marketing  
v[10]=v[1]+v[3]+v[5];  
else  
v[10]=v[1]+v[5];  
 
 
res=v[10];  
goto end;  
}  
Return 
Variable V 
In Object  Firm  
Used in: Entry_DBF Ex  
Using: Firm_Type Precision_V  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"V"))  
{  
/*  
Total adoption costs  
v[1]=p->cal("Scope_V",0); In the version without Entry of firms  
of type 2 make sure that this is included in the costs  
*/  
 
v[0]=p->cal("Firm_Type",0);  
if (v[0]==3)  
v[2]=0;  
else  
v[2]=p->cal("Precision_V",0);  
 
res=v[2];  
goto end;  
}  
Return 
Variable Adoption_Draw 
In Object  Firm  
Used in: Entry_DBF S_Adoption_De P_Adoption_De_1 P_Adoption_De_2  
Using: (nothing) 
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Adoption_Draw"))  
{  
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/*  
The adoption draw determines the adoption succes of the firm. It is 
the same for  
all the firms. It is located at the industry level.  
*/  
 
v[0]=UNIFORM(0,1);  
res=v[0];  
goto end;  
}  
Return 
Variable S_Adoption_De 
In Object  Firm  
Used in: (never used) 
Using: v B Adoption_Draw Scope_WA Scope_Adoption Scope_Adoption_Date 
S_td  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"S_Adoption_De"))  
{  
/*  
Technology S Adoption Decition. This function determines whether the 
firm adopt  
a new form of technology after a technological discontinuity has taken 
place.  
This function is located at the level of the firm  
*/  
v[0]=(double)t;  
v[1]=p->cal("S_td",0);  
if (v[0] > v[1])  
  {  
   v[2]=p->son->cal("Scope_Adoption",0);  
//In the scenario "Entry DS_companies" make sure that this parameter 
is set to "0" for the LFs form the traditional of Firm Type 1. In the 
scenario with no entry DS_companies make sure that all companies have 
this parameter set to "1".  
   v[3]=p->son->cal("Scope_WA",0);  
   v[4]=p->cal("Adoption_Draw",0);  
   v[5]=p->son->cal("B",0);  
   v[6]=p->up->cal("v",0);  
 
     if (v[2] == 0 && v[3] > v[4] && v[5]>2*v[6])  
       {  
        cur1=p->search("Scope_Tech");  
        cur1->write("Scope_Adoption",1,0);  
        cur1->write("Scope_Adoption_Date",(double)t,0);  
       }  
 }  
res=1;  
goto end;  
}  
Return 
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Variable P_Adoption_De_1 
In Object  Firm  
Used in: (never used) 
Using: v Adoption_Draw L_Budget Precision_WA Precision_Adoption_1 
Precision_Adoption_1_Date P_td_1  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"P_Adoption_De_1"))  
{  
/*  
technology B Adoption Decition. This function determines whether the 
firm adopt  
a new form of technology after a technological discontinuity (the 
transition from random to rational search  
has taken place. This function is located at the firm level.  
*/  
v[0]=(double)t;  
 
v[1]=p->cal("P_td_1",0);  
 
 
 
if (v[0] > v[1])  
  {  
   v[2]=p->cal("Precision_Adoption_1",0);  
   v[3]=p->cal("Precision_WA",0);  
   v[4]=p->cal("Adoption_Draw",0);//At the level of the firm  
   v[5]=p->son->cal("L_Budget",0);  
   v[6]=p->up->cal("v",0);  
 
     if (v[2] == 0 && v[3] > v[4] && v[5]>2*v[6])  
       {  
         cur1=p->search("Precision_Tech");  
         cur1->write("Precision_Adoption_1",1,0);  
         cur1->write("Precision_Adoption_1_Date",(double)t,0);  
       }  
  }  
res=1;  
goto end;  
}  
Return 
Parameter j 
In Object  Firm  
Used in: Entry_DBF DS_SO DP_SO Scope_V Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter v_decr_rate 
In Object  Firm  
Used in: Precision_V Scope_V  
Go to: Description,  Initial values,  Model Structure 
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Variable Innovation_Draw 
In Object  Firm  
Used in: Entry_DBF I  
Using: (nothing) 
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Innovation_Draw"))  
{  
/*  
The innovation draw determines the innovation succes of the firm.  
It is the same for all the firms. It is located at the industry level.  
*/  
v[1]=UNIFORM(0,1); //Random uniform value in the interval [0,1].  
res=v[1] ;  
goto end;  
}  
Return 
Variable L_Budget 
In Object  Firm  
Used in: Entry_DBF Ex LW_Invest LB_Invest P_Adoption_De_1 
P_Adoption_De_2  
Using: beta B  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"L_Budget"))  
{  
/*  
Level of buget for learning  
*/  
v[1]=p->cal("B",1);  
v[2]=p->cal("beta",0);//Learning parameter  
 
res=v[1]*v[2];  
goto end;  
}  
Return 
Parameter Firm_Type 
In Object  Firm  
Used in: Entry_DBF Delete DS_SO DP_SO DS DP B beta lambda Alpha LW_KP 
Abs_P col_Knowl V Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter col_number 
In Object  Firm  
Used in: col_Knowl Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter cp 
In Object  Firm  
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Used in: Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Variable LC_KP 
In Object  Firm  
Used in: KP  
Using: t_entry_DBF Abs_P col_Knowl  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"LC_KP"))  
{  
/*  
Capabilities in the technology B through through collaboration  
 
*/  
 
v[0]=(double)t;  
v[1]=p->cal("t_entry_DBF",0);  
if(v[0]>v[1])  
{  
v[4]=p->cal("Abs_P",0);//Absorptive capacity  
v[6]=p->cal("col_Knowl",0);  
v[7]=v[4]*v[6];  
}  
else  
v[7]=0;  
res=v[7];  
goto end;  
}  
Return 
Parameter CW 
In Object  Firm  
Used in: Collaboration  
Go to: Description,  Initial values,  Model Structure 
Parameter distance 
In Object  Firm  
Used in: Collaboration  
Go to: Description,  Initial values,  Model Structure 
Variable col_Knowl 
In Object  Firm  
Used in: LC_KP  
Using: t_entry_DBF Firm_Type col_number col_KP  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"col_Knowl"))  
{  
/*  
Sum of firm's capabilities through colaboration in the technology B  
306  
*/  
 
v[0]=(double)t;  
v[1]=p->cal("t_entry_DBF",0);  
v[2]=p->cal("Firm_Type",0);  
v[3]=p->cal("col_number",0);  
if(v[0]>v[1] && v[2]!=3 && v[3]>0)  
v[7]=p->sum("col_KP",0);//capabilities transferred in all collabora-
tion  
else  
v[7]=0;  
res=v[7];  
goto end;  
}  
Return 
Variable Max_Drug_q 
In Object  Firm  
Used in: Entry_DBF Max_Drug_q_Industry  
Using: Drug_q  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Max_Drug_q"))  
{  
/*  
Quality of the drug with highest quality level in the portfolio of the 
firm  
*/  
v[0]=p->overall_max("Drug_q",0);  
res=v[0];  
goto end;  
}  
Return 
Parameter P_Knowl_firm 
In Object  Firm  
Used in: P_Knowl Entry_DBF  
Go to: Description,  Initial values,  Model Structure 
Parameter Alpha_f 
In Object  Firm  
Used in: Entry_DBF Alpha  
Go to: Description,  Initial values,  Model Structure 
Parameter beta_f 
In Object  Firm  
Used in: Entry_DBF beta  
Go to: Description,  Initial values,  Model Structure 
Parameter lambda_f 
In Object  Firm  
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Used in: Entry_DBF lambda  
Go to: Description,  Initial values,  Model Structure 
Parameter DP_SO_p 
In Object  Firm  
Used in: DP_SO P_SO  
Go to: Description,  Initial values,  Model Structure 
Parameter DS_SO_p 
In Object  Firm  
Used in: DS_SO S_SO  
Go to: Description,  Initial values,  Model Structure 
Variable DS_SO 
In Object  Firm  
Used in: (never used) 
Using: KS j Firm_Type DS_SO_p  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"DS_SO"))  
{  
/*  
This variable updates the level of Technology B (precision) spillovers 
each firm may have access to "DP_SO_p".  
These do not consider capabilities of the DBFs.  
*/  
 
 
  v[10]=p->cal("j",0);  
  v[0]=0;  
  for(cur1=p->up->search("Firm"); cur1!=NULL; cur1=go_brother(cur1) )  
     {  
      v[6]=cur1->cal("Firm_Type",0);  
      v[11]=cur1->cal("j",0);  
      if (v[6]==3 || v[11]==v[10])  
            v[1]=0;  
                  else  
      v[1]=cur1->cal("KS",0); //Technology S (Scope) capabilities at 
firm level  
 
      v[0]=v[0]+v[1];  
      p->write("DS_SO_p",v[0],0);//Maximum amount of spillovers  
 
     }  
 
res=0;  
goto end;  
}  
Return 
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Variable DP_SO 
In Object  Firm  
Used in: (never used) 
Using: KP j Firm_Type DP_SO_p  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"DP_SO"))  
{  
/*  
This variable updates the level of Technology B (Precision) spillovers 
each firm may have access to "DP_SO_p".  
These do not consider capabilities of the DBFs.  
*/  
 
  v[10]=p->cal("j",0);  
  v[0]=0;  
  for(cur1=p->up->search("Firm"); cur1!=NULL; cur1=go_brother(cur1) )  
     {  
      v[6]=cur1->cal("Firm_Type",0);  
      v[11]=cur1->cal("j",0);  
      if (v[6]==3 || v[11]==v[10])//Firm type=3 are DBFs  
      v[1]=0;  
      else  
      v[1]=cur1->cal("KP",0); //Technology B (precision) capabilities 
at firm level  
      v[0]=v[0]+v[1];  
      p->write("DP_SO_p",v[0],0); //Spillovers availiable  
     }  
 
res=0;  
goto end;  
}  
Return 
Variable P_SO 
In Object  Firm  
Used in: P_Knowl  
Using: P_SO_r DP_SO_p  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"P_SO"))  
{  
/*  
Spilovers in Technolgy B (Precision)  
*/  
 
v[1]=p->cal("DP_SO_p",0);//Volume of capabilities availiable  
v[2]=p->cal("P_SO_r",0);//Spillover rate  
res=v[1]*v[2];  
goto end;  
}  
Return 
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Variable S_SO 
In Object  Firm  
Used in: S_Knowl  
Using: S_SO_r DS_SO_p  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"S_SO"))  
{  
/*  
Spilovers in the Technolgy S (Scope)  
*/  
 
v[1]=p->cal("DS_SO_p",0);//Volume of capabilities availiable  
v[2]=p->cal("S_SO_r",0);//Spillover rate  
res=v[1]*v[2];  
goto end;  
}  
Return 
Variable P_Adoption_De_2 
In Object  Firm  
Used in: (never used) 
Using: v Adoption_Draw L_Budget Precision_WA Precision_Adoption_2 
Precision_Adoption_2_Date P_td_2  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"P_Adoption_De_2"))  
{  
/*  
Technology B Adoption Decition. This function determines whether the 
firm adopt  
a new form of technology after a technological discontinuity (the 
transition from random to rational search  
has taken place. This function is located at the firm level.  
*/  
v[0]=(double)t;  
 
v[1]=p->cal("P_td_2",0);  
 
 
 
if (v[0] > v[1])  
  {  
   v[2]=p->cal("Precision_Adoption_2",0);  
   v[3]=p->cal("Precision_WA",0);  
   v[4]=p->cal("Adoption_Draw",0);//At the level of the firm  
   v[5]=p->son->cal("L_Budget",0);  
   v[6]=p->up->cal("v",0);  
 
     if (v[2] == 0 && v[3] > v[4] && v[5]>2*v[6])  
       {  
         cur1=p->search("Precision_Tech");  
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         cur1->write("Precision_Adoption_2",1,0);  
         cur1->write("Precision_Adoption_2_Date",(double)t,0);  
       }  
  }  
res=1;  
goto end;  
}  
Return 
   
 
Object Portfolio 
 
Contained in Object: Root->Root2->World->Industry->Firm 
Containing: Drug  
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
   
 
Object Drug 
 
Contained in Object: Root->Root2->World->Industry->Firm->Portfolio 
Containing: (none) 
List of Variables:  (no Variables) 
List of Parameters:  Drug_C, Drug_d, Drug_del, Drug_i, Drug_l, Drug_lp, Drug_M, 
Drug_phase, Drug_q, Drug_qo, Drug_Type, U 
Parameter Drug_q 
In Object  Drug  
Used in: Entry_DBF Search Merit Max_Drug_q Collaboration  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_i 
In Object  Drug  
Used in: Search  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_qo 
In Object  Drug  
Used in: Search  
Go to: Description,  Initial values,  Model Structure 
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Parameter Drug_d 
In Object  Drug  
Used in: Entry_DBF Search Image Merit Collaboration  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_Type 
In Object  Drug  
Used in: Entry_DBF Search Merit  
Go to: Description,  Initial values,  Model Structure 
Parameter U 
In Object  Drug  
Used in: Entry_DBF Merit U_Firm  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_phase 
In Object  Drug  
Used in: Search  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_C 
In Object  Drug  
Used in: Entry_DBF Image Merit  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_M 
In Object  Drug  
Used in: Entry_DBF Search Image  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_del 
In Object  Drug  
Used in: Delete Search  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_l 
In Object  Drug  
Used in: Collaboration  
Go to: Description,  Initial values,  Model Structure 
Parameter Drug_lp 
In Object  Drug  
Used in: Collaboration  
Go to: Description,  Initial values,  Model Structure 
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Object Scope_Tech 
 
Contained in Object: Root->Root2->World->Industry->Firm 
Containing: (none) 
List of Variables:  Scope(1), Scope_Gap(0), Scope_r(1), Scope_TP(0), 
Scope_V(1), Scope_WA(0) 
List of Parameters:  a1, a2, Scope_Adoption, Scope_Adoption_Date, 
Scope_Theta 
Variable Scope 
In Object  Scope_Tech  
Used in: Entry_DBF Search Scope Scope_TP Scope_Gap  
Using: Scope Scope_r Scope_Adoption S_F1 S_F2  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"Scope"))  
{  
/*  
Technological achievement of the firm in the Technology S . Time and 
firm specific  
*/  
v[0]=p->cal("Scope",1);  
v[2]=p->cal("Scope_r",1);  
v[4]=p->cal("Scope_Adoption",0);  
 
if (v[4]==0)//No adoption  
  {  
   v[1]=p->cal("S_F1",0);  
   if (v[0]>=v[1])  
   v[3]=v[1];  
   else  
   v[3]=v[0]+v[2];//No exponential growth  
  }  
 
else  
  {  
   v[1]=p->cal("S_F2",0);  
   if (v[0]>=v[1])  
   v[3]=v[1];  
   else  
   v[3]=v[0]+v[2];//No exponential growth  
  }  
 
res=int(v[3]);  
goto end;  
}  
Return 
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Variable Scope_Gap 
In Object  Scope_Tech  
Used in: Scope_r  
Using: Scope Scope_Adoption S_F1 S_F2  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Scope_Gap"))  
{  
/*  
Technological Gap. Distance of the technological level of the firm to 
the  
technological frontier.  
*/  
 
v[0]=p->cal("Scope",0);  
v[4]=p->cal("Scope_Adoption",0);  
if (v[4]==0)  
v[2]=p->cal("S_F1",0);  
else  
v[2]=p->cal("S_F2",0);  
 
v[3]=abs(v[2]-v[0]);  
 
res=int(v[3]);  
goto end;  
}  
Return 
Parameter Scope_Theta 
In Object  Scope_Tech  
Used in: Scope_r  
Go to: Description,  Initial values,  Model Structure 
Variable Scope_r 
In Object  Scope_Tech  
Used in: Entry_DBF Scope  
Using: KS Scope_Gap Scope_Theta a1 a2  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"Scope_r"))  
{  
/*  
Rate of technological change of the Technology S . The variable is 
time and  
firm specific. Log linear function.  
v[5]=v[0]*pow((1-v[1]),v[3])*pow(v[2],v[4]);  
*/  
 
v[0]=p->cal("Scope_Theta",0);//Scalling Parameter  
v[1]=p->cal("Scope_Gap",0);  
//Distance of the technological level achieved to the technological 
frontier  
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v[2]=p->cal("KS",0);//Stock of capabilities in Technology S  
v[3]=p->cal("a1",0);  
v[4]=p->cal("a2",0);  
v[5]=UNIFORM(0.8,1.2);  
 
 
v[6]=v[0]*pow((v[1]),v[3])*pow(v[2],v[4])*v[5];//With random factor  
/*  
v[6]=v[0]*pow((v[1]),v[3])*pow(v[2],v[4]);  
*/  
v[7]=int(v[6]*1000);  
res=v[7]/1000;  
goto end;  
}  
Return 
Parameter a1 
In Object  Scope_Tech  
Used in: Scope_r  
Go to: Description,  Initial values,  Model Structure 
Parameter a2 
In Object  Scope_Tech  
Used in: Scope_r  
Go to: Description,  Initial values,  Model Structure 
Variable Scope_TP 
In Object  Scope_Tech  
Used in: Scope_WA  
Using: Scope Scope_Adoption S_F1 S_F2 Scope_Min  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Scope_TP"))  
{  
/*  
Fraction of the frontier cover by the firm  
*/  
v[0]=p->cal("Scope_Adoption",2);  
v[1]=p->cal("Scope",0);  
v[3]=p->cal("Scope_Min",0);  
 
if (v[0]==0)  
v[2]=p->cal("S_F1",0);  
else  
v[2]=p->cal("S_F2",0);  
 
v[4]=(abs(v[1]-v[3])/abs(v[2]-v[3]));  
v[5]=int(v[4]*10);  
 
res=v[5]/10;  
goto end;  
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}  
Return 
Variable Scope_WA 
In Object  Scope_Tech  
Used in: S_Adoption_De  
Using: LB_KK ap v Scope_TP  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Scope_WA"))  
{  
v[0]=p->cal("LB_KK",0);//Level of capabilities in extenal learning  
v[1]=p->cal("Scope_TP",0);//Technological position of the firm  
v[2]=p->cal("ap",0);//Scalling Parameter  
v[3]=p->cal("v",0);//Uncertainty and other factors that influence the 
adoption decition  
/*  
Uncertainty and other factors that influence the adoption decition.  
The probability of adopting a technology after a technological discon-
tinuity is a  
function of the level of capabilities in external learning, the tech-
nological position  
of the firm in the technology applied.  
*/  
 
v[5]=1-exp(-v[2]*pow(v[0],2)*pow(v[1],0.1)/v[3]);  
/*  
v[6]=int(v[5]*10);  
 
res=v[6]/10;  
*/  
res=v[5];  
goto end;  
}  
Return 
Parameter Scope_Adoption 
In Object  Scope_Tech  
Used in: S_Knowl Entry_DBF S_Adoption_De Scope_V Scope Scope_TP 
Scope_Gap  
Go to: Description,  Initial values,  Model Structure 
Variable Scope_V 
In Object  Scope_Tech  
Used in: Scope_V  
Using: v j v_decr_rate Scope_Adoption Scope_V Scope_Adoption_Date  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"Scope_V"))  
{  
/*  
The adoption expenditures for adopting advances in the Technology S  
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*/  
 
v[0]=p->cal("Scope_Adoption",0);  
v[1]=p->cal("Scope_Adoption_Date",0);  
v[2]=p->cal("v",0);  
v[3]=p->cal("Scope_V",1);  
v[4]=(double)t-1;  
v[6]=p->cal("v_decr_rate",0);  
v[7]=p->cal("j",0);  
 
if (v[0]!= 0)  
  {  
   if (v[1]==v[4])  
   v[5]=v[2];  
   else  
   v[5]=v[6]*v[3];  
  }  
else  
v[5]=0;  
 
res=v[5];  
goto end;  
}  
Return 
Parameter Scope_Adoption_Date 
In Object  Scope_Tech  
Used in: S_Adoption_De Scope_V  
Go to: Description,  Initial values,  Model Structure 
   
 
Object Precision_Tech 
 
Contained in Object: Root->Root2->World->Industry->Firm 
Containing: (none) 
List of Variables:  Precision(1), Precision_Gap(0), Precision_r(1), 
Precision_TP(0), Precision_V(1), Precision_WA(0) 
List of Parameters:  b1, b2, Precision_Adoption_1, Precision_Adoption_1_Date, 
Precision_Adoption_2, Precision_Adoption_2_Date, Precision_Theta, 
pwa_power 
Variable Precision 
In Object  Precision_Tech  
Used in: Entry_DBF Search Precision Precision_TP Precision_Gap  
Using: Precision Precision_r Precision_Adoption_1 Precision_Adoption_2 P_F1 
P_F2 P_td_1 P_F3  
Go to: Description,  Initial values,  Model Structure 
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Equation Code:  
if(!strcmp(label,"Precision"))  
{  
/*  
Technological Level of the firm in the Technology B. Firm and time 
specific  
*/  
v[0]=p->cal("Precision",1);  
v[2]=p->cal("Precision_r",1);  
v[4]=p->cal("Precision_Adoption_1",0);  
v[41]=p->cal("Precision_Adoption_2",0);  
 
v[7]=p->cal("P_td_1",0);  
  if (v[4]==0 && v[41]==0)  
  /*  
  If the "if condition" in the previous line is true, the company has 
not adopted  
  */  
    {  
     v[5]=p->cal("P_F1",0);  
     if (v[0]<=v[5])  
     v[3]=v[5];  
     else  
     v[3]=v[0]-v[2];//No exponential growth  
    }  
  if (v[4]==1 && v[41]==0)  
    {  
     v[6]=p->cal("P_F2",0);  
     if (v[0]<=v[6])  
     v[3]=v[6];  
     else  
     v[3]=v[0]-v[2];//No exponential growth  
    }  
  if (v[4]==1 && v[41]==1)  
        {  
     v[6]=p->cal("P_F3",0);  
     if (v[0]<=v[6])  
     v[3]=v[6];  
     else  
     v[3]=v[0]-v[2];//No exponential growth  
    }  
 
res=int(v[3]);  
goto end;  
}  
Return 
Variable Precision_Gap 
In Object  Precision_Tech  
Used in: Precision_r  
Using: Precision Precision_Adoption_1 Precision_Adoption_2 P_F1 P_F2 P_F3  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Precision_Gap"))  
{  
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/*  
technology B Technological Gap.  
Distance to the technological frontier of  
the Technology B.  
*/  
 
v[0]=p->cal("Precision",0);  
v[4]=p->cal("Precision_Adoption_1",0);  
v[5]=p->cal("Precision_Adoption_2",0);  
 
 if (v[4]==0 && v[5]==0)  
 v[2]=p->cal("P_F1",0);  
  if (v[4]!=0 && v[5]==0)  
 v[2]=p->cal("P_F2",0);  
 if (v[4]==1 && v[5]==1)  
 v[2]=p->cal("P_F3",0);  
   
v[3]=v[0]-v[2];  
 
res=int(v[3]);  
goto end;  
}  
Return 
Parameter Precision_Theta 
In Object  Precision_Tech  
Used in: Precision_r  
Go to: Description,  Initial values,  Model Structure 
Variable Precision_r 
In Object  Precision_Tech  
Used in: Entry_DBF Precision  
Using: KP Precision_Gap Precision_Theta b1 b2  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"Precision_r"))  
{  
/*  
Rate of technological change in the Technology B. The variable is  
time and firm specific. Log linear function. If the min Precision is 
1000  
and the simulation has 100 runs I need a change of about 1% (0.01) a  
nd 2% (0.02)per period.  
*/  
v[0]=p->cal("Precision_Theta",0); //Scale-Parameter  
v[2]=p->cal("KP",0); //Stock of capabilities in the Technology B  
v[1]=p->cal("Precision_Gap",0); //Distance to the technological fron-
tier  
v[3]=p->cal("b1",0);  
v[4]=p->cal("b2",0);  
v[6]=UNIFORM(0.8,1.2);  
 
/*v[5]=v[0]*pow(v[1],v[3])*pow(v[2],v[4])*v[6];//With the precision 
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gap  
*/  
v[5]=v[0]*pow(v[1],v[3])*pow(v[2],v[4]);//With the precision gap with-
out random!  
 
v[7]=int(v[5]*1000);  
res=v[7]/1000;  
goto end;  
}  
Return 
Parameter b1 
In Object  Precision_Tech  
Used in: Precision_r  
Go to: Description,  Initial values,  Model Structure 
Parameter b2 
In Object  Precision_Tech  
Used in: Precision_r  
Go to: Description,  Initial values,  Model Structure 
Variable Precision_TP 
In Object  Precision_Tech  
Used in: Entry_DBF Precision_WA  
Using: Precision Precision_Adoption_1 Precision_Adoption_2 P_F1 P_F2 
Precision_Max P_F3  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Precision_TP"))  
{  
/*  
Fraction of the frontier cover by the firm  
*/  
v[0]=p->cal("Precision_Adoption_1",2);  
v[4]=p->cal("Precision_Adoption_2",2);  
v[1]=p->cal("Precision",0);  
v[3]=p->cal("Precision_Max",0);  
 
 
 
 if (v[0]==0 && v[4]==0)  
 v[2]=p->cal("P_F1",0);  
  if (v[0]!=0 && v[4]==0)  
 v[2]=p->cal("P_F2",0);  
 if (v[0]==1 && v[4]==1)  
 v[2]=p->cal("P_F3",0);  
 
v[4]=(abs(v[1]-v[3])/abs(v[2]-v[3]));  
/*  
v[5]=int(v[4]*10);  
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res=v[5]/10;  
*/  
res=v[4];  
goto end;  
}  
Return 
Variable Precision_WA 
In Object  Precision_Tech  
Used in: Entry_DBF P_Adoption_De_1 P_Adoption_De_2  
Using: LB_KK ap v Precision_TP pwa_power  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Precision_WA"))  
{  
/*  
The probability of adopting a technology after a technological discon-
tinuity is a function of the level of capabilities in external learn-
ing, the technological position of the firm in the technology applied  
*/  
 
v[0]=p->cal("LB_KK",0);  
v[1]=p->cal("Precision_TP",0);//Technological position of the firm  
v[2]=p->cal("ap",0);//scalling parameter  
v[3]=p->cal("v",0);//Uncertainty and other factors that influence the 
adoption decition  
v[7]=p->cal("pwa_power",0);//set to 2!!!  
/*  
v[5]=1-exp(-v[2]*pow(v[0],v[7])*v[1]/v[3]);  
*/  
v[5]=1-exp(-v[2]*pow(v[0],v[7])/v[3]);//without influence of the 
TP!!!!  
 
 
/*  
v[6]=int(v[5]*10);  
res=v[6]/10;  
*/  
 
res=v[5];  
goto end;  
}  
Return 
Parameter Precision_Adoption_1 
In Object  Precision_Tech  
Used in: P_Knowl Entry_DBF P_Adoption_De_1 Precision_V Precision 
Precision_TP Precision_Gap  
Go to: Description,  Initial values,  Model Structure 
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Variable Precision_V 
In Object  Precision_Tech  
Used in: Precision_V V  
Using: v v_decr_rate Precision_Adoption_1 Precision_V 
Precision_Adoption_1_Date  
Go to: Description,  Initial values,  Model Structure 
Equation Code:  
if(!strcmp(label,"Precision_V"))  
{  
/*  
The adoption expenditures for adopting advances in the Technology B  
*/  
 
v[0]=p->cal("Precision_Adoption_1",0);  
v[1]=p->cal("Precision_Adoption_1_Date",0);  
v[2]=p->up->cal("v",0);//Initial Adoption cost  
v[3]=p->cal("Precision_V",1);  
v[4]=(double)t-1;  
v[6]=p->cal("v_decr_rate",0);//decreasing rate of adoption costs  
 
if (v[0] != 0)  
  {  
   if (v[1]==v[4])  
   v[5]=v[2];  
   else  
   v[5]=v[6]*v[3];//The adoption cost decreses at the .9 rate  
  }  
else  
v[5]=0;  
 
res=v[5];  
goto end;  
}  
Return 
Parameter pwa_power 
In Object  Precision_Tech  
Used in: Precision_WA  
Go to: Description,  Initial values,  Model Structure 
Parameter Precision_Adoption_1_Date 
In Object  Precision_Tech  
Used in: P_Adoption_De_1 Precision_V  
Go to: Description,  Initial values,  Model Structure 
Parameter Precision_Adoption_2 
In Object  Precision_Tech  
Used in: Entry_DBF Search P_Adoption_De_2 Collaboration Precision 
Precision_TP Precision_Gap  
Go to: Description,  Initial values,  Model Structure 
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Parameter Precision_Adoption_2_Date 
In Object  Precision_Tech  
Used in: P_Adoption_De_2  
Go to: Description,  Initial values,  Model Structure 
   
 
Object Network 
 
Contained in Object: Root->Root2->World->Industry->Firm 
Containing: col  
List of Variables:  (no Variables) 
List of Parameters:  (no Parameters) 
   
 
Object col 
 
Contained in Object: Root->Root2->World->Industry->Firm->Network 
Containing: (none) 
List of Variables:  (no Variables) 
List of Parameters:  col_date, col_DBF, col_divorce, col_divorce_date, col_j, 
col_KP, col_LF, DW 
Parameter col_LF 
In Object  col  
Used in: Collaboration  
Go to: Description,  Initial values,  Model Structure 
Parameter col_date 
In Object  col  
Used in: Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter col_KP 
In Object  col  
Used in: col_Knowl Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter col_j 
In Object  col  
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Used in: (never used) 
Go to: Description,  Initial values,  Model Structure 
Parameter col_DBF 
In Object  col  
Used in: Collaboration Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter col_divorce_date 
In Object  col  
Used in: Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter DW 
In Object  col  
Used in: Divorce  
Go to: Description,  Initial values,  Model Structure 
Parameter col_divorce 
In Object  col  
Used in: Divorce  
Go to: Description,  Initial values,  Model Structure 
   
 
Object Space 
 
Contained in Object: Root->Root2->World 
Containing: Mol  
List of Variables:  Generics(0), Init2(0) 
List of Parameters:  fda, Pd, Size 
Variable Init2 
In Object  Space  
Used in: (never used) 
Using: Size Ip i q_average1 q_st_dv1 q Mol_d Mol_phase q_average2 q_st_dv2  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Init2"))  
{  
 /*  
  Technical initialization function. It is computed only once and then 
it is transformed in a parameter and never computed again. This equa-
tion sets the search space of molecules availiable for the drug pro-
ducers to discover and develop drugs.  
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 */  
 cur=p->search("Mol");//Object  
 v[0]=cur->cal("i",0);//Identification parameter  
 v[1]=p->cal("Size",0);//Size or the search space  
   
 while( v[0] < v[1] )  
 {  
   cur1=p->add_an_object("Mol",cur);  
   cur1->write("i", v[0]+1, 0 );  
   cur1->write("Ip", 0 , 0);  
   /*Protection from imitation. Parameter for the protection status of 
the molecule.  
   The firm that first discovers it has a monopoly in its explotation 
for a given  
   number of periods. When the patent protection desapears the mole-
cule can be  
   exploited by any firm as a generic.  
   */  
     
   /*  
   The next two lines determine whether the molecule can be discovered 
before the  
   advent of modern biotech  
   */  
   v[20]=rnd_integer(1, 3);  
   if (v[20]!=1)  
   cur1->write("Mol_phase", 2, 0); 
    //2==rational searching phase , the number of mols is larger to 
capture the larger opportunities for innovation  
   else  
   cur1->write("Mol_phase", 1, 0);//1==random screening phase  
     
   /*  
   Mol_d is the date the molecule is discovered. This parameter is 
useful to calculate  
   the period in which the discovery looses patent protection. The pa-
rameter has the value  
   1000 as long as the molecule has not been discovered. The value 0 
is not used in order  
   to make sure that the equation "Generics" works.  
   */  
     
   cur1->write("Mol_d", 1000, 0); //Patent protection  
    
   /*  
   True Quality of the Molecule. Is calculated for every molecule at 
the beginning  
   of the model and it does not change. It is determined by a random 
process. The average  
   depends on the phase the molecule can be discovered (phase 1 or 2).  
   */  
     
    if (v[20]!=1)  
     {  
     v[11]=p->cal("q_average2",0);//Quality average for drugs that can 
be discovered in the rational searching phase  
     v[12]=p->cal("q_st_dv2",0);//  
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     }  
    else  
     {  
     v[11]=p->cal("q_average1",0);//Quality average for drugs that can 
be discovered in the random screening phase  
     v[12]=p->cal("q_st_dv1",0);  
     }  
     
   v[10]=norm(v[11],v[12]);  
   v[13]=round(v[10]);//Quality of the potential drugs  
   if (v[13]<0)  
   cur1->write("q", 0 , 0); //True Quality can not be negative  
   else  
   cur1->write("q", v[13] , 0);  
    
   v[0] = v[0] + 1;  
 }  
   
 param=1;  
 res=0;  
 goto end;  
}  
Return 
Parameter Size 
In Object  Space  
Used in: Init2 Search Start  
Go to: Description,  Initial values,  Model Structure 
Parameter Pd 
In Object  Space  
Used in: Generics  
Go to: Description,  Initial values,  Model Structure 
Variable Generics 
In Object  Space  
Used in: Search  
Using: Pd Ip Mol_d  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Generics"))  
{  
/*  
This action explores the search space every time is activated in order 
to vary the parameter  
Ip according to the statuts of the molecule (discovered or not) and if 
appropiate (according  
to the patent duration parameter) transform it into a drug that can be 
imitated.  
*/  
last_update--;//repeat the computation any time is requested  
if(c==NULL)//Avoids to be computed when the system activates the equa-
tion  
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 {  
  v[0]=p->cal("Pd",0);//Patent duration  
  CYCLE(cur, "Mol")  
   {  
    v[1]=(double)t;//Current period  
    v[2]=cur->cal("Ip",0);//Protection Status  
    v[3]=cur->cal("Mol_d",0);//Discovery date. If it has not been dis-
covered Mol_d=1000  
      
    if (v[2] == 1 && v[1]-v[3] >= v[0])  
    cur->write("Ip",2,0);  
   }  
    
  res=-1;  
  goto end;  
 }  
 
res=1;  
goto end;  
}  
Return 
Parameter fda 
In Object  Space  
Used in: Search  
Go to: Description,  Initial values,  Model Structure 
   
 
Object Mol 
 
Contained in Object: Root->Root2->World->Space 
Containing: (none) 
List of Variables:  (no Variables) 
List of Parameters:  i, Ip, Mol_d, Mol_phase, q, q_average1, q_average2, 
q_st_dv1, q_st_dv2, qo 
Parameter Ip 
In Object  Mol  
Used in: Init2 Generics Search  
Go to: Description,  Initial values,  Model Structure 
Parameter i 
In Object  Mol  
Used in: Init2 Search  
Go to: Description,  Initial values,  Model Structure 
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Parameter q_average1 
In Object  Mol  
Used in: Init2  
Go to: Description,  Initial values,  Model Structure 
Parameter q_st_dv1 
In Object  Mol  
Used in: Init2  
Go to: Description,  Initial values,  Model Structure 
Parameter q 
In Object  Mol  
Used in: Init2 Search  
Go to: Description,  Initial values,  Model Structure 
Parameter qo 
In Object  Mol  
Used in: Search  
Go to: Description,  Initial values,  Model Structure 
Parameter Mol_d 
In Object  Mol  
Used in: Init2 Generics Search  
Go to: Description,  Initial values,  Model Structure 
Parameter Mol_phase 
In Object  Mol  
Used in: Init2 Search  
Go to: Description,  Initial values,  Model Structure 
Parameter q_average2 
In Object  Mol  
Used in: Init2  
Go to: Description,  Initial values,  Model Structure 
Parameter q_st_dv2 
In Object  Mol  
Used in: Init2  
Go to: Description,  Initial values,  Model Structure 
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Object Knowledge_Base 
 
Contained in Object: Root->Root2->World 
Containing: (none) 
List of Variables:  P_Knowl(0), Rational_Phase_Knowlbase(0), S_Knowl(0), 
Scope_New_Knowlbase(0) 
List of Parameters:  P_complex, P_complex_2, P_complex_3, P_F1, P_F2, P_F3, 
P_PR_1, P_PR_2, P_sc, P_sc_2, P_td_1, P_td_2, Precision_Max, S_complex, 
S_complex_2, S_F1, S_F2, S_PR_1, S_PR_2, S_sc, S_sc_2, S_td, Scope_Min 
Parameter S_PR_1 
In Object  Knowledge_Base  
Used in: S_Knowl  
Go to: Description,  Initial values,  Model Structure 
Parameter P_PR_1 
In Object  Knowledge_Base  
Used in: P_Knowl  
Go to: Description,  Initial values,  Model Structure 
Parameter S_PR_2 
In Object  Knowledge_Base  
Used in: S_Knowl  
Go to: Description,  Initial values,  Model Structure 
Parameter P_PR_2 
In Object  Knowledge_Base  
Used in: P_Knowl  
Go to: Description,  Initial values,  Model Structure 
Parameter S_F1 
In Object  Knowledge_Base  
Used in: Scope Scope_TP Scope_Gap  
Go to: Description,  Initial values,  Model Structure 
Parameter S_F2 
In Object  Knowledge_Base  
Used in: Scope Scope_TP Scope_Gap  
Go to: Description,  Initial values,  Model Structure 
Parameter P_F1 
In Object  Knowledge_Base  
Used in: Precision Precision_TP Precision_Gap  
Go to: Description,  Initial values,  Model Structure 
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Parameter P_F2 
In Object  Knowledge_Base  
Used in: Precision Precision_TP Precision_Gap  
Go to: Description,  Initial values,  Model Structure 
Parameter S_td 
In Object  Knowledge_Base  
Used in: Scope_New_Knowlbase S_Adoption_De  
Go to: Description,  Initial values,  Model Structure 
Parameter P_td_2 
In Object  Knowledge_Base  
Used in: Rational_Phase_Knowlbase Rational_Phase_Industry Search 
P_Adoption_De_2  
Go to: Description,  Initial values,  Model Structure 
Parameter P_td_1 
In Object  Knowledge_Base  
Used in: Rational_Phase_Knowlbase P_Adoption_De_1 Precision  
Go to: Description,  Initial values,  Model Structure 
Variable Rational_Phase_Knowlbase 
In Object  Knowledge_Base  
Used in: (never used) 
Using: P_td_2 P_td_1 P_complex P_complex_2 P_sc_2 P_complex_3  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Rational_Phase_Knowlbase"))  
{  
/*  
The technological discontinuity with the revolution of molecular biol-
ogy in the 1950s.  
Transition to rational drug discovery.  
*/  
v[0]=(double)t;  
v[1]=p->cal("P_td_1",0);//Phase II starts- Revolution of mol biol 
1950s  
v[11]=p->cal("P_td_2",0);//Phase III starts- Modern Biotech  
v[2]=p->cal("P_complex_2",0);//complexity after the revolution of mol 
biol  
v[22]=p->cal("P_complex_3",0);//complexity after the emergence of mod-
ern biotech  
v[3]=p->cal("P_sc_2",0);//Depreciation Rate of technological capabili-
ties after the revolution of mol biol  
 
if (v[0] >= v[1] && v[0] < v[11])  
{  
 p->write("P_complex",v[2], 0);//complexity after the revolution of 
mol biol  
}  
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if (v[0] >= v[11])  
 p->write("P_complex",v[22], 0);//complexity after the emergence of 
modern biotech  
   
res=1;  
goto end;  
}  
Return 
Variable Scope_New_Knowlbase 
In Object  Knowledge_Base  
Used in: (never used) 
Using: S_td S_complex S_complex_2 S_sc S_sc_2  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"Scope_New_Knowlbase"))  
{  
/*  
The technological discontinuity in the Technology S produces changes 
in the knolwedge base.  
Attention: In the version of the thesis there is no discontinuity in 
the Scope Technology!!!  
*/  
v[0]=(double) t;  
v[1]=p->cal("S_td",0);//not used in the version of the thesis. Set to 
t=0.  
v[2]=p->cal("S_complex_2",0);//complexity after the discontinuity  
v[3]=p->cal("S_sc_2",0);//Depreciation Rate of technological capabili-
ties after the discontinuity  
 
/*  
if (v[0] >= v[1])it has been changed for the version without disconti-
nuity  
*/  
 
if (v[0] >= 0)  
{  
 p->write("S_complex",v[2], 0);//complexity  
 p->write("S_sc",v[3], 0);//speed change  
}  
   
res=1;  
param=1;  
goto end;  
}  
Return 
Parameter Scope_Min 
In Object  Knowledge_Base  
Used in: Scope_TP  
Go to: Description,  Initial values,  Model Structure 
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Parameter Precision_Max 
In Object  Knowledge_Base  
Used in: Precision_TP  
Go to: Description,  Initial values,  Model Structure 
Variable S_Knowl 
In Object  Knowledge_Base  
Used in: LB_KS  
Using: S_SO Scope_Adoption S_PR_1 S_PR_2  
Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"S_Knowl"))  
{  
/*  
Knowledge base to develop the Technology S . It is firm specific in 
the sense that  
it depends on whether the companies have perceived discontinuities or 
not.  
 
In the version of the HFM model developed in the thesis technology S 
does not experience any discontinuity.  
*/  
 
last_update--;//repeat the computation any time is requested  
if(c==NULL)//Avoids to be computed when the system activates the equa-
tion  
{  
res=-1;  
goto end;  
}  
 
v[0]=c->cal("S_SO",0);//Spillovers are firm specific  
 
v[1]=c->cal("Scope_Adoption",0);//This parameter does not change since 
in this version of the model there is no discontinuity in the scope 
technology!!!!!  
if (v[1]==0)  
 v[2]=p->cal("S_PR_1",0);//Contribution to the knowledge base of tech-
nology S of public research before a doscontinuity  
else  
 v[2]=p->cal("S_PR_2",0);//Contribution to the knowledge base of tech-
nology S of public research after a discontinuity  
   
res=v[0]+v[2];  
goto end;  
}  
Return 
Variable P_Knowl 
In Object  Knowledge_Base  
Used in: LB_KP  
Using: P_Knowl_firm P_SO Precision_Adoption_1 P_PR_1 P_PR_2  
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Go to: Description,  Model Structure 
Equation Code:  
if(!strcmp(label,"P_Knowl"))  
{  
/*  
Knowledge base to develop the Technology B. Knowledge base to develop 
the Technology S. It is firm specific in the sense that it depends on 
whether the companies have perceived discontinuities or not.  
*/  
 
last_update--;//repeat the computation any time is requested  
if(c==NULL)//Avoids to be computed when the system activates the equa-
tion  
{  
res=-1;  
goto end;  
}  
 
v[0]=c->cal("P_SO",0);// Spillovers are firm specific  
v[1]=c->cal("Precision_Adoption_1",0);  
 
if (v[1]==0)  
 v[2]=p->cal("P_PR_1",0);//Contribution to the knowledge base of tech-
nology B of public research before the discontinuity  
else  
v[2]=p->cal("P_PR_2",0);//Contribution to the knowledge base of tech-
nology B of public research after the discontinuity  
 
v[3]=v[0]+v[2];  
c->write("P_Knowl_firm",v[3],0);  
res=v[3];  
goto end;  
}  
Return 
Parameter S_complex 
In Object  Knowledge_Base  
Used in: Scope_New_Knowlbase Abs_S  
Go to: Description,  Initial values,  Model Structure 
Parameter S_complex_2 
In Object  Knowledge_Base  
Used in: Scope_New_Knowlbase  
Go to: Description,  Initial values,  Model Structure 
Parameter P_complex 
In Object  Knowledge_Base  
Used in: Rational_Phase_Knowlbase Abs_P  
Go to: Description,  Initial values,  Model Structure 
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Parameter P_complex_2 
In Object  Knowledge_Base  
Used in: Rational_Phase_Knowlbase  
Go to: Description,  Initial values,  Model Structure 
Parameter S_sc 
In Object  Knowledge_Base  
Used in: Scope_New_Knowlbase KS  
Go to: Description,  Initial values,  Model Structure 
Parameter S_sc_2 
In Object  Knowledge_Base  
Used in: Scope_New_Knowlbase  
Go to: Description,  Initial values,  Model Structure 
Parameter P_sc 
In Object  Knowledge_Base  
Used in: Rational_Phase_Industry KP  
Go to: Description,  Initial values,  Model Structure 
Parameter P_sc_2 
In Object  Knowledge_Base  
Used in: Rational_Phase_Knowlbase Rational_Phase_Industry  
Go to: Description,  Initial values,  Model Structure 
Parameter P_F3 
In Object  Knowledge_Base  
Used in: Precision Precision_TP Precision_Gap  
Go to: Description,  Initial values,  Model Structure 
Parameter P_complex_3 
In Object  Knowledge_Base  
Used in: Rational_Phase_Knowlbase  
Go to: Description,  Initial values,  Model Structure 
 
